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A B S T R A C T
Proteome complexity presents a major challenge in the field of proteomics. The majority of 
bottom-up methods begin with proteolysis, which increases the number of analytes in the 
mixture by about 30-50 fold. This level of complexity demands simplification, and there is an 
increasing requirement for strategies and reagents that reduce the complexity of a total 
proteome mixture.
It may be argued that when analysing a complete protein digest, for instance by 
standard shotgun methods, more peptides are analysed than strictly necessary. An efficient 
proteomic strategy simplifies the proteome while preserving most of the information necessary 
for comprehensive analysis. A practical approach to proteome simplification is to target a 
specific structural region of the protein molecule. The ultimate simplification strategy would be 
to select a single signature peptide from each protein in the proteome.
The primary goal of this study was to develop an advanced strategy for proteome 
simplification that reduces each protein to its N-terminal most proteolytic peptide, termed 
‘positional proteomics’. Under these circumstances, knowledge of the location of the peptide in 
the protein (at the N-terminal end) is a powerful adjunct to effective identification. In brief, a 
complex protein mixture is N-acetylated in its native state and proteolysed to generate a 
mixture of acetylated (blocked) N-terminal peptides and unmodified internal peptides. 
Subsequent incubation of the peptide mixture with an immobilised amine scavenger, results in 
binding of unblocked a-amino groups i.e. all internal peptides. The unbound N-terminal 
peptides are separated from the Sepharose and analysed with out further treatment.
N-terminal regions of protein molecules are, in general, poorly represented within 
published datasets due to a plethora of modification events which can occur both co- and 
post-translationally (e.g. Na-acetylation, methionine excision, signal peptide excision and 
exopeptidase activity). The positional proteomics strategy provides method to characterise the 
true N-terminal region of proteins, identifying potential signal peptide cleavage sites, truncation 
by exopeptidase activity and modification by Na-acetylation.
Once developed, this strategy was applied to the soluble fractions of three complex 
proteomes (E. coli, S. cerevisiae and mouse liver) in order to rapidly characterise and define 
the true N-termini of large numbers of proteins.
The issue of sample complexity is further complicated by the dynamic expression 
range of proteins in most biological mixtures. The profile of N-terminal peptides from human 
plasma allows identification of proteins that are previously obscured by peptides from other 
highly abundant proteins. N-terminal profiling of human plasma, in combination with protein 
normalisation, led to the detection of over fifty proteins, including low abundance proteins and 
potential diagnostic biomarkers.
The ability to determine the frequency of a specific amino acid within a peptide 
sequence will provide an additional parameter for database searching. In an approach termed 
MIDAR (mass isotopomer distribution analysis of amino acid residues), two labelled variants 
of acetic anhydride, separated by 1Da, were mixed asymmetrically (10% of the lighter, and 
90% of the heavier variant). When peptides are labelled with this reagent, the isotope pattern 
of the products is complex, but the ratio of two specific ions gives a precise measure of the 
number of amino groups in each peptide. The approach is generally applicable to any peptide- 
based proteome analysis, but is used here as part of a positional proteomics based analysis. 
Knowledge of the number of amino groups can provide valuable information that can be used 
as an added parameter in accurate mass and retention time strategies.
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Chapter 1: Introduction to Proteome Simplification
1. IN T R O D U C T IO N  TO  P R O T E O M E  S IM P L IF IC A T IO N
1.1 Proteomics Overview
The rapid pace of genome sequencing efforts since 1995 has led to the complete, or almost 
complete, sequencing of over 1218 genomes, of which 792 are Bacteria, 136 Eukarya, 49 
Archaea and 241 Viruses. The majority of these sequences are accessible in the public 
domain (http://ergo.integratedgenomics.com/ERGO/) (Overbeek et al., 2003). The present 
challenge is to determine the function of the genes contained within these genomes and link 
their function to phenotype. The quest to elucidate gene function has led to the analysis of 
expression levels of the components that make up a biological system, most importantly, 
mRNA (transcriptomics), proteins (proteomics), and metabolites (metabolomics). Recent 
advances in protein separation sciences, coupled with mass spectrometry, have laid the 
groundwork for a comprehensive analysis of proteins. Because proteins control the majority of 
biochemical processes, either through interaction with other proteins or between proteins and 
their substrates (Matthews et a/., 2001; Walhout and Vidal, 2001) it is anticipated that new 
strategies which rapidly and efficiently characterise proteins, will provide valuable insights into 
understanding gene function.
The term proteome was first used in 1994 and can be described as the global 
collection of proteins produced by an organism. Proteomics refers to the branch of discovery 
science focusing on proteins (Wilkins et al., 1996). Understanding the proteome, the structure 
and function of each protein, along with the complexities of protein-protein interactions (protein 
complexes), is necessary in order to fundamentally understand and appreciate cellular 
systems.
1.2 Proteome complexity
As the proteome is encoded by the genome, one might expect a one-to-one correspondence 
between genes and proteins. However, proteomes are typically of higher complexity than 
genomes. Single cell prokaryotes and eukaryotes typically contain a few thousand protein 
coding genes, for example, Escherichia coli contains around 4,200 genes (Blattner et al., 
1997) and Saccharomyces cerevisiae has 6000 (Goffeau et al., 1996). Recent estimates 
predict that the human genome is comprised of around 20,000 to 25,000 unique genes 
(International Human Genome Sequencing Consortium, 2004), which is significantly lower
1
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than previously thought (Ewing and Green, 2000). The increased physiological complexity 
seen in vertebrates is due to a complex set of processes used to regulate gene expression, 
and not simply an increased number of genes. Proteome complexity can be attributed to 
diversification at both the mRNA level and following translation of mRNA into protein, by 
covalent modification, in a process known as post-translational modification (PTM).
1.2.1 Diversity at the mRNA level
Diversification of mRNAs can arise by the use of alternative promoter sequences in the 5’ 
upstream ends of mRNAs, leading to the generation of several homologous proteins of 
variable length, due to different starting points (also known as a nested set).
A much more significant factor in the generation of mRNA diversity is the alternative 
splicing of primary mRNA molecules. Alternative splicing is a process that increases 
transcriptome and proteome complexity by generating multiple mRNA products from a single 
gene. The mechanism involves processing of the mRNA transcript into different mRNA 
molecules by separating exons and reconnecting them in various ways to produce alternative 
ribonucleotide rearrangements (Sharp, 1985). Recent studies estimate that >60% of human 
and mouse genes undergo alternative splicing (Lander et at., 2001; Sharov et at., 2005; 
Johnson et at., 2003). The process was originally thought to be the main mechanism for the 
generation of higher order diversity within eukaryotes (Ewing and Green, 2000). However, the 
use of expressed sequence tag (EST) analysis demonstrated that the amount of alternative 
splicing is comparable, with no large differences, between humans and other animals (Brett et 
at., 2002). Therefore, it is thought that alternative splicing plays only a small role in the 
diversification of novel gene products. The difference in complexity seen throughout 
eukaryotic organisms is mainly a result of PTM of proteins.
1.2.2 Diversity at the protein level
The release of a completed polypeptide chain from a ribosome is often not the last physical 
step in the formation of a protein. In both prokaryotic and eukaryotic cells, a vast set of 
changes occur to amino acid residues in proteins after their emergence from the ribosome. 
These alterations (PTMs) serve to increase the diversity and heterogeneity of functional 
groups beyond that of the 20-22 types of amino acid incorporated into the nascent polypeptide 
chain (reviewed in Krishna and Wold, 1993).
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Side chains in proteins, which potentially act as nucleophiles, are common targets for 
PTM; furthermore, the NH2 and COO- groups (at the N and C-terminus of protein molecules 
respectively), which can also potentially act as nucleophiles, provide common targets for 
modification.
Various covalent modifications often occur, either during or after assembly of the 
polypeptide chain. Most proteins undergo PTMs that play a pivotal role in many biological 
processes, such as gene expression, cell signalling and mitosis. PTMs can be divided into two 
classes: covalent addition of one or more groups, such as phosphoryl, acetyl or glycosyl, to 
one or more of the amino acid side chains and hydrolytic cleavage of one or more peptide 
bonds by the action of proteases. More than 200 different types of PTM are known and it is 
likely that additional ones are yet to be discovered (Creasy and Cottrell, 2004). All modified 
forms of each protein can potentially vary in abundance, activity or location within a cell. 
Modifications can be reversible or irreversible and can occur spontaneously or through 
enzymatic mechanisms.
The reversal of PTMs adds yet another level of complexity and functional regulation of 
proteomes. As a rule, reversible PTMs are most likely to be involved as on-off switches in the 
regulation of the biological activity of the proteins modified. In most cases, only the modified or 
unmodified form of the protein substrate retains biological activity, additionally, separate 
enzymes are required for the forward and reverse reactions. This type of modulation occurs 
through cascades of activation and inactivation which represent a powerful tool for living cells 
to amplify biological signals (Chock et al., 1980). Reversible protein phosphorylation, 
principally on serine, threonine or tyrosine residues, is one of the most important and well- 
studied PTMs. In eukaryotes, protein phosphorylation can be a key regulatory event. Many 
enzymes and receptors are switched "on" or "o ff by phosphorylation and dephosphorylation 
(Krebs and Beavo, 1979).
The majority of naturally occurring PTMs are non-reversible and lead to permanent 
changes in the protein sequence. Some of these permanent changes occur as a result of a 
spontaneous reaction without the involvement of enzymes. An example of a spontaneous non- 
enzymic process is deamidation of asparagine residues to a mixture of isoaspartate and 
aspartate (Rivers et al., 2008). Deamidation of glutamine residues can occur but does so at a 
much lower rate and as a result, is limited to proteins with long half-lives (Robinson et al., 
1973). The role of deamidation is not clear, however, it has been proposed that deamidation 
may provide a signal for protein degradation, thereby regulating intracellular levels.
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In addition to naturally occurring (in vivo) protein modifications, modifications can 
occur as a result of sample treatment and preparation (in vitro). Some of these modifications 
are relatively easy to recognise, such as methionine oxidation (Chao et al., 1997) and cysteine 
carbamidomethylation (Wilm et al., 1996), which are routinely incorporated into database 
search engines. However, the extent of in vitro protein modification is difficult to estimate as 
most are present substochiometrically (Wilmarth et al., 2006).
1.2.3 Heterogeneity at the N-terminus
The work in this thesis is based predominantly on methods to characterise protein N-termini. 
Therefore, the focus of the following section will centre on complexity and heterogeneity at the 
N-terminal region. The a-amino group at the N-terminus of protein molecules is targeted by a 
variety of enzymatic processes which occur both during translation (co-translational) and 
following release of the polypeptide chain from the ribosome (post-translational). Three types 
of reactions prevail: hydrolytic cleavage to remove one or more amino acids, modification of 
the a-amino group and side chain specific changes.
Proteolytic events
N-terminal peptidases (aminopeptidases) function to systematically remove or ‘trim’ individual 
amino acid residues from the N-terminus of proteins, revealing new N-terminal residues which 
can potentially become substrates for enzymes that modify the a-amino group (Taylor, 1993).
All nascent peptide chains begin with a methionine residue, which is either unblocked 
(archaea and eukaryotes) or N-formylated (prokaryotes). In most cases, this residue is 
removed or excised by the action of methionine aminopeptidase (MetAP), which acts alone or 
in combination with peptide deformylase, which is responsible for N-formyl removal (Giglione 
et al., 2000). N-terminal methionine excision (NME) is the major proteolytic pathway 
responsible for the diversity of amino acids in proteins and occurs in as much as 80% of 
proteins in any given proteome (Frottin et al., 2006). NME is an irreversible co-translational 
mechanism that occurs before the nascent polypeptide chain is released from the ribosome 
(Espagne et al., 2007). As a rule, the initial N-terminal methionine residue is removed from 
proteins in which alanine, cysteine, glycine, proline, serine threonine or valine is the 
penultimate residue (Prchal et al., 1986). The lack of action of MetAP on proteins with large 
penultimate residues is a result of steric hindrance; In general, methionine is cleaved from 
penultimate residues having radii of gyration of 1.29 A or less (Hirel et al., 1989).
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Functions of NME include an important role in protein turnover, in proteins targeted by 
the ubiquitin pathway (Giglione et al., 2003). Furthermore, a recent study into N-terminal 
modification in eukaryotes suggests that NME acts as a marker, tagging the most abundant 
proteins in a biological system, which mostly have alanine in the penultimate position 
(Martinez et al., 2008).
Some proteins containing proline as the antepenultimate (the third) residue are 
resistant to NME (Moerschell et al., 1990). Methionine cleavage was completely inhibited from 
the Met-Val-Pro sequence of mutant human haemoglobin (Prchal et al., 1986), which under 
normal circumstances would have undergone NME.
The signal hypothesis, originally proposed by Blobel and Sabatini in 1971 (Sabatini et 
al., 1971), proposed that all mRNAs to be translated on bound polyribosomes contained a 
unique set of codons immediately preceding the start codon. When translated these codons 
result in a unique sequence of amino acid residues, the signal peptide (SP), at the N-terminal 
end of the nascent polypeptide. The SP sequence triggers the attachment of the ribosome to 
the endoplasmic reticulum (ER) membrane, providing appropriate conditions for translocation 
of the polypeptide chain across the membrane. SP removal is a co-translational process and 
occurs once the N-terminal portion of the nascent polypeptide has crossed the plasma 
membrane. This sequence of events is not restricted to secretory proteins (extracellular) but 
also applies to the synthesis of proteins synthesised in the cytoplasm that are destined for 
various cellular compartments (mitochondrion, plastid, endoplasmic reticulum, etc) and for 
membrane proteins. Proteins which remain in the cytoplasm do not possess signal peptides. 
SPs consist of a short transient sequence that is made up of three regions: a positively 
charged n-region, a hydrophobic h-region and a polar c-region leading up to the cleavage site 
(Figure 1.1; Schatz and Beckwith, 1990). The removal of signal peptides from secreted 
proteins is executed by the action of signal or transit peptidases located at the membrane of 
the targeted compartment (Jackson and Blobel, 1977). Mitochondrial targeting signals are rich 
in arginine, serine and alanine residues and lack aspartic acid and glutamic acid residues (von 
Heijne et al., 1989). These peptides often form amphiphilic helices which are essential for their 
function (Roise et al., 1988). Proteins that are targeted to the ER tend to have a high content 
of leucine residues (Nielsen et al., 1996).
The prediction of signal peptides from primary sequence is a major component of 
automated protein annotation. Many software tools have been developed for cellular 
localisation prediction, using machine learning techniques such as neural networks and
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Figure 1.1. Signal peptide structure.
Signal peptides have a three-region design consisting of a positively charged N- 
terminal region (n-region), a hydrophobic central region (h-region) and a neutral, polar 
C-terminal region (c-region).
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hidden Markov models (reviewed in Klee and Ellis, 2005). Most prediction programs predict 
intracellular signal peptides in proteins by identifying an N-terminal signal sequence, a signal 
sequence cleavage site, or a combination of both features, in a target sequence. Examples of 
signal peptide prediction algorithms include: SignalP (Bendtsen et a/., 2004), TargetP 
(Emanuelsson et a/., 2000) and PrediSi (Hiller et at., 2004).
Propeptide cleavage is usually combined with SP cleavage, once the protein has 
reached its desired location. N-terminal propeptide removal occurs in combination with SP 
removal in the classic plasma protein serum albumin, which is cleaved at position 25, following 
the occurrence of two arginine residues (Dugaiczyk et at., 1982). Propeptide cleavage often 
involves autocatalysis which can function to activate or switch on biological activity. Many 
enzymes are synthesised as inactivate precursors, otherwise known as zymogens (Stroud et 
at., 1977). Trypsinogen is a zymogen which is converted to its active form (trypsin) by removal 
of a hexapeptide from the N-terminus. This cleavage reaction is mediated by the enzyme 
enteropeptidase, a membrane-bound serine protease. The enzyme hydrolyses a specific 
lysine-isoleucine peptide bond in the zymogen as it enters the duodenum from the pancreas 
(Maroux et ai, 1971). The small amount of trypsin produced in this process activates the 
conversion of more trypsinogen to trypsin, in a proteolytic reaction termed autoactivation. 
Conversion of trypsinogen to trypsin is of particular importance in the digestion process, as 
trypsin is responsible for the activation of all the pancreatic zymogens (pre-trypsinogen, 
chymotrypsinogen, proelastase and procarboxypeptidase; Bode e ta i, 1978).
NME, SP cleavage and propeptide removal are all proteolytic mechanisms leading to 
the generation of new, mature N-termini. The main residues unmasked by NME are alanine 
and serine, which together account for 33% of the intracellular N-termini generated by 
endoproteolytic cleavage (Gevaert et at., 2003).
N-blocking mechanisms
The a-amino group of a protein is also subject to various modification processes which result 
in the addition of a functional group. These modification processes include acetylation, 
myristoylation and propionylation.
Amino terminal modification by acetylation is extremely common in eukaryotes. 
Around 50% of the proteins in fungi are Na-acetylated (Lee etal., 1989a) and as many as 90% 
in animals (Polevoda and Sherman, 2000). Na-acetylation is much less common in 
prokaryotes, although it does still occur (Charbaut et at., 2002).
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The process of N°-acetylation, which occurs co-translationally, can modify the initiator 
methionine residue or the penultimate residue if the methionine is cleaved. The enzymes 
responsible for Na-acetylaion in eukaryotes are N-acetyltransferases (Nats), which transfer 
acetyl groups from acetyl-CoA to a protein’s a-amino group, via substitution with an active 
hydrogen atom. There are a total of three distinct Nat enzymes (NatA, NatB and NatC) each 
with different specificities. Unlike NME, the rules governing Na-acetylation are not clear-cut. 
Eukaryotic proteins which are susceptible to Na-acetylation have a variety of different N- 
terminal sequences with no simple consensus motif, and with no dependence on a single type 
of amino acid residue (Polevoda etal., 1999). In accordance with NME, N°-acetylation is partly 
dependent on the nature of the second encoded residue. Both alanine and serine are the most 
commonly Na-acetylated amino acids, in addition to the uncleaved methionine residue when 
followed by either aspartic or glutamic acid (Flinta et al., 1986). NatA typically modifies serine 
and alanine residues following methionine excision. In contrast, NatB and C have been shown 
to modify uncleaved methionine residues showing strong preference for proteins with a 
negatively charged (aspartic or glutamic acid) residue in the penultimate position.
The exact biological role of Na-acetylation remains poorly understood. In S. cerevlsiae 
the process is required for normal growth and mating (Lee et al., 1989b), however in a 
separate study, the viability of ard1-A, nat1-A, mak3-L and nat3-A mutants suggests that the 
role of acetylation may be subtle and not absolute for most proteins (Polevoda and Sherman, 
2003). It is likely that only a subset of proteins actually require this modification for activity or 
stability, whereas the remaining proteins are acetylated only because their N-terminal 
sequences correspond to the required consensus.
N-myristoylation, the covalent attachment of myristic acid (from myristoyl CoA) to the 
N-terminal glycine of proteins, is an irreversible co-translational process. Myristic acid, a 14 
carbon saturated fatty acid (C14:0), is a rare fatty acid in biological systems, representing less 
that 1% of fatty acids in living cells (Boutin, 1997; Utsumi et al., 2001). The process of 
attachment is an acylation reaction in which the acyl group is provided by a long chain fatty 
acid. The reaction is catalysed by the enzyme N-myristoyltransferase (NMT). The presence of 
myristoylate on the surface of a protein molecule increases lipophilicity allowing interaction 
with cellular membranes or other proteins. The majority of proteins targeted by NMT have an 
N-terminal consensus sequence of Met-Gly-X-X-X-Ser/Thre, although the initial methionine 
residue must be excised before attachment can occur (for a more detailed sequence motif, 
see Figure 1.2). N-myristoylation forms part of a multi-step process in which proteins are
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Figure 1.2. Myristoylation
a) Structure of myristic acid
b) Consensus sequence for recognition of protein substrates by NMT
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transported to their functional locations. Many of the proteins modified by this process have 
crucial roles in disease progression. NMT is more active in colonic epithelial neoplasms than 
in corresponding normal-appearing colonic tissue (Magnuson et al., 1995). Additionally, an 
increased expression of NMT was also observed in gall bladder carcinoma (Rajala et al.,
2000). Therefore, a greater understanding of the functions of NMT has important implications 
for cancer treatment and diagnosis.
Propionylation has recently been characterised as an N-terminal modification 
(Dormeyer et al., 2007), and is thought to have a role in histone modification (Chen et al., 
2007).
N-terminal status and protein half-life
The N-terminal amino acid is thought to define the in vivo half life of a protein, according to the 
N-end rule (Varshavsky, 1992), a fundamental principle of regulated proteolysis that is 
conserved from bacteria to mammals. Although prokaryotes and eukaryotes employ a 
different set of components for degradation of N-end rule substrates, they share similar 
mechanisms of substrate recognition. In eukaryotes the N-end rule pathway forms part of the 
ubiquitin (Ub) system which is the pathway by which proteins are broken down into amino 
acids. Proteins are identified as being metabolically unstable and targeted for degradation, by 
the presence of degradation signals or degrons (Varshavsky, 1992). The essential component 
of a degron is a destabilising N-terminal residue, the N-degron. In eukaryotes the N-degron 
consists of not only a destabilising amino acid residue but also an accessible internal lysine 
residue which forms the site of the multi-ubiquitin chain (Varshavsky, 1997). Prior to 
degradation the Ub tag is attached to the e-amino group of the internal lysine. Successive 
addition of activated Ub moieties to internal Lys48 of the previously attached molecule leads 
to generation of the polyubiquitin chain that is the degradation signal recognised by the 26S 
proteasome (Ciechanover and Schwartz, 1989). The ability of aminopeptidases to excise N- 
terminal residues could potentially influence a protein’s interaction with the N-end rule 
machinery and modulate stability. If the aminopeptidase, for example MAP 1, revealed a 
destabilising or stabilising residue as the new N-terminus it could have a profound effect on 
the stability of the protein.
For most N-end rule substrates the initial Ub molecule is attached to the protein 
through its C-terminal Gly76 residue to the £-amino group on the internal lysine. More recent 
findings indicate that, for some proteins, the first Ub molecule is attached to the a-amino group
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on the N-terminus of the protein (Giglione et al., 2003; Ciechanover and Ben-Saadon, 2004). 
In contrast to the traditional N-end rule pathway, N-terminal ubiquitination requires a free N- 
terminal amino acid to accept an Ub moiety.
1.3 Dynamic range of protein expression
The issue of proteome complexity is further complicated by the wide range of protein 
abundance present in most biological samples, referred to as the dynamic expression range 
(Corthals et al., 2000). The dynamic range problem, in which the higher abundance proteins in 
the sample impede detection of the lower abundance proteins, presents a major concern for 
proteomic analysis. Proteins exhibit a very wide range in concentration, with a dynamic range 
of 105 in bacteria to 107-108 in human cells (Corthals et al., 2000). Since there is no technique 
to amplify low-abundance proteins (comparable to the polymerase chain reaction for nucleic 
acids), both gel based and mass spectrometry methods often fail to detect the lower 
abundance complement (Kenyon et al., 2002).
Substantial efforts have been made towards the global analysis of protein expression 
and localisation in the model organism S. cerevisiae which contains in the region of 6000 
genes (Ghaemmaghami et al., 2003; Huh et al., 2003). The groups of O’shea and Weissman 
have utilised the availability of high-throughput technologies and the complete genome 
sequence of S. cerevisiae to systematically analyse a eukaryotic proteome. In this approach 
an alternative strategy for proteome characterisation was adopted. The groups created S. 
cerevisiae fusion libraries by tagging open reading frames (ORFs) with a high affinity epitope. 
These fusion proteins, which are expressed under the control of the organism’s natural 
promoter, allow both immunodetection and immunopurification of the resulting fusion proteins. 
Creating this library allowed the researchers to demonstrate that around 80% of the yeast 
proteome is expressed at normal growth conditions, and also enabled the identification of 
miss-annotated genes. This study also showed that protein abundance can range from less 
than 50 to more than 106 molecules per cell. A total of 4,156 proteins (75% of the yeast 
proteome) were classified in this study, and subsequently organised into 22 distinct subcellular 
localisations. This global analysis of protein expression and localisation in a eukaryotic 
organism provides the most complete and physiologically relevant view to date. There are,
however, concerns over the affect the epitope tag may have on protein turnover. When
present on the N-terminal end of a protein the fusion tag may affect stability. If tagging affects 
the process of protein degradation then localisation of the protein could be compromised.
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The dynamic range issue is of particular relevance when considering the proteome of 
blood, which is considered to be the most complex proteome in the human body (Anderson 
and Anderson, 2002). Virtually all cells in an organism come into contact with the blood, either 
directly or through tissue or biological fluids, as a consequence blood plasma contains not 
only characteristic plasma proteins but potentially every protein present in the body. Human 
serum or plasma, with a typical protein concentration of between 60 and 80 mg/ml is 
estimated to contain proteins spanning a concentration range of at least ten orders of 
magnitude (Anderson and Anderson, 2002). The six most abundant proteins (albumin, 
transferrin, haptoglobulin, a-1-antitrypsin, IgG, and IgA) account for approximately 95% of the 
proteome, with albumin alone representing 50% of the total protein content (Tirumalai et al., 
2003; Figure 1.3). The most clinically relevant proteins in plasma, i.e. biomarkers, are likely to 
occupy the low concentration range (present at ng/ml to pg/ml; Issaq et al., 2007). 
Considering the nominal dynamic range of a mass spectrometer is at best three to four orders 
of magnitude, it is apparent that most proteomic studies will result in the identification of only 
the highly abundant (most likely the least interesting) portion of the plasma proteome. To 
have any chance of obtaining a comprehensive analysis of plasma proteins it is necessary to 
develop strategies to overcome the issue of sample complexity and dynamic range associated 
with such a complex biological sample.
The Plasma Proteome Project (PPP) was initiated by the Human Proteome 
Organisation (HUPO) in 2002 and involved a collaboration of 55 participating laboratories 
worldwide. In the space of three years substantial datasets were created and utilised to 
construct an integrated database of proteins identified in human plasma. The Core Dataset 
consisted of 3020 proteins identified by two or more peptide matches (Omenn et al., 2005). 
This dataset has provided a strong foundation for future studies using human plasma and has 
developed understanding of both complexity and dynamic range.
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Figure 1.3. Protein concentration ranges in human plasma.
Serum and plasma are thought to contain a very complex set of protein signatures 
from most cell types in the body; however, these signature proteins are present at far 
lower concentrations than the classical plasma proteins.
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1.4 Mass spectrometry
Mass spectrometry (MS) is one of the most informative techniques, widely used today for 
protein characterisation. MS based proteomics has been made possible by the availability of 
gene and genome sequence databases coupled with technical advances in the discovery and 
development of protein ionisation methods.
1.4.1 Ionisation methods
Ionisation techniques are a key requirement to convert molecules to gas-phase ions so that 
they can then be separated by electric or magnetic fields. For proteomics, the two most widely 
used ionisation techniques at present are electrospray ionisation (ESI; Whitehouse et al., 
1985) and matrix-assisted laser desorption/ionisation (MALDI; Karas and Hillenkamp, 1988). 
ESI ionises the molecules in-solution and is therefore readily coupled to liquid based (e.g. 
chromatographic) separation tools. In contrast, MALDI sublimates and ionises the samples out 
of dry, crystalline matrix via laser pulses (Figure 1.4). Both methods of ionisation are 
fundamentally the same, as the analyte mixtures are transferred into the gas phase and 
ionised. MALDI-MS is most commonly used to analyse relatively simple peptide mixtures, 
whereas integrated liquid chromatography ESI-MS systems (LC-ESI-MS) are preferred for the 
analysis of complex samples. Both ESI and MALDI are known as “soft” ionisation techniques 
which relates to the nature in which the ions are created. In these techniques peptide ions are 
generated with low internal energy and as a result undergo little fragmentation. In order to 
obtain structural information from an ion it is necessary to apply more aggressive ionisation 
methods such as electron ionisation which is described as a “hard” ionisation technique.
1.4.2 Mass analysers
Once the ions have been produced, they must be separated according to their mass to charge 
ratios (m/z). The most common types of mass analyser are time of flight (ToF), quadrupole, 
ion trap, ion cyclotron resonance (ICR) and more recently, Orbitrap mass analysers (Figure 
1.5).
ToF analysers boost ions to the same kinetic energy by passage through an electric 
field and measure the times they take to reach the detector. While the nominal kinetic energy 
of all the ions is the same, the resultant velocity is different, thereby causing lighter ions (and 
also more highly charged ions) to reach the detector first (Figure 1.5a; Stephens, 1946).
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Figure 1.4. Ionisation techniques.
Matrix assisted laser desorption ionisation (MALDI; a) is used to generate gaseous 
phase analyte ions from the solid state. The analyte is spotted onto a stainless steel 
target and allowed to air dry. The analyte spot is then overlayed with matrix solution. The 
analyte and matrix co-crystallise to form a homogeneous layer, which is irradiated with a 
pulsed UV nitrogen laser. Energy adsorbed by the matrix is transferred to the analyte 
causing vaporisation of the analyte/matrix into a dense plume of molecules. A series of 
ion formation reactions occur, creating predominantly positively charged matrix and 
analyte ions. Electrospray ionisation (ESI; b) generates gaseous phase ions from the 
liquid phase. The sample solution is passed through a fine charged metallic capillary 
towards the entrance of the mass analyser. Because like charges repel, the liquid 
pushes itself out of the capillary and forms an aerosol. The aerosol is produced by the 
formation of a Taylor cone. As the solvent evaporates, the analyte molecules are forced 
closer together, repel each other and split into droplets. This process “Coulombic fission" 
repeats until the analyte is free of solvent and is a gaseous ion.
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Figure 1.5. Mass Analysers.
The ToF mass analyser (a) measures the m/z of ions by pulsing them from the ionisation 
source into the flight tube. The m/z values are calculated by the time it takes the ions to hit 
the detector. In a quadrupole mass analyser (b), the correct magnitude of the radio 
frequency and direct current voltages applied to the rods allows ions of a single m/z to 
maintain stable trajectories from the ion source to the detector, whereas ions with different 
m/z values are unable to maintain stable trajectories. Ions in a quadrupole ion trap (c) 
maintain stable trajectories inside the device as a result of the application of a RF voltage 
to the ring electrode. Mass analysis is achieved by making ion trajectories unstable in a 
mass-selective manner. In an Fourier-transform ion-cyclotron resonance (FT-ICR; d), ions 
oscillate around the magnetic field at frequencies that are related to their m/z scales. As 
the ions oscillate near the top and bottom metal plates of the cubic trapping cell, they 
induce an alternating current that can be measured and then related to their m/z. Note that 
whereas the FT-ICR cell is small, it is in a high magnetic field (typically a super-conducting 
magnet), so the actual instrument size is large.
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The quadrupole mass analyser is a "mass filter" consisting of four cylindrical rods 
arranged in parallel and a detector (Figure 1.5b). Combined direct current (DC) and radio 
frequency (RF) potentials on the quadrupole rods create an oscillating electric field which 
allows only ions with stable trajectories to pass through. By changing the applied electric field 
over time, it is possible to selectively transmit ions of a given m/z ratio to pass through and 
reach the detector (Horning et al, 1977).
In the ion trap technique ions are focused using an electrostatic lensing system into 
the ion trap (Figure 1.5c). An electrostatic ion gate pulses open (-V) and closed (+V) to inject 
ions into the ion trap. The pulsing of the ion gate differentiates ion traps from "beam" 
instruments such as quadrupoles where ions continually enter the mass analyser. The time 
during which ions are allowed into the trap, termed the "ionisation period", is set to maximise 
signal while minimising space-charge effects, which are caused by too many ions in the trap 
causing distortion of the electrical fields leading to an overall reduction in performance (Kaiser 
ef al, 1991; Jonscher etal., 1993).
ICR analysers (Baldeschwieler, 1968; Figure 1.5d) are based on the omegatron 
device (Hippie et al., 1950) in which resonance is detected when ions starting from a fixed 
point achieve sufficiently large orbital radii to reach a fixed collector. The ICR analyser traps 
ions inside a cell consisting of four electrodes in a strong magnetic field (penning trap). Inside 
the trap, ions are excited, causing them to oscillate with a frequency perpendicular to the 
magnetic field, forming a “packet”. The signal is detected as an image current on a pair of 
plates which the packet of ions passes close to as they cyclotron. Fourier Transform ICR 
(FTICR; Marshall et al., 1998) MS is a high resolution technique in which masses are 
determined with very high accuracy.
Orbitrap mass analysers are the most recently introduced mass analysers 
(commercially available since 2005). Ions are electrostatically trapped in an orbit around a 
central, spindle-shaped electrode. The ion movement resembles a ring that oscillates along 
the axis of the spindle. This oscillation generates an image current in detector plates which is 
recorded. The frequencies of these image currents depend on the m/z ratios of the ions in the 
trap. Orbitraps share similar characteristics to FT-ICR instruments, in terms of resolution and 
mass accuracy but without the requirement of an expensive superconducting magnet 
(Scigelova and Makarov, 2006).
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1.4.3 Peptide mass fingerprinting
One of the major applications of MALDI-ToF MS is peptide mass fingerprinting (PMF). This 
technique is used to identify single proteins by connecting a series of peptide masses to a 
known protein sequence within a database (Henzel et a/., 2003).The peptide mass is defined 
by the number and type of amino acids it is composed of, including any modifications the 
amino acids may have undergone. Information is obtained from a unique collection of 
peptides that occur when the molecule is digested with a proteolytic enzyme such as trypsin or 
Lys-C. Provided the digestion is complete the peptides produced will be of varying masses 
that are characteristic of that protein. The set of intact masses of the peptides produced by 
enzymatic digestion constitutes a unique set of masses or “fingerprint" for a specific protein. 
The experimental mass profile is matched against the theoretical masses obtained from the in 
silico digestion at the same enzyme cleavage sites of all protein amino acid sequences in the 
database. The matched proteins are then ranked according to the number of corresponding 
peptide masses within a given mass error tolerance. Proteins can be identified in this way with 
relatively high throughput (Pappin, 2003) and a high sensitivity, even below the femtomole 
range (Schuerenberg et a/., 2000).
1.4.4 Tandem MS
In order to generate data related to the amino acid sequence of a protein or peptide a variety 
of instruments have been developed to isolate ions, fragment them and determine the m/z of 
the fragments. These devices are collectively known as tandem mass spectrometers. These 
instruments differ in terms of overall design of mass resolution, mass accuracy, robustness 
and ease of operation.
Tandem MS (MS/MS) can be used to generate short amino acid sequences via 
fragmentation along the peptide backbone, by a technique known as collision induced 
dissociation (CID). The series of fragments produced differ in mass by a single amino acid and 
the differences can used to ascertain the amino acid sequence (Perkins et a/., 1999). The 
identification of peptides by MS/MS has substituted almost completely the more time 
consuming and relatively insensitive method of Edman degradation. Un-interrupted peptide 
CID fragmentation spectra are used to identify peptides and proteins with the help of programs 
like MASCOT (Perkins et at., 1999) or SEQUEST (Sadygov et al, 2004), which use mass 
fragmentation data to explore either protein databases (for example, SwissProt and NCBI) or
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nucleotide data, such as the incomplete nucleotide sequences contained in EST databases 
(Choudhary et al., 2001).
1.4.5 Improved MS capabilities for second generation proteomics
Together, PMF and MS/MS searches constitute the methodology used in most proteomics 
laboratories over the past decade. Many proteins have been identified in this way, for example 
characterisation of the Haemophilus influenzae proteome (Langen et a/., 2000) and isolation 
and characterisation of subnuclear compartments from Trypanosoma brucei (Rout and Field,
2001).
Proteomics studies are now moving away from “classical proteomic approaches" 
described above and shifting towards more sophisticated strategies in which high numbers of 
proteins are identified in a single experiment. High throughput protein identification, 
quantitative differences in protein expression and the global study of PTMs are among the 
applications desired by researchers. New methodologies are under development, which 
attempt to maximise the output from current instrumentation capabilities.
Traditionally the acquisition of MS/MS spectra is done in a data-dependent way 
through a process termed data-dependent acquisition (DDA; Belov et a!., 2001). A preliminary 
scan is carried out in MS mode and this scan is used to determine the ions chosen for 
fragmentation. Once an ion is selected (above a specified threshold) the instrument switches 
from full scan mode to MS/MS mode. The time required for the instrument to perform a full 
scan followed by one MS/MS scan is determined by the instruments duty cycle. In a typical 
DDA experiment, the most intense ions present at a given time are selected by the instrument 
for MS/MS. For complex samples this typically results in many lower abundance ions being 
ignored by the instrument, as a consequence these ions will remain uncharacterised and will 
not be represented in the dataset.
One of the most desired improvements in MS technology is shorter duty cycles, 
allowing more frequent sampling of ions. The acquisition of more MS/MS spectra per unit time 
would, in turn, improve dynamic range as lower abundant ions would be more likely to be 
sequenced. This improvement in scan speed coupled with other improvements in mass 
accuracy, sensitivity and pre-analysis separation methods will move researchers closer to 
achieving the goal of global protein characterisation. Currently, several different types of mass 
analysers (QToF, FTICR and Orbitrap) are competing with each other for high mass accuracy,
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high throughput applications. This diversity means that the field of MS, although a century old, 
is still in the fast evolving phase.
1.5 Protein simplification
A complex protein mixture can be simplified through a series of separation or purification steps 
that exploit physicochemical properties between individual components within a mixture.
1.5.1 SDS-PAGE
Electrophoresis is a simplification technique that is routinely used to monitor the complexity of 
a protein mixture by separation on polyacrylamide gels. Sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) is a technique used to separate proteins 
according to their electrophoretic mobility (Shapiro et al., 1967). Prior to separation the protein 
molecules are denatured and coated with SDS so that they carry a large negative charge. 
During electrophoresis an electric field is applied through the gel causing the denatured 
proteins to migrate down the gel towards the positive electrode. The gel acts as a molecular 
sieve, separating the proteins on the basis of their molecular weight. Low molecular weight 
proteins migrate through the gel more freely than high molecular weight species and reach the 
bottom more rapidly. Separation of proteins on a polyacrylamide gel by mass alone is a one 
dimensional (1-D) separation. Two dimensional (2-D) electrophoresis begins with a 1-D step 
then targets a second characteristic of protein molecules for an additional phase of separation. 
In a typical 2-D electrophoresis experiment proteins are first resolved by their isoelectric point. 
To achieve this, proteins are first separated according to their charge (pi) by the process of 
isoelectric focusing (IEF; Laemmli, 1970). IEF pH gradients can be generated by adding 
ampholytes to an acrylamide gel. These are a mixture of amphoteric species with a range of pi 
values (O'Farrell, 1975). At pH values other than their isoelectric point, proteins will carry a 
charge. On application of an electric potential across the gel, the proteins migrate towards a 
point on the gel and accumulate at a position that corresponds to their isoelectric point. Once 
a protein reaches its isoelectric point its net charge will be 0 (i.e. neutral). There are issues 
regarding reproducibility between 2-D gels generated with carrier ampholyte IEF because of 
pH gradient instability. The problems of pH gradient instability and reproducibility were 
overcome by the introduction of immobilised pH gradients (IPG) for IEF (Bjellqvist et al., 
1982).
21
Chapter 1: Introduction to Proteome Simplification
In the second dimension the proteins are separated by mass, as in 1-D SDS-PAGE. 
In this instance the electric field is applied at a 90° to the first field, which results in a gel with 
proteins spread out over the surface. The proteins can then be visualised using a variety of 
protein specific staining techniques including Coomassie blue and silver staining. Once 
visualised the individual protein spots can be excised for identification through various MS 
based approaches. 2-D gel profiles are particularly useful for comparative proteomic studies, 
in which proteins from control and experimental biological samples can be compared either by 
manual inspection or through a variety of computer based algorithms (Young et at., 2004).
Although 2-D SDS-PAGE has been used for many years as a standard approach to 
protein separation, the drawbacks associated with this technique make it less suitable for 
high-throughput analysis of complete proteomes (Pieper, 2003; Hu et at., 2007). Portions of 
proteomes including proteins with extremes in pi and molecular weight, low abundance 
proteins and membrane associated and bound proteins are rarely seen in a 2-D SDS-PAGE 
study. These factors lead to the visual under representation of the complexity of the protein 
sample on the gel. Another contributing factor to the lack of visual representation is poor 
dynamic range which severely restricts the ability to detect low-copy number and low 
abundance proteins. Also, the technique remains relatively low throughput due to the 
requirement for individual extraction, digestion and analysis of each spot from the gel 
(Washburn etal., 2001).
1.5.2 High-performance liquid chromatography
High-performance liquid chromatography (HPLC; Regnier and Gooding, 1980) is a non-gel 
method of protein or peptide separation. The availability of different HPLC resins with different 
selectivity’s offer alternative strategies for protein purification. The basic principle in HPLC is to 
flow the protein solution through a column packed with a specific matrix or resin. The material 
of choice will exploit a particular characteristic of the protein molecules causing individual 
proteins to react differently with the column. Proteins are separated by the time taken to flow 
through the column, or the conditions required to elute the protein from the column. Proteins 
are typically detected as they elute, by their absorbance at 280 and 214nm. There is a wide 
range of different chromatography methods routinely used in proteomics.
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Reversed-phase
The most widely used mode of HPLC for separation of peptides or proteins is reversed phase 
liquid chromatography (RP-LC). The analyte interacts with the RP media based on the 
differences in magnitude of the hydrophobic interactions. The non-polar stationary phase is 
generally made up of hydrophobic alkyl chains (-CH2-CH2-CH2-CH3) that interact with the 
analyte. There are three common chain lengths, C4, C8, and C18. C4 is generally used for 
proteins and C18 and C8 are generally used to capture peptides or small molecules. With 
these stationary phases, retention time is longer for molecules which are more non-polar, 
while polar molecules elute more readily. Once bound, the analytes can be separated by 
running a linear gradient of an organic solvent such as acetonitrile (ACN) or methanol 
(MeOH).
Size exculsion
Size exclusion chromatography shares similarities with electrophoresis in that proteins are 
separated according to their size (Lathe and Ruthven, 1956; Porath and Flodin, 1959). The 
protein solution is passed through a column of porous beads. The large proteins in the mixture 
are not able to enter the beads and as a consequence pass straight through the column and 
elute first. The proteins that are small enough to access the beads will therefore take longer to 
elute from the column (Figure 1.6). The porosity of the beads can be adjusted to exclude all 
molecules above a given size. Sepharose and Sephadex are trade names of gel that are 
commonly available commercially in a broad range of porosities. A disadvantage of this 
method is its limited resolving power; however, it can be useful if the protein of interest is of 
extreme size relative to the other
Ion exchange
Individual proteins differ from one another in the proportions of the charged amino 
acids they contain. Lysine, arginine and histidine residues all carry positive charges, whereas 
glutamate and aspartate are negatively charged residues. The proportion of these charged 
amino acids will determine the net charge on a protein molecule. Protein separation by ion 
exchange chromatography relies on the interaction of charged molecules in the mobile phase 
(protein solution) with oppositely charged groups on the stationary phase (ion exchange 
matrix). The charges on these amino acids will vary depending on the pH of the solution they 
are dissolved in (Righetti and Caravaggio, 1976). Optimisation of the buffer conditions is 
therefore required in order to purify a specific protein for which the isoelectric point is known. 
Prior to chromatographic separation, a buffer is pumped through the column to equilibrate the
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Figure 1.6. Size exclusion chromatography.
The column is filled with semi-solid beads of a polymeric gel that allow the 
admission of small molecules into their interior. When a mixture of proteins is 
introduced to the column, the small molecules are distributed through a larger 
volume of solvent than is available to the larger molecules. Consequently, the larger 
molecules move more rapidly through the column allowing fractionation of the 
mixture.
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differentially charged ions on the ion exchange matrix. The protein mixture is introduced to the 
column in a solution of low salt. Under these conditions, charges on proteins bind to the 
charged matrix. To elute and separate the proteins, a gradient of increasing salt concentration 
is applied causing sequential dissociation of proteins from the column (Figure 1.7). The 
duration of binding or retention for each protein molecule will depend on the strength of 
interaction it shares with the matrix. Proteins carrying a high charge will interact strongly with 
the column causing them to remain associated for longer. Weakly charged molecules will elute 
from the column early on in the gradient followed by a succession of molecules of increasing 
charge.
There are two main types of resin used in ion exchange chromatography; cation 
exchange and anion exchange resins. Cation exchange resins have negatively charged 
groups on the surface and these are used to bind positively charged proteins. Anion exchange 
resins contain positively charged groups and these interact with negatively charged proteins. 
The type of resin used will depend on the pi of the protein or subset of proteins to be purified.
Affinity
The ability of specific protein molecules to interact with other structures forms the basis of 
affinity chromatography (Ostrove, 1990). This separation strategy uses specific ligands, 
attached to the chromatography resin, to target protein molecules for purification. The ligand is 
immobilised onto the chromatography resin in such a way that it retains its biological activity. 
Affinity columns can be used to select a specific protein, or class of proteins, from a complex 
protein mixture. Ligands typically function in a way similar to that of antibody-antigen 
interactions. This “lock and key” fit between the ligand and its target compound makes it highly 
specific, resulting in a single chromatographic peak, while the other components in the sample 
pass through the column, without interaction with the resin (Figure 1.8). An advantage of 
affinity chromatography over other techniques is its ability to purify target molecules present at 
low concentrations within a mixture. Two of the more widely used forms of affinity 
chromatography are Lectin and immunoaffinity based systems.
The main types of liquid chromatography methods are summarised in Table 1.1.
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Figure 1.7. Ion exchange chromatography.
The column consists of beads displaying ionic functional groups. This type of 
chromatography is further subdivided into cation exchange and anion exchange 
(shown here) chromatography. When a mixture of proteins is applied to the column, 
molecules that possess a net charge opposite to that of the beads will bind, allowing 
their separation from proteins which have the same net charge as the beads, which 
will pass through. The bound proteins are eluted from the column in order of their 
binding affinity, by the application of a salt gradient.
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protein
Figure 1.8. Affinity chromatography.
The column consists of an immunadsorbant matrix to which the ligand (green) has been 
coupled. The sample is passed over the matrix and the molecules that are specific to the 
ligand will bind with high affinity. Non-specific molecules will pass through the column 
unimpeded. The bound proteins can be eluted from the column using a variety of different 
reagents depending on the nature of the column (for example, salt gradient or urea).
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Name Abbreviation Separation
principle
Reversed-phase liquid chromatography RPLC Hydrophobicity
Size-exclusion chromatography SEC Size
Ion-exchange chromatography (strong cation exchange, 
strong anion exchange)
I EX (SCX, 
SAX)
Charge
Affinity chromatography AC Specific binding
Table 1.1. Basic types of liquid chromatography used in protein and peptide separation.
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1.5.3 Depletion based simplification strategies
When complex biological samples contain large differences in protein abundance, separation 
by chromatography or 2-D SDS-PAGE will not be sufficient to characterise the low abundance 
proteins in the sample. To achieve a global proteomics analysis of a complex sample, it is 
therefore necessary to apply a combination of separation techniques to gain a comprehensive 
profile. The standard separation methods listed above cannot address problems of sample 
complexity and dynamic range without the incorporation of a more targeted approach. In 
samples that exhibit a wide dynamic range, an obvious strategy would be to remove or 
deplete the high abundance proteins and enrich the low abundance components prior to 
analysis. In the case of human plasma, in which half the total protein mass is accounted for by 
albumin, it would be beneficial to remove albumin from the sample, along with other abundant 
proteins such as immunoglobulin and transferrin. Current serum and plasma proteomic 
analysis strategies typically aim to overcome the dynamic range problem by employing a 
variety of protein-depletion methods. Once depletion has taken place the remaining proteins 
can be enriched and subjected to further proteomic analysis such as 2-D SDS-PAGE or gel- 
free chromatography based methods.
Non-specific methods
The simplest of these depletion techniques is non-specific depletion, in which chemicals are 
used to remove a major component. Many chemicals have been utilised for the removal of 
albumin from plasma. The dye Cibacron Blue has good binding affinity for albumin and is 
available at low cost (Hinerfeld et al., 2004). A disadvantage of this method is the non-specific 
nature of the reagents leading to co-depletion of other components of the mixture, which could 
potentially include molecules of analytical importance.
Specific methods
Immunoaffinity depletion of albumin from plasma is far more efficient and specific than the 
chemical dye based methods. The use of affinity purified polyclonal antibodies to specifically 
remove albumin, Immunoglobulin, transferrin or fibrinogen was successful for the enrichment 
of low abundance proteins from human plasma samples (Tam et al., 2004). There are 
currently at least seven commercially available affinity removal columns or kits for depletion of 
the six major proteins of human plasma. Although these kits effectively remove the high 
abundant components, the remaining proteins are still sufficiently abundant to prevent 
adequate detection of the low abundance proteins. Additionally, even though these methods
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are greatly superior to the traditional chemical depletion methods, there still remains concern 
over co-depletion of low-abundance proteins. Albumin associates with a variety of other 
proteins that will be removed in the bound fraction and as a consequence will not be analysed. 
A combination of stepwise immunoglobulin G and albumin depletion followed by 2-D LC- 
MS/MS resulted in the identification of over 2000 proteins from a single plasma sample (Shen 
et al., 2005). However, depletion of serum albumin also led to the co-depletion of a further 815 
proteins. Depletion of IgG led to the co-depletion of a further 209 species. In a separate study, 
a commercially available albumin depletion kit was used to determine if removal of albumin 
would measurably reduce detection of lower abundance cytokine proteins in human plasma 
(Granger, 2005). The results from this study demonstrated that there may be a non-specific 
loss of cytokines following albumin depletion, which may also affect subsequent proteomic 
analysis.
1.5.4 Membrane removal
An alternative strategy to immunological depletion of abundant proteins in plasma is the 
membrane removal method. This strategy utilises membrane filtration to separate high- 
molecular weight proteins from low-molecular weight proteins in a sample. A recent strategy 
by Tanaka et al (Tanaka et al., 2006) teamed this membrane removal method with a 3-D LC 
separation prior to MS/MS, resulting in the characterisation of around 1800 proteins. The initial 
separation stage used a device based on a hollow-fibre-membrane (HFM) system for the 
removal of high-molecular weight proteins. Many low-abundance proteins in plasma, including 
biomarkers, are smaller than albumin. Removal of the high-molecular weight fraction should 
therefore result in improved detection of low-abundance components. The HFM based device 
consists of a separation unit and a concentration unit, allowing for simultaneous separation 
and concentration of the low-molecular weight fraction. The device uses a multi-stage filtration 
process to ensure all high-molecular weight components are completely removed from the 
system. The resulting solution of low-molecular weight proteins was then subjected to a 3-D 
LC based separation which involved initial separation of the protein mixture using RP-LC 
followed by proteolysis then 2-D LC of the peptide mixture prior to MS/MS analysis.
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1.5.5 Immobilised ligand libraries
A novel strategy for the normalisation of protein concentrations has recently been described 
by Righetti et al (Righetti and Boschetti, 2007; Righetti et al, 2006; Sennels et al., 2007). The 
approach involves the use of Protein Equalizer™ Technology to reduce protein concentration 
differences in complex protein samples. The methodology exploits the same physicochemical 
properties of proteins as those targeted in affinity chromatography. A complex library of 
ligands (immobilised onto the surface of beads) is used to effectively normalise the relative 
concentrations of proteins in a complex mixture. With sufficient diversity of ligands it should, in 
theory, be possible to capture every protein in the proteome. When mixed with the ligand 
library beads each unique ligand has the potential bind to a unique protein structure. Because 
bead capacity limits binding, high abundance proteins will rapidly saturate their available 
binding sites and most of the protein will remain unbound. In contrast, low abundance proteins 
will become concentrated on their specific ligands (Figure 1.9). It is this normalisation effect 
that serves to reduce the dynamic range of the sample and provides access to proteins that 
would be otherwise hidden. The bound proteins are retained at different strengths, allowing a 
stepwise elution process providing further simplification by sub-fractionation.
The ligands used are in the form of synthetically produced hexapeptides which are 
synthesised via a short spacer on poly(hydroxymethacrylate) beads. A batch containing 
millions of microscopic porous chromatographic beads are distributed into twenty separate 
vessels, corresponding to the number of building blocks (amino acids) used to create the 
library. Each bead vessel is assigned a different building block, which is chemically attached 
to the beads. The vessels are then mixed together, washed and split again into twenty 
individual batches and the building blocks attached. The whole process is then repeated until 
the desired sequence length is reached. In theory each bead, which contains millions of 
copies of the same ligand, will be different and the complete library will provide a ligand 
complementary to every protein present in a complex mixture.
This approach, in comparison to time consuming affinity depletion strategies has 
several advantages: Firstly, depletion techniques do not significantly enrich the trace 
components in the mixture, which often results in them being undetected and uncharacterised. 
Protein Equalizer™ technology normalises the concentration differences, which in turn serves 
to enrich trace components in relation to the high abundance species. Also, since ligand 
library beads do not deplete high abundance proteins, the problem of co-depletion is not an 
issue with this strategy. The use of this approach coupled to additional fractionation methods
31
Application o f a com plex  
protein sam ple
V
* > V r > V
w ash Elution o f bound
proteins
Figure 1.9. The mechanism of action of Protein Equalizer™ beads.
A complex protein sample is mixed with the ligand library causing the proteins in the 
sample to bind to their specific ligands. Abundant proteins quickly saturate their 
corresponding ligands and are removed from the mixture by subsequent wash steps. 
In contrast, low-abundance proteins are concentrated onto their binging partners. 
Following elution the resulting protein mixture exhibits reduced dynamic range of 
protein concentration.
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resulted in an increased number of protein identifications and removes the problem of co­
depletion associated with immunological based depletion techniques. However, due to the 
nature of the normalisation process, ligand library beads are not suitable for quantitative 
proteomic studies.
1.6 Peptide separation methods
Top-down proteomic approaches analyse intact protein molecules to identify both the protein 
and any potential structural modification. Due to the difficulty associated with processing intact 
mass data, these measurements are generally less effective for protein identification than 
peptide level analyses. The first step in top-down proteomics is fractionation at the protein 
level in order to reduce complexity and dynamic range (Righetti et al., 2001). The main 
advantage of the top-down approach is that information regarding the intact protein structure 
is retained, which increases the likelihood of identifying protein isoform, polymorphism and 
PTMs.
The majority of in-solution based proteome studies are performed at the peptide level 
by bottom-up approaches (Link et al., 1999; Washburn et al., 2001). The disadvantage of 
bottom-up methods is the increased complexity that comes with digestion of proteins into 
peptides. It is feasible that a proteome consisting of 10,000 proteins will generate 
approximately 3.0x105 peptides, given that an average protein is digested into approximately 
30 tryptic peptides. Additionally, proteolysis of a protein mixture leads to loss of connectivity 
between resulting peptides. Therefore, it appears satirical to introduce another level of 
complexity to the protein mixture by proteolysis. The rationale behind this strategy is the 
improved ability to analyse peptides over intact proteins. Peptides are characteristically more 
soluble than proteins; therefore, proteolysis will result in a wider range of available analytes.
Complexity demands simplification and in most “bottom-up” proteomics studies there 
is a point at which a transition must be made from ‘protein space’ into ‘peptide space’. The 
transition is mediated by proteolysis, however, there is no set rule regarding when this step 
must occur (Figure 1.10). A key component in any proteomics analysis is the separation of 
peptides and proteins. Some proteomics studies aim to simplify a complex proteome, to the 
level of subproteomes (for example, a subcellular fraction) or individual proteins (such as 
proteins separated by 2-D gel electrophoresis) before proteolysis (Figure 1.10a). Other more 
global approaches begin with proteolysis of a complex sample, followed by peptide 
fractionation steps, for example HPLC, to achieve simplification (Figure 1.10b). In both cases,
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Figure 1.10. Outline of a standard approach to protein identification.
A complex proteome may be simplified using a variety of separation techniques in protein 
space (a). The resulting subproteomes can either be proteolysed directly or subjected to 
further separation into individual proteins. After proteolysis, the resulting peptides are 
analysed by mass spectrometry, with or without chromatographic separation, depending on 
the complexity of the peptide mixture. Proteolysis of a complete proteome creates a peptide 
mixture so complex that mass-spectrometric analysis is highly challenging. Simplification in 
peptide space (b) can be achieved be targeting specific structural regions on peptides, the 
mixture can be selectively purified in such a way that the majority of the proteome is 
discarded. The resulting simplified peptide mixture may be analysed by mass spectrometry, 
with or without chromatographic separation.
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separation provides a way of reducing complexity and can also function as a method of 
delivering molecules to the mass spectrometer.
The term “shotgun proteomics” describes a bottom-up method in which HPLC is 
coupled to MS. A critical factor in the shotgun approach is the resolution of separation 
generated by the LC analysis. Straight forward LC-MS/MS analysis by shotgun proteomic 
approaches will only be capable of identifying a small portion of high abundance proteins in 
the sample. To dig deeper into the proteome it is necessary to apply more sophisticated 
simplification strategies. The application of multiple chromatographic stages prior to MS 
provides a way to address the issues of dynamic expression range and sample complexity. 
The combination of multidimensional separation methods with MS was first reported in 1997 
(Opiteck et ai, 1997). A multidimensional separation includes two or more independent 
separation techniques (i.e. RP, IEX, SE and affinity chromatography), coupled for the analysis 
of an individual sample. The techniques used are complementary and achieve enhanced 
separation by exploiting different characteristics of peptides. To date, the most common 
multidimensional technique consists of two dimensions of chromatography (IEX and RP) 
allowing for enhanced resolution and peak capacity with the added advantage of solvent 
compatibility. By applying an additional dimension of peptide separation the quantity of 
peptides delivered to the mass spectrometer in a given time frame is reduced. The outcome or 
this is reduced ion suppression leading to an increased amount of peptides ionised at one 
time.
Later attempts at peptide separation by multidimensional chromatography led to the 
development of a more refined technique termed Multidimensional Protein Identification 
Technology or MudPIT, which can be described as a fully automated, online, coupled 2-D 
column MS/MS approach for the analysis of complex peptide mixtures (Link et at., 1999; 
Washburn et al., 2001). The peptide digest is loaded onto a column containing two or more 
chromatography resins in series. Peptides are eluted from each component of the column in a 
stepwise manner using salt solution plugs of increasing concentration. The first resin the 
peptides come into contact with is a SCX resin. Peptides bind the resin and are washed off 
sequentially using a salt step gradient. Eluted peptides then come into contact with the next 
component of the column which is typically RP resin. A second buffer with an increasing 
gradient of ACN is then used to wash peptides from the RP resin into the mass spectrometer 
(Figure 1.11).
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Figure 1.11. Multidimensional peptide chromatography.
Multi-dimensional peptide chromatography permits the analysis of thousands of 
proteins from a single sample. A highly complex peptide mixture is separated in the 
first dimension by SCX chromatography (a). The collected fractions are then analysed 
individually by RP LC-MS/MS (b ).
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The MudPIT method of peptide separation has several benefits. Because an SDS- 
PAGE step is avoided, liquid phase protein samples can be easily proteolysed, loaded onto 
the 2-D chromatography column, and directly injected into the mass spectrometer. 
Additionally, when packing two types of media into a single column both types of media are 
exposed to all of the buffers used for equilibration, elution and washing steps. The advantage 
of using SCX coupled to RP media is that the two buffer systems are complementary. The salt 
solution plugs used to elute peptides from the SCX media are fully compatible with RP media. 
Furthermore, the addition of salt to the aqueous environment effectively increases the 
peptides binding affinity to the RP column by increasing the hydrophobicity of the solution 
(Mant and Hodges, 2002). Once the peptides have bound the RP media all salt containing 
buffers are sent to waste in the wash stage which ensures that no salt is allowed to enter the 
ion source of the mass spectrometer. Subsequent removal of peptides from the RP column by 
ACN mediates direct infusion of eluted peptides into mass spectrometer.
When applied to the analysis of the S. cerevisiae proteome, MudPIT resulted in the 
identification of 1,484 proteins, which included 131 proteins containing three or more predicted 
transmembrane domains (Washburn et a!., 2001). MudPIT has also been applied to the 
analysis of human plasma, where it was shown to increase identification of lower abundant 
proteins (Raida etal., 1999).
Although multidimensional chromatographic methods are far superior to 
straightforward 1-D LC-MS/MS techniques, the number of peptides produced from a complex 
mixture of proteins generates extensive mass spectral data to be interpreted. Even with the 
benefit of 2-D chromatography, the mixture may deliver more peptides to the mass 
spectrometer than can be analysed in real time. Additionally, DDA is likely to direct MS/MS 
analysis to more abundant proteins, limiting dynamic range.
1.7 Proteolytic background
Shotgun proteomic approaches such as MudPIT are based on the assumption that each 
protein is present in a sample reproducibly and predictably generates a relatively small 
number of peptides. The peptides generated by an in-solution digest are restricted by the 
enzyme used and its cleavage specificity. The most commonly used enzyme for shotgun 
approaches is trypsin, which generates, on average 10 peptides for a stretch of 100 amino 
acids (based on the frequency of lysine and arginine residues). In shotgun based approaches, 
protein identification is typically achieved by searching multiple MS/MS files against protein
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databases. When trypsin is chosen as a search parameter the peptides matched are restricted 
to full tryptic peptides. It is feasible that the products of a tryptic digest may contain many other 
components other than standard tryptic cleavages that are never seen, including partial trypic 
peptides and miscleavages. The implications for this hypothesis is a level of complexity that 
far exceeds current expectations for standard shotgun type approaches.
A recent study by Aebersold’s group used a targeted peptide sequencing approach to 
investigate the true products of a tryptic digestion (Picotti et at., 2007). The group used a set of 
well characterised proteins including (3-lactoglobulin, carbonic anhydrase and P-casein which 
were individually proteolysed to perform an in-depth analysis. The targeted approach involved 
extensive characterisation of digestion products by MS/MS. Standard shotgun approaches 
employ a DDA strategy which targets the three most intense signals for fragmentation. This 
results in a large amount of unfragmented digestion products that are missed by the 
instrument. The group used an alternative sequencing approach to DDA which involved the 
construction of extensive inclusion lists which were subsequently used to trigger CID of the 
precursor ions. Samples were initially analysed using a high mass accuracy instrument in full 
scan mode. The data from this initial MS experiment was then extensively processed off-line 
in order to construct a comprehensive list of the species within the sample. The sample was 
then subjected to MS/MS using the inclusion list to direct fragmentation of all the ions detected 
in the sample. Each MS/MS sequence was subjected to manual assignment and only high 
quality matches were accepted.
An in silico digest of p-lactoglobulin produces 12 fully tryptic peptides containing more 
than five amino acids. In this study, using a conventional DDA sequencing approach 32 
peptides were identified from the tryptic digest of (3-lactoglobulin. In contrast, the targeted 
sequencing approach developed in this study resulted in the identification of 117 distinct 
peptides. Among these peptides were missed cleavages, amino acid substitutions and tryptic 
autolysis products, however, 89 (3-lactoglobulin peptides were identified containing a non- 
tryptic terminus at the C-terminal residue.
The non-tryptic products generated in this experiment, although present in high 
numbers, were much less abundant than the fully tryptic peptides identified. For a complex 
biological sample, an extremely high number of low abundant peptides are expected to create 
a dense proteolytic background in the mass spectral data. For biological samples exhibiting 
large dynamic range, the proteolytic background from the high abundance proteins will serve 
to hide the signals of fully tryptic peptides from low abundance components in the sample.
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This study revealed that the number of peptides observed from one protein is at least one 
order of magnitude higher than previously assumed. This unexpected complexity of tryptic 
digests has deep implications for the success of shotgun type proteomic approaches. Despite 
substantial efforts, the mapping of complex proteomes by shotgun methods is proving to be 
highly challenging. Findings from this study into proteolytic background may explain why 
shotgun approaches fail to provide in-depth coverage of complex proteomes such as plasma. 
This study highlights the requirement for alternative strategies to DDA and prompts the need 
for sample simplification techniques to simplify complex peptide mixtures.
1.8 Targeted analysis of peptides
It may be argued that when analysing a complete protein digest, for instance by standard 
shotgun methods, more peptides are analysed than strictly necessary. An efficient proteomic 
strategy simplifies the proteome while preserving most of the information necessary for 
comprehensive analysis. A variety of methods exist that exploit particular features of peptides 
in order to separate them from the total peptide pool. The isolation and analysis of a small but 
representative group of peptides has been shown to reduce sample complexity by 80% or 
more in a single separation step (Mirzaei and Regnier, 2005). Features such as the presence 
of specific amino acids (cysteine and histidine), PTMs and in vitro modifications have been 
targeted, along with the characteristics of peptides originating from protein termini. The 
identification procedure is greatly enhanced by knowledge derived from structure-based 
selection.
1.8.1 Targeting of specific amino acids
Low abundance amino acids such as cysteine and histidine are prime candidates for targeted 
peptide simplification. In silico analysis indicates that these amino acids occur in around 10- 
20% of tryptic peptides (Mirzaei and Regnier, 2005). The use of sequence-specific chemistry 
to capture peptides containing distinct amino acids provides a strategy to isolate a small but 
informative subset of peptides from, in most cases, each protein in a complex mixture.
Isolation of histidine containing peptides has been demonstrated using copper loaded 
immobilised metal affinity chromatography (Cu(ll)IMAC; Raggiaschi et al., 2005). In this study 
an entire tryptic digest was applied to the column and resulted in the purification of less than 
5% of the total peptide mixture.
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Cysteine containing peptides are typically selected by derivatisation of cysteine 
residues with a biotin reagent. Proteins are first reduced and alkylated with a biotinylated 
alkylating reagent followed by proteolysis. Peptides are then purified by a cation exchange 
chromatography step, which is necessary to remove excess reagents, the peptide mixture is 
then affinity purified using immobilised avidin to select cysteine containing peptides. Once 
desorbed from the column the purified peptides are characterised by LC-MS/MS based 
approaches.
Cysteine selection has also been used to study protein expression. A protocol for the 
specific enrichment and quantification of cysteine containing peptides developed by Aebersold 
and co-workers was first published in 1999 (Gygi et ai, 1999). The method is based on a 
group of novel chemical reagents termed isotope-coded affinity tags (ICATs) and MS/MS. The 
reagents consist of three components: a biotin tag, a linker containing either heavy or light 
stable isotope signatures and a thiol reactive group (Figure 12a). In the original ICAT reagent 
the heavy form contained eight deuteriums and the light form contained no deuteriums in the 
linker, this resulted in an 8 Da mass difference that could be differentiated by mass 
spectrometry. The next generation ICAT reagent, termed cleavable ICAT (cICAT), utilises 
carbon-13 instead of deuterium to create a heavy reagent. In this version of the ICAT reagent 
(Shiio and Aebersold, 2006), the mass difference between heavy and light isoforms is 9 Da 
which is due to the isotopically labeled linker that substitutes nine 13C atoms. cICAT also 
employs an acid-cleavable biotin group which facilitates removal of the bound peptides from 
the immobilised avidin.
In order to quantify cysteine containing peptides control and experimental samples 
are treated with the two isotopically distinct reagents and mixed prior to the proteolysis and ion 
exchange steps that precede avidin selection. If cleavable ICAT reagents are used, the biotin 
tag is released by acid cleavage after affinity chromatography. The isolated peptides are then 
separated and analysed by LC-MS/MS based methods. Each pair of light and heavy ICAT- 
labelled peptides are identical in terms of chemical composition and elution properties, but 
have a mass difference of 8 Da for original ICAT and 9 Da for cleavable ICAT (due to the 
incorporation carbon-13). Peaks corresponding to the same peptide are identified as doublets 
in the mass spectra due to the mass difference between the heavy and light reaction products. 
Changes in expression are quantified by analysing the LC MS data, the peak intensities 
correlate directly with the relative abundance of the proteins from the two samples (Figure 
12b).
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Figure 1.12. The ICAT strategy for isolation and quantification of cysteine 
containing peptides.
The ICAT reagent (a) consists of a thiol-reactive group which covalently binds to 
cysteine residues on proteins, a linker that can incorporate stable isotope signatures 
and a biotin tag used to purify the ICAT-labelled peptides by avidin affinity 
chromatography. There are two different tags, which are structurally identical except 
one has a linker containing eight hydrogen atoms, the other a linker with eight 
deuterium atoms. The two different samples are treated with different affinity tags (b). 
The samples are mixed and proteolysed to generated ICAT labeled peptides. The 
cysteine containing peptides are purified by avidin affinity chromatography, then 
characterised and quantified using MS based applications.
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Present constraints to the ICAT technique centre on the issue of insufficient proteome 
coverage, which remains a concern for all MS based proteomics methods. A number of 
limitations have also been reported in the literature, including missed identification of proteins 
with few or no cysteine residues and lost information for PTMs. A small number of proteins 
naturally carry covalently bound biotin, in this case these proteins would also be selected by 
this process. The original ICAT reagent showed differential reversed-phase elution of identical 
peptides labelled with the hydrogen/deuterium isotope pairs, however, this issue was resolved 
when cICAT was developed (Wu et at., 2006). Self alkylation of ICAT compounds can also 
occur which leads to instability of the ICAT reagents (Zhang et al, 2005). In addition, 
fragmentation of the large affinity tag can further complicate mass spectra. Despite these 
issues ICAT technology has been applied to the analysis of whole-cell protein expression 
changes, and has provided unique insights into many biological systems.
Recently a new quantitative method, isobaric tags for relative and absolute 
quantification (iTRAQ) was developed. In contrast to ICAT, the introduction of stable isotopes 
using iTRAQ reagents occurs at the level of proteolytic peptides. The iTRAQ technology uses 
an NHS ester to modify primary amino groups on the peptides (Wiese, 2007). Although this 
method provides a powerful means of studying protein expression in multiple systems, the 
issue of simplification is not addressed. The iTRAQ quantification technique is discussed in 
detail in Section 3.3.
1.8.2 Targeting of post-translational modifications
Enrichment of phosphopeptides provides a way of simplifying a complex peptide mixture by 
discarding a large amount of peptides which are not phosphorylated and retaining those which 
are. Specific enrichment of phosphopeptides by immobilised metal affinity chromatography 
(IMAC) is a commonly used technique in proteomics. Using this approach it is possible to 
characterise hundreds of phosphopeptides from a whole-cell lysate in a single experiment 
(Ficarro et al., 2002). IMAC exploits an immobilised transition state metal to bind 
phosphopeptides by virtue of their negative charge. IMAC is used routinely to purify 
phosphopeptides from peptide mixtures with iron and gallium being the metals of choice. 
Limitations to this method include the non-specific binding of carboxyl groups to the IMAC 
resins which compromises specificity of the system. Methyl esterification of carboxyl groups 
coupled with a low pH environment reduces the issue of non-specific binding.
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Protein glycosylation is also acknowledged as a major PTM, with significant effects on 
protein folding, conformation distribution, stability and activity. These covalent modifications 
are known to play a key role cellular function and regulation (reviewed in Rademacher et al., 
1988), as well as being a key factor associated with disease by influencing regulatory and 
developmental processes. Carbohydrates in the form of aspargine-linked (N-linked) or 
serine/threonine (O-linked) oligosaccharides are major structural components of many cell 
surface and secreted proteins. To detect and characterise glycoslylated pepitdes with 
sufficient sensitivity it is often necessary to enrich for glycopeptides. As with other PTM’s, 
digestion of glycoproteins often results in suppression of the glycosylated peptides by more 
abundant non-glycosylated peptides. A general approach for enrichment of glycoprotein and 
glycopeptides utilises the natural affinity that lectins have for glycans (Xiong et al., 2003). 
Lectins are available that target either 0- or N-linked oligosaccharides.
1.8.3 Diagonal chromatography
Diagonal chromatography is based on an old paper chromatography technique that has been 
updated for modern HPLC based proteomic applications. The original protocol was published 
in 1966 and was used in the characterisation of disulphide bridges in bovine 
chymotrypsinogen A (Brown and Hartley, 1966). The approach involved the initial 
chromatographic separation of a peptide mixture on a paper medium, which was then reacted 
with vapours of performic acid converting free cysteine to cysteic acid. Following this 
modification step the paper was rotated 90° and chromatographed in a second dimension 
using the same mobile phase. On separation, non-cysteinyl peptides migrated in the same 
way as in the first dimension, whereas cysteinyl peptides exhibited different mobility. The end 
result is that non-cysteinyl peptides appeared on a diagonal line and the modified cysteinyl 
residues migrated outside the line, hence the two types of peptides were resolved.
In recent years a variety of peptide separation methods have been developed that 
centre around diagonal RP liquid chromatography. These methods operate by targeting 
classes of peptides through specific chemical modification of the signature of interest. This 
technique has since been applied to the analysis of PTMs (Liu et al, 2004). The method used 
was essentially 2-D HPLC with derivatisation. A set of tryptic peptides from a protein digest 
was separated by RP-HPLC, all fractions were collected, subjected to a derivatisation reaction 
and then re-chromatographed on the same column using the same conditions. This study also 
served to optimise the conditions for successful fractionation.
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Combined fractional diagonal chromatography (COFRADIC) was first described in 
2002 where it was used in the identification of more than 800 E.coli proteins (Gevaert et al.,
2002). This adaptation of the original diagonal chromatography method consists of three 
distinct stages: (1) a primary RP-HPLC fractionation of a complex peptide mixture; (2) a 
derivatisation or modification step on the peptide fractions; (3) a series of secondary RP-HPLC 
separations on the modified peptide fractions, using identical conditions to the primary 
fractionation (Figure 1.13). In the original application COFRADIC was used to isolate 
methionine containing peptides from a highly complex protein mixture. When examining model 
proteomes, methionine containing peptides provided the best representation of the predicted 
proteins. For the E. coli proteome, between 99.7 and 95.8% of the predicted proteins 
contained at least one methionine residue, in contrast only 85.4% of the proteins contained 
cysteine. This same trend in amino acid representation was observed in other model 
organisms.
In this investigation COFRADIC was used to select methionine peptides via 
oxidisation of methionine to Met-SO as the sorting criteria. The protocol began with a tryptic 
digest of a total, unfractionated cell lysate of E. coli. During the first chromatographic step, the 
peptides were separated and collected at appropriate time intervals. The individual fractions 
were then treated with hydrogen peroxide, leading to modification of the subset of methionine 
containing peptides. The specific conversion of methionine to its sulfoxide derivative occurs 
without affecting other susceptible amino acids like cysteine or tryptophan. Each fraction was 
then run under the same chromatographic conditions as the primary run, this separation is 
referred to as the secondary run. Since methionine sulfoxide is more hydrophobic than 
methionine, the modified peptides undergo a hydrophobic shift which is predictable if peptides 
contain one methionine. During the second COFRADIC dimension the oxidised methionyl 
peptides migrate out of the primary collection interval and are automatically collected for 
further MS/MS analysis.
COFRADIC has proven to be an extremely powerful technique for gel-free 
proteomics. One of the major advantages of this method over other targeted simplification 
strategies is its versatility. Diagonal chromatography is not restricted towards the analysis of 
one class of peptides, in contrast to techniques such as ICAT in which one given set of 
peptides is selected. By changing the key modification reaction, it is possible to tailor the 
process so that different classes of peptides are sorted and analysed. Applications for 
separation of proteins through virtue of cysteinyl (Gevaert, 2004), amino terminal (Gevaert, et
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Modified
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Figure 1.13. Peptide elution profiles during the primary and secondary run 
of COFRADIC.
During the primary run (a) several fractions are collected and treated with a 
specific modification reagent. During the secondary run (b) the modified peptides 
shift to earlier or later elution times than previously observed in the primary run. 
Unaltered peptides elute at the same interval.
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al. 2003) and phosphorylated peptides (Gevaert et al., 2006) have been reported in the 
literature.
1.9 Positional specific peptide isolation
All of the peptide simplification techniques reviewed so far have the potential to extract more 
than one peptide for each protein and in some instances, no peptides will be recovered. 
Furthermore, because the peptide can have been derived from any part of the parent protein 
sequence, no information on the location of the peptide is obtained, which complicates the 
search strategy for identification proteomics.
The ultimate simplification strategy would be to select a single signature peptide from 
each protein in the proteome. Methods that isolate either the N-terminal or the C-terminal most 
peptide from a complex peptide mixture are the obvious choices for such a strategy. By 
isolating a specific peptide from a known location in a complex peptide mixture it is possible to 
achieve not only simplification but added information regarding the location of the peptide 
within the parent protein molecule (Figure 1.14).
1.9.1 C-terminal peptide isolation strategies
Methods for recovery of C-terminal peptides are predominantly based on capture of internal 
tryptic peptides using immobilised anhydrotrypsin (Kasai, 1992; Sechi and Chait, 2000). A 
characteristic of tryptic digests is that all internal and N-terminal peptides terminate at basic 
residues (lysine or arginine). This method exploits this characteristic and uses the basicity of 
internal peptides as sorting criteria. Anhydrotrypsin is a catalytically inert form of trypsin 
containing a dehydroalanine residue in place of Ser-195 at the catalytic site. Although it has 
no catalytic activity, anhydrotrypsin retains strong affinity for peptides with C-terminal lysine 
and arginine residues. Anhydrotrypsin is synthesised by reacting trypsin with 
phenylmethylsulfonyl fluoride followed by potassium hydroxide treatment (Ako et al., 1974). 
Incubation of a mixture of tryptic, Lys-C or Arg-C peptides with the immobilised anhydrotrypsin 
results in a covalent interaction with peptides terminating in a basic residue (i.e. N-terminal 
and internal peptides) leaving behind the C-terminal fragment. The anyhrotrypsin C-terminal 
enrichment protocol begins with proteolysis of a single protein or protein mixture with either 
trypsin or endopeptidase Lys-C (a combination of the two proteases may be used for 
enhanced coverage). The resulting peptide mixture is incubated with immobilised
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Figure 1.14. Strategies for targeted peptide simplification.
Proteolysis of a complex protein mixture generates large sets of peptides from each 
protein (a). Shotgun peptide analysis (b) randomly sequences a few peptides from 
each protein. Positional proteomic strategies achieve simplification by isolating specific 
peptides (N or C-terminal, depending on chemistry used) from each protein in the 
mixture.
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anhydrotrypsin. The unbound fraction contains the purified C-terminal peptides that may be 
characterised by MS (Figure 1.15).
One problem potentially associated with this method is the failure to purify C-terminal 
peptides terminating with lysine or arginine. This issue can be addressed by incubation of the 
protein mixture (prior to proteolysis) with carboxypeptidase B, an exopeptidase known to 
catalyse the removal of basic amino acid residues from the C-terminus of proteins (Perryman 
etal., 1984).
Despite a variety of potentially useful chemical modifications of the C-terminal amino 
acid including conversions of the carboxyl group to thiohydantoins, carboxylic acid esters, 
alcohols, acylureas, isothioureas, azides and hydrazides, researchers have found the 
published procedures challenging. The most likely avenue for C-terminal isolation by a 
chemical tagging strategy is through the utilisation of oxazolone chemistry (Nakazawa et al., 
2004; Yamaguchi et al., 2006). Although modification of C-terminal groups on proteins is less 
effective than the established techniques for N-terminal modification (for example, Edman 
chemisry), it provides the sole means to deal with C-terminal carboxyl groups, discriminating 
against the same group on side chains. A major breakthrough in C-terminal peptide isolation 
could therefore be achieved through the use of oxazolone chemistry.
1.9.2 N-terminal peptide isolation strategies
There are many N-terminal isolation strategies available in the literature. These methods are 
typically based on a series of chemical modifications, proteolysis and a final sorting stage in 
which the N-terminal most peptide from each protein is selected. These methods vary in the 
types of chemistries involved and the way in which the targeted peptides are isolated from the 
mixture.
N-terminal COFRADIC
As previously described, COFRADIC is a highly versatile peptide fractionation 
technique that can be applied to a variety of classes of peptides. When isolating methionyl or 
cysteinyl peptides, the complexity of the analyte mixture is reduced to around five fold. In most 
global proteomics studies this will continue to generate too many peptides to analyse. By 
altering the sorting chemistry to specifically target N-terminal peptides it is possible, in theory, 
to limit each protein in the mixture to one characteristic signature peptide. COFRADIC has 
been adapted for the selection of N-terminal peptides from a complex peptide mixture
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Figure 1.15. Purification of C-terminal peptides using immobilised anhydrotrypsin.
The protein (or protein mixture) is proteolysed with trypsin generating a set of lysine and 
arginine terminated tryptic peptides. Internal peptides are removed from the mixture through 
incubation with immobilised anhydrotrypsin which binds to and retains basic (lysine and 
arginie terminated) peptides. The C-terminal peptide, which potentialy contains any amino 
acid residue (X) at the C-terminus, remains in the supernatant fraction (providing X is not 
arginine or lysine) and is retained for further analysis.
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(Gevaert et al., 2003). The rationale behind the sorting of N-terminal peptides is as follows: (1) 
reduction, alkylation and acetylation of a complex protein mixture; (2) digestion of the modified 
proteins; (3) RP-HPLC fractionation of the modified peptides (primary separation); (4) 
derivatisation of free a-amino groups on the newly formed peptides in the HPLC fractions 
using 2,4,6 - trinitrobenzenesulfonic acid (TNBS); (5) a second RP-HPLC separation of the 
modified peptide fractions using identical conditions to the primary run (secondary run).
Beginning with a whole-cell lysate, the cysteine residues are first reduced and 
alkylated. All exposed amino groups (a and z) are then acetylated with N-hydroxysuccinimidyl 
(NHS) acetate and the modified protein mixture proteolysed with trypsin. Blocking of lysine 
residues by acetylation makes them inaccessible to trypsin, which will subsequently only 
cleave only at arginine residues. The resulting arginine terminated peptide mixture will consist 
of blocked N-terminal peptides mixed with internal peptides containing free amino groups on 
the newly generated N-termini. The complex mixture of acetylated peptides is then 
fractionated by RP HPLC, typically in 12 fractions (primary run). The peptide fractions are 
dried and reconstituted in an appropriate, non-amine containing, buffer. Each fraction contains 
a mixture of internal (unblocked) and N-terminal (blocked) peptides. Each fraction is then 
reacted with TNBS in which a trinitrophenyl group is placed upon the N-terminus of the 
internal peptides. Each TNBS treated primary fraction is then fractionated separately on the 
same column under identical separation conditions as the primary run. During a series of 
secondary COFRADIC separations, the TNBS-modified internal peptides exhibit increased 
hydrophobicity and as a consequence shift out of their primary collection interval. By excluding 
the acetylation stage in the protocol it is possible to isolate non-lysine containing N-terminal 
peptides from in vivo acetylated proteins. The entire COFRADIC N-terminal strategy is 
summarised in Figure 1.16.
This procedure was applied to the proteomic analysis of a cytosolic and membrane 
skeleton fraction of human thrombocytes. A total of 264 proteins and 78 in vivo acetylated 
proteins were identified. A problem associated with N-terminal peptide analysis by MS based 
approaches is the variable processing of protein N-termini. Therefore, it is not always possibly 
to identify processed N-terminal peptides using existing databases due to the incomplete 
knowledge of N-terminal boundaries. To successfully identify the whole range of N-terminal 
peptides it was necessary to generate a database containing sequentially trimmed Arg-C 
peptides. The use of this database in combination with established database search tools led 
to an increase in identification of around 50%.
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Figure 1.16. Outline of the N-terminal COFRADIC strategy.
All cysteine residues are reduced and alkylated. Then, all free amines (a and e-amines) are 
acetylated and the protein mixture is proteolysed with trypsin. This creates two types of 
peptides: N-terminal peptides with blocked N-termini and internal peptides with free N- 
termini. Following the primary reverse phase HPLC separation of the peptide mixture, 
peptides present in each fraction are treated with TNBS which modified internal peptides at 
the a-amino group. During the secondary chromatographic run, which is identical to the 
primary run, the TNBS modified peptides shift out of their original elution profile. The internal 
peptides are discarded and the N-terminal peptides, which elute at the same time interval as 
the primary run are collected and analysed.
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Positional proteomics
A novel approach to the selective isolation and recovery of the N-terminal most peptide of 
each protein in a proteome was also developed in our laboratory, in a proteome simplification 
strategy termed “positional proteomics” (McDonald et a i, 2005). The strategy is as follows: (1) 
acetylation of a complex protein mixture; (2) digestion of the modified proteins; (3) biotinylation 
of newly formed amino groups on internal peptides; (4) Removal of biotinylated peptides by 
streptavidin.
The complex protein mixture is acetylated in its native state, without reduction and 
alkylation of cysteines. Disulphide bonds are rare in cytosolic proteins, since the cytosol is 
generally a reducing environment (Derman and Beckwith, 1991). In order to limit the number 
of analytical steps and simplify the chemistry involved, reduction and alkylation steps are 
omitted from this method. Subsequent proteolysis reveals new amino groups for all peptides 
but the N-terminal most peptide. The unwanted internal peptides can then be targeted through 
the newly exposed amino group by biotinylation and removed by streptavidin Sepharose. The 
residual positional signature peptides (NTpeps) are then analysed, in the knowledge that each 
peptide represents a different protein species and is anchored informatically at the N-terminus 
of the protein (Figure 1.17).
Protein sequence tags (PSTs)
An alternative method for the sorting and isolation of N-terminal peptides has been developed 
by Kuhn et al. This strategy employs a set of chemistries to specifically characterise a group of 
hydrophobic proteins. The method, referred to as the PST process, (Kuhn et al., 2003; Kuhn 
et al., 2005) consists of the following steps: (1) solubilisation of the hydrophobic protein 
mixture using CNBr; (2) reduction and alkylation of the polypeptide mixture; (3) derivatisation 
of free amino groups using a basic mass tag (BMT); (4) digestion of modified polypeptides; (5) 
selection of N-terminal CNBr fragments using NHS-activated medium.
When working with hydrophobic proteins it is necessary to incorporate a pre­
solubilisation step. In this strategy, cyanogen bromide (CNBr) is used to fragment the 
insoluble proteins. This stage results in the formation of multiple polypeptide chains for each 
protein molecule in the system. As a consequence of this step, each polypeptide chain 
generated by CNBr cleavage will result in a new a-amino group, leading to multiple N-termini 
for each protein in the mixture. This process was initially applied to a mitochondrial protein 
suspension from yeast, as follows:
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Figure 1.17. Outline of the N-terminal ‘positional proteomics’ strategy.
Free amino groups (a and t )  are acetylated prior to proteolysis, which results in a 
mixture of N-terminally acetylated (true N-terminal) and non-acetylated (internal) 
peptides. Biotinylation of the proteotytically exposed a-amino groups, using NHS- 
biotin, and subsequent incubation with immobilised streptavidin creates a 
preparation enriched in N-terminal peptides, which are blocked by acetylation and 
therefore resistant to biotinylation.
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The isolated protein suspension was solubilised by dilution in formic acid followed by 
addition of CNBr and purification by size exclusion chromatography. The resulting polypeptide 
mixture was then reduced in order to break disulphide bridges and cysteine residues blocked 
by alkylation. The free amino groups were then derivatised with BMT which consisted of N,N- 
dimethylglycine N-hydroxysuccimide ester. To remove all excess labelling reagents, the 
polypeptide mixture was subjected to a second fractionation step by size exclusion 
chromatography. The purified mixture was then digested with trypsin, which as in the 
previously described N-terminal strategies, generated a set of arginine terminated tryptic 
peptides, due to blockage of lysine residues. The N-terminal sorting stage involved the use of 
scavenging beads which were prepared using N-hydroxysuccinimide to capture all free amino 
groups present on the internal peptides. The end result of this process is a pool of peptides 
that represents the N-terminal most peptide from each CNBr cleavage product. The PST 
rationale is illustrated in (Figure 1.18).
The use of BMT reagents to block amino groups on amino acid side chains has an 
additional function. BMTs provide an easily protonatable group at the a-amino group, which 
has been shown to improve MS/MS fragmentation by enhancing the formation of b-ions 
(Cárdenas, 1997).
To demonstrate the validity of the PST approach to study membrane proteins, the 
method was applied to a well characterised biological system, the yeast mitochondrion. This 
subcellular fraction is known to contain approximately 770 proteins, of which 18% are 
hydrophobic (Kumar et al., 2002). The PST process resulted in the identification of 147 
proteins, including 50 membrane proteins. To compare the PST technology to previously 
applied gel-based methods, the group also performed a separation of the mitochondrial 
sample by 2-D SDS-PAGE. This analysis produced 501 gel spots which were subjected to MS 
analysis, resulting in the identification of 412 proteins corresponding to 112 different gene 
products. The total number of membrane proteins identified by the 2-D SDS-PAGE approach 
was 13. This comparison highlights the benefits associated in the application of this method 
to a set of hydrophobic proteins.
The initial use of CNBr to facilitate solubilisation of hydrophobic proteins results in the 
generation of multiple polypeptide chains for each protein. A consequence of this step is that 
each protein will be represented by multiple peptides originating from the newly formed a- 
amino groups from the CNBr cleaved products. Although this has the advantage of improving 
coverage of abundant proteins, from a global proteomics perspective, it is not desirable for
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Figure 1.18. Outline of the N-terminal positional sequence tag (PST) strategy.
The first step in the PST isolation process involves chemical cleavage of the protein mixture 
with cyanogen bromide. This step is necessary in order to solubilise hydrophobic proteins. 
The polypeptide chains are then reduced and alkylated to break disulphide bonds. Free 
amino groups (lysine side chains and N-terminal) are blocked using the amine reactive 
BMT. Proteolysis results in a peptide mixture consisting of BMT blocked N-terminal 
peptides, from the cyanogen bromide fragments and unblocked internal peptides. Coupling 
of internal peptides to amine scavenger beads allows separation from the N-terminal 
peptides which remain in the supernatant.
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each protein to be represented by multiple peptides. For this reason the PST procedure is not 
the best method for global proteomics analysis.
Biotin-avidin method
Another approach for selection of N-terminal peptides has been described by Yamaguchi et al. 
This approach, based on the biotin-avidin strategy utilises a novel biotinylation reagent, 
biotinylcysteic acid which introduces a sulfonic acid group to the a-amino group on the N- 
terminal peptide (Yamaguchi et al., 2005). The introduction of a sulfonic group is an effective 
method to facilitate de novo sequencing (Marekov, 2003). Incorporation of the sulfonic group, 
in addition to the biotin tag, provides a combined method for improved sequencing efficiency 
and N-terminal isolation. The key steps are as follows: (1) reduction and alkylation of the 
polypeptide mixture; (2) guanidination of lysine residues (3) biotinylation of the a-amino group; 
(4) proteolysis of the modified proteins; (5) selection of N-terminal peptides using avidin resin. 
The full scheme for this procedure is shown in (Figure 1.19).
The guanidination reaction is necessary to prevent biotinylation of lysine side chains 
at a later stage of the protocol. In this reaction O-methylisourea hemisulfate and NH4OH, are 
used to convert lysine residues into homoarginine (Warwood et al., 2006). Following the 
guanidination reaction the protein mixture is reacted with biotinylcysteic acid which specifically 
targets the a-amino group of the proteins. Proteolysis generates a peptide mixture consisting 
of biotinylated N-terminal peptides and unmodified internal and C-terminal peptides. 
Subsequent incubation of the peptide mixture with avidin resin results in binding of N-terminal 
peptides, which are eluted from the resin using acetic acid and ACN. The method was 
validated using the model proteins bovine serum albumin (BSA) and chicken egg white 
lysozyme. The published protocol was not applied to a complex biological sample.
An adaptation to this method has recently been published in which proteins are 
initially pre-fractionated by 1-D/2-D SDS-PAGE (Yamaguchi, 2007). The initial stages of the N- 
terminal sorting procedure were carried out in-gel as follows: The spot of interest was excised 
from a Coomassie stained 1-D or 2-D SDS gel. Gel spots were washed and dehydrated using 
ACN. The dried gel piece was then incubated with dithiothreitol to reduce disulphide bridges 
and iodoacetamide to block cysteine residues. The gel piece was then washed to remove 
excess reagents and dehydrated for a second time with ACN. The dried gel piece was 
incubated with the guanidination reagents (as before). Following guanidination the gel piece 
was washed and dehydrated for the third time. The next stage was biotinylation of the free a-
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Figure 1.19. Outline of the biotin-avidin method for N-terminal peptide 
isolation.
All cysteine residues are reduced and alkylated. Then, lysine residues are 
converted to homoarginine by guanidination. The a-amino group is then 
derivatised with biotincysteic acid and the protein digested with trypsin. The 
resulting peptide mixture is passed through an avidin column. The internal 
peptides pass through the column and are discarded. The biotinylated N-terminal 
peptides, which are retained by the column, are eluted and subjected to further 
analysis.
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amino group on the N-terminal of the protein. The reagent used for this purpose was sulfo- 
NHS-SS-biotin which consists of a biotin molecule coupled to a NHS ester reactive group. 
Following a final wash and dehydration step the gel piece was incubated with trypsin to digest 
the modified protein. The recovered solution consisted of a mixture of guanidinated internal 
peptides and guanidinated, biotinylated N-terminal peptides. The peptide solution was then 
added to a fresh suspension of avidin in which the biotinylated N-terminal peptides bound with 
high affinity. The internal peptides were washed off the bead suspension and the N-terminal 
fragments desorbed using ACN and formic acid.
Following optimisation of this protocol using model proteins (BSA, lysozyme and 
cytochrome C), the method was applied to proteins present in E. coli extracts. The cell lysate 
was first resolved using 2-D SDS-PAGE and stained with Coomassie. A total of 34 protein 
spots were selected from the gel and subjected to the N-terminal isolation protocol. The 
resulting N-terminal fragments were analysed by MALDI-ToF MS. This study demonstrates a 
potential advantage of the method, which is its ability to discriminate between multiple proteins 
present in the same spot. A major disadvantage of this strategy is the amount of derivatisation 
and subsequent washing steps involved in the protocol, for this reason this method would not 
be suitable for global analysis.
Isocyanate resin
The N-terminal peptide purification methods described so far have all required the modification 
of £-amino groups present on the side chains of lysine residues. This step is necessary to 
prevent loss of N-terminal containing lysine residues during the final sorting stage in the 
protocol. A recent strategy by Mikami et al. for the isolation of blocked N-terminal peptides 
using isocyanate resin, achieves purification without lysine modification (Mikami and Takao, 
2007). This method works by exploiting the slight difference in pKa between a-amino (9.06) 
and £-amino (10.4) groups. By optimising the reaction conditions to favor coupling of a-amino 
groups, they have demonstrated it is feasible to isolate in-vivo Na-acetylated, lysine containing 
peptides.
The method can be summarised in four steps: (1) proteolysis of the protein mixture; 
(2) incubation of the peptide mixture with isocyanate resin; (3) centrifugation and collection of 
supernatant; (4) MS characterisation of purified blocked N-terminal peptides. The key step in 
this procedure is coupling of peptides to an isocyanate resin via reaction of the a-amino group 
on the internal peptides. The isocyanate-coupled resin was prepared by reacting a divalent
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isocyanate, methylenediphenyl 4,4’-diisocyanate (MDI), with aminopropyl resin (porous-NH), 
as a support medium. Under weak acidic conditions, the isocyanate resin specifically reacts 
with a-amino groups on internal peptides and not with £-amino groups of lysine. Optimisation 
of the reaction conditions revealed that a pH lower than 3 resulted in incomplete coupling of a- 
amino groups to the resin. The optimum pH for the coupling reaction is pH 3.5 -  4.0. 
Additionally, reaction conditions containing >20% water cause the isocyanate to decompose. 
Reactions were carried out in 85-90% ACN which also reduced non-specific hydroadsorption 
of peptides to the resin. Excess use of the resin was shown to lead to non-specific coupling 
with e-amino groups of lysine and therefore led to a reduced yield of lysine containing blocked 
N-terminal peptides (Figure 1.20).
The resin was validated using the synthetic peptide (YGGFLSYPLK), in both its 
unblocked and Na-acetylated form. Following incubation of the two peptides with the resin in
0.05 M phosphoric acid (pH3.5) in non-aqueous conditions the signal corresponding to the 
unblocked peptide was no longer present, while the signal corresponding to the blocked 
peptide was distinctly observed. This experiment suggested that selective capture of 
unblocked peptides with the isocyanate resin permits exclusive isolation of Na-acetylated 
peptides without the need for protection of £-amino groups. A potential disadvantage to this N- 
terminal isolation strategy is the requirement for a constant low pH. Failure to maintain the 
required reaction environment would result in loss of lysine containing N-terminal peptides. 
Although this strategy has the potential to provide a high throughput survey of N-terminal 
peptides in a complex biological sample, this study did not demonstrate the application of this 
method to a global proteomic analysis.
Ion exchange chromatography
It has been established that in vivo acetylated tryptic peptides originating from the true N- 
terminus of proteins can be isolated using ion exchange chromatography (Betancourt et al., 
2001). This method for N-terminal isolation exploits the reduced basicity of Na-acetylated 
peptides. In contrast to the majority of N-terminal sorting methodologies this protocol requires 
no derivatisation steps. Instead, the tryptic peptide mixture from the blocked protein is 
incubated with carboxypeptidase B which specifically removes the basic amino acid (lysine or 
arginine) from the C-terminal end of the peptide. At acidic pH, the resulting mixture consists of 
charged internal peptides and the uncharged N-terminal peptide. The N-terminal peptide is 
retrieved from the mixture using an SCX resin which is deposited as a thin layer over the top
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Figure 1.20. Purification of N-blocked peptides using isocyanate resin.
Cysteine residues are first reduced and alkylated. The protein is then proteolysed and 
the resulting peptides incubated with isocyanate-coupled resin under weak acidic 
conditions. All internal peptides bind to the resin through interaction with the a-amino 
group. The blocked N-termlnal peptides remain in the supernatant.
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of an ultrafiltration tube. Following a brief centrifugation step the NQ-acetylated peptide, which 
is not retained by the resin, is collected for analysis by mass spectrometry.
A more recent method for the targeted analysis of protein termini adopts a similar 
principle to this ion exchange simplification strategy. Because C-terminal regions of tryptic 
peptides tend to be basic (arginine or lysine), they also elute later from a SCX column 
compared to C-terminal and Na-acetylated peptides. This strategy has been applied to the 
enrichment of N and C-terminal tryptic peptides from a membrane enriched fraction of human 
embryonic carcinoma cells (Dormeyer et al, 2007). The cells were initially digested using Lys- 
C and trypsin to yield a complex mixture of lysine and arginine terminated peptides. The 
rationale behind the use of two enzymes is to broaden the range of peptide length, leading to 
increased coverage by MS. The peptide mixtures were fractionated by SCX. An initial screen 
of the fractions by LC-MS/MS analysis revealed that the majority of blocked N-terminal and C- 
terminal peptides eluted from the SCX column between six and seven minutes, with later 
fractions mainly comprising internal peptides. This process is summarised in Figure 1.21.
1.9.9 Summary of N-terminal isolation strategies
The N-terminal isolation methods described above are all unique with regard to the 
chemistries involved and the sorting strategies used. It is therefore important to consider the 
individual strengths and weaknesses of each protocol before deciding on the most appropriate 
technique to use. Table 1.1 provides a summary of the methods discussed and highlights their 
specific advantages and disadvantages.
Identification of a protein from a single peptide sequence has been described in the 
literature as a ‘one hit wonder’ (Veenstra et al., 2004), whereby a protein is identified using 
data derived from a single peptide. If this single peptide was identified using a standard 
shotgun approach then this would be cause for concern. Part of this concern relates to the 
lack of information regarding the location of the peptide within the parent protein, and also to 
the search space required for identification (the entire database of candidate proteins must be 
given equal validity in the analysis). Techniques that isolate a single specific peptide from 
complex mixture overcome the issues associated with ‘one hit wonders’, by anchoring the 
peptides at a precise location within the parent protein, it is therefore possible to limit the 
database search to a small subset of peptides.
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Figure 1.21. Strategy for the enrichment of C-terminal and blocked N-terminal 
peptides by SCX chromatography.
A mixture of N-terminally blocked (N-acetylated) proteins are proteolysed with trypsin 
generating a mixture of blocked N-terminal peptides, internal peptides (lysine and arginine 
terminated) and C-terminal peptides. The entire peptide mixture is then subjected to SCX 
chromatography. Due to their reduced basicity compared with internal peptides, the blocked 
N-terminal and C-terminal peptides are enriched in the early fractions and internal peptides 
are eluted at later intervals. Fractions containing N-terminal and C-terminal peptides are 
retained for further analysis.
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Chapter 1: Introduction to Proteome Simplification
As discussed earlier, the N-terminal region of a protein molecule is targeted by a 
variety of modification processes. Therefore, strategies that specifically isolate a protein’s N- 
terminal region provide an efficient way of characterising these modifications in a targeted 
manner. Events such as signal peptide cleavage, exopeptidase activity, PTMs and methionine 
removal can all be determined using N-terminal isolation. In addition to determining the true N- 
terminal status of a protein, isolation of a specific peptide from each protein in a mixture 
provides a powerful means of simplification. The failure of shotgun proteomic techniques to 
provide a comprehensive analysis of individual proteomes is mainly due to the vast complexity 
of tryptic digests. Reducing the products of proteolysis to as little as one peptide per protein 
addresses the issue of complexity and provides an alternative strategy to standard shotgun 
approaches. The use of positional proteomic strategies in combination with other protein 
simplification techniques such as MudPIT or Protein Equalizer™ technology could potentially 
lead to increased depth of proteomics analysis and bring the goal of global proteomics one 
step closer.
1.10 A ims and objectives
This thesis describes the progressive development of a novel N-terminal terminal enrichment 
strategy termed “positional proteomics”. The effectiveness of this strategy is demonstrated on 
a variety of complex biological samples in order to achieve efficient and rationalised 
simplification.
Chapter 2 describes the methodologies used throughout the study including sample 
preparation and mass spectrometric instrumentation. Chapter 3 explains the concepts behind 
the N-terminal simplification protocol, including optimisation of the various chemistries 
involved using model peptides and purified proteins, before application of the strategy to a 
variety of complex biological samples. Chapter 4 focuses on the use of this method to 
characterise human plasma and the issues associated with biomarker based applications. 
Finally, Chapter 5 introduces the rationale behind a novel isotope coded acetylation reagent 
which is utilised to quantify the occurrence of lysine residues in proteolytic peptides. The 
approach, termed Mass Isotopomer Distribution Analysis of amino acid Residues (MIDAR), 
lends itself well to positional proteomics based strategies as it brings with it additional 
information regarding amino acid composition.
6 4
2. MATERIALS AND METHODS.................................................................................................................................66
2.1 Reagents..................................................................................................................................................................... 66
2.2 Equipment.............................................................................   68
2.3 Software.....................................................................................................................................................   69
2.4 Samples............................................................................................   69
2.5 General protocols..................................................................................................................................................... 73
2.5.1 1-D SDS-PAGE........................................    73
2.5.2 In-gel proteolysis...............................................................................'......................... ................................... . 73
2.5.3 Esterification of peptides................................................................................................................................... 73
2.5.4 In-solution proteolysis......................   74
2.6 Development of the N-terminal isolation strategy............................................................................................. 75
2.6.1 Acetylation of proteins....................................................................................................................................... 75
2.6.3 Proteolysis of acetylated proteins.....................................................................................................................75
2.6.4 N-terminal recovery using biotin/streptavidin method......................................................................................75
2.6.5 N-terminal recovery using NHS-activated Sepharose................... 76
2.6.6 Reversal of O-acetylation..................................................................................................................................76
2.7 Normalisation of human plasma using Protein Equalizer™ beads................................................................ 76
2.8 N-terminal isolation of proteins bound to Protein Equalizer™ beads.... ......................................................77
2.9 Chromatography................................     78
2.10 Mass Spectrometry.................................................................................................................................................78
2.10.1 ZipTip™ Sample Preparation.........................................................................................................................78
3.10.2 MALDI-ToF MS Analysis................................................................................................................................ 78
2.10.3 ESI Q-ToF MS/MS.....................................................................................................................  80
2.10.4 Quadrupole ion trap MS/MS....... ................................................................................................................... 80
2.10.5 Orbitrap data acquisition..................................................................................................................................81
2.11 Protein Identification............................................  81
2.11.1 Peptide mass fingerprinting............................................................................................................................ 81
2.11.2 Manual (de novo) sequencing........................................................................................................................81
2.11.3 MS/MS ion search........................................................................................................................................... 81
2.11.4 Construction of N-terminal databases............................................................................................  84
Chapter 2: Materials and Methods
2. M A T E R I A L S  A N D  M E T H O D S
2.1 Reagents
General
•  HPLC grade water
•  HPLC grade acetonitrile (ACN)
•  Trichloroacetic acid (TCA)
•  Trifluoroacetic acid (TFA)
•  Formic acid (FA)
•  Diethyl ether (C4H10O)
•  Dimethylformamide (DMF)
•  Hydrochloric acid (HCI)
•  Methanol (MeOH)
•  Acetyl chloride (CH3COCI)
Sample preparation
•  Homogenisation buffer: 20mM Na2HPC>4 (pH7.5)
•  Luria broth (LB; Merck, Nottingham, UK)
•  Bugbuster protein extraction reagent (Novagen, Nottingham, UK)
•  YPD medium : 1% (w/v) yeast extract, 2% (w/v) peptone, 2% (w/v) glucose
•  Yeast lysis buffer: 20mM HEPES pH7.4, 100mM KOAc pH7.6, 2.5mM MgAc, 2mM 
DTT, yeast protease inhibitor cocktail (Sigma)
•  Protease inhibitor tablets (Roche Diagnostics, Lewes, UK)
•  Coomassie Plus® protein assay (Pierce, Northumberland, UK)
•  Protein Equalizer™ beads (ligand library beads; Louisville, KY, USA)
1-D SDS-PAGE
•  2 x SDS-PAGE sample buffer: 62.5mM Tris HCI pH6.8, 10% (v/v) glycerol, 100mM 
DTT, 2% (w/v) SDS, 0.001% (w/v) bromophenol blue.
•  SDS-PAGE running buffer: 25mM Tris, 192mM glycine, 1% (w/v) SDS
•  Coomassie brilliant blue stain: 0.25% (w/v) Coomassie brilliant blue, 50% (v/v) 
methanol, 12.5% (w/v) acetic acid
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•  Coomassie destain solution: 50% (v/v) methanol, 5% (v/v) acetic acid
In-gel D igestion
•  Digestion buffer: 10mM NH4HCO3
•  Destain solution: 50% (v/v) acetonitrile (ACN), 50% (v/v) 100mM NH4HCO3 (pH 8.2)
•  Reduction solution: 10mM dithiothreitol (DTT) prepared in 10mM NH4HCO3
•  Alkylation solution: 55mM iodoacetamide (IAN) prepared in 10mM NH4HCO3
•  Extraction buffer: 1% (v/v) FA, 2% (v/v) ACN
Desalting (SjpTip) solutions
•  Wash buffer: 0.1 % (w/v) trifluoroacetic acid (TFA)
•  Elution buffer: 50% (v/v) ACN, 0.1 % (w/v) TFA
N°terminal purification
•  Acetic anhydride (Fisher Scientific, Leicestershire, UK)
•  Acetic anhydride D6 (Cambridge Isotope Laboratories, Andover, MA, USA)
•  Streptavidin Sepharose™, High Performance (GE Healthcare, Bucks, UK)
•  NHS-activated Sepharose™ 4 Fast Flow (GE Healthcare)
•  NHS-Biotin (Pierce)
•  Sulfo-NHS acetate (Pierce)
•  Amine scavenging beads (Tris (2-aminoethyl) amine polymer bound; Sigma, Dorset, 
UK)
•  Acetylation buffer: 20mM sodium carbonate (Na2CÛ3), pH 8.5
•  Digestion buffer: 20mM sodium phosphate (Na2HPC>4), pH7.5
•  Binding buffer: 20mM Na2HPÛ4 and 0.15M sodium chloride (NaCI), pH 7.5
•  1 mM HCI for NHS-activated Sepharose washing
MIDAR Reagent
•  (C[2H3]C0)20 and ([13C]H3[13C]0)20 mixed in a 9:1 ratio (Cambridge Isotope 
Laboratories)
MADI solutions
•  MALDI matrix: ~10mg a-cyano-4-hydroxycinnamic acid (CHCA; Sigma) in 1ml, 50% 
(v/v) ACN, 0.1% (v/v) TFA
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Reversed-phase HPLC solutions
•  RP running buffer (A) 2% (v/v) ACN:0.1 % (v/v) FA
•  RP eluting buffer (B) 90% (v/v) ACN:0.1% (v/v) FA
2.2 Equipment
•  MALDI-R, MALDI-ToF mass spectrometer (Waters, Manchester, UK)
•  ESI-QToF Micro, tandem mass spectrometer (Waters)
•  LTQ ion trap, tandem mass spectrometer (Thermo Scientific, Hemel Hempstead, UK)
•  LTQ Orbitrap hybrid MS (Thermo Scientific)
•  Ultimate 3000 nanoflow chromatography system (Dionex, Surrey, UK)
•  RP column: C18, 3pm particle size (100Â), 75pm diameter x 150mm long (LC 
Packings, Dionex)
•  Multiskan plate reader (Thermo Scientific)
•  Slide-A-Lyzeh® dialysis cassettes, 500pl to 3ml, 10,000 mw cut-off (Pierce)
•  ZipTip™ C18 RP pipette tips (Millipore, Watford, UK)
•  pH paper (Sigma)
•  Homogeniser (Ystral; SIC, Hampshire, UK)
•  Vacuum centrifuge (Jouan RC10.22; Thermo Scientific)
2.3 Software
•  MassLynx version 4 (Waters)
•  Xcalibur version 2.0.7 (Thermo Scientific)
•  Chromeleon version 6.7 (Dionex)
•  Ascent software (Thermo Scientific)
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2.4 Samples
In this study, a range of model peptides, purified proteins and biological samples were used 
for method development and proteomic analysis.
Model peptides
Des-Arg-bradykinin, neurotensin, adrenocorticotrophic hormone (ACTH) fragment 1-17, ACTH 
fragment 18-39, [Glu 1 ]-Fibrinopeptide B and insulin (3-chain were all purchased from Sigma. 
Details, including sequence and [M+H]+ values can be found in Table 2.1.
Model proteins
Bovine serum albumin (BSA; Pierce), those phosphate isomerise (TPI) from rabbit muscle and 
pyruvate kinase (PK) from rabbit muscle (Sigma). Tryptic and Arg-C peptide maps are 
displayed in Figure 2.1.
Mouse skeletal muscle and liver soluble protein fractions
Skeletal muscle and liver tissue from the house mouse (Mus musculus domesticus) were 
obtained in-house and dissected immediately post-mortem. The tissue (1g wet weight) was 
homogenised in 20mM Na2HPC>4, pH7.5 (10ml) containing protease inhibitors. The whole 
homogenate was centrifuged for 45min at 13,000 x g at 4°C. The resultant supernatant 
fraction was stored at -20°C or used immediately without further purification. The 
concentration of the soluble fraction was determined using the Coomassie Plus Protein assay.
E. c o l i  cell lysate
A single colony of E. coli strain BL21(A)DE3, of genotype: F-, ompT, hsdSB (rB-ms ) gal.dcm 
was used to inoculate 10ml Luria broth (LB) and incubated overnight at 37 °C with shaking. 
The overnight culture (0.5ml) was inoculated into 50ml of fresh LB media, prewarmed to 37°C 
(1:100 dilution) and incubated with shaking. Samples were removed at hourly intervals and the 
absorbance at 600nm determined. Growth rate was monitored until early stationary phase was 
reached. The culture was transferred to a pre-weighed 50ml centrifuge tube and centrifuged at 
1,200 x g for 10min at 4 °C. The supernatant was decanted and the tube weighed again to 
determine the wet weight of the cell pellet. For 1g of wet cell pellet 2.5ml Bugbuster protein 
extraction reagent was added and the cells were placed on a rocker platform at room 
temperature for 20min in order to ensure good resuspension and cell breakage. Workflow to 
this point was conducted by Deborah Simpson. The supernatant was removed (soluble
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Peptide [M+H]* Sequence
1 Des-Arg-bradykinin 904.47 RPPGFSPF
2 Neurotensin 1072.92 pELYENKPRRPYIL
3 [Glu1]-Fibrinopeptide B human 1571.20 EGVNDNEEGFFSAR
4 ACTH, human, rat fragment 1-17 2093.09 SYSMEHFRWGKPVGKKR
5 ACTH, human, rat fragment 18-39 2465.20 RPVKVYPNGAEDESAEAFPLEF
6 Insulin P-chain 3495.89 FVNQHLCGSHLVEALYLVCGERGFFYTPKA
(pE = pyroglutamate)
Table 2.1. Sequences and [M+H]+ values of model peptides used throughout this thesis.
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Figure 2.1. Peptide maps for purified proteins.
Amino acid sequences for rabbit pyruvate kinase (a), bovine serum albumin (b) and rabbit triosephosphate 
isomerase (c) were retrieved from SwissProt, imported into Peptide Mapper and subjected to in  s ilico  
proteolysis using trypsin (green) and Arg-C (purple). Monoisotopic masses [M+H]* and C-terminal amino 
acid residue are labelled for each peptide
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fraction) and used immediately or stored at -20 °C. The protein concentration was determined 
using the Coomassie Plus Protein assay.
The soluble fraction of the E. coli cell lysate (3 ml) was dialysed into 20mM Na2C0 3  
pH 8, using Slide-A-Lyser cassettes ® . The sample was dialysed for 4h at room temperature, 
with stirring. The concentration of the dialysed sample was determined using the Coomassie 
Plus Protein assay.
S. c e r e v i s i a e  cell lysate
Cell extracts were provided by John Hughes and Abigail Stevenson of the McCarthy Lab 
(University of Manchester). S. cerevisiae cells (“wild-type" strain PTC49) were grown in YPD 
medium in shaking incubators (200 rpm) at 30°C, harvested and cell lysates prepared by 
bead-beating in yeast lysis buffer.
Human plasma samples
Pooled human plasma was obtained lysophilised from Sigma. Individual samples were 
obtained from healthy volunteers. Plasma was extracted by centrifugation from heparinised 
peripheral venous blood samples.
71
Resolving gel
R eagent A m o u n t
1 30% (w/v) acrylamide 4.0 ml
2 1.5M TrlsHCI pH 8.8 2.5 ml
3 MilliQ water 3.3 ml
4 10% (w/v) SDS 50.0 pJ
5 10% (w/v) APS 75.0 pi
6 TEMED 7.5 M
Stacking gel
R eag en t A m o u n t
1 30% (w/v) acrylamide 0.6 ml
2 0.5M TrisHCI pH 6.8 1.25 ml
3 MilliQ water 3.07 ml
4 10% (w/v) SDS 50.0 |J
5 10% (w/v) APS 25.0 M
6 TEMED 2.5 pi
Table 2.2. Resolving and stacking gel solutions for 1-D SDS-PAGE.
Quantities are for two mini (10cm ) acrylamide gels (10ml resolving gel/5ml stacking gel).
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2.5 General protocols
2.5.1 1-D SDS-PAGE
SDS-PAGE separations were performed according to manufacturers instructions. Recipes for 
gel solutions are described in Table 2.2. Samples were diluted (1:1) by the addition of an 
equal volume of 2 x SDS-PAGE sample buffer and heated at 100°C for 5min. Samples were 
allowed to cool and centrifuged briefly. The appropriate volume of sample was loaded onto the 
gel to deliver 10-15pg protein. Gels were placed in Coomassie brilliant blue stain overnight 
with rocking. To destain, gels were placed in Coomassie destain solution.
2.5.2 In-gel proteolysis
Gel plugs containing protein spots of interest were excised from 1-D gels using a glass pipette 
and transferred to a 96-well plate. To each tube 25pil of destain solution was added and 
incubated at 37 °C for 20min. This process was repeated until all of the stain had been 
removed. The plugs were then washed in 50mM ammonium bicarbonate, which was 
subsequently discarded. Reduction solution (25pl) was added to each plug and incubated at 
37 °C. After 30 min, the supernatant was discarded, alkylation solution (25(jl) was added to 
each tube, and incubation continued in the dark for 60min. The gel was dehydrated using 25pil 
of ACN, and incubation at 37°C was resumed for 15min. The supernatant was removed from 
the dehydrated plug, which was allowed to air dry. Once dry the gel was rehydrated in 
digestion buffer (9|jl) containing trypsin (Roche Diagnostics; 1pl of 100ng/pil trypsin stock 
reconstituted in 50mM acetic acid). After 30min, 50mM NH4HCO3 (10pl) was added to each 
tube, and digestion was allowed to continue overnight at 30 °C.
2.5.3 Esterification of peptides
A stock solution of MeOH (1 ml previously stored at -20 0 C for 15min) and acetyl chloride 
(150pl) was prepared immediately prior to use. An aliquot (10pl) of this mixture was added to a 
portion of desalted tryptic peptides (purified using ZipTip™ C18 pipette tip), previously dried 
under vacuum. The mixture was incubated at room temperature for 45min prior to drying in a 
vacuum centrifuge. Esterified peptides were analysed by MALDI-ToF MS.
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2.5.4 In-solution proteolysis
Proteins were reduced by the addition of DTT (50mM) and alkylated by the addition of IAN 
(100mM). Proteins were precipitated by adding five volumes of cold TCA (30% (w/v)), samples 
were vortexed and incubated on ice for 1h. Samples were then centrifuged at 13,000 x g for 
2min to pellet the protein. The TCA was removed from the tube and discarded. Diethyl ether 
(200|jl) was added to the protein and agitated using a pipette tip. The sample was centrifuged 
at 13,000 x g for 10sec in order to re-pellet the protein. The pellet was washed in diethyl ether 
a total of three times, in order to completely remove residual TCA. The tube containing the 
pellet was placed at 37°C for 5min with the lid open to ensure removal of ether. Once dry the 
pellet was resuspended in 50mM digestion buffer (10pil) containing trypsin (1 |jl of 100ng/|jl 
trypsin stock reconstituted in 50mM acetic acid). Digestion was allowed to continue overnight 
at 37°C.
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2.6 Development of the N-terminal isolation strategy
2.6.1 Acetylation of proteins
Acetylation reactions were performed on 50|jg (~30nmol) of the soluble protein mixtures 
described above. The material was treated with 1mg (30pmol) sulfo-NHS acetate or 1pl 
(10pmol) acetic anhydride (~1000-fold excess of reagent), for 60min at pH9. Following this 
reaction, excess reagent was removed using a 10-fold excess (10mg) of amine scavenging 
beads (binding capacity 3.5-5.0mmol/g), a treatment that had a major effect on the overall 
success of the process, and obviated the addition of free amines to inactivate excess reagent.
2.6.3 Proteolysis of acetylated proteins
Following TCA precipitation (as above), the protein pellet was resuspended in 20mM 
Na2HP0 4 , pH7.5 (50pl) and digested overnight at 37°C with 1pg trypsin (1:50 
enzyme:substrate).
2.6.4 N-terminal recovery using biotin/streptavidin method
Biotinylation was performed on 1pg (~0.6nmol) of desalted (C18 ZipTip), acetylated peptide 
mixture, reconstituted in binding buffer (20mM Na2HPC>4 , 0.15M NaCI, pH 7.5; 20pl). The 
peptides were modified with a 100-fold molar excess NHS-biotin, prepared immediately before 
use by reconstituting 1mg of biotin in 100pl DMF and 2pl (60nmol) of biotin was added to the 
desalted peptide mixture. The biotinylation reaction was allowed to proceed for 2h at room 
temperature. Excess biotin was removed from the sample by the addition of a 100-fold excess 
of amine scavenging beads (1mg). Biotinylated peptides (1pg) were desalted on a C18 ZipTip 
followed by the separation of biotinylated internal and unbiotinylated N-terminal peptides on 
streptavidin Sepharose (High Performance). The Sepharose (20pl) was washed three times 
with binding buffer before adding 1pg (~0.6 nmoles) of desalted peptides (made up to 20pl in 
binding buffer). The flow through was retained and the column was washed with a further 10pl 
of wash buffer. The unbound material was pooled and analysed by MS without further 
treatment.
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2.6.5 N-terminal recovery using NHS-activated Sepharose
NHS-activated Sepharose™ 4 Fast Flow, stored in propanol (50pl; GE Healthcare), was 
transferred to a 1.5ml microcentrifuge tube and washed twice with cold 1mM HCI, then once 
with binding buffer (20mM Na2HPC>4, 0.15M NaCI, pH 7.5) immediately before use. The total 
acetylated digest (approximately 30nmol of digested peptides) was made up to 100pl in 
binding buffer and added to the beads. The Sepharose contains 18pmol NHS/ml of medium, 
therefore, 50pl of Sepharose will provide 900nmol of NHS, giving a 30-fold excess. The 
mixture was vortexed briefly then incubated for 4h at room temperature on a rotary mixer. The 
mixture was centrifuged and the supernatant removed. The supernatant was then added to 
another 50pl aliquot of NHS-activated Sepharose (equilibrated as before) and the mixture was 
incubated overnight at 4°C with continuous mixing. The supernatant containing unbound 
peptides was removed and analysed by MS without further treatment.
2.6.6 Reversal of O-acetylation
Partial acetylation of serine and tyrosine residues was reversed by the addition of 1 pi (30 
pmol) hydroxylamine to the final N-terminal preparation.
2.7 Normalisation of human plasma using Protein Equalizer™ beads
Lyophilised human plasma (Sigma) was reconstituted in 20mM Na2C03, pH8.5 (1ml), to give a 
final protein concentration of 30mg/ml (concentration determined using the Coomassie Plus 
Protein assay). Protein Equalizer™ beads were prepared for use as follows: The beads 
(20mg) were weighed out and transferred to a 0.5ml microcentrifuge tube. MeOH 100% (v/v; 
1ml) was added to the beads and the suspension was incubated for 10min, on a rotary mixer. 
Beads were allowed to settle and the supernatant was removed and discarded. MeOH 50% 
(v/v; 1ml) was added to cover to surface of the beads, which were allowed to swell overnight 
at 4° C. Once swollen, 20mg beads (constituting 100pl settled bead volume) were transferred 
to a 1.5ml microfuge tube. Beads were washed in 1 ml double distilled H2O on a rotary mixer 
for 30min prior to equilibration by repeated washing in 20mM Na2C03, pH8.5 for 30min (three 
washes in total). After each wash, beads were left to settle for 5min and the supernatant 
removed. Approximately 1 ml sample containing 30mg soluble protein was added to the beads 
and mixed for 2h with turning. The supernatant fraction, containing unbound material, was 
collected after beads had settled for 5min. The beads were subsequently washed eight times 
in 1 ml 20mM Na2C03 and each supernatant fraction was retained for analysis.
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2.8 N -ter m in a l  iso latio n  of p r o tein s  bound  to  Pro tein  Eq u a lize r ™ beads
An adapted N-terminal isolation protocol was performed directly with plasma proteins coupled 
to Protein Equalizer™ beads, as follows: A portion of beads containing bound plasma proteins 
(20pl) was removed from the final suspension. The bead/protein mixture was acetylated by the 
addition of 1mg sulfo-NHS acetate (reconstituted in 30pl acetylation buffer). The acetylation 
reaction was allowed to proceed at room temperature for 2h. The reaction was stopped by the 
addition of 50pl 1M Tris-HCI, pH 9, which serves to quench residual acetylation reagent. The 
beads were allowed to settle and the supernatant was removed. The beads were washed 
repeatedly in 20mM Na2HPC>4, pH 7.5, (1ml) a total of five times. Once the final wash had 
been removed, 20mM Na2HP04 pH 7.5 (20pl) was added to the beads and the bound proteins 
digested overnight at 37°C with 1pg trypsin (1:50 enzyme:substrate). The digested peptides 
were removed from the beads in the supernatant and subjected to N-terminal isolation using 
NHS-activated Sepharose. Immediately prior to use the Sepharose (50pl) was washed twice 
with cold 1mM HCI then once with binding buffer. The peptide mixture was made up to 50pl in 
binding buffer and added to Sepharose. The mixture was vortexed briefly then incubated for 
4h at room temperature on a rotary mixer. The mixture was centrifuged and the supernatant 
removed. The filtered peptide containing solution was then added to another 50pl aliquot of 
NHS-activated Sepharose (equilibrated as before) and the mixture was incubated overnight at 
4°C on a rotary mixter. The supernatant containing the unbound N-terminal peptides was 
removed and analysed by MS without further treatment.
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2.9 Chromatography
Peptide mixtures were separated by RP-HPLC prior to ESI-MS analysis. For ESI-LC-MS/MS 
analysis on the ion trap mass spectrometer peptides were separated using the Ultimate 3000 
HPLC system fitted with a C18 RP column (C18, 3pm particle size (100A), 75pm diameter x 
150mm long). Depending on the sample complexity, either the standard 60min gradient or an 
extended 180min ACN gradient was used (Figure 2.2a and b) with a flow rate of 300nL/min. 
For analysis on the LTQ-Orbitrap hybrid MS, chromatographic separations were carried out 
using a surveyor MS pump and Micro AS autosampler (Thermo Fisher Scientific). 
Chromatographic separation was achieved using a linear gradient of 0% B to 40% B in 
160min at a flow rate of 300nl/min (Figure 2.2c).
2.10 Mass Spectrometry
Mass spectrometers used to acquire data in this thesis included, MALDI-ToF MS, ESI-Q-ToF 
MS, linear quadruple ion trap (LTQ). In addition, selected samples were ran on an LTQ 
Orbitrap hybrid MS by Gary Woffendin.
2.10.1 ZipTip™ Sample Preparation
The C18 RP ZipTip was prepared by wetting in 10pl of elution buffer (50% (v/v) ACN, 0.1% 
(w/v) TFA) a total of three times. The tip was equilibrated in wash buffer (0.1% (w/v) TFA) a 
total of three times prior to sample loading. The sample to be desalted was loaded onto the 
ZipTip in 10pl aliquots until all the sample had passed through the tip. The ZipTip was then 
washed using wash buffer (0.1% (w/v) TFA) a total of three times. The desalted peptides were 
then eluted into 10pl elution buffer for MS analysis.
3.10.2 MALDI-ToF MS Analysis
Peptide preparations were mixed in a 1:1 ratio with matrix solution and spotted directly onto a 
MALDI target for analysis. Samples were allowed to air dry and analysed using a MALDI-ToF 
mass spectrometer (M@LDI™; Waters). The mass spectrometer was calibrated using a four 
point calibration of standard peptides: 12pmol des-arg bradykinin (mw 903.47), 12pmol 
neurotensin (1,671.92), adrenocorticotropic hormone (2,464.2) and 75pmol insulin (3 chain 
(3,493.65). Data was collected over the range of 900-3500 Thomsons. Instrument operating 
parameters included: pulse voltage of 3200V, source voltage of 15000V, reflectron voltage of
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Figure 2.2. Acetonitrile HPLC gradients.
Depending on the complexity of the analyte and the instrument used, a choice 
of three RP gradients were implemented. For LC-M S/M S on the LTQ ion trap 
instrument either a standard one hour gradient (a) or an extended three hour 
gradient was used. For analysis on the LTQ Orbitrap mass spectrometer a 
linear three hour gradient (c) was implemented.
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500V and MCP voltage of 1950V. Matrix suppression was set to 400 mass units. Spectral 
acquisition was controlled through the MS tune page. Data acquisition and processing was 
performed through the MassLynx software suite (version 4.0). For spectral acquisition, the 
laser energy was optimised and acquisition parameters set at 5 laser shots/sec and 10 laser 
shots/scan. Raw data was processed by combining between 20-30 spectra, subtracting 
background noise (polynomial order 10 with 40% of the data points below this polynomial 
curve and a tolerance of 0.01) and smoothing the data (Savitzky Golay method).
zi03ESiQIjoFMS/MS....... ..................... .... ................................................. .
Simple peptide mixtures were desalted into 50% (v/v) ACN: 0.1% (v/v) FA using a C18 ZipTip 
and infused directly into the ESI-Q-ToF micro (Waters) at a flow rate of 0.5pJ/min. To scan for 
precursor ions data was acquired over the range 400-2000m/z with the capillary voltage set at 
1900V, collision energy 10V and sample cone 55V. Precursor ion charge states were 
determined by manual inspection of the isotope envelope, noting the m/z difference between 
the monoisotopic and the first [13C] peak. For MS/MS analysis, the mass range of the 
quadrupole was set to transmit the precursor ion and fragment ion spectra collected over the 
expected mass range, and the peptide was fragmented by CID using a collision energy of 
30%. Once the fragmentation pattern of the product ion spectrum was optimised by tuning the 
collision energy, up to 100 individual spectra were collected and combined to produce to final 
mass spectrum for processing. The product ion spectrum was processed using MaxENT3 
software.
2.10.4 Quadrupole ion trap MS/MS
A linear quadrupole ion trap (LTQ; Thermo Scientific) was used for high throughput protein 
identification from in-gel digests, in-solution digests and N-terminal preparations. Ionised 
peptides were analysed in the mass spectrometer, by DDA, using the “triple play” mode, 
consisting initially of a survey (MS) spectrum from which the three most abundant ions were 
determined. The charge state of each ion was then assigned from the C13 isotope envelope 
“zoom scan” and finally subjected to a third MS/MS scan. The LTQ was tuned using a 
500fmol/p,l solution of GFP and calibrated according to manufacturers instructions.
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2.10.5 Orbitrap data acquisition
The LTQ Orbitrap mass spectrometer consists of an LTQ XL linear ion trap mass 
spectrometer with an Orbitrap high resolution accurate mass detector. The instrument was 
operated in parallel mode that provided high resolution (set to 30,000) and accurate mass full 
scan data concurrently with high sensitivity MS/MS peptide fragment ion spectra from the LTQ 
XL.
2.11 P ro tein  Id e n tif ic a t io n
2.11.1 Peptide mass fingerprinting
The monoisotiopic mass values (m/z) were manually extracted from a single MALDI-ToF mass 
spectrum and compiled into a list. The list of m/z values was used to search a variety of 
databases through the Mascot server (Peptide Mass Fingerprint search) against the 
SwissProt. Search parameters allowed a single missed tryptic cleavage, carbamidomethyl 
modification of cysteine (fixed) oxidation of methionine (variable) and a peptide tolerance of 
±150ppm. The taxonomic space was restricted to the species being searched. Peptide maps, 
indicating peptide coverage, were produced using the peptide mapping tool (Beynon, 2005).
2.11.2 Manual (de novo) sequencing
Processed MS/MS data obtained from direct infusion of peptide mixtures into the ESI-QToF 
was sequenced (de novo) using the PepSeq software in the MassLynx package. The resulting 
sequence tags were used to search the NCBI database using the BLASTP algorithm (Altschul 
et al., 1997).
2.11.3 MS/MS ion search
Xcalibur raw data files, generated by LC-ESI-LTQ MS/MS, were processed using Bioworks 
browser (Thermo Scientific) using the turbosequest tool. DTA (peak list) files for each sample 
were merged and converted to Mascot Generic Format (MGF) for database searching. MS/MS 
data were searched using the Mascot search engine (MS/MS ion search) with varying 
parameters depending on the nature of the sample being searched. In all cases, a peptide 
tolerance of 1.5Da and an MS/MS tolerance of 0.6Da were used. The data format was set to 
Mascot generic and the instrument set to ESI-TRAP.
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Protein identifications are ranked according to a probability based Mowse score, which is 
assigned to each peptide ion matched (also known as the ion score; Pappin et a/., 1993). 
Individual ion scores are reported for each peptide matched (from MS/MS data), and these 
scores are combined to give the protein score. The score for an MS/MS match is based on the 
absolute probability (P) that the observed match between the experimental data and the 
database sequence is a random event. For each Mascot search an ion score significance 
threshold is reported based on -10Log(P). For example, if 1.5 x 105 peptides fell within the 
mass tolerance window about the precursor mass, and the significance threshold was chosen 
to be 0.05, (a 1 in 20 chance of a false positive), this would translate into a score threshold of 
65.
Searching and identifying proteins from in-solution digests
When searching MS/MS data generated by in-solution, tryptic, proteolysis, the enzyme 
specificity was set to trypsin and the variable modification of oxidised methionine was chosen. 
MS/MS data was searched against the SwissProt database and the taxonomy was restricted 
to the experimental species. Protein matches with scores over the reported threshold indicate 
extensive homology and, therefore, these were taken as significant identifications.
Strategy for searching and identifying N-terminal peptides
When searching data from N-terminal preparations, the enzyme specificity was set to Arg-C 
(no cleavage is observed at lysine residues), fixed modifications of acetyl N-term (+42Da at 
the N-terminus) and acetyl lysine (+42Da for each lysine residue) were used, in addition to 
variable modifications of methionine oxidation (+16Da) and acetyl serine (+42Da; allows for 
the occasional acetylation at serine residues; Figure 2.3).
N-terminal peptide identifications with ion scores above the reported threshold were 
taken as confident assignments. However, N-terminal peptide identifications with scores under 
the given threshold were examined individually (manual inspection of MS/MS data), and 
providing a strong ion series (b or y ion) was observed, these peptides were also allowed.
Initially the N-terminal MS/MS data was used to interrogate the SwissProt database to 
obtain annotated protein identifications. However, N-terminal peptide identifications made 
using the SwissProt database are restricted to proteins that have undergone no cleavage at 
the N-terminus. In order to identify N-termini that have undergone SP removal the same 
MS/MS data was searched using Mascot against specialised N-terminal databases, 
constructed in house (see Section 2.11.4), for the species studied.
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Figure 2.3. MASCOT MS/MS search form.
The M S/M S ions search accepts data in the form of peak lists containing mass and 
intensity pairs, in this case, the data is in the form of a Mascot generic file (mgf). The  
parameters shown here are tailored for a complex N-terminal preparation.
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Screening for non N-terminal peptides
To screen for non N-terminal (internal and C-terminal) peptides, the N-terminal datasets were 
searched using the same parameters as when searching N-terminal peptides. However, as an 
alternative of using N-acetylation as a fixed parameter, this modification was set to variable to 
allow for non-acetylated, internal or C-terminal, Arg-C peptides. The non N-terminal matches 
were examined using the same criteria as for the N-terminal peptides.
2.11.4 Construction of N-terminal databases
To create various N-terminal databases all £  coli, S. cerevisiae, Mus musculus and Homo 
sapiens, sequences were extracted from SwissProt as a FASTA file. The databases were 
pre-processed (using software written in house by Robert Beynon) to create Arg-C N-terminal 
peptides, reading where possible feature entries (FT lines), to remove signal peptides and to 
allow for additional processing events such as signal peptide removal (for an example 
SwissProt entry see Figure 2.4). Additionally, if the N-terminal amino acid was a methionine 
residue, two entries were created, one in which the methionine residue was included in the 
entry and a second in which the N-terminal methionine was removed. This database was then 
searched using our in-house Mascot server.
2.12 M o deling  Exp ected  Iso tope  D istr ibutio n  Profiles  of MIDAR D er ivatives
To model the expected isotope distribution patterns, isotope envelope profiles were calculated 
for peptides at 1000Da, 2000Da and 3000Da (the masses typically encountered in a 
proteomics experiment). For each peptide, the isotope profile was calculated using the 
“averagine” atomic composition for a typical peptide (Senko et al., 1995), using the tool “MS- 
Isotope” that is part of the Protein Prospector Suite (http://prospector.ucsf.edu). These isotope 
profiles were used to calculate the expected mass spectrum for the three peptides, with 0,1,2 
or 3 amino groups and a reagent mixture of 10% PC-»] acetic anhydride and 90% [2He] acetic 
anhydride (when the acetyl group is incorporated, the mass gains are 44Da and 45Da for the 
two labelled variants, respectively).
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Figure 2.4. SwissProt feature table for E. co li p-lactamase (P62593).
The FT (Feature Table) lines provide a precise but simple means for the annotation 
of the sequence data. The table describes regions or sites of interest in the 
sequence. In general, the feature table lists signal peptide cleavage sites, 
posttranslational modifications, binding sites, local secondary structure or other 
characteristics reported in the cited references. Sequence conflicts between 
references are also included in the feature table.
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3. D E V E L O P M E N T  OF N O V E L  S T R A T E G I E S  F O R  N - T E R M IN A L  
P E P T I D E  IS O L A T IO N
3.1 Introduction
Chemical modification of biological constituents has been used for many years in protein 
chemistry (reviewed in Wong, 1991). Proteins can be covalently modified in a variety of ways 
to suit the purpose of a particular study or goal. The most common targets for protein labelling 
are primary amines, which occur mainly on lysine side chains (s-amino groups) and on the N- 
terminus (a-amino group) of protein molecules. Derivatisation of primary amines in proteins 
and peptides provides the basis for many widely used proteomic strategies.
3.2 Edman degradation
All current enzymic ladder sequencing methods are based on the strategy developed by Pehr 
Edman in 1949, referred to as “Edman degradation” (Edman, 1949). This strategy utilises the 
isothiocyanate derivative phenylisothiocyanate (PITC; Edman’s reagent) for the stepwise 
degradation of peptides. In this process the derivatised amino acid is removed from the 
protein without modifying the remaining peptide chain, thus allowing sequential degradation of 
the peptide. Each derivatised amino acid (phenylthiohydantoin [PTH] amino acid) is identified 
by one cycle of Edman chemistry followed by HPLC to analyse the PTH amino acid. This 
method led to the development of an automated sequencing instrument in 1967 (Edman and 
Begg, 1967), and shortly after to the construction of the solid-phase sequencer, in which the 
degraded peptides were covalently attached to a solid support (Laursen, 1971).
The Edman reaction is divided into three stages: (1) coupling of reagent to the amino 
terminal; (2) cleavage of the modified amino acid and (3) conversion to the PTH amino acid 
(Figure 3.1). In the coupling reaction, phenylisothiocyanate (PITC) reacts with the amino acid 
residue at the N-terminus under basic conditions to form a phenylthiocarbamyl derivative 
(PTC-protein). At pH9 coupling is favoured at a-amino groups and occurs within 15-30min. In 
the cleavage reaction, TFA is used to cleave the first amino acid to yield an anilinothiozolinone 
derivative (ATZ-amino acid) and the n-1 polypeptide. The shortened n -1 polypeptide has a 
new N-terminal amino acid with a reactive amino group, which can undergo another round of 
coupling and cleavage. In the conversion stage, the unstable ATZ amino acid is converted to a
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Figure 3.1. The Edman reaction.
The first reaction (coupling) modifies the amino terminus by the addition of 
phenylisothiocyanate (PITC) to the amino group. The resulting phenylthiocarbamyl (PTC) 
protein is then treated with an anhydrous acid in a second reaction (cleavage) which 
allows the sulfur from the PTC group to react with the first carbonyl carbon in the protein 
chain. This cyclisation reaction results in the removal of the first amino acid as an 
anilinothiozolinone (ATZ) derivative and leaves the next amino acid in the protein exposed 
for the next round of PITC coupling. In a third reaction (conversion), the ATZ amino acid is 
converted to a phenylthiohydantoin (PTH) amino acid in aqueous acid. The PTH is more 
stable than the ATZ and can be easily analysed. This process may be continued until the 
limitations of the chemistry or the sample preclude further analysis.
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stable phenylthiohydantoin derivative (PTH-amino acid) with anhydrous acid. The PTH-amino 
acid is transferred to a RP C18 column for detection at 270nm. A standard mixture of 19 PTH- 
amino acids is also injected onto the column to provide standard retention times of the PTH 
amino acids.
There are a number of limitations associated with Edman chemistry, including low 
sensitivity (detection limit of 1pmol; Shively, 2000) and the requirement for purified proteins. 
However, the major limitation is inhibition of the reaction by blocked N-terminal peptides. The 
majority of eukaryotic proteins are blocked by Na-acetylation and although it is sometimes 
possible to unblock Na-acetylated proteins using acylaminoacyl-peptide hydrolase (Krishna et 
al. 1991; Fames etal., 1991) this remains a major problem for Edman chemistry.
Despite its associated limitations, Edman sequencing has proved a valuable tool in 
proteomic research, in defining the true N-terminal regions of proteins. In a pioneering study, 
Edman sequencing was used in combination with 2-D SDS-PAGE to identify the true N- 
terminal protein sequences of 223 unique proteins from E. coli (Link et al., 1997). In this study 
39% of the identified proteins were found to have undergone NME and 24% SP removal. In 
accordance with published data, the initiator methionine was cleaved when the penultimate 
residue was alanine or serine. However, when the penultimate amino acid was threonine, 
glycine or proline, cleavage was variable. Valine did not permit cleavage.
3.3 Amine reactive isobaric tagging reagents
A recently developed NHS ester-based strategy for isobaric, stable isotope labelling of 
peptides (iTRAQ; Ross et al., 2004) is now an established technique in proteomics (Zieske 
2006; Aggarwal et al., 2006). This strategy was originally developed using a multiplex set (4- 
plex) of isobaric reagents that modify exposed amino groups (a and z) on the target proteins. 
More recent versions of the iTRAQ strategy use a greater number of isobaric reagents (8-plex) 
(Choe et al., 2007). In both cases, the derivatised peptides are indistinguishable in MS, but 
following CID yield signature or reporter ions that can be utilised to identify and quantify 
individual members of the multiplexed set. The reagents are non-polymeric isobaric tagging 
agents consisting of a reporter group, a balance group and a peptide reactive group (Figure 
3.2a). The reporter group differs in mass in each of the variants from m/z 114.1 to 117.1 while 
the balance group ranges in mass from 28 to 31 Da, thus yielding a constant combined mass 
of 145.1 Da for each of the four reagents.
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R eporter-B a lance-P eptide IN T A C T  
4  sam ples identical m /z
Figure 3.2. Components of the multiplexed isobaric tagging strategy.
The complete molecule consists of a reporter group (based on N-methylpiperazine), a 
mass balance group (carbonyl) and an amine reactive group (NHS ester; a). In the 
multiplexed reaction of four different samples (S1-S4; b), the reporter group ranges in 
mass from m/z 114.1 to 117.1, while the balance group ranges in mass from 28 to 31Da. 
As the combined mass remains constant (145.1 Da), there is no difference observed 
between samples at the MS stage of analysis. Following fragmentation by CID, the four 
reporter group ions appear as distinct masses (114-117Da), where as all other fragment 
ions (for example, b and y ion series) stay the same. The relative concentration of the 
peptides is thus deduced from the relative intensities of the reporter ions.
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In a typical iTRAQ experiment, four different biological samples are proteolysed and 
the resulting peptides are derivatised with a distinct, differentially labelled tag. The labelled 
peptides from each sample are mixed and analysed by LC-MS and MS/MS. The isobaric 
nature of these reagents means that the same peptide in each sample appears as a single 
peak in the MS spectrum which reduces complexity of the spectra compared with other 
techniques such as ICAT (Shiio and Aebersold, 2006). Following CID the multiplexed isobaric 
tags produce abundant signature ions at m/z 114.1, 115.1, 116.1 and 117.1, the relative 
intensities of these ions correspond to the proportions of the labelled peptides (Figure 3.2b).
The iTRAQ approach has been successfully applied to a variety of biological samples 
in order to simultaneously identify and quantify, in relative terms, proteins. Quantitative studies 
have been performed on low abundance proteins and transcription factors in E. coli (Aggarwal 
etal., 2005), human saliva (Hardt etal., 2005) and human fibroblasts (Cong etal., 2006).
3.4 Amino group derivatisation
When performing coupling reactions of amino groups with amine reactive agents, it is 
important to create a reaction environment that will favor adequate reactivity. Many amine 
reactive reagents, for example acid anhydrides, are unstable in aqueous solutions due to 
hydrolysis and depletion of the reagent in these conditions is unavoidable. However, the rate 
of hydrolysis is dependent on the particular reagent, temperature, pH and buffer composition.
Derivatisation reactions are most commonly performed in phosphate, bicarbonate/ 
carbonate, or borate buffers at concentrations between 50-200mM. Other buffers may also be 
used if they do not contain primary amines. N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic 
acid (HEPES), for example, can be used because it contains only tertiary amines. Tris is a 
primary amine, which makes it an unacceptable buffer for use with an amine reactive agent. 
However, a large excess of Tris, at neutral-to-basic pH may be added at the end of a reaction 
to quench residual reagent. Glycine also contains a primary amine and may be used in a 
similar manner. Reactions are typically performed at pH7-9, between 4°C and room 
temperature and from 30min to 2h. Reagents are typically used at 2-50 fold molar excess 
depending on the concentration of the protein to be modified.
The risk factors associated with the stability of amine reactive agents along with 
strategies for minimising their effects are listed in Table 3.1.
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P ro b lem S o lu tio n
Instability of reagent Prepare all reagents immediately prior to 
derivatisation
Acidification of reaction environment by 
hydrolysis of excess reagent
Use reaction buffer able to maintain 
optimal pH for the duration of the reaction
Competition from other reagents in the 
reaction mixture
Ensure that no amine-containing buffers, 
for example Tris, have been added to the 
reaction mixture
Table 3.1. Risk factors commonly associated with amine modification in  vitro.
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3.4.1 Acylating agents
The most commonly used amine specific reagents for protein modification are acylating 
agents. These agents are compounds that contain an activated acyl group in which the 
nucleophile on the primary amino group attacks at the carbonyl carbon, displacing a leaving 
group. Commonly used acylation reagents include: acid anhydrides, isocyanates, 
isothiocyanates, N-hydroxysuccinimidyl (NHS) and other activated esters (Figure 3.3). All 
nucleophiles contained within the protein molecule are susceptible to acylation. Under 
aqueous conditions, O-acylation of hydroxyl-containing amino acid residues (serine, threonine, 
and tyrosine) may be a significant side reaction. An important distinction between O-acylation 
and N-acylation is that O-acylation is easily reversible. Hydroxylamine (or strongly alkaline 
conditions) is sufficient to remove acyl groups from hydroxyl-containing amino acid residues 
(Miller, 1996).
An acid anhydride is an organic compound that has two acyl groups bound to the 
same oxygen atom (Moss et at., 1995). When the two acyl groups are directly derived from a 
carboxylic acid (the most common case), the general formula is RC(0)0C(0)R. Symmetrical 
acid anhydrides of this type are named by replacing the word acid in the name of the parent 
carboxylic acid by the word anhydride.
Acetic anhydride is an organic solvent with the formula (CH3C0)20 (Figure 3.4a). It is 
the most commonly used acetylation reagent in organic synthesis and it is widely used in the 
production of drugs such as heroin (diacetylmorphine; Klemenc, 2002). Aqueous solutions of 
acetic anhydride have limited stability because, like most acid anhydrides, acetic anhydride 
hydrolyses to give acetic acid (Figure 3.4b).The instability of acetic anhydride in aqueous 
conditions will cause the pH of a reaction to fall significantly. Therefore, when using acetic 
anhydride as a derivatising agent in a pH sensitive environment, it is necessary to use a 
system with adequate buffering capacity.
Both isocyanates and isothiocyanates are extremely reactive. Reactions mainly occur 
through addition to the double bond joining the carbon and nitrogen atoms (Figure 3.3). The 
nucleophile (protonated amino group) attacks the electrophilic carbon atom and the active 
hydrogen is added to the nitrogen atom. Isocyanates have the reactive group -N=C=0, 
whereas isothiocyanates have the chemical group -N=C=S, formed by substituting sulfur for 
oxygen in the isocyanate group. As discussed earlier, phenylisothiocyanate is a derivative of 
isothiocyanate that has important implications in Edman sequencing.
9 2
Figure 3.3. Reactions of commonly used acylation reagents with a-amino groups.
Reaction with: (a) Isocyanate; (b) isothiocyanate; (c) NHS ester and (d) acid anhydride.
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O O
- A A c h 3
b) (CH3C 0)20  +  H20  -------- 2(CH3C 0 2H)
c) CH3C 0 2H CH3C 0 2" +  H+
Figure 3.4. Structure and hydrolysis of acetic anhydride.
a) Acetic anhydride consists of two acetyl groups bound to the same oxygen atom.
b) Aqueous solutions of acetic anhydrides hydrolyse to produce acetic acid.
c) Acetic acid dissociates to release [H+], therefore adequate buffering is important.
9 4
Chapter 3: Development of novel strategies for N-terminal pep tide isolation
3.4.2 Biotin NHS esters
Biotin, also known as vitamin H or vitamin B7, is a relatively small molecule (226Da) 
that can be covalently attached to selected amino acid residues, in most cases, without a 
significant effect on biological activity. Derivatisation of proteins and peptides through 
biotinylation has increased significantly over the past two decades (Wilchek and Bayer, 1988; 
Wilchek and Bayer, 1989). The addition of biotin groups can be exploited using the extremely 
high affinity of biotin for the tetrametic proteins avidin, which is a glycoprotein found in egg 
white and also streptavidin from the microorganism Streptomyces avidinii, with a dissociation 
constant in the order of 1015mol/l (Wilchek and Bayer, 1988). Biotin can be covalently linked to 
proteins or peptides using one of the many commercially available biotinylation reagents, the 
most popular is biotinyl NHS-ester (NHS-biotin). Figure 3.5 shows the structure of NHS-biotin 
and the mechanism of reaction with primary amines. NHS ester-mediated derivatisation of 
primary amino groups was first described by Becker et al., in the study of biotin transport in 
yeast (Becker and Wilchek, 1972; Becker et al., 1971). Since then many other applications 
have been developed, for example the previously described techniques of ICAT and iTRAQ.
3.5 N-term inal  peptide  isolation
Amino group derivatisation is also routinely applied to N-terminal peptide purification 
strategies (reviewed in Chapter 1). In contrast to Edman degradation, the more recent 
chemistries for N-terminal isolation are not impeded by N^acetylation. In addition to the 
benefits gained by simplification, these strategies have a useful application in determining the 
true nature of protein N-termini.
This chapter describes the development of two novel ‘positional proteomic’ 
approaches for enrichment of N-terminal peptides from complex protein mixtures using 
different types of reagents in the post-proteolytic stages. Both approaches involve an initial 
acetylation step, which is necessary to block the a-amino group on the true N-terminal of the 
proteins and also to block and protect the c-amino group on the side chains of lysine residues. 
The success of this initial acetylation step requires the optimisation of reaction conditions to 
maximise the yield of derivatised proteins. Before developing the N-terminal isolation 
procedure, it is necessary to carry out a series of experiments designed to optimise the 
reaction conditions for acetylation. The initial experiments will involve monitoring the change in 
pH of sodium carbonate buffer on addition of the acetylation reagents using pH paper. Once 
pH is optimised the next stage will be to modify a model peptide (ACTH 1-17) with two
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V
O
N H S  leaving group
Figure 3.5. Modification of protein amino groups with NHS biotin.
The nucleophile (amino group) is attacked by the electrophile (carbonyl carbon) from the 
NHS group.
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reagents: acetic anhydride and sulfo-NHS acetate. Both of these reagents introduce an acetyl 
group to exposed amino groups on protein molecules, however, the chemistries in which they 
achieve this modification differ (Figure 3.3). The two reagents will be optimised using the 
modification of ACTH 1-17 in a time course experiment. Once the conditions for acetylation 
are established the reaction will be applied to a purified protein. The purpose of this 
experiment is to determine if acetylation of an intact protein in its native state is feasible. If 
successful then acetylation can be applied to real biological samples in their native state, 
followed by further stages of the N-terminal isolation procedure.
Following acetylation and proteolysis, the first approach for N-terminal isolation 
involves biotinylation of the peptide mixture using NHS-biotin. All internal peptides become 
biotinylated, however, the acetylated N-terminal peptides are resistant to modification, 
providing a basis for segregation. Removal of the biotinylated internal peptides, through 
interaction with streptavidin, results in a preparation enriched in N-terminal peptides. The 
unbound material containing the N-terminal peptides can be directly analysed by MS (Figure 
1.17). As each protein yields a single signature peptide from each protein, the resultant 
mixture, in theory, should have the same level of complexity as the initial unproteolysed 
proteome (McDonald etal., 2005).
To summarise approach one: samples are dialysed into a compatible (non-amine 
containing) buffer prior to acetylation. In some cases the protein mixture can be generated 
using a compatible buffer which removes the need for dialysis. Excess acetylation reagent is 
removed using amine scavenger beads (structure represented in Figure 3.6), which facilitates 
the removal of excess reagent without adding amines to the mixture and can be separated 
from the sample by centrifugation. The proteins are then concentrated by acid precipitation 
and the pellet washed prior to proteolysis. The proteolysed mixture is biotinylated using NHS- 
biotin which adds a biotin moiety to the newly formed a-amino groups on the N-termini of the 
internal peptides. The peptide mixture, which now consists of biotinylated internal peptides 
and acetylated N-terminal peptides, is passed over streptavidin Sepharose, which binds to 
and retains the internal peptides. The derivatisation reactions used in this approach are 
initially optimised using model peptides and purified proteins, before being applied to the 
soluble proteins of mouse skeletal muscle. This protocol, although effective, requires multiple 
rounds of peptide purification following each derivatisation stage to separate the peptides from 
the excess reagents used which, in turn, results in a reduced yield of material.
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Figure 3.6. Structure of Tris(2-aminoethyl)amine, polymer-bound.
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The second approach consists of enhanced methodologies to minimise the number of 
processing steps, yet maximise yield. The most significant enhancement to the method is the 
elimination of the biotinylation step. All pre-proteolytic steps remain the same as in the first 
approach, including the initial acetylation stage to block a-amino groups on the intact proteins. 
However, following proteolysis, instead of targeting internal peptides by biotinylation and 
removing them with streptavidin, a commercially available amine reactive immobilised reagent 
(NHS-activated Sepharose) is used to react with and retain internal peptides in one step. 
NHS-activated Sepharose is efficient, both in respect of amine binding and subsequent 
leakage of bound amines (Van Sommeren et al., 1993). The acetylated peptide mixture is 
incubated with the NHS-Sepharose by centrifugation and analysed without further treatment 
(Figure 3.7; McDonald and Beynon, 2006).
To clarify, all steps in approach two, up to and including proteolysis are the same as 
in the first approach described above. The proteolysed mixture is exposed to NHS-activated 
Sepharose, which binds to and retains all peptides with unblocked a-amino groups i.e. all 
internal peptides. This strategy for N-terminal isolation will initially be performed on the same 
sample as the first method (mouse skeletal muscle soluble fraction), before being applied to 
the more complex proteomes of mouse liver, S. cerevisiae and E. coli cell lysate, to obtain 
global proteomic datasets from three distinct biological samples. In all cases, samples will 
initially be subjected to MALDI-ToF MS to assign N-terminal peptides to abundant species in 
the mixture. To obtain a greater number of identifications, samples will be fractionated by RP- 
HPLC over an extended three hour gradient, and analysed by MS/MS on the LTQ ion trap 
instrument.
The strategies for N-terminal purification described in this chapter share similarities 
with other methods available in the literature (see Table 1.2). However, our strategy 
represents the simplest set of chemistries for identifying both forms of N-terminal peptides (Na- 
acetylated and unblocked) in complex eukaryotic and prokaryotic proteomes. In contrast to the 
alternative methods outlined in Chapter 1 (Section 1.9.2), our methods do not contain the 
initial reduction and alkylation stages required to reduce and block disulphide bonds. 
Therefore, the two strategies demonstrated in this chapter are only suitable for the analysis of 
soluble protein fractions.
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Block primary amines (amino 
termini and lysine residues)
HUNT
H2N
Proteolyse exposing new amino 
groups on internal peptides
i f ,,Lr '  R H2N1 • H N *
H2NI
Remove internal peptides by reaction with 
NHS-activated Sepharose
• H N I
•  HN K 'R
Preparation highly enriched in 
true N-terminal peptides
•  Acetyl group
Figure 3.7. Scheme outlining the chemistry involved in N-terminal purification using 
the NHS-Sepharose method.
Free amino groups (a and z) are acetylated prior to proteolysis, which results in a mixture 
of N-terminally acetylated and non-acetylated (internal) peptides. Subsequent incubation 
of the peptide mixture with NHS-Sepharose results in a preparation enriched in N-terminal 
peptides.
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3.6 D e te r m in a tio n  of N -term inal  acetylation  state
Although rare in prokaryotes, amino terminal modification by acetylation is extremely common 
in eukaryotes. Around 50% of the proteins in fungi are N°-acetylated (Lee et a!., 1989b) and 
as many as 90% in animals (Polevoda and Sherman, 2000).
Unlike NME, the rules governing N°-acetylation are not clear-cut. Eukaryotic proteins 
which are susceptible to N°-acetylation have a variety of different N-terminal sequences with 
no simple consensus motif and with no dependence on a single type of amino acid residue 
(Polevoda etal., 1999). In accordance with NME, N°-acetylation is dependent on the nature of 
the second encoded residue. Both alanine and serine are the most commonly Na-acetylated 
amino acids, in addition to the uncleaved methionine residue when the penultimate residue is 
either aspartic or glutamic acid (Flinta et at., 1986).
Using the conventional N-terminal purification methods described here it would not be 
possible to distinguish between chemically derived and naturally occurring acetyl groups on N- 
termini, as both acetyl groups are identical and can not be distinguished by mass. Therefore, 
in order to discriminate between naturally and chemically acetylated N-termini, the positional 
proteomics protocol will be adapted using a deuterated from of acetic anhydride 
((C[2H3]C0)20). Under these circumstances a chemically acetylated (in vitro acetylated) N- 
terminal will have a mass difference of 45Da and a naturally acetylated (in vivo acetylated) N- 
terminal will have a mass difference of 42Da. When analysed by MS, the difference in mass 
will be exploited to determine the acetylation status of the true N-terminal peptide. When 
applied to the set of complex proteomes (mouse liver, S. cerevisiae and E. coli), this modified 
version of the positional proteomics strategy will provide a useful survey of the true Na- 
acetylation status of a large number of mature proteins.
MALDI-ToF MS has been used to determine the N°-acetylation status of 68 ribosomal 
proteins from a normal strain of S. cerevisiae and from three mutant stains each lacking a 
catalytic subunit of three different acetyltransferases (Arnold et al, 1999). A total of 30 of the 
68 ribosomal proteins were N°-acetylated, and 24 of these (80%) had serine at the N-terminus 
(NatA substrates). In contrast to this time consuming and complex approach to study N°- 
acetylation, the N-terminal positional proteomic strategy demonstrated in this chapter should 
be capable of generating the same dataset in a rapid, high-throughput manner.
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3.7 Limitations to N-terminal analysis
Protein N-termini are, in general, poorly identified by routine MS analysis (reviewed in Meinnel 
and Giglione, 2008). Truncated and immature cDNAs or missed 5' introns in genomic DNA 
frequently result in incorrect N-terminal assignment. In addition, proteolytic events such as N- 
terminal trimming and SP removal will cause the true N-terminus of a protein to differ from the 
database entry for the amino acid sequence. Proteins that have undergone proteolytic events 
will be represented in the database in their precursor form, making it difficult, if not impossible, 
to identify the mature N-terminal by sequence similarity searching methods alone. Most MS 
analysis software now includes dedicated tools to address these issues. In addition to the 
standard enzyme options, software now includes ‘no enzyme’ or ‘nonspecific (half) cleavage’ 
options for a particular enzyme, allowing truncated proteins, including those with abnormal N- 
terminal cleavage to be identified (Palagi et at., 2006). However, the general use of non­
specific cleavage is compromised due to the substantial increase in the amount of data to be 
searched, leading to a significant increase in analysis time (Craig, 2003). For instance, the ’no 
enzyme’ search must test all possible subsequences of each protein, rather than just (say) 
tryptic or Arg-C peptides. For a modest size protein of 250 residues, this is an increase of 
three orders of magnitude in the number of peptides which must be considered.
A separate issue to consider when performing N-terminal searches using existing 
software tools is the implicit limitation associated with so called “one hit wonders" (Veenstra et 
at., 2004). This is the phrase coined to describe a protein identification based on one peptide 
match alone. From a validation point of view, it is preferred that proteins are identified by at 
least two MS/MS sequenced peptides. However, in the case of an N-terminal preparation 
each protein is ideally represented by a single peptide. The added information gain obtained 
from the knowledge of the peptide location within the parent protein is sufficient, in most 
cases, to validate the assignment. Although, in the case of a poor quality MS/MS spectrum 
acquired from a low abundant protein in the sample, the confidence of identification will be 
poor and most likely insignificant. The fundamental problem is that currently MS search 
software does not incorporate tools to permit the inclusion of positional information. 
Subsequently, the added information gain relating to the position of the peptide is lost and will 
not directly contribute to the confidence of the match.
The use of existing proteomic databases (for example, SwissProt) using standard MS 
searching software, such as Mascot and Sequest, limits the full potential of the positional 
proteomics approach. In order to maximise the number of identifications obtained from the N-
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terminal datasets, it is necessary to construct specialised (processed) N-terminal databases 
using protein sequence data from the existing repositories. These ‘N-terminal databases’ will 
represent mature proteins sequences by allowing for NME and ensuring the removal of signal 
peptides using the information on predicted cleavage sites. However, these databases will 
only be representative of true N-terminal peptides provided the algorithms used for SP 
removal are accurate and they will not allow for other forms of N-terminal modification such as 
N-terminal trimming through the action of aminopeptidases.
3.8 A ims and  O bjectives
In this chapter, the development of two distinct strategies for N-terminal purification will be 
described. The key step to both of these strategies, protein acetylation, will initially be 
optimised to ensure complete modification. Optimisation will begin with model peptides before 
being applied to an intact purified protein, then to a complex protein mixture. Once developed 
fully, the N-terminal isolation strategy will be applied to real proteomes in order to achieve 
rational simplification of complex protein mixtures.
In addition to simplification, this analysis will provide a survey of the true nature of N- 
termini in a range of proteomes. To determine the in vivo N°-acetylation status of the N- 
terminal peptides identified in this study, the complex protein mixtures will be acetylated with a 
deuterated form of acetic anhydride ((C[2H3]C0)20). Progression of the N-terminal isolation 
strategy, using this reagent, will allow determination of the true Na-acetylation status of the 
proteins identified.
Finally, the peptides identified from each biological sample will be collated and 
analysed to enable a survey, including N-terminal amino acid frequency and N°-acetylation 
status, of a large number of mature proteins.
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3.9 Results and D iscussion
3.9.1 Optimisation of buffer conditions for acetylation
Acetic anhydride hydrolyses rapidly in aqueous conditions to produce acetic acid (Figure 3.4). 
For this reason, it is necessary to monitor the pH change of the analytical system in order to 
ensure adequate buffering capacity. To acetylate both a and £-amino groups effectively, the 
pH must be kept above 7 (to ensure that all amino groups are nucleophiles). It is therefore 
important that hydrolysis of the reagent does not cause the pH to drop below 7, as this will 
potentially prevent acetylation.
To optimise the reaction environment, acetylation buffer (Na2C0 3 ), which is amine 
free, was prepared at a range of molar concentrations (0.1, 0.2, 0.3, 0.4 and 0.5M) at pH9. 
Acetic anhydride (1pl/10pmol) was added to individual samples of buffer (50pl) and the pH 
change monitored using pH paper. The addition of 1 pi acetic anhydride caused the pH of the 
0.1-0.4M buffers to drop immediately from pH9 down to pH2. This pH drop is due to the high 
concentration of protons produced by hydrolysis of acetic anhydride (Figure 3.4). In aqueous 
conditions 10pmol of acetic anhydride hydrolyses to produce 20pmol of acetic acid, which in 
turn, will require 20pmol of base to buffer the system. To maintain a constant pH, it was 
necessary to use 50pl of 0.5M Na2CC>3 (providing 25pmol of base). However, under these 
conditions it is expected that O-acetylation of serine and tyrosine residues will be extensive.
Unlike acid anhyrides, NHS esters do not hydrolyse rapidly in aqueous conditions. For 
this reason the addition of sulfo-NHS acetate to an aqueous environment should not result in a 
substantial drop in pH. The addition of 1mg sulfo-NHS acetate to 50pl of 20mM Na2C0 3  at 
pH9, caused only a small pH drop (pH9 to 7), which should be sufficient for amino group 
derivatisation (Wong, 1991).
3.9.2 Acetylation of model peptides
To establish the most suitable reaction conditions for amino group acetylation, two separate 
time course experiments were set up using two different acetylation reagents: acetic 
anhydride and sulfo-NHS acetate. The model peptide ACTH fragment 1-17 was chosen for 
this experiment. This standard peptide (2092.08Da) contains three lysine residues, two serine 
residues and one tyrosine residue (Figure 3.8). In addition to the a-amino group, this makes a 
total of seven possible acetylation sites (four N-acetylation and three O-acetylation sites).
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o O-acetylation site
Figure 3.8. Sequence of ACTH fragment 1-17, highlighting potential N and 0- 
acetylation sites.
N o. acety la tion  sites [M + H ]+ [M + 2H ]2+ [M + 3H ]3+
0 2 0 9 3 .0 9 1 0 4 7 .0 5 6 9 8 .3 7
1 2 1 3 5 .1 0 1 0 6 8 .0 5 7 1 2 .3 7
2 2 1 7 7 .1 1 1 0 8 9 .0 6 7 2 6 .3 7
3 2 2 1 9 .1 2 1 1 1 0 .0 6 7 4 0 .3 8
4 2 2 6 1 .1 3 1 1 3 1 .0 7 7 5 4 .3 8
5 2 3 0 3 .1 4 1 1 5 2 .0 7 7 6 8 .3 8
6 2 3 4 5 .1 5 1 1 7 3 .0 8 7 8 2 .3 8
7 2 3 8 7 .1 6 1 1 9 4 .0 8 7 2 6 .3 9
Table 3.2. m/z of ACTH fragment 1-17 in multiply acetylated forms.
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Table 3.2 indicates the expected m/z values ([M+H]+, [M+2H]2+ and [M+3H]3+) for the 
unmodified peptide, all partially acetylated intermediates and the fully modified peptide.
Each time course experiment consisted of 10 samples of ACTH 1-17, each containing 
10pg (5nmol) of the peptide. In the first experiment, the peptide was diluted in 0.5M Na2CC>3, 
pH9 (50pl) and 1pl acetic anhydride was added to each aliquot. In the second experiment, the 
peptide was diluted in 20mM Na2C0 3 , pH9 (50pl) and 0.1 mg sulfo-NHS acetate was added to 
each aliquot. The samples were mixed by vortexing and the reactions halted by the addition of 
1 MTris, pH8 (10|jl). Hydroxylamine (1pl/30|jmol) was added to the final sample in both 
experiments to remove potential acetyl groups from serine or threonine residues. Each sample 
was desalted using a C18 ZipTip prior to MALDI-ToF and ESI-Q-ToF analysis.
Figure 3.9 shows the MALDI-ToF spectra for the acetic anhydride time course 
experiment. From the masses listed in Table 3.2, it can be seen that immediately after the 
addition of 1 pi acetic anhydride, the peptide was present in three forms, corresponding to the 
addition of 4, 5 and 6 acetyl groups. After 1min an additional peak appears corresponding to 
the [M+H]+ value for 7 acetyl groups, indicating that the peptide is acetylated on all possible 
sites. Following the addition of 1pil (30|jmol) hydroxylamine a single peak is present at 
2261.13 m/z corresponding to the [M+H]+ value of four acetyl groups. The results were similar 
for the NHS acetate time course (Figure 3.10). In this case the peptide was not fully N- 
acetylated immediately after the addition of the reagent; however, acetylation was complete 
after 30min.
It is not possible to determine the precise location of the acetyl groups from mass 
alone. In order to establish which amino acid residues have been modified, it is necessary to 
obtain de novo sequence data. Each sample was diluted to Ipmol/pil and infused into the ESI- 
Q-ToF for MS/MS analysis. Product ion spectra were collected for the unmodified peptide 
(Figure 3.11), all acetylated intermediates (Figures 3.12-3.14), the fully acetylated peptide 
(Figure 3.15) and the hydroxylamine treated peptide (Figure 3.16). All ions observed were 
[M+3H]3+. Table 3.2 shows the expected [M+3H]3+ values for all modified forms of the peptide. 
The de novo sequence data shows that acetylation occurs initially on the primary amino 
groups (a-amino group and lysine residues) followed by modification at serine and tyrosine 
residues (Figure 3.12-3.15). Addition of 1(j I hydroxylamine facilitated the removal of acetyl 
groups from serine and tyrosine, resulting in the presence of a single, fully N-acetylated 
peptide (Figure 3.16).
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Figure 3.9. ACTH 1-17 acetylation time course (acetic anhydride).
The model peptide ACTH 1-17 (10pg) was acetylated using 1pl acetic anhydride. The reaction was 
quenched at 0, 1, 15, 30, 60 and 120min by the addition of 5pl Tris (1M, pH8.5). The final sample was 
treated with 1pl of hydroxylamine to reverse O-acetylation at serine and tyrosine residues. The unmodified 
and acetylated peptides were desalted on a C18 ZipTip prior to MALDI-ToF MS. [M+H]+ values for the 
unmodified peptide and acetylated intermediates are represented in Table 3.2.
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Figure 3.10. ACTH 1-17 acetylation time course (sulfo-NHS acetate).
The model peptide ACTH 1-17 (10pg) was acetylated using 1mg sulfo-NHS acetate. The reaction was 
quenched at 1, 1, 15, 30, 60 and 120min by the addition of 5pl Tris (1M, pH8.5). The final sample was 
treated with 1pl of hydroxylamine to reverse O-acetylation at serine and tyrosine residues. The unmodified 
and acetylated peptides were desalted on a C18 ZipTip prior to MALDI-ToF MS. [M+H]+ values for the 
unmodified peptide and acetylated intermediates are represented in Table 3.2.
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Figure 3.11. Sequence determination of unmodified ACTH 1-17.
The model peptide ACTH 1-17 was diluted in 0.1%  (v/v) FA: 50%  (v/v) ACN, to give a 
final concentration of 1pmol/pl. The solution containing the peptide was introduced into 
the ES I-Q -ToF by direct infusion at a rate of 0.5pl/min. From the MS spectrum (upper 
panel) the precursor ion at [M +3H]3+ 698.36 was selected using the quadrupole 
fragmented using a collision energy of 30% . The product ion spectra were combined and 
processed using M axENT3. The resulting M S/M S spectrum was sequenced de novo 
using the Biolynx software tool (lower panel).
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Figure 3.12. Determination of the position of acetyl groups coupled to ACTH 1-17 
[M+3H]3+ 754.21.
Sample t=0 from the acetic anhydride acetylation time course was desalted using a C18  
ZipTip and diluted (1in20) using 0.1%  (v/v) FA: 50%  (v/v) ACN. The differentially 
acetylated peptide mixture was introduced into the ES I-Q -ToF by direct infusion at a rate 
of 0.5pl/m in. From the MS spectrum (upper panel), the precursor ion at [M +3H]3+ 754.21 
was selected using the quadrupole and fragmented using a collision energy of 30% . The 
product ion spectra were combined and processed using M axENT3. The resulting M S/M S  
spectrum was sequenced de novo using the Biolynx software tool (lower panel).
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Figure 3.13. Determination of the position of acetyl groups coupled to ACTH 1-17 
[M+3H]3+ 768.26 .
Sample t=1min from the acetic anhydride acetylation time course was desalted using a 
C 18 ZipTip and diluted (1in20) using 0.1%  (v/v) FA: 50%  (v/v) ACN. The differentially 
acetylated peptide mixture was introduced into the ES I-Q -ToF by direct infusion at a rate 
of 0.5pl/min. From the M S spectrum (upper panel) the precursor ion at [M +3H]3+ 768.26  
was selected using the quadrupole and fragmented using a collision energy of 30% . The 
product ion spectra were combined and processed using M axENT3. The resulting 
M S/M S spectrum was sequenced de novo using the Biolynx software tool (lower panel).
111
Figure 3.14. Determination of the position of acetyl groups coupled to ACTH 1-17 
[M+3H]3+ 782.26.
Sample t=1min from the acetic anhydride acetylation time course was desalted using a 
C 18 ZipTip and diluted (1in20) using 0.1%  (v/v) FA: 50%  (v/v) ACN. The differentially 
acetylated peptide mixture was introduced into the ESI-Q -ToF by direct infusion at a rate 
of 0.5pl/min. From the MS spectrum (upper panel) the precursor ion at [M +3H]3+ 782.26  
was selected using the quadrupole and fragmented using a collision energy of 30% . The 
product ion spectra were combined and processed using M axENT3. The resulting 
M S/M S spectrum was sequenced cte novo using the Biolynx software tool (lower panel).
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Figure 3.15. Determination of the position of acetyl groups coupled to ACTH 1-17 
[M+3H]3+ 796.26.
Sample t=120min from the acetic anhydride acetylation time course was desalted using a 
C18 ZipTip and diluted (1in20) in 0.1% (v/v) FA: 50% (v/v) ACN. The differentially 
acetylated peptide mixture was introduced into the ESI-Q-ToF by direct infusion at a rate 
of 0.5pl/min. From the MS spectrum (upper panel) the precursor ion at [M+3H]3+796.26 
was selected using the quadrupole and fragmented using a collision energy of 30%. The 
product ion spectra were combined and processed using MaxENT3. The resulting 
MS/MS spectrum was sequenced de  n o vo  using the Biolynx software tool (lower panel).
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Figure 3.16. Determination of the position of acetyl groups coupled to 
hydroxylamine treated ACTH 1-17.
Sample t=120min (hydroxylamine treated) from the acetic anhydride acetylation time 
course was desalted using a C18 ZipTip and diluted (1in20) using 0.1% (v/v) FA: 50% 
(v/v) ACN. The differentially acetylated peptide mixture was introduced into the ESI-Q- 
ToF by direct infusion at a rate of 0.5pl/min. From the MS spectrum (top panel) the 
precursor ion at [M+3H]3+ 754.25 was selected using the quadrupole and fragmented 
using a collision energy of 30%. The product ion spectra were combined and processed 
using MaxENT3. The resulting MS/MS spectrum was sequenced d e  n o v o  using the 
Biolynx software tool (lower panel).
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The behaviour observed from the two time course experiments can be explained by 
the strength of buffer used. Due to the fact that acetic anhydride hydrolyses rapidly in aqueous 
conditions to produce acetic acid, it is necessary to use a strong buffer to sustain a pH greater 
than pH9. The enhanced buffering capacity drives the acetylation reaction to completion faster 
than when a weaker buffer is used, but as a consequence leads to a greater occurrence of 0- 
acetylation. In contrast, sulfo-NHS acetate does not hydrolyse to produce acid and can 
acetylate effectively in 20mM Na2C0 3 . Under these conditions it is more suitable to use sulfo- 
NHS acetate as the amino group acetylation agent.
3.9.3 Acetylation of a purified protein
Although it has been demonstrated that complete N-acetylation of peptides is readily 
achieved, the efficient acetylation of an intact protein should also be investigated. Native 
proteins can have complex structures that may prevent access of the reagent to specific 
regions of the molecule. To investigate the extent to which an intact protein can be acetylated, 
pyruvate kinase from rabbit muscle was derivatised using sulfo-NHS acetate.
Pyruvate kinase is a cytosolic protein and is characteristic of the soluble proteins 
targeted in this study. Disulfide bonds are extremely rare in cytosolic proteins, since the 
cytosol is generally a reducing environment (Derman and Beckwith, 1991). For this reason, it 
should be feasible to modify cytosolic proteins in their native state without the need for 
reduction and alkylation steps.
The protein was acetylated using sulfo-NHS acetate in 20mM Na2CC>3, pH9. A 
comparison was made between the non-acetylated (control) tryptic digest and the acetylated 
protein. Samples were set up in duplicate to allow for experimental variation. Following 
acetylation, polymer bound Tris was added to the samples to quench residual reagent. 
Samples were also treated with hydroxylamine at this stage, which is required to remove 0- 
acetylation of serine and tyrosine. Prior to digestion, all samples were subjected to a TCA 
precipitation and multiple ether washes to remove all traces of TCA. The protein pellets were 
resuspended in 50mM ammonium bicarbonate and digested overnight with trypsin. The 
resulting peptide mixture was analysed by MALDI-ToF MS (Figure 3.17).
In Figure 3.17a, both lysine and arginine terminated tryptic peptides have been 
labelled; the peptide map represents the coverage observed. The acetylated protein, when 
digested with trypsin, yields only arginine terminated tryptic peptides (Figure 3.17b). The
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Figure 3.17. Acetylation of pyruvate kinase.
Pyruvate kinase (10pg) was acetylated by the addition of 0.1 mg sulfo-NHS acetate in 20mM Na2C0 3  The 
acetylated protein was then digested, alongside 10pg of unmodified protein, with trypsin (1:50 
enzyme:substrate ratio) overnight. The resulting peptide mixtures, unmodified (a) and acetylated (b), were 
analysed by MALDI-ToF MS. The unmodified protein gave rise to both lysine and arginine terminated tryptic 
peptides (indicated in green of the peptide map) and the acetylated protein gave rise to arginine terminated 
tryptic peptides exclusively (Arg-C peptides, indicated in purple on the peptide map). Non-lysine containing 
tryptic peptides appeared in both digests, for example [M+H]+ ion at 1171.58 (c). The absence of lysine 
terminated peptides from the acetylated digest, in addition to the mass shift of +42Da for lysine containing 
peptides (d), provides evidence that acetylation is complete.
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absence of lysine cleaved tryptic peptides in Figure 3.17b infers that acetylation is complete, 
as proteolysis at lysine residues has been blocked by side chain modification. Peaks common 
to both non-acetylated and acetylated digests are the result of two successive arginine 
cleavages, without the presence of an internal lysine residue (Figure 3.17c). The presence of 
an internal lysine residue in the acetylated peptide mixture produces a mass increase of 42Da 
corresponding to the acetylated amino group (e-amino group; Figure 3.17d).
3.9.4 SDS-PAGE and PMF of mouse skeletal muscle soluble proteins
The soluble fraction of skeletal muscle is comprised mainly of glycolytic enzymes and is 
sufficiently enriched in a relatively small number of proteins, thus providing useful test material 
for the N-terminal protocol (Hayter et a/., 2003).
To assess the complexity and characterise the dominant protein species in mouse 
skeletal muscle soluble fraction, the protein mixture (15pg) was separated by 1-D SDS-PAGE 
and visualised using Coomassie. The resulting 1-D profile is dominated by 11 major bands, 
corresponding to the most abundant proteins in the sample (Table 3.3). To obtain protein 
identification, the major bands were excised and subjected to in-gel proteolysis using trypsin. 
The digested peptide mixtures were characterised by MALDI-ToF MS (Supplementary data 
A). The proteins were identified from their peptide mass fingerprint by manual searching 
against a locally implemented Mascot server against the MSDB database. Search parameters 
allowed a single missed tryptic cleavage, carbamidomethyl modification of cysteine (fixed) 
oxidation of methionine (variable), and a peptide tolerance of ±150ppm. The taxonomic 
space was restricted to Mus musculus. The proteins were all identified with high confidence 
and were predominantly found to be glycolytic enzymes. Figure 3.18 shows the coverage 
observed for each protein hit from the PMF experiment.
3.9.5 Acetylation of mouse muscle soluble fraction
The soluble fraction of mouse skeletal muscle (50pg protein) was acetylated using 1mg NHS 
acetate. In an attempt to decrease the number of experimental steps, the intact protein 
mixture was acetylated without prior reduction and alkylation. Soluble skeletal muscle proteins 
are mainly cytosolic proteins that have uncomplicated tertiary or quaternary structures due to 
lack of disulphide bridges. For this reason, it is not necessary to denature the protein by 
reduction in order to achieve modification. The acetylated protein mixture was treated with 
polymer bound Tris, which serves to remove excess acetylation reagent. The mixture was
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Chapter 3: Development of novel strategies for N-terminal pep tide isolation
precipitated using TCA and the protein pellet washed in ether to ensure removal of residual 
acid, prior to overnight proteolysis. A control digest of mouse skeletal muscle soluble fraction 
was also prepared to compare the unmodified and acetylated digestion products. Small 
amounts (5pl) of the resulting peptide mixtures were desalted using a C18 ZipTip and 
analysed by MALDI-ToF MS. A further aliquot (1pl) of the unmodified and acetylated peptide 
mixture was diluted (1 in 200) and 10pl of each dilution was subjected to LC-MS/MS analysis 
on the LTQ ion trap instrument.
Figure 3.19 shows the peptide profiles for the unmodified (a) and acetylated (b) tryptic 
peptides. The MALDI-ToF spectra generated for both the unmodified and modified tryptic 
digests represent the most abundant peptides in the sample. Peptides generated from the 
acetylated protein mixture appear as arginine terminated tryptic peptides, as the lysine 
residues are blocked by acetylation and are resistant to proteolysis. The data generated from 
LC-MS/MS analysis was used to assign peptide identifications and annotate the most 
abundant ions in the MALDI-ToF spectra. The major ions in both spectra can be assigned to 
abundant proteins in skeletal muscle (seen in Figure 3.18).
MALDI-ToF analysis at this stage of the protocol serves as a ‘check point’ in which the 
effectiveness of the acetylation step can be monitored, provided a few key peptides can be 
identified. The precise level of acetylation is difficult to determine, however, the observation of 
arginine terminated, as opposed to lysine terminated, tryptic peptides provide a good 
indication that a sufficient degree of modification has occurred. The N-terminal isolation 
protocol is a “self-cleaning” method; as a result, the presence of a small amount of unmodified 
peptides would not have a detrimental effect on the overall procedure, as these unmodified 
peptides would be removed in later stages of the protocol (biotinylation of peptides/ removal of 
peptides with streptavidin/NHS-Sepharose). A low level of acetylation, however, will result in a 
reduced yield of N-terminal peptides.
3.9.6 Biotinylation of acetylated digest of mouse skeletal muscle proteins
The remaining peptide mixture produced from digestion of acetylated mouse skeletal muscle 
proteins (50pg), was biotinylated by the addition of 1mg NHS-biotin. The subsequent peptide 
mixture consisted of biotinylated internal and C-terminal peptides and non-biotinylated N- 
terminal peptides. Following the biotinylation reaction, the modified peptide mixture was 
desalted using a C18 ZipTip and subjected to MALDI-ToF analysis. Figure 3.20 shows the 
spectra obtained from the acetylated digest (a) and the biotinylated form of the peptide mixture
1 2 0
b) ENOB R1 
AMQKIFAR + MetOx
G PR 5
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Figure 3.19. Comparison of tryptic digests from unmodified and acetylated mouse 
skeletal muscle soluble fraction.
Unmodified (a) and acetylated (b) mouse skeletal muscle soluble proteins were digested 
with trypsin (50:1 substrate enzym e ratio) at 37°C overnight. Peptides were analysed by 
M ALDI-ToF MS using a laser energy of 30% . Peptide ions in (a) were representative of the 
most abundant proteins in mouse skeletal muscle. Tryptic peptides identified by LC-M S/M S  
on the LTQ ion trap instrument were matched to the most intense ions in the spectrum. The 
acetylated protein mixture (b), when digested with trypsin, yielded arginine terminated 
peptides only, containing a mass shift of +42D a for each internal lysine. Peptides from the 
major proteins in the sample were matched to the most intense ions. The absence of ions 
corresponding to lysine terminated tryptic peptides coupled with the observation of a +42Da  
increase for each internal lysine in (b) is sufficient to confirm peptide acetylation.
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Figure 3.20. Comparison of acetylated and acetylated/biotinylated peptides from 
mouse skeletal muscle soluble fraction.
Acetylated (a) and acetylated/biotinylated (b) peptides were analysed by MALDI-ToF 
MS using a laser energy of 30% . The majority of the ions exhibited a mass shift of 
+226D a indicating the addition of a biotin group.
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(b). All internal peptides contain a free a-amlno group and react with the NHS-biotin 
undergoing a mass shift of +226Da. In contrast to the acetylation step, it is important that 
biotinylation of peptides is complete. If any internal peptides remain unmodified they will not 
be retained by the streptavidin Sepharose and will pass through along with the N-terminal 
peptides. Tryptic peptides are, in general, easier to modify than intact proteins due to their size 
and accessibility. A 100-fold excess of NHS-biotin in a controlled reaction environment (pH7.5) 
is sufficient to ensure complete biotinylation.
3.9.7 Streptavidin purification of internal peptides
To separate internal from N-terminal peptides, the biotinylated peptide mixture was subjected 
to affinity purification by streptavidin Sepharose. The Sepharose (20pl) was washed three 
times with binding buffer (20mM Na2HP0 4 , 0.15M NaCI, pH7.5) before adding the starting 
material equivalent of 1 pig desalted peptides (made up to 20pl in binding buffer). The flow 
through was retained and the column was washed with a further 10pl of binding buffer. The 
unbound material containing the purified N-terminal peptides was pooled. A small amount of 
flow through was desalted using a C18 ZipTip and analysed by MALDI-ToF MS and the 
remaining material was subjected to LC-M/SMS analysis on the LTQ ion trap instrument. 
Figure 3.21 represents the MALDI-ToF spectrum of the purified N-terminal peptides. The most 
notable observation is the high level of simplification gained by the removal of internal 
peptides from the complex mixture. The N-terminal MALDI-ToF spectrum contains around 10 
major peaks, in contrast with the spectrum from the in-solution digests of mouse muscle, 
which contain in excess of 50 intense peaks (Figure 3.19). Table 3.4 lists the most abundant 
proteins in mouse skeletal muscle soluble fraction (as seen on gel in Figure 3.19), along with 
the predicted N-terminal “Arg-C” sequences and [M+H]+ values. Three major ions present in 
the MALDI-ToF spectrum (Figure 3.21), correspond to N-terminal peptides from beta enolase 
(m/z 1048.59) and GAPDH (m/z 1116.66). The ion at m/z 1060.59 corresponds to the 
methionine oxidised form of the beta enolase peptide at m/z 1048.59. Lower intensity signals 
are also present for the N-termini of annexin (m/z 1191.69), serum albumin (m/z 1261.68) and 
glycogen phosphorylase (m/z 1285.70). The N-terminal peptides from the two proteins 
fructose-bisphosphate aldolase and phosphoglucomutase, both have similar m/z values 
(2553.22 and 2553.38 respectively). The resolution of the MALDI-ToF instrument is not 
capable of distinguishing between these two m/z values. The remaining low abundant ions in 
the spectrum remain unidentified.
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Chapter 3: Development of novel strategies for N-terminal peptide isolation
LC-MS/MS analysis of the mouse muscle N-terminal sample identified a total of five 
N-terminal “Arg-C” peptides from mouse skeletal muscle (Table 3.5). The relatively low 
number of hits can be attributed partly to the nature of skeletal muscle soluble proteins, which 
is dominated by approximately 10-20 major proteins (predominantly glycolytic enzymes; 
Hayter et al., 2003; Doherty et al., 2004). This preparation has the advantage of generating 
relatively simple spectra and provides a valuable test system with which to establish the 
method. The low number of hits is also due to the reduced yield of N-terminal peptides 
generated by the biotin/streptavidin method.
3.9.8 Removal of internal peptides by NHS-activated Sepharose
The acetylated peptide mixture was diluted 1:1 in binding buffer and incubated with NHS- 
Sepharose for 4h at room temperature (with turning), then again in a fresh aliquot of 
Sepharose overnight at 4°C. The supernatant containing the N-terminal peptides was 
removed from the Sepharose. A small amount (5pl) of N-terminal peptides was desalted using 
a C18 ZipTip. The desalted peptide preparation was analysed by MALDI-ToF MS. The 
remaining material (100pl) was split into 10pl aliquots, which were either subjected to LC- 
MS/SMS analysis on the LTQ ion trap instrument, or stored at -20°C for later use. Figure 3.22 
shows a comparison of the MALDI-ToF spectrum observed for the N-terminal peptides 
generated by both methods. There appears to be no difference in the major peaks seen in 
both spectra, which indicates that both methods are equally effective for separating non- 
acetylated internal from acetylated N-terminal peptides. The LC-MS/MS analysis from the N- 
terminal peptides generated in the NHS-Sepharose method resulted in the identification of 50 
N-terminal peptides (Table 3.6) representing a 10-fold increase in identifications compared 
with the biotin method. Out of these 50 peptides, 41 proteins had undergone NME and four SP 
removal. The remaining five peptides were unmodified.
The gain in peptide identification can be attributed to the increased yield of product 
obtained in the NHS-Sepharose method, which is a direct result of fewer analytical steps. Due 
to the increased yield the NHS-Sepharose method for N-terminal purification will be the 
method adopted for use on more complex samples.
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1 Beta-enolase (P21550) 1047.55 AMQKIFAR M 102
2 Glyceraldehyde-3-phosphate dehydrogenase (P16858) 1115.61 VKVGVNGFGR M 150
3 Bisphosphoglycerate mutase (P15327) 1232.76 SKHKLIILR M 54
4 Serum albumin (mature)( P07724) 1260.62 EAHKSEIAHR SP 475
5 Glycogen phosphorylase, muscle form (Q9WUB3) 1326.65 SRPLSDQDKR M 32
6 Fructose-1,6-bisphosphatase isozyme 2 (P70695) 1823.87 TDRSPFETDMLTLTR M 47
7 Fructose-bisphosphate aldolase A (P05064) 2552.30 PHPYPALTPEQKKELSDIAHR M 29
Table 3.5. Identification of mouse skeletal muscle proteins by LC-MS/MS analysis of N- 
terminal peptides generated using the NHS-Biotin method.
The N-terminal peptide preparation of mouse skeletal muscle soluble fraction was analysed by 
LC-M S/M S on the LTQ ion trap instrument using a three hour RP gradient. M S/M S data was 
used to search the mouse N-terminal database using the M ASCO T search engine. The 
taxonomy was restricted to Mus musculus; fixed modifications: N-terminal acetylation and lysine 
acetylation; variable modification: oxidation of methionine; protease: Arg-C; missed cleavages: 
1; peptide tolerance: 1.5Da; M S/M S tolerance: 0.6Da; instrument: ESI-TRAP; peptide charge: 
1+, 2+ and 3+. Protein identifications with a Mowse score greater than 20 were accepted as 
confident identifications.
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1048.50
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AMQKIFAR
Glyceraldehyde 3-phosphate dehydrogenase 
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Figure 3.22. Comparison of NHS-biotin and NHS-Sepharose methods for N- 
terminal purification.
M ALDI-ToF spectra from the N-terminal peptide preparations generated using the NHS- 
biotin (a) and the NHS-Sepharose methodologies (b), are displayed for comparative 
purposes.
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1 40S ribosomal protein S 12  (P63323) 701.32 AEEGIAR M 34
2 Nuclear localisation protein 4 (P60670) 842.49 AESIIIR M 21
3 Ferritin heavy chain (P09518) 987.50 TTASPSQVR M 29
4 Ribonucléase P protein subunit p30 (088796) 1032.52 AAFADLDLR M 42
5 Beta-enolase (P21550) 1047.55 AMQKIFAR M 210
6 Voltage-dependent calcium channel (070578) 1059.60 SQTKTAKVR M 20
7 Homeobox protein Hox-C13 (P50207) 1078.61 TTSLLLHPR M 25
8 Bisphosphate ^nucleotidase 1 (Q9HS1) 1084.53 ASSHTVLMR M 56
9 S-formylglutathione hydrolase (Q9R0P3 ) 1099.60 ALKQISSNR M 41
10 Glyceraldehyde-3-phosphate dehydrogenase (P16858) 1115.61 VKVGVNGFGR M 190
11 Dimethylarginine dimethylaminohydrolase (Q9CWS0) 1152.57 AGLGHPSAFGR M 41
12 14-3-3 protein eta (P68510) 1155.60 GDREQLLQR M 87
13 Annexin A6 (P14842) 1191.61 AKIAQGAMYR M 98
14 Mitochondrial 28S ribosomal protein S21 (P58059) 1208.70 AKHLKFIAR M 50
15 Bisphosphoglycerate mutase (P15327) 1232.76 SKHKLIILR M 89
16 Serum albumin (mature)( P07724) 1260.62 EAHKSEIAHR M 150
17 40S ribosomal protein S15  (P62843) 1282.69 AEVEQKKKR M 54
18 Glutathione S-transferase Mu 1 (P10649) 1289.66 PMILGYWNVR M 32
19 Glutathione S-transferase Mu 2 (P15626) 1292.62 PMTLGYWDIR M 62
20 Glycogen phosphorylase (Q9W83) 1326.65 SRPLSDQDKR M 78
21 Macrophage migration inhibitory factor (P34884) 1328.69 PMFIVNTNVPR M 23
22 Peptidyl-prolyl cis-trans isomerase (P26883) 1355.67 GVQVETISPGDGR M 47
23 Glutathione S-transferase P1 (P19157) 1392.74 PPYTIVYFPVR M 50
24 14-3-3 protein gamma (P61982) 1424.77 DREQLVQKAR M 71
25 Fatty acid-binding protein (Q05816) 1427.74 ASLKDLEGKWR M 29
26 Tubulin polymerisation-promoting protein (Q9CRB6) 1507.70 AASTDIAGLEESFR M 20
27 Calseqestrin-1 (mature) (009165) 1667.70 EDGLDFPEYDGVDR SP 40
28 Acyl-CoA-binding protein (P31786) 1782.33 SQAEFDKAAEEVKR M 48
29 aspartate-beta-hydroxylase (CAM26685) 1800.85 AEDKEAKHGGHKNGR M 75
30 Fructose-1,6-bisphosphatase isoyme 2 (P70695) 1823.87 TDRSPFETDMLTLTR M 89
31 Myosin-1 (Q5SX40) 184.850 SSDAEMAVFGEAAPYLR M 56
32 Cytosolic non-specific dipeptidase (Q9D1A2) 1979.96 SALKAVFQYIDENQDR M 30
33 Peptidyl-prolyl cis-trans isomerase A (P17742) 2046.98 VNPTVFFDITADDEPLGR M 51
34 Phosphoglycerate kinase 1 (P09411) 2166.19 SLSNKLTLDKLDVKGKR M 96
35 Peroxiredoxin-6 (008709) 2183.09 PGGLLLGDEAPNFEANTTIGR M 75
36 Cofilin-1 (P18760) 2217.15 ASGVAVSDGVIKVFNDMKVR M 102
37 14-3-3 protein eta/delta (P63101) 2268.14 MDKNELVQKAKLAEQAER 136
38 Myosin light chain 3 (P05978) 2303.11 SFSADQIADFKEAFLLFDR M 23
39 Cofilin-2 (P45591 ) 2346.19 ASGVTVNDEVIKVFNDMKVR M 48
40 14-3-3 protein epsilon (P62259) 2363.11 MDDREDLVYQAKLAEQAER 69
41 Calreticulin (mature) (P14211) 2369.10 DPAIYFKEQFLDGDAWTNR SP 48
42 Histidine triad nucleotide-binding protein 1 (P70349) 2523.33 ADEIAKAQVAQPGGDTIFGKIIR M 21
43 Fructose-bisphosphate aldolase A (P05064) 2552.30 PHPYPALTPEQKKELSDIAHR M 90
44 Phosphog!ucomutase-1 (Q9D0F9) 2553.38 VKIVTVKTQAYPDQKPGTSGLR M 87
45 Tropomyosin-1 alpha chain (P58771) 2770.41 MDAIKKKMQMLKLDKENALDR 69
46 Adenylate kinase isoen^me 1 (Q9R0Y5) 2823.51 GKKLSAIMEKGELVPLDTVLDMLR M 49
47 Actin, cytoplasmic 2 (P63260 ) 2861.28 EEEIAALVIDNGSGMCKAGFAGDDAPR 68
48 Hemoglobin subunit alpha (P01942) 3380.66 VLSGEDKSNIKAAWGKIGGHGAEYGAEALER 47
49 Alpha-1-antitrypsin 1-2 (mature) (P22599) 3748.73 EDVQETDTSQKDQSPASHEIATNLGDFAISLYR SP 40
50 Alpha-1-antitrypsin 1-4 (mature) (Q00897) 3385.55 EDVQETDTSQKDQSPASHEIATNLGDFALR SP 59
Table 3.6. Identification of mouse skeletal muscle proteins by LC-MS/MS analysis of N- 
terminal peptides generated using the NHS-Sepharose method.
The N-terminal peptide preparation of mouse skeletal muscle soluble fraction was analysed by LC- 
M S/M S using a three hour RP gradient. M S/M S data was used to search the mouse N-terminal 
database using the M ASCO T search engine. The taxonomy was restricted to Mus musculus; fixed 
modifications: N-terminal acetylation and lysine acetylation; variable modification: oxidation of 
methionine; protease: Arg-C; missed cleavages: 1; peptide tolerance: 1.5Da, M S/M S tolerance: 
0.6D a, instrument: ESI-TRAP, peptide charge: 1+, 2+ and 3+. Protein identifications with a Mowse 
score greater than 20 were accepted as confident identifications.
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3.9.9 Atypical isotope distribution of the GAPDH N-terminal peptide
When analysing the MALDI-ToF spectrum of the mouse skeletal muscle N-terminal peptide 
mix, the peak representing the GAPDH N-terminal peptide exhibited an abnormal isotope 
distribution (Figure 3.23a). The same isotope distribution is also observed for the unmodified 
form of the tryptic peptide obtained from an in-gel digest of GAPDH the mouse skeletal muscle 
sample (Figure 3.23b). In addition, analysis of soluble proteins from skeletal muscle over a 
range of species reveals the same isotope distribution for the protein (data not shown).
The mass isotopmer envelope is consistent with the analyte being a mixture of two 
peptides: one with a monoisotopic mass of 1031.6Da and one with the monoisotopic mass of 
1032.6Da. The higher m/z value could have arisen from contamination; however, since the 
peptide contains an asparagine residue, the most probable explanation for the 1Da mass 
increase is deamidation of asparagine to aspartic acid. A combination of the acid and amide 
form of the peptide would account for the atypical isotope pattern observed.
To validate this hypothesis, the in-gel digest of mouse muscle GAPDH (taken from the 
SDS-PAGE analysis in Figure 3.18) was subjected to methyl esterification. This reaction 
results in the addition of a methyl group (+14Da) to each acidic residue in the peptide. In the 
case of the asparagine containing peptide this should result in one methyl esterification to the 
carboxyl group on the C-terminal of the peptide. In the case of the aspartic acid peptide this 
should result in two methyl esterifications, one on the carboxyl group on the C-terminal of the 
peptide and an additional methyl esterification on the carboxyl group of the acidic residue.
In the MALDI-ToF spectrum obtained after methyl esterification the ions in the 1032- 
1036 m/z region disappeared, and two new ions appeared, the first representing the peptide 
with the addition of one methyl group (m/z 1032.58 + 14.03 = 1046.61) and the second 
representing the peptide with the addition of two methyl groups (m/z 1033.58 + 28.06 = 
1061.64; Figure 3.23c). This experiment confirms that the atypical isotope pattern observed 
for the N-terminal peptide of GAPDH is indeed the result of deamidation. What is not clear 
from this, however, is whether this deamidation event occurs in vivo or is an artifact of sample 
preparation and processing. Further analysis (monitored proteolysis and absolute 
quantification of proteolytic products) showed that this modification occurs post-proteolysis {in 
vitro), due to relieved constraint of the peptide backbone trajectory, which permits the 
deamidation reaction to take place (Rivers et al., 2008).
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[M+H]* 1032.6 + 2(42) = 1116.6
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Figure 3.23. Atypical isotope distribution of the GAPDH N-terminal.
Both the unmodified (a) and N-acetylated (b) forms of the GAPDH tryptic peptide 
exhibit an atypical isotope distribution when analysed by MALDI-ToF MS. When  
reacted with acetyl chloride and methanol (esterification), the two overlapping forms of 
the peptide are resolved into two distinct reaction products (c). The asparagine 
containing peptide undergoes the addition of one methyl group (+14D a) and the 
aspartic acid containing peptide undergoes the addition of two methyl (+28D a) groups.
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3.9.10 Global analysis of complex proteomes using positional proteomics
The NHS-Sepharose method for N-terminal enrichment was applied to three complex 
biological samples: mouse liver, S. cerevisiae and £  coil cell lysate. In all cases, only the 
soluble protein fraction was analysed. To allow for experimental variation, three separate N- 
terminal preparations were made and each preparation was subjected to LC-MS/MS analysis 
on the LTQ ion trap instrument using the extended gradient. Three separate LC-MS/MS 
experiments were performed for each N-terminal preparation. The experimental strategy is 
summarised in Figure 3.24.
Each of the acetylated digests were initially analysed by MALDI-ToF MS to provide a 
comparison between the total acetylated digest and the N-terminal preparation (Figures 3.25- 
3.27a). Due to the complexity of the peptide mixtures generated, it is difficult to assign 
peptides to individual peaks in the spectra. Following N-terminal enrichment by NHS- 
Sepharose, the mixtures generated spectra in which all major ions can be assigned to N- 
terminal peptides (Figures 3.25-3.27b; MALDI-ToF peak assignments are listed in Table 3.7, 
3.8 and 3.9).
Although simplified, the N-terminal mixtures generated are too complex to be analysed without 
separation. Each sample was subjected to three identical LC-MS/MS runs on the LTQ ion trap 
instrument, using the extended, three hour, RP gradient (a total of nine LC-MS/MS 
experiments for each proteome). The MS/MS data was processed in Sequest to generate an 
MGF file which was used for database searching (SwissProt and specialised N-terminal 
databases) through the Mascot search engine. Parameters included: a single missed tryptic 
cleavage; acetylation of lysine and the N-terminal amino group (fixed) oxidation of methionine 
and acetylation of serine (variable); peptide tolerance: 1.5Da; MS/MS tolerance: 0.6Da; 
instrument: ESI-TRAP; peptide charge: 1+, 2+ and 3+ and the taxonomic space was restricted 
to the species analysed. MS/MS matches with ion scores over the reported threshold 
(indicating extensive homology) were taken as significant identifications.
Additionally, MS/MS matches reported with ion scores lower than the given threshold 
were manually inspected, and provided a strong y or b ion series could be identified, these 
matches were included as significant N-terminal identification. All identifications obtained by 
LC-MS/MS are listed in Supplementary data B. A total of 220 were identified for mouse liver, 
186 for S. cerevisiae and 337 for £  coli.
132
3h LC-MS/MS
Figure 3.24. Scheme for the preparation and analysis of N-terminal peptides 
from three complex biological samples.
To allow for experimental variation, N-terminal preparations from each complex 
proteome (mouse liver, S. cerevisiae and E. coli) were generated in triplicate. Each 
preparation was analysed a total of three times on the LTQ ion trap instrument, 
using the extended three hour RP gradient (nine LC -M S/M S runs in total).
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Figure 3.25. Isolated N-terminal peptides from mouse liver soluble 
fraction.
The acetylated digest (a) and the N-terminal preparation (b) of mouse liver 
proteins were analysed by MALDI-ToF MS using a laser energy of 30%. All of 
the major ions in the N-terminal spectra can be assigned to N-terminal peptides 
from mouse liver (Table 3.7 represents the labelled ions).
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1 60S ribosomal protein L39 (P62892) 945.47 SSHKTFR M 58
2 Esterase D (Q9R0P3) 1099.6 ALKQISSNR M 81
3 Glyceraldehyde-3-phosphate dehydrogenase (P16858) 1115.61 VKVGVNGFGR M 118
4 Estradiol 17 beta-dehydrogenase 5 (P70694) 1175.56 MDSKQQTVR 125
5 Serum albumin (mature) (P07724) 1260.62 EAHKSEIAHR SP 129
6 Glutathione S-transferase Mu 2 (P15626) 1292.62 PMTLGYWDIR M 102
7 SteroM-alpha-carboxylate 3-dehydrogenase (Q9R1J0) 1370.64 MEQAVHGESKR 20
8 Glutathione S-transferase P 1 (P19157) 1392.74 PPYTIVYFPVR M 356
9 Fatty acid-binding protein (Q05816) 1427.33 ASLKDLEGKWR M 29
10 Glutathione S-transferase Yc (P30115) 1442.73 AGKPVLHYFDGR M 161
11 D-dopachrome tautomerase (035215) 1513.78 PFVELETNLPASR M 349
12 Liver carboxylesterase 31 (mature) (Q63880) 1619.85 PKVTQPEVDTPLGR SP 100
13 Liver fructose 1, 6 Bisphoshate (Q9QXD6) 1713.83 ANHAPFETDISTLTR M 304
14 Acyl-CoA-binding protein (P31786) 1732.83 SQAEFDKAAEEKVR M 391
15 Betaine-homocysteine S-methyltransferase (035490) 1775.03 APVAGKKAKKGILER M 678
16 Peptidyl-prolyl cis-trans isomerase A (P17742) 2046.99 VNPTVFFDITADDEPLGR M 243
17 Sorbitol dehydrogenase (Q64442) 2084.1 AAPAKGENLSLWHGPGDIR M 85
18 Phosphoglycerate kinase 1 (P09411) 2124.18 SLSNKLTLDKLDVKGKR M 98
19 Peroxiredoxin 6 (008709) 2183.06 PGGLLLGDEAPNFEANTTIGR M 247
Table 3.7. N-terminal peptides from soluble mouse liver proteins, observed by MALDI- 
ToF MS.
The N-terminal peptide preparation of mouse skeletal muscle soluble fraction was analysed by 
LC-MS/MS using a three hour RP gradient. MS/MS data was used to search the mouse N- 
terminal database using the MASCOT search engine. The taxonomy was restricted to M us  
m uscu lu s ; fixed modifications: N-terminal acetylation and lysine acetylation; variable 
modification: oxidation of methionine; protease: Arg-C, missed cleavages: 1; peptide tolerance: 
1.5Da, MS/MS tolerance: 0.6Da, instrument: ESI-TRAP, peptide charge: 1+, 2+ and 3+. Protein 
identifications with a mowse score greater than 20 were accepted as confident identifications. 
Peptide identifications corresponding to the ions observed in the MALDI-ToF spectrum are listed 
hers, for a complete list of identifications see supplementary data.
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Figure 3.26. Isolated N-terminal peptides from S. cerevisiae  cell lysate.
The acetylated digest (a) and the N-terminal preparation (b) of S. cerevisiae 
proteins were analysed by MALDI-ToF MS using a laser energy of 30yAII the 
mapr ions in the N-terminal spectra can be assigned to N-terminal peptides 
from S. cerevisiae (Table 3.8 represents the labelled ions).
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1 Phosphoglycerate mutase 1 (P00950) 907.59 PKLVLVR M 400
2 Enolase 1 (P00924) 976.53 AVSKVYAR M 98
3 Fructose-bisphosphate aldolase (P14540) 1025.59 GVEQILKR M 180
4 40S ribosomal protein S3 (P05750) 1039.64 VALISKKR M 36
5 60S ribosomal protein L1 (P53030) 1088.58 SKITSSQVR M 84
6 Elongation factor 2 (P32324) 1107.54 VAFTVDQMR M 54
7 40S ribosomal protein S15  (Q01855) 1126.61 SQAVNAKKR M 57
8 60S ribosomal protein L37-A (P49166) 1159.60 GKGTPSFGKR M 39
9 60S ribosomal protein L15-A (P05748) 1452.72 GAYKYLEELQR M 87
10 Pyruvate decarboxylase (P06169) 1538.80 SEITLGKYLFER M 189
11 60S ribosomal protein L5 (P26321) 1670.79 AFQKDAKSSAYSSR M 69
12 Cytochrome C (P00044) 2150.41 TEFKAGSAKKGATLFKTR M 87
Table 3.8. Identification N-terminal peptides from soluble S. cerevisiae, observed by 
MALDI-ToF MS.
The N-terminal peptide preparation of S. cerevisiae total cell lysate soluble proteins was 
analysed by LC-M S/M S using a three hour RP gradient. M S/M S data was used to search the 
mouse N-terminal database using the M ASCO T search engine. The taxonomy was restricted 
to S. cerevisiae; fixed modifications: N-terminal acetylation and lysine acetylation; variable 
modification: oxidation of methionine; protease: Arg-C; missed cleavages: 1; peptide tolerance: 
1.5Da; M S/M S tolerance: 0.6Da; instrument: ESI-TRAP; peptide charge: 1+, 2+ and 3+. 
Protein identifications with a Mowse score greater than 20 were accepted as confident 
identifications. Peptide identifications corresponding to the ions observed in the MALDI-ToF  
spectrum are represented, for a complete list of identifications see Supplementary data B.
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Figure 3.27. Isolated N-terminal peptides from E. co li cell lysate.
The acetylated digest (a) and the N-terminal preparation (b) of soluble E. coli 
proteins were analysed by M ALDI-ToF MS using a laser energy of 30% . All the 
major ions in the N-terminal spectra can be assigned to N-terminal peptides 
from E. coli (Table 3.9 represents the labelled ions).
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1 UPF0304 protein yfbU (P0A8W8) 1021.43 MEMTNAQR 60
2 Elongation factor Tu (EF-Tu) (P0A6N1) 1048.52 SKÉKFER M 103
3 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase (P62707) 1081.69 AVTKLVLVR M 46
4 Enolase (P0A6P9) 1138.71 SKIVKIIGR M 113
5 10 kDa chaperonin (groES protein) (P0A6G1) 1192.61 MNIRPLHDR 39
6 Glyceraldehyde-3-phosphate dehydrogenase A (P0A9B4) 1244.69 TIKVGINGFGR M 123
7 Copper resistance protein D (Q47455) 1274.67 MNDLIMIVIR 40
8 o.o-heptose 1,7-bisphosphate phosphatase (Q8FKZ1) 1299.72 AKSVPAIFLDR M 42
9 Putative HTH-type transcriptional regulator yeaT (P76250) 1353.71 MNNLPLLNDLR M 31
10 Elongation factorTs (EF-Ts) (P0A6P1) 1412.79 AEITASLVKELR M 285
11 Phosphoglycerate kinase (P0A799) 1671.89 SVIKMTDLDLAGKR M 97
12 (5-lactamase (P62593) 2107.12 pEQLIDWMEADKVAGPLLR PG 84
13 Cysteine synthase A (P0ABK5) 2110.11 SKIFEDNSLTIGHTPLVR M 64
14 3-lactamase (P62593) 2132.30 HPETLVKVKDAEDQLQR SP 313
Table 3.9. Identification N-terminal peptides from soluble E. coli, observed by MALDI-ToF 
MS.
The N-terminal peptide preparation of E. coli total cell lysate was analysed by LC-M S/M S using a 
three hour RP gradient. M S/M S data was used to search the mouse N-terminal database using 
the M ASCO T search engine. The taxonomy was restricted to E. coli; fixed modifications: N- 
terminal acetylation and lysine acetylation; variable modification: oxidation of methionine; 
protease: Arg-C; missed cleavages: 1; peptide tolerance: 1.5Da; M S/M S tolerance: 0.6Da; 
instrument: ESI-TRAP; peptide charge: 1+, 2+ and 3+. Protein identifications with a Mowse score 
greater than 20 were accepted as confident identifications. Peptide identifications corresponding 
to the ions observed in the MALDI-ToF spectrum are represented, for a complete list of 
identifications see Supplementary data B.
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Figure 3.28. Sequencing of an unidentified internal peptide from the E. co li N- 
terminal preparation.
The E. coli N-terminal peptide preparation was desalted using a C 18 ZipTip and 
introduced into the ES I-Q -ToF by direct infusion at a rate of 0.5pl/min. The precursor 
ion at [M +2H]2+ 1055.02 was selected using the quadrupole and fragmented using a 
collision energy of 30% . The product ion spectra were processed using M axENT3. The 
resulting M S/M S spectrum was sequenced cfe novo using the Biolynx software tool.
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To screen for non N-terminal (internal or C-terminal) peptides, the MS/MS data was 
searched against Mascot, using the same parameters as in the N-terminal search. However, 
in this search N-terminal acetylation was chosen as a variable modification, to allow for any 
non N-acetylated peptides, in addition to N-acetylated, true N-terminal peptides. In all cases 
non N-terminal peptides were identified (Supplementary data C). In each case, the percentage 
of non N-terminal peptides represented <10% of the total identifications made. Moreover, 
many of the non N-terminal identifications made were matched with low confidence and are 
likely to be false positives.
The MALDI-ToF spectrum of the E. coli N-terminal preparation contained a major ion 
at m/z 2108.13, which was not identified by the N-terminal specific Mascot search. MS/MS 
analysis on the ESI-Q-ToF instrument, followed by manual de novo sequencing, revealed that 
this peptide is derived from the protein (3-lactamase, with the sequence 
(R)pEQLIDWMEADKVAGPLLR (Figure 3.28). This internal peptide contained a modification 
at the N-terminus in which the glutamine residue was converted to pyroglutamate (pE). This 
spontaneous modification involves the cyclisation of N-terminal glutamine into pyroglutamate 
(Bateman et at., 1990). When this reaction occurs the a-amino group becomes blocked and is 
consequently resistant to NHS-Sepharose coupling. As this peptide is arginine flanked, it is 
likely that this modification has occurred post-proteolysis (in vitro) and was not an in vivo 
modification.
A large percentage of the total protein identifications in S. cerevisiae were from 
ribosomal proteins (28%). These identifications were from both the 40S and the 60S subunits 
(24 and 26 proteins respectively).
From the lists of N-terminal peptide assignments, it is possible to explore the nature of 
the true N-terminus of the proteins identified. Figure 3.29 shows the frequency of amino acid 
residues at the N-terminal position in each of the three species analysed. In E. coli there is a 
large number of unprocessed N-terminal peptides (47% of total peptides identified) containing 
the N-terminal methionine residue. The percentage of unprocessed N-terminal peptides in the 
eukaryotic samples is much lower (15% in S. cerevisiae and 13% in mouse liver). SP 
cleavage products were observed in both £  coli and mouse liver samples. None of the 
proteins identified in S. cerevisiae showed evidence of SP cleavage, which is possibly due to 
the lack of secretary proteins present in the soluble preparation.
141
Figure 3.29. Nature of the N-terminal amino acid residues, determined by 
positional proteomics.
In total, 210 mouse liver, 185 S. cerevisiae and 333 E. coli proteins were identified by 
LC-M S/M S analysis on the ion trap instrument (data available in Supplementary data 
B). Data is from both blocked (N-acetylated) and unblocked N-termlni and is grouped 
according to the N-terminal processing status.
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3.9.11 Determination of naturally acetylated N-termini
It is well documented that between 80 and 90% of proteins from higher eukaryotes are 
naturally N-acetylated in vivo (Polevoda and Sherman, 2000). Na-acetylation is much less 
common in prokaryotes, although it does still occur (Charbaut et al, 2002).
The N-terminal methods described in this chapter both use acetylation to block N- 
termini. Therefore it is not possible to distinguish a naturally acetylated N-terminal from a 
chemically derivatised peptide (both produce a mass shift of +42Da). However, by switching to 
a labelled form of acetic anhydride it is possible to discriminate between chemical (in vitro) 
and natural (in vivo) Na-acetylation. Deuterated acetic anhydride ((C[2H3]C0)20) reacts with 
primary amines, introducing a mass shift of +45Da instead of +42Da. This reagent was used 
to label N-terminal peptides from mouse liver, S. cerevisiae and E. coli soluble fractions. To 
illustrate the difference in mass between the incorporation of a standard (light) acetyl group 
and a deuterated (heavy) acetyl group, the standard peptide ACTH (Fragment 18-39, human) 
was acetylated by each reagent and analysed using MALDI-ToF MS (Figure 3.30). This 
peptide contains three possible acetylation sites. When acetylated, the pH of the environment 
was kept low (pH5), allowing partially acetylated forms to be analysed also.
Each of the three complex proteomes (mouse liver, S. cerevisiae and E. coli) were 
used to generate N-terminal preparations using (C[2H3]C0)20 as the amino group blocking 
reagent. The deuterated N-terminal preparations were subjected to analysis by MALDI-ToF 
MS and LC-MS/MS analysis. In order to discriminate between natural and chemical Na- 
acetylation, the search parameters were adapted to incorporate a heavy acetyl group as a 
fixed modification on lysine residues and as a variable modification on the protein N-terminal. 
N°-acetylation due to a normal acetyl group (+42Da) was also included as a variable 
modification. The search results were examined for the occurrence of either a light (+42Da), or 
a heavy (+45Da) acetyl group on the N-terminal. Data derived from the LC-MS/MS 
experiments is represented in Supplementary data B. In total, 98 mouse liver, 165 S. 
cerevisiae and 239 E. coli proteins were identified and their in vivo N-terminal acetylation 
status determined.
A comparison between the mouse liver N-terminal preparation derived using normal 
and deuterated acetic anhydride can be seen in Figure 3.31a. For each chemically added 
acetyl group, a mass shift of +3Da is observed. For example, the N-terminal of Sterol-4-alpha- 
carboxylate 3-dehydrogenase (Figure 3.31b; Q9R1J0) has an m/z value of 1370.78
1 4 3
Figure 3.30. Acetylation of ACTH 18-39 using standard and deuterated acetic 
anhydride.
For comparative purposes, ACTH fragment 18-29 (Sigma) was analysed by MALDI- 
ToF MS in its unmodified form (a). The peptide (10pg) was acetylated with 1pl acetic 
anhydride (b) and 1 pi deuterated acetic anhydride (c) for 1 h at room temperature and 
analysed by M ALDI-ToF MS. Acetylation reactions were performed in 20m M  Na2C 0 3, 
pH8.5. Under these conditions the pH of the reaction drops substantially upon addition 
of acetic anhydride which favors incomplete reaction, thus ensuring the presence of 
multiply acetylated forms.
1 4 4
Figure 3.31. N-terminal purification of mouse liver soluble fraction using 
deuterated acetic anhydride.
Soluble proteins from mouse liver were subjected to two separate N-terminal isolation 
protocols, one using standard acetic anhydride, and the other using a stable isotope 
labeled variant (C[2H3]C 0 )20 .  The resulting preparations were analysed by M ALDI-TOF  
MS (a). Mass shifts of +3Da were observed for the addition of each in vitro acetylated 
amino group. For non-lysine containing peptides a shift of +3Da is indicative of in vitro 
acetylation. For lysine containing peptides a mass shift of +3Da per lysine residue was 
observed, additional mass differences were evidence for in vitro N°-acetylation. When no 
additional mass difference was observed in vivo acetylation was assumed. Sterol-4- 
alpha-carboxylate 3-dehydrogenase (b) and glutathione S-transferase P1 (c) are used as 
examples of in vivo and in vitro acetylation respectively. MALDI-ToF peptide ions are 
represented in Table 3.10.
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corresponding to the amino acid sequence (MEQAVHGESKR) with the addition of two acetyl 
groups. In the spectrum derived from the deuterated N-terminal preparation, this peptide is 
represented by the peak at 1373.78 m/z. The difference of 3Da between the two variants 
indicates that one chemically derived acetyl group has been added to the lysine residue, 
which in turn would indicate that this peptide is Na-acetylated in vivo. In contrast, the N- 
terminal of glutathione S-transferase P1 (Figure 3.31c; P19157) has the m/z value of 1393.85, 
corresponding to the amino acid sequence (PPYTIVYFPVR) with the addition of one acetyl 
group. In the spectrum derived from the deuterated N-terminal preparation this peptide is 
represented by the peak at 1396.85 m/z. The mass difference of 3Da corresponds to the 
chemically induced acetyl group on the a-amino group, which implies that the N-terminal 
acetylation occurred in vitro. The data obtained from comparison of the two MALDI-ToF 
spectra is shown in Table 3.10. Naturally (in vivo) derived acetyl groups were observed in 87% 
(86 out of 98) of the proteins identified in mouse liver (Supplementary data B); a figure that is 
consistent with published data (Polevoda and Sherman, 2000).
This analysis was repeated for S. cerevisiae (Figure 3.32; MALDI-ToF peak 
assignments are listed in Table 3.11). The data derived from the LC-MS/MS analysis is listed 
in Supplementary material B. Acetyl groups derived naturally (in vivo) were observed in 57 of 
the 128 proteins identified (44%), which is again consistent with published data (Lee et al., 
1989b).
The nature of the Na-acetylated amino acid for both mouse liver proteins and S. 
cerevisiae proteins can be seen in Figure 3.33. Na-acetylation occurs predominantly N- 
terminal alanine residues in mouse (53%) and serine residues in S. cerevisiae (80%). In both 
cases, the modification occurs on small amino acid residues that have undergone NME, in 
addition to a smaller level of Na-acetylation on the uncleaved methionine residue (12% in 
mouse and 3% in S. cerevisiae). The. lack of acetylation on proteins initiating with valine and 
glycine in S. cerevisiae, implies that acetylation on these residues plays some kind of 
evolutionary role, as these residues were acetylated in the mouse liver sample.
When performed on S. cerevisiae, this analysis provided data on the Na-acetylation 
status of 54 ribosomal proteins. The results obtained in this positional proteomics N-terminal 
study were in total agreement to those obtained by Arnold et al. (Arnold et al., 1999). In 
contrast to their time consuming and complex approach, the N-terminal positional proteomic 
strategy achieved the same goal but with substantially less experimental stages.
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Figure 3.32. N-terminal purification of S. cerevisiae  soluble proteins using 
deuterated acetic anhydride.
Soluble proteins from S. cerevisiae were  subjected to two separate N-termlnal isolation 
protocols, one using standard acetic anhydride, and the other using a stable isotope 
labeled variant (C[2H3]C 0 )20 .  The resulting preparations were analysed by M ALDI-TOF  
M S (a). Mass shifts of +3D a were observed for the addition of each in vitro acetylated 
amino group. For non-lysine containing peptides a shift of +3Da is indicative of in vitro 
acetylation. For lysine containing peptides a mass shift of +3Da for each lysine residue 
was observed, additional mass differences were evidence for in vitro N°-acetylation. 
W hen no additional mass difference was observed in vivo acetylation was assumed. 
Pyruvate decarboxylase (b) and enolase (c) are used as examples of in vivo and in vitro 
acetylation respectively. M ALDI-ToF peptide ions are represented in Table 3.11.
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a) 2
b)
c)
Pyruvate decarboxylase 
SEITLGKYLFER 
1539.66 1542.97
In vivo acetylation
Enolase
AVSKVYAR
977.43 983.65
In vitro acetylation
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Figure 3.33. Nature of the Na-acetylated N-terminal amino acid in mouse liver 
and S. cerevisiae proteins.
A total of 70 mouse liver proteins and 57 S. cerevisiae proteins were found to be Na- 
acetylated in vivo (out of a total of 98 and 128 identified proteins respectively). 
Percentage values for the occurrence of each N-terminal amino acid were calculated. 
Data is grouped according to N-terminal processing status.
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In contrast to eukaryotes, prokaryotes undergo a much lower rate of Na-acetylation in 
vivo. To date, only five endogenous proteins have been reported to be N°-acetylated in E. coli 
(Yoshikawa et al, 1987; Tanaka et a!., 1989; Arai et al., 1980; Smith et ai, 1996). To 
determine the extent to which Na-acetylation occurs in the proteins contained within our E. coli 
N-terminal dataset, the N-terminal isolation procedure was performed on the soluble proteins 
from E. coli, using deuterated acetic anhydride as the acetylation reagent. The MALDI-ToF 
spectra obtained for N-terminal peptides acetylated using normal acetic anhydride and 
deuterated acetic anhydride are shown in Figure 3.34a. The majority of N-terminal peptide 
ions identified in this analysis were showed evidence of chemical acetylation. For example, 
the ion at m/z 2132.26 corresponding to (3-lactamase (Figure 3.34c; 
HPETLVKVKDAEDQLQR) is represented in the deuterated form at m/z 2141.30. The +9Da 
difference is due to the addition of three chemical acetyl groups, corresponding to two lysine 
residues and the N-terminal amino group. This mass difference indicates that the N-terminal of 
enolase is acetyated in vitro. In contrast, the N-terminal of elongation factor Tu (EFTu) is 
represented in the light N-terminal spectra as m/z 1049.51 corresponding to the peptide 
sequence (Figure 3.34c; SKEKFER) plus three acetyl groups. In the spectra from the 
deuterated N-terminal peptides, this peptide is represented as 1055.60 m/z, giving a 
difference of +6Da corresponding to two acetyl groups (from two lysine residues), indicating 
that the protein is naturally NQ-acetylated. This is consistent with previously published data, as 
the N-terminal of EFTu is documented as being Na-acetylated in vivo (Arai et al., 1980). Both 
MALDI-ToF and LC-MS/MS data showed that the ion corresponding to the N-terminal peptide 
of copper resistance protein D (Figure 3.34d; MNDLIMIVIR) is Na-acetylated in vivo. This 
previously unreported modification was validated by running a separate N-terminal isolation 
experiment in which the acetylation/blocking step was omitted. The rationale behind this 
experiment is that none lysine containing, in vivo Na-acetylated peptides should be the only 
species resistant to NHS-Sepharose coupling. The resulting peptide preparation was analysed 
by MALDI-ToF MS and LC-MS/MS on the ion trap instrument (Figure 3.35). The base peak in 
this spectrum corresponds to the [M+H]+ value of the N-terminal sequence for copper 
resistance protein D (verified by MS/MS spectrum; Figure 3.35c), thus proving that this 
peptide is N°-acetylated in vivo. The ion at m/z 1745.55 was not fragmented sufficiently for 
interpretation and this peak remains uncharacterised.
Other putative E. coli Na-acetylated proteins identified in this study were hypothetical 
protein ydeR (P77294) and export protein SecB (P0AG86). However, it was not possible to 
obtain good quality MS/MS data from these two peptides by ESI-QToF or ESI-LTQ MS/MS.
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Figure 3.34. N-terminal purification of E. co li soluble proteins using deuterated 
acetic anhydride.
Soluble proteins from E. coli were subjected to two separate N-terminal isolation 
protocols, one using standard acetic anhydride, and the other using a stable isotope 
labeled variant (C[2H3]C 0 )20 .  The resulting preparations were analysed by M ALDI-TOF  
MS (a). Mass shifts of +3D a were observed for the addition of each in vitro acetylated 
amino group. For non-lysine containing peptides a shift of +3Da is indicative of in vitro 
acetylation. For lysine containing peptides a mass shift of +3D a for each lysine residue 
was observed, additional mass differences were evidence for in vitro Na-acetylation. 
W hen no additional mass difference was observed in vivo acetylation was assumed. 13- 
lactamase is used as an example of in vitro acetylation (b) and elongation factor Tu (c) 
and copper resistance protein D (d) are used as examples of in vivo acetylation MALDI- 
ToF peptide ions are represented in Table 3.12.
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a)
b)
c)
d)
Beta-lactamase (P62593) 
HPETLVKVKDAEDQLQR
9 Da
--------- >
2142.30
In vitro acetylation
Elongation factor Tu (P02990) 
SKEKFER
1049.60
>
1055.62
In vivo acetylation
Copper resistance protein D (Q47455) 
MNDLIMIVIR
1275.79
»
1275.79
In vivo acetylation
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Figure 3.35. Isolation of naturally acetylated, non-lysine containing N-terminal 
peptides from E. coli.
E. coli soluble proteins (50pg) were digested with trypsin (1:50 enzym e substrate ratio). 
The resulting peptides were incubated with NHS-Sepharose (twice in total). The  
supernatant was removed by centrifugation and desalted using a C18 ZipTip prior to 
M ALDI-ToF MS (b). For comparative purposes the previously characterised E. coli N- 
terminal preparation was also analysed (a). The peptides from the non-acetylated digest 
(b) correspond exclusively to naturally acetylated N-terminal peptides. The ion at m/z 
1275.67 corresponds to copper resistance protein D. confirmed by LC-M S/M S analysis 
on the LTQ ion trap instrument (c). The ion at m /z 1745.71 remains unidentified.
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3.10 Summary
The majority of proteins encoded in any genome undergo some form of N-terminal 
modification and as a result, N-terminal peptides are generally poorly represented in published 
datasets. Modification events (for example, NME, SP removal, N°-acetylation and 
exopeptidase activity), hinder identification by routine proteomic approaches and make protein 
characterisation highly challenging (Meinnel and Giglione, 2008).
Positional proteomics strategies, that specifically target the N-terminal, provide a 
powerful tool to characterise the true N-termini of proteins. Unlike conventional methods 
based on Edman degradation, it is also possible to identify proteins that are naturally Na- 
acetylated. The use of deuterated acetic anhydride ((C[2H3]C0)20) enables the true nature of 
N°-acetylation to be determined, at the MS stage, either by comparison of MALDI-ToF spectra 
or by searching LC-MS/MS data for a combination of natural and chemical mass shifts. 
Application of this method to a prokaryote (where N-acetylation is rare) and eukaryotic 
samples (in which the modification is common) illustrates the broad applicability if the 
approach.
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Chapter 4: Reducing the complexity of human plasma using positional proteomics
4. R E D U C I N G  T H E  C O M P L E X I T Y  OF H U M A N  P L A S M A  U S IN G  
P O S I T I O N A L  P R O T E O M I C S
Plasma is the liquid component of blood (comprising 55% of the total volume), in which the 
blood cells are suspended. It consists of about 90% water which provides the solvent for 
dissolving and transporting nutrients and gasses (principally oxygen, carbon dioxide and 
nitrogen). Approximately 8% of plasma consists of protein and the remaining 2% consists of 
amino acids, glucose and other nutrients (Table 4.1). Plasma also contains inorganic ions 
which are important in regulating cell function and maintaining homeostasis (reviewed in Van 
Wynsberghe, 1995; Table 4.2).
Serum is prepared from plasma by the removal of fibrinogen via its conversion to a 
fibrin clot, together with platelets. Varying amounts of other proteins are also removed in the 
fibrin clot, through both specific and non-specific interactions (Lundblad, 2005). However, 
despite conflicting statements in the literature (Adkins et a/., 2002), serum retains many 
coagulation factors such as factor IX, factor X and factor XI (Lundbald, 2005).
4.1 Plasma proteins
True or “classical” plasma proteins are those that carry out specific functions in the circulation. 
Proteins that, for example, serve as messengers between tissues (e.g. peptide hormones) or 
that leak into the blood from tissues are not classed as classical plasma proteins. True plasma 
proteins are largely secreted by the liver and intestine. These proteins perform a variety of 
roles including transportation of insoluble substances around the body, blood clotting, 
response to disease (inflammatory response) and protection from infection (immune response; 
Van Wynsberghe et al., 1995).
As discussed in Chapter 1, the dynamic range of proteins in plasma spans ten orders 
of magnitude or more (Veenstra et al., 2005), which is far greater than the measurement 
capability of current technologies. Furthermore, clinically relevant proteins that are present in 
the blood, for example, as a result of tissue damage, are masked by the overwhelming 
abundance of relatively few proteins. As much as 99% of the total protein mass in plasma is 
made up from 22 proteins (Tirumalai et al., 2003; Figure 4.1).
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Constituent %
W ater 90.0
Protein 8.0
Organic substances 1.1
Inorganic ions 0.9
Table 4.1. Constituents of human plasma as percentages of total volume.
Ion Symbol Concentration (mmol/l)
Sodium Na+ 135-146
Potassium \C 3.1-5.2
Calcium Ca*+ 2.1-2.7
Chloride c r 98-108
Hydrogen carbonate H C 0 3‘ 23-31
Phosphate “ P Ö 7 0.7-1.4
Table 4.2. The normal range of concentration of inorganic ions in human plasma.
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Albumin is the most abundant protein in plasma and is responsible for around half of 
the total protein mass. A typical albumin molecule is present within the body for approximately 
21 days and in its life span makes around 15,000 passes through the circulatory system, 
transporting different types of molecular cargo. The main function of albumin is to promote 
water retention in the blood, which in turn maintains osmotic pressure needed for efficient 
distribution of body fluids between intravascular compartments and body tissues (reviewed by 
Peters, 1995).
Albumin binds various proteins and peptides, for example, peptide hormones, 
interferon, serum amyloid A, glucagons, bradykinin and insulin (Baczynskyj et at., 1994; 
Carter, 1981). These complexes form naturally occurring subproteomes (the albuminome). 
The association of albumin with small proteins poses a problem for simplification techniques 
based on albumin depletion, as the removal of large amounts of albumin will result in the 
subsequent co-depletion of these smaller, potentially relevant proteins that are specifically 
bound (Granger, 2005).
The plasma proteome is also dominated by the immunoglobulins, which represent 
around 15% of the protein content. Immunoglobulins, or antibodies, function in plasma to 
target and destroy foreign objects such as bacteria and viruses. Each immunoglobulin 
monomer consists of four chains, two heavy chains (-440 amino acids) and two light chains 
(-220 amino acids), held together by disulphide bonds (Figure 4.2). Each heavy and light 
chain is made up of two regions: a constant domain, which is identical in all immunoglobulins 
of a given class, and a variable domain, which resides at the tip of the immunoglobulin 
structure. It is this variable domain that is responsible for the immense variety of 
immunoglobulins that exist with slightly different tip structures. Each of these variants can bind 
to a different target, known as an antigen. This huge diversity of immunoglobulins allows the 
immune system to recognise an equally wide diversity of antigens. The unique part of the 
antigen recognised by the immunoglobulin is known as an epitope. These epitopes bind to 
their antigen in a highly specific interaction known as an induced fit, which allows the 
immunoglobulin to identify and bind to their antigen in the presence of millions of different 
protein molecules within the organism (Honjo and Habu, 1985; Davies et ai, 1990).
Immunoglobulins represent a unique class of proteins because of their complexity. 
There are thought to be in the order of 10 million different sequences of immunoglobulin in 
circulation in a normal adult (Anderson and Anderson, 2002). The basis for this diversity lies in 
the production of many different configurations of immunoglobulin in human lymphocytes. The
1 6 2
Figure 4.2. The immunoglobulin molecule.
Each Immunoglobulin consists of four polypeptides: two heavy chains and two light 
chains joined to form a “Y ” shaped molecule. The amino acid sequence in the tips of 
the “Y ” varies greatly among different immunoglobulins. This variable region, 
composed of 110-130 amino acids, gives the immunoglobulin its specificity for antigen 
binding.
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variable portions of an antibody’s heavy and light chains is coded by several hundred coding 
regions and these regions, or gene segments, can be joined in different combinations to 
produce millions of immunoglobulins. There are five classes of immunoglobulin designated 
IgG, IgA, IgM, IgD and IgE. The constant region of the immunoglobulin heavy chain identifies 
its class and each class had a separate defensive role in the immune response (Van 
Wynsberghe etal., 1995).
Antigen-antibody complexes trigger the mammalian complement system, which is a 
biological cascade that facilitates the removal of pathogens from an organism. The system 
consists of more than 30 proteins (Schmidt and Colten, 2000), which under normal 
circumstances are present in plasma as inactive zymogens. When stimulated by inflammation 
or an immune response, proteases in the system cleave specific components to release 
cytokines, initiating an amplification cascade of further cleavages. The main functions of the 
pathway include: host cell defense against microorganisms, elimination of immune complexes 
and apoptotic cells and the facilitation of adaptive immune responses. Complement is 
activated by three different pathways: classical, lectin and alternative. All three pathways 
share the common step of activation of complement component C3, but differ accordingly in 
the nature of regulation (reviewed by Reid and Porter, 1981).
Complement component C3 is regulated by conformational changes induced by 
selective proteolysis. The cleavage of mature C3 is mediated by enzyme complexes and 
generates the anaphylatoxin containing C3a and the major fragment C3b (Hugh, 1975). The 
C3a anaphylatoxin is generated when the C-terminal arginine is cleaved from fragment C3a 
and given the large amounts of carboxypeptidase present in plasma, is the major component 
of this fragment (de Bruijn and Fey, 1985). C3a anaphylatoxin is identical in terms of amino 
acid composition, molecular mass and N-terminal amino acid sequence as acylation- 
stimulating protein (ASP; Baldo et a/., 1993), which stimulates triacylglycerol synthesis in 
human adipocytes (Cianflone et at., 1989) and is associated with obesity, cardiovascular 
disease, diabetes, and dyslipidemia (reviewed in Cianflone et at., 2003). More recently, C3a 
anaphylatoxin was found in significantly higher levels in serum from patients with colorectal 
adenomas and carcinomas, than in healthy individuals. This suggests that a robust, 
reproducible clinical test for the quantification of C3a anaphylatoxin in plasma, could replace 
existing screening tests for colorectal cancer (Habermann et at., 2006).
Plasma also contains a variety of proteins responsible for blood clot formation. The 
thrombin system consists of several blood proteins that become activated when a blood
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vessel is traumatised and bleeding occurs. When platelets in the bloodstream come into 
contact with a damaged blood vessel, they release the enzyme thrombokinase, which brings 
about the conversion of the inactive zymogen prothrombin into the active thrombin which, in 
turn, catalyses the conversion of the soluble protein fibrinogen to the insoluble protein fibrin. 
This is a fibrillar protein that is polymerised to form a mesh that coagulates (in conjunction with 
platelets) to form a hemostatic plug or a clot. Calcium, vitamin K, and a variety of enzymes, 
known as clotting factors, are also necessary for efficient blood clotting (Doolittle, 1984).
4.2 Biomarkers
Proteins that normally function within tissues can leak into plasma as a result of cell death or 
tissue damage. These proteins include many of the most important diagnostic markers, also 
known as biomarkers. Examples of biomarkers include: cardiac troponins, creatine kinase, or 
myoglobin used in the diagnosis of myocardial infarction (McComb et al., 1984).
A biomarker can be defined as “a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacological response to a therapeutic intervention” (Atkinson et al., 2001). The most 
valuable biomarkers are highly sensitive, specific and reproducible.
Despite the complexity issue discussed in Chapter 1, plasma remains the current 
sample of choice for proteomic biomarker discovery. In addition to containing proteins from 
every tissue and cell type within the body (Anderson et al., 2004), plasma is easily accessible 
and can be repeatedly sampled from a patient. Therefore, plasma provides a valuable 
resource for monitoring protein expression changes and can provide important insights into 
disease status even before clinical symptoms are observed (Veenstra et al., 2005). For 
diseases such as cancer early diagnosis is a crucial factor in the administration of effective 
treatment (Aebersold et al., 2005). The ability to detect and characterise novel biomarkers 
associated with specific forms of cancer will therefore have great impact on public health. For 
this reason protein biomarker discovery in plasma has become one of the most significant 
applications of proteomics, with over 900 reported studies to date (PubMed). However, MS 
based protein identification approaches will only be successful if the protein of interest is 
reliably detectable using current instrumental capabilities.
In recent years, proteomics studies have generated a range of putative biomarkers 
(Polanski and Anderson, 2006). However, the list of candidates is limited by the general lack
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of sensitivity and specificity exhibited by the majority of proteins found to date. This lack of 
sensitivity has discouraged many potential follow on studies from candidate biomarkers.
The lack of validation and verification of candidate biomarkers has led to a striking 
shortfall in the number of protein diagnostic tests emerging from proteomic studies. In order to 
bridge the gap between biomarker discovery and clinical use it will be necessary to develop 
innovative approaches to target known biomarkers and quantitatively detect them in multiple 
clinical samples.
The issue of biomarker validation also relates to preanalytical factors regarding the 
robustness of the clinical study. The problem of bias is described as “the most important threat 
to validity in biomarker research” (Ransohoff, 2005). Bias occurs if the affected and non- 
affected groups are handled in systematically different ways, introducing a diagnostic 
signature into one group but not the other. For example, if a sample of patients is much older 
than a sample of controls, then differences due to age may be misattributed to disease (Zhang 
et al., 2005), or such differences may be induced through variations in the handling and 
processing of clinical specimens (Statland et al., 1973; Villanueva et al., 2006). Such factors 
may provide an explanation for "discrimination" in current proteomic studies (Baggerly et al., 
2004). The issue of bias reinforces the need for consistency in sample handling and the 
requirement for all samples in studies to be handled identically. The ability to provide 
consistent data from multiple samples is a critical factor in the application of proteomics to 
biomarker discovery and validation.
4.3 Strategies employed to study the human plasma proteome
As biomarkers are likely to occupy the low concentration range (present at ng/ml to pg/ml) of 
the plasma proteome, protein biomarker discovery from plasma presents an immense 
analytical challenge that requires a combination of experimental approaches and data 
handling. The PPP, described in Section 1.3, has integrated a collection of datasets produced 
by 55 laboratories worldwide; in order to generate a Core Dataset of 3020 confidently 
assigned plasma proteins (Omenn et al., 2005). The PPP utilised a range of experimental 
protocols including depletion, fractionation, MS and immunoassay methods. In addition to the 
substantial dataset produced, the PPP has laid the groundwork for the development and 
validation of putative biomarkers linked with human disease.
1 6 6
Chapter 4: Reducing the complexity of human plasma using positional proteomics
An independent approach to the PPP, involved the extensive fractionation of human 
plasma using 2-D chromatography (105 SCX fractions, followed by RP-LC analysis) and 
MS/MS led to the identification of 2392 proteins with high confidence (Shen et. al., 2005). 
Immunodepletion of high abundance proteins, followed by LC-MS/MS analysis, has previously 
been the method of choice for the preparation of complex biological samples (described in 
Section 1.5.3). However, these methods are of limited success as removal of several 
abundant species (as much as 90% of the overall protein amount), means that the dynamic 
range issue is not fully addressed. Furthermore, depletion of high-abundance proteins will lead 
to co-depletion, effectively removing a portion of the plasma proteome together with the 
abundant proteins (Granger, 2005).
Protein Equalizer ™ technology (described in Section 1.5.5) has the ability to reduce 
dynamic range without depletion. This technology is based on the interaction of complex 
protein samples with a large, highly diverse, library of ligands coupled to 
poly(hydroxymethacrylate) beads. The library contains around 64 million different ligands 
which can, in principle, capture every protein species within a complex proteome (Righetti et. 
at., 2006). This technology has been applied to the characterisation of the human plasma 
proteome (Sennels et. al., 2007). In this study, separation of the ligand-bound (normalised) 
portion of the plasma proteome, using 1-D SDS-PAGE, followed by LC-MS/MS analysis of 20 
gel slices (GeLC-MS/MS), led to identification of 1559 proteins with a 95% confidence rate.
One drawback to Protein Equalizer™ technology is linked to the nature of the 
‘normalisation’ process, which enriches low abundance proteins whilst simultaneously diluting 
abundant proteins. This modification to protein abundance levels makes the process 
problematic for quantification studies, as information regarding the absolute amount of 
individual proteins in the starting material is lost. However, the technology provides a useful 
tool for the identification of low abundance proteins within complex proteomes, exhibiting high 
dynamic range.
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4.4 A ims and objectives
Characterisation of the plasma proteome by standard bottom-up proteomic approaches leads 
to the generation of large amount of peptides from the most abundant proteins in the mixture 
(i.e., the classical plasma proteins). Signals from these peptides will consequently mask 
signals produced from the lower abundance portion of the plasma proteome. This chapter 
demonstrates the use of the N-terminal positional proteomics strategy to substantially reduce 
the complexity of a human plasma digest. Reducing the number of peptides representative of 
each protein in the mixture to, in theory, one peptide will improve the ability to identify proteins 
present in lower concentrations by minimising the suppression affect inflicted by peptides from 
abundant proteins.
Plasma proteins are subjected to a variety of proteases that target their N and C- 
termini (exopeptidases). As a result, proteins will potentially be present in a range of truncated 
forms. In addition to a reduction in peptide complexity, the N-terminal method will define the 
true N-terminal region of the proteins identified and can be used to identify substrates of 
exopeptidases activity.
The utilisation of a positional proteomics approach to prefactionation brings with it 
several improvements to the standard shotgun methodologies. Removal of internal peptides 
from a complex peptide mixture will result in a sample with substantially less proteolytic 
‘noise’, which is a major problem in standard shotgun approaches. Furthermore, 
characterisation of the true N-termini of plasma proteins will serve to further improve our 
understanding of the plasma proteome.
The use of Protein Equalizer™ technology to reduce the dynamic range in human 
plasma is also demonstrated. This method effectively normalises the concentration range of 
complex protein mixtures without depletion of abundant proteins. When used in combination 
with the N-terminal enrichment protocol, this technology should serve to improve the number 
of plasma protein identifications, leading to the identification of candidate biomarkers which 
could then be quantified by alternative methods.
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4.5 Results and discussion
Prior to N-terminal purification of human plasma proteins, the major protein species were 
separated using 1-D SDS-PAGE and identified by PMF. This analysis was performed to 
highlight the broad dynamic range exhibited by this complex biological sample.
In-solution proteolysis of the entire plasma proteome was performed to demonstrate 
the suppression effect inflicted by serum albumin peptide ions, in terms of both MALDI-ToF 
MS and ESI-LC-MS/MS analysis using an extended three-hour gradient. This was necessary 
to appreciate the gain in coverage observed through targeted simplification of the sample by 
N-terminal abstraction.
Analysis of the N-terminal preparation of human plasma was performed on the LTQ 
ion trap instrument (in-house) and also on the LTQ Orbitrap (analysis performed by Gary 
Woffendin). The data was interrogated to assess the true nature of N-terminal peptides in 
human plasma, in addition to checking for the presence of ‘leaked’ internal peptides.
Human plasma was normalised using Protein Equalizer™ technology to reduce 
dynamic range. When a substantial reduction in concentration differences was achieved, 
compared with starting material (assessed using SDS-PAGE), the sample was subjected to 
LC-MS/MS analysis. The bound portion of the plasma proteome was also subjected to N- 
terminal purification to ascertain the effect of normalisation in combination with targeted 
peptide isolation in providing increased proteome coverage, compared with current strategies.
4.5.1 SDS-PAGE of human plasma proteins
To asses the complexity of human plasma, 15pg of protein was separated on a 1-D gel and 
proteins were visualised using Coomassie. The resulting 1-D profile is dominated by five major 
bands, corresponding to the most abundant proteins in the sample. A total of 11 protein bands 
were chosen for identification by PMF, including the five major bands and a further six weaker 
bands. To obtain identifications the bands were excised from the gel and subjected to in-gel 
proteolysis using trypsin. The digested peptide mixture was characterised by MALDI-ToF MS. 
Proteins were identified from their peptide mass fingerprint by manual searching against the 
SwissProt database using a locally implemented Mascot server. Search parameters allowed a 
single missed tryptic cleavage, carbamidomethyl modification of cysteine (fixed) oxidation of 
methionine (variable), and a peptide tolerance of ±150ppm. The taxonomic space was 
restricted to Homo sapiens. The proteins were all identified with high confidence (Table 4.3)
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as “classical” plasma proteins. Figure 4.3 shows the peptide coverage obtained for each 
identified protein. The MALDI-ToF spectra are shown in Supplementary material D.
4.5.2 In-solution tryptic digestion of human plasma proteins
Unlike the soluble cytosolic proteins found in skeletal muscle and liver, the majority of the 
proteins found in plasma are secreted. This implies that plasma proteins will have a greater 
abundance of disulphide bonds. For this reason, the solubilised human plasma (10pg, Sigma) 
was reduced and alkylated prior to proteolysis in order to remove the disulphide bonds 
between cysteine residues. The reduced and alkylated plasma was then TCA precipitated and 
ether washed, prior to overnight proteolysis with trypsin (50:1 substrate enzyme ratio). The 
resulting peptide mixture (1pl of digest diluted in 10pl 0.1% (v/v) TFA) was desalted using a 
C18 ZipTip and analysed by MALDI-ToF MS. Figure 4.4 shows that the entire digest of human 
plasma produces a complex MALDI-ToF spectrum. The in silico tryptic digestion of the human 
serum albumin (HSA) sequence revealed that most of the peaks in the spectrum can be 
attributed to this protein, shown using the peptide coverage map. Considering the high 
concentration of HSA in plasma it is not surprising that peptide ions originating from this 
protein dominate the mass spectrum.
Analysis by LC-MS/MS using the ion trap instrument led to the identification of only 
five abundant proteins from the sample (Table 4.4).
4.5.3 N-terminal isolation of human plasma proteins
Human plasma (50pg) was reduced and alkylated as before. The plasma was then TCA 
precipitated and ether washed to remove any residual reagents prior to acetylation. The dried 
pellet was resuspended in 20mM Na2C0 3  (acetylation buffer) and acetylated using 1mg of 
sulfo NHS-acetate. The acetylated proteins were incubated with polymer bound Tris in order 
to remove excess reagent. The modified protein mixture was precipitated and washed (as 
before) prior to overnight proteolysis with trypsin (50:1 substrate enzyme ratio). A small 
amount of the peptide mixture (1pl of digest diluted in 10pl 0.1% (v/v) TFA) was desalted on a 
C18 ZipTip and subjected to MALDI-ToF analysis. The MALDI-ToF spectrum in Figure 4.5 
corresponds to the acetylated digest of human plasma. In accordance with the non-acetylated 
tryptic digest (Figure 4.4), the majority of the high intensity signals can be attributed to albumin 
(Arg-C peptides). The peptide map indicates which peptides are present in the spectrum.
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Figure 4.4. In-solution tryptic digest of human plasma.
Human plasma (1 O^ tg; SIGM A) was reduced and alkylated prior to digestion with 
trypsin (50:1 substate:enzyme). The resulting peptide mixture was desalted using a 
C18 ZipTip and analysed by MALDI-ToF MS. The majority of the major ions in the 
spectrum can be assigned to tryptic peptides from HSA. The peptide map represents 
coverage.
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Prote in  (A ccession ) M ow se
score
C overage
(%)
P eptides
m atched
M ass
(kD a)
1 Serum albumin (P02768) 820 57 25 69.32
2 Serotransferrin (P02787) 216 18 8 79.28
3 Apolipoprotein A-l (P02647) 91 12 3 30.76
4 Ig kappa chain C region (P01834) 87 35 2 11.7
5 Ig lambda chain C region (P15814) 64 14 1 11.4
Table 4.4. Identification of human plasma proteins by in-solution tryptic digestion and 
LC-MS/MS analysis.
The peptide mixture derived from in-solution tryptic digestion of human plasma (10pg, 
Sigm a) was analysed by LC -M S/M S using a three hour RP gradient. M S/M S data was used 
to search the SwissProt database using the M ASCO T search engine. The taxonomy was 
restricted to Homo sapiens; fixed modifications: carbamidomethylation of cysteine; variable 
modification: oxidation of methionine; protease: trypsin; missed cleavages: 1; peptide 
tolerance: 1.5Da; M S/M S tolerance: 0.6Da; instrument: ESI-TRAP; peptide charge: 1+, 2+ 
and 3+. Protein identifications with a Mowse score greater than 50 were accepted as 
confident identifications.
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Figure 4.5. In-solution tryptic digest of acetylated human plasma.
Human plasma (50p.g; S IG M A) was reduced, alkylated and acetylated prior to 
digestion with trypsin (50:1 substate:enzyme). The resulting peptide mixture was 
desalted using a C18 ZipTip and analysed by M ALDI-ToF MS. The majority of the 
major ions in the spectrum can be attributed to arginine terminated tryptic peptides 
from HSA. Peptides containing internal lysines show an increased mass of +42Da for 
each residue. The peptide map represents coverage.
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Following the N-terminal enrichment protocol, using NHS-activated Sepharose, the 
peptide mixture was substantially simplified (Figure 4.6a). The number of peptide ions arising 
from HSA was reduced from 18 to a single ion corresponding to the true N-terminal Arg-C 
peptide, produced as a result of pre-pro-peptide cleavage (Dugaiczyk et a/., 1982). A small 
peak corresponding to the O-acetylated form of the albumin N-terminal peptide was also 
present (Figure 4.7). NHS esters readily react with hydroxyl groups on serine groups located 
in linear His-X-Ser or Ser-X-His sequences (Miller, 1996), and although the N-terminal peptide 
preparation was treated with hydroxylamine (30 pmol), this was not sufficient to remove the 
high level of O-acetylated exhibited in this peptide.
Multiple LC-MS/MS analysis on the ion trap instrument using an extended (three hour) 
RP gradient led to the identification of 50 proteins by virtue of their N-terminal Arg-C peptide 
sequence (Table 4.5). A large percentage of the proteins identified were immunoglobulins 
(40%; Table 4.5b) and the remaining 60% were mainly classical plasma proteins (Table 4.5a). 
A small number of the proteins identified were non-classical plasma proteins including 
antigens and cell receptor proteins.
Although a greater number of protein identifications are obtained through application 
of the positional proteomics protocol, the data set was not as extensive as in samples 
analysed previously from mouse liver and E. coli. The failure to identify a higher number of low 
abundance proteins in the sample is probably a direct result of the large dynamic 
concentration range found in plasma. In human plasma as much as 99% of the total protein 
mass in plasma is made up from 22 proteins (Tirumalai et al., 2003; Figure 4.1). Therefore, 
any additional proteins identified are from the remaining 1% of the proteome, making 
comprehensive proteome coverage highly challenging
The N-terminal preparation was also analysed by LC-MS/MS using the Orbitrap mass 
spectrometer, which can routinely deliver ~ ppm mass accuracy and resolution of 30,000- 
60,000. Under these conditions many N-terminal Arg-C peptides are distinct, in terms of mass, 
and can be identified by this parameter alone. To demonstrate this, extracted ion 
chromatograms for N-terminal Arg-C sequences from the most abundant proteins in plasma 
were prepared (Figure 4.8). In all cases the major ion in each MS spectrum, corresponded to 
the exact m/z value (to two decimal places) of the N-terminal peptide ion searched. 
Furthermore, the retention times of the isolated peptides were consistent with values predicted 
by the Sequence Specific Retention Calculator (SSRcalc) application (Krokhin et al., 2004).
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Serum albumin (mature)
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Figure 4.6. Human plasma N-terminal peptide preparation.
The acetylated tryptic peptides (50pg) were incubated with 1mg NHS-activated 
Sepharose. A  small portion (10pl) of the of supernatant was removed and desalted 
using a C 18 ZipTip and analysed by MALDI-ToF MS. The major ions in the spectrum (a) 
can be assigned to masses of acetylated, arginine terminated, mature N-terminal 
peptides originating from abundant plasma proteins. The cluster of ions around 1900Da  
(b) corresponds to N-terminal peptides from a varienty of Immunoglobulins. Peptide 
identifications were obtained by LC-M S/M S analysis on the ion trap instrument and are 
listed in Table 4.5.
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1 Serotransferrin (P02787) 897.49 VPDKTVR SP 85
2 Transmembrane protein 163 (Q8TC26) 1013.5 MEPAAGIQR 42
3 C3a anaphylatoxin (P01024) 1044.57 SVQLTEKR M 35
4 Mitochondrial import receptor (094826) 1081.5 GTAGPGTGGLPR 28
5 antigen MLAA-39 (Q96EA4) 1103.53 MEADITNLR 22
6 Alpha-2-HS-glycoprotein (P02765) 1121.6 APHGPGLIYR SP 36
7 apolipoprotein A-IV (P06727) 1145.57 LEPYADQLR SP 45
8 Glutathione S-transferase Mu 1 (P09488) 1175.60 PMILGYGDIR M 41
9 Oxidoreductase HTATIP2 (Q9BUP3) 1200.63 AETEALSKLR M 20
10 Serum albumin (P02768) 1232.6 DAHKSEVAHR SP 201
11 Apolipoprotein A-l (P02647) 1267.55 DEPPQSPWDR SP 185
12 Carboxypeptidase B2 (Q96IV4) 1327.73 FQSGQVLAALPR SP 59
13 Antithrombin-Ill (P01008) 1520.74 HGSPVDICTAKPR SP 48
14 Fibrinogen alpha chain (P02671) 1577.7 ADSGEGDFLAEGGGVR SP 95
15 Serum amyloid P-component (P02743) 1585.83 HTDLSGKVFVFPR SP 92
16 antigen NY-CO-43 1655.68 MEQGTSSSMTESSPR 32
17 Transcription factor ETV6 (P41212) 1658.76 SETPAQCSIKQER M 21
18 Inter-alpha-trypsin inhibitor (Q14624) 1792.88 EKNGIDIYSLTVDSR SP 36
19 FBXW12 mature 1826.88 SPTHQIQDPKHWNR SP 25
20 Apolipoprotein E (P02649) 1836.91 KVEQAVETEPEPELR SP 65
21 Tyrosin kinase receptor erbB-3 (P21860) 2104.86 EPCGGLCPKACEGTGSGSR SP 29
22 cyclin G associated kinase 2116.1 SLLQSALDFLAGPGSLGGASGR M 24
23 Alpha-1-antichymotrypsin (P01011) 2176.96 HPNSPLDEENLTQENQDR SP 72
24 Guanylate kinase (Q16774) 2247.27 SGPRPWLSGPSGAGKSTLLKR M 47
25 Transthyretin (P02766) 2483.24 EAGPTGTGESKCPLMVKVLDAVR SP 88
26 Apolipoprotein C-l (P02654) 2701.34 TPDVSSALDKLKEFGNTLEDKAR SP 102
27 Replication protein A 30 kDa subunit 2776.19 SKSGFGSYGSISAADGASGGSDQLCER M 22
28 HIV-1 like protein (095081) 2997.44 VMAAKKGPGPGGGVSGGKAEAEAASE M 26
29 Hemoglobin subunit beta (P68871) 3286.68 VHLTPEEKSAVTALWGKVNVDEVGGEA M 77
30 Hemoglobin subunit alpha 3362.69 VLSPADKTNVKAAWGKVGAHAGEYGAE M 95
Table 4.5. Identification of human plasma proteins by LC-MS/MS analysis of the N-terminal 
peptide preparation.
The N-terminal peptide preparation of human plasma was analysed by LC -M S/M S using a three hour 
R P gradient. M S/M S data was used to search the human N-terminal database using the M ASCO T  
search engine. The taxonomy was restricted to Homo sapiens; fixed modifications: N-terminal 
acetylation and lysine acetylation; variable modification: oxidation of methionine; protease: Arg-C; 
missed cleavages: 1; peptide tolerance: 1.5Da; M S/M S tolerance: 0.6Da; instrument: ESI-TRAP; 
peptide charge: 1+, 2+ and 3+. Protein identifications with a Mowse score greater than 20 were 
accepted as confident identifications. Immunoglobulin N-terminal identifications are listed in (b), all 
other identifications are listed in (a).
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1 immunoglobulin heavy chain variable region (ABM67294) 1140.55 GESGGGWQPGR M 36
2 immunoglobulin heavy chain variable region 1621.85 QVQLVQSGGGAVQPGR M 54
3 Ig heavy chain V-lll region CAM (P01768) 1651.85 QVELVESGGGWQPGR M 21
4 Ig heavy chain V-lll region GA (P01769) 1665.83 QVELVESGGGAVQPGR M 32
5 Ig heavy chain V-lll region BRO (P01766) 1823.94 VQLEESGGGLVQPGGSLR M 49
6 Ig kappa chain V-l region BAN (P04430) 1901.93 DIQLTQSPSSLSASVGDR M 74
7 Ig kappa chain V-l region Mev (P01612) 1905.87 DVQMTQSPSSLSASVGDR M 47
8 Ig kappa chain V-l region Wes (P01611) 1905.87 DIQMTQSPSSVSASVGDR M 55
9 Ig heavy chain VHDJ region (BAC02290) 1908.99 EVQLVESGGGWQPGGSL M 102
10 Ig lambda chain V-lll region SH (P01714) 1911.99 SELTQDPAVSVALGQTVR M 66
11 Ig kappa chain V-l region DEE (P01597) 1919.89 DIQMTQSPSSLSASVGDR M 28
12 Ig heavy chain V-lll region LAY (P01775) 1921.03 AVQLLESGGGLVQPGGSLR M 58
13 Ig heavy chain V-lll region BRO (P01766) 1923.01 EVQLVESGGGLVQPGGSLR M 47
14 Ig kappa chain V-lll region SIE (P01620) 1925.01 EIVLTQSPGTLSLSPGER M 105
15 Ig kappa chain V-l region CAR (P01596) 1933.91 DIQMTQSPSTLSASVGDR M 98
16 Ig heavy chain V-lll region TIL (P01765) 1937.02 EVQLLESGGGLVQPGGSLR M 85
17 Ig kappa chain V-lll region VG precursor (P04433) 1939.03 EIVLTQSPATLSLSPGER M 62
18 Ig heavy chain V-lll region JON (P01780) 1951.04 DVQLVESGGGLVKPGGSLR M 25
19 Ig heavy chain V-lll region BUT (P01767) 1951.04 EVQLVETGGGLIQPGGSLR M 89
20 Ig kappa chain V-IV region Len (P01625) 1958.96 DIVMTQSPDSLAVSLGER M 45
21 Ig heavy chain V-lll region TRO (P01762) 1963.09 QVQLVQSGGGLVKPGGSL M 88
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Serum albumin (N and O-acetylated) 
DAHKSEVAHR
v
Figure 4.7. Effect of hydroxylamine treatment on the N-terminal of HSA.
N-terminal peptides recovered from NHS Sepharose incubation were treated with 1pl 
(30pmol) hydroxylamine in an attempt to reverse O-acetylation of hydroxyl groups. The 
upper spectrum includes two forms of the N-terminal HSA peptide, in which the major 
ion can be attributed to the O-acetylated form. The lower spectrum, obtained after 
treatment with hydroxylamine, shows incomplete removal of the O-acetylated form.
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Figure 4.8. Chromatographic data from human plasma N-terminal peptides.
The N-terminal peptide preparation of human plasma was resolved by RP  
chromatography and analysed by high resolution ion trap MS on the Orbitrap 
instrument. The total ion chromatogram shows data for all peptides. Extracted ion 
chromatograms were prepared using the exact masses (+/- 0.01 Da) for the true N- 
termini of four of the major proteins in human plasma.
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4.5.4 Identification of multiple Immunoglobulin N-termini
A cluster of peaks visible in the 1900Da region of the MALDI-ToF mass spectrum (Figure 
4.6b) were all identified, by LC-MS/MS on the ion trap instrument, as variable regions of 
unique Immunoglobulin N-terminal peptides (peak assignments shown in Table 4.5b). Variable 
regions of immunoglobulin molecules are contained within the amino (NH2) terminal end of the 
polypeptide chain (amino acids 1-110; Davies et at., 1990). When comparing one antibody to 
another, these amino acid sequences are quite distinct (Figure 4.2). The LC-MS/MS run 
identified in excess of 30 different immunoglobulin variable chains (Table 4.5b). The N- 
terminal immunoglobulin peptide sequences were aligned using ClustalW2 algorithm (Larkin 
et. at., 2007; http://www.ebi.ac.uk/Tools/clustalw2/), in order to highlight the variation in amino 
acid sequence (Figure 4.9). The identification of multiple Immunoglobulin variable N-terminal 
peptides was seen in both pooled plasma samples (Sigma) and samples from individual 
subjects (data not shown).
In addition to its function in triggering an immune response, the immune system plays 
an important role in inhibiting cancer progression (Smyth eta l., 2001). Moreover, the immune 
system itself may act as a biomarker for the presence, type and possible even stage of cancer 
(Finn, 2005). It is possible that immunoglobulin profiling may provide insights into the 
molecular mechanisms of cancer progression (Tan, 2001). For this reason, utilisation of the N- 
terminal positional proteomics strategy could provide a rapid screening method for antibody 
profiling, by efficiently targeting the variable regions of immunoglobulin molecules.
4.5.5 Identification of N-termini derived from complement proteins
Activation of complement component C3 and subsequent generation of various fragments is 
fundamental to most of the biological activities exerted by complement (see Section 4.2). The 
sequence of complement C3 and the associated fragments can be seen in Figure 4.10. 
Because complement C3 is stored in SwisProt as a single protein entry (P01024; Figure 4.11), 
database searching using MS/MS data generated from the plasma N-terminal preparation, 
fails to identify N-terminal peptides from proteolytically derived complement fragments. In 
order to screen the N-terminal preparation for complement C3 fragments, extracted ion 
chromatograms were prepared manually on the accurate mass data from the Orbitrap mass 
spectrometer. The sequence of complement C3 precursor was retrieved using the Sequence 
Retrieval System (SRS; http://srs.ebi.ac.uk) by entering the SwissProt accession number. The 
N-terminal sequences for each of the fragments were taken from the feature table entry
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Figure 4.9. Clustal alignment of immunoglobulin N-terminal (Arg-C) peptides.
Sequences were aligned using the C lu s ta lW 2  algorithm .
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MGPTSGPSLL LLLLTHLPLA LGSPMYSIIT PNILRLESEE TMVLEAHDAQ GDVPVTVTVH 
DFPGKKLVLS SEKTVLTPAT NHMGNVTFTI PANREFKSEK GRNKFVTVQA TFGTQWEKV 
VLVSLQSGYL FIQTDKTIYT PGSTVLYRIF TVNHKLLPVG RTVMVNIENP EGIPVKQDSL 
SSQNQLGVLP LSWDIPELVN MGQWKIRAYY ENSPQQVFST EFEVKEYVLP SFEVIVEPTE 
KFYYIYNEKG LEVTITARFL YGKKVEGTAF VIFGIQDGEQ RISLPESLKR IPIEDGSGEV 
VLSRKVLLDG VQNPRAEDLV GKSLYVSATV ILHSGSDMVQ AERSGIPIVT SPYQIHFTKT 
PKYFKPGMPF DLMVFVTNPD GSPAYRVPVA VQGEDTVQSL TQGDGVAKLS INTHPSQKPL 
SITVRTKKQE LSEAEQATRT MQALPYSTVG NSNNYLHLSV LRTELRPGET LNVNFLLRMD 
RAHEAKXRYY TYLIMNKGRL LKAGRQVREP GQDLWLPLS ITTDFIPSFR LVAYYTLIGA 
SGQREWADS VWVDVKDSCV GSLWKSGQS EDRQPVPGQQ MTLKIEGDHG ARWLVAVDK 
GVFVLNKKNK LTQSKIWDW EKADIGCTPG SGKDYAGVFS DAGLTFTSSS GQQTAQRAEL 
QCPQPAARRR RSVOLTEKRM DKVGKYPKEL RKCCEDGMRE NPMRFSCQRR TRFISLGEAC 
KKVFLDCCNY ITELRRQHAR ASHLGLARSN LDEDIIAEEN IVSRSEFPES WLWNVEDLKE 
PPKNGISTKL MNIFLKDSIT TWEILAVSMS DKKGICVADP FEVTVMQDFF IDLRLPYSW 
RNEQVEIRAV LYNYRQNQEL KVRVELLHNP AFCSLATTKR RHQQTVTIPP KSSLSVPYVI 
VPLKTGLQEV EVKAAVYHHF ISDGVRKSLK WPEGIRMNK TVAVRTLDPE RLGREGVQKE 
DIPPADLSDQ VPDTESETRI LLQGTPVAQM TEDAVDAERL KHLIVTPSGC GEQNMIGMTP 
TVIAVHYLDE TEOWEKFGLE KROGALELIK KGYTQQLAFR QPSSAFAAFV KRAPSTWLTA 
YWKVFSLAV NLIAIDSQVL CGAVKWLILE KQKPDGVFQE DAPVIHQEMI GGLRNNNEKD 
MALTAFVLIS LQEAKDICEE QVNSLPGSIT KAGDFLEANY MNLQRSYTVA IAGYALAQMG 
RLKGPLLNKF LTTAKDKNRW EDPGKQLYNV EATSYALLAL LQLKDFDFVP PWRWLNEQR 
YYGGGYGSTQ ATFMVFQALA QYQKDAPDHQ ELNLDVSLQL PSRSSKITHR IHWESASLLR 
SEETKENEGF TVTAEGKGOG TLSWTMYHA KAKDOLTCNK FDLKVTIKPA PETEKRPODA 
KNTMILEICT RYRGDQDATM SILDISMMTG FAPDTDDLKQ LANGVDRYIS KYELDKAFSD 
RNTLIIYLDK VSHSEDDCLA FKVHQYFNVE LIQPGAVKVY AYYNLEESCT RFYHPEKEDG 
KLNKLCRDEL CRCAEENCFI QKSDDKVTLE ERLDKACEPG VDYVYKTRLV KVQLSNDFDE 
YIMAIEQTIK SGSDEVQVGQ QRTFISPIKC REALKLEEKK HYLMWGLSSD FWGEKPNLSY 
IIGKDTWVEH WPEEDECQDE ENQKQCQDLG AFTESMWFG CPN
Signal peptide 
C3 beta chain
C3 alpha chain/C3a anaphylatoxin 
C3a alpha chain fragment 
C3g fragment 
C3d fragment 
C3f fragment
C3c alpha chain fragment 2
Figure 4 .10. Fragm ents o f hum an com p lem ent com ponent C3 precursor.
The sequence of human complement component C3 was retrieved from SwissProt. 
Specific fragments are represented in different colours and N-terminal Arg-C peptide 
sequences are underlined.
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I General information f\
Entry name C03_HUMAN
Accession number P01024
Integrated 21-JUL-1986, UniProtKB/Swiss-Prot.
Sequence update 12-DEC-2006, sequence version 2
Annotation update 10-1UN-2008, entry version 115
UniSave P01024
UniReflOO maiKefiPfl p p iq 2^
UniParc UPIQ00013EC9B
Key Begin End Length Description
SIGNAL 1 22 22
CHAIN 23 1663 1641 ComDlement C3. /FTId-PRO 0000005907.
CHAIN 23 667 645 Complement C3 beta chain. /FTId-PRO 0000005908.
CHAIN 672 1663 992 Complement C3 alpha chain. /FTId-PRO 0000005909.
CHAIN 672 748 77 C3a anaDhvlatoxin. /FTId-PRO 00O000S91O.
CHAIN 749 1663 915 Complement C3b alpha' chain. /FTId=PRO 0000005911.
CHAIN 749 954 206 Complement C3c alpha’ chain fraament 1. /FTId«PRO 0000005912.
CHAIN 955 1303 349 Complement C3da fraament. /FTId=PRO 0000005913.
CHAIN 955 1001 47 Complement C3a fraament. /FTId«PRO 0000005914.
CHAIN 1002 1303 302 Complement C3d fraament. /FTId-PRO 0000005915.
PEPTIDE 1304 1320 17 Complement C3f fragment. /FTId-PRO 0000005916.
CHAIN 1321 1663 343 Complement C3c alpha' chain fraament 2. /FTId-PRO 0000273948.
Figure 4.11. SwissProt entry for Complement C3 precursor.
The entry was retrieved through SRS. The feature table shows how the component 
fragments in vivo to produce various polypeptides.
185
Chapter 4: Reducing the complexity of human plasma using positional proteomics
(Figure 4.11). The m/z values for the N-acetylated, Arg-C, N-terminal peptides were calculated 
using the Protein/Peptide Editor tool in MassLynx. The calculated m/z values were used to 
interrogate the Orbitrap data by preparing extracted ion chromatograms for the N-terminal of 
each complement fragment (Figure 4.12).
The most notable identification is that of the C3a anaphylatoxin N-terminal. As 
mentioned earlier, levels of this protein (which represents 5% of the parent C3 molecule; 
Hugli, 1975) have been shown to indicate the presence of colorectal tumours (Habermann et 
a!., 2006). Rapid and efficient identification of this protein in multiple human plasma samples 
could provide the basis of a diagnostic screen for this candidate biomarker. Furthermore, 
screening of high resolution MS data, using precise masses from other putative biomarkers, 
could provide the basis of a targeted approach to screen the preparation for other clinically 
interesting proteins.
4.5.6 Screen for unbound internal peptides
Due to the high abundance of proteins such as HSA in the sample, even trace amounts of 
internal peptides from these species could obscure the identification of lower abundance 
protein components in the mixture. It is possible to manually screen for internal peptides by 
preparing extracted ion chromatograms using m/z values from predicated internal Arg-C 
peptides. Figure 4.13 shows the predicted peptide sequences for an Arg-C digest of HSA. 
Extracted ion chromatograms were prepared using data from the Orbitrap mass spectrometer. 
When the intensity scale is fixed to that of the true N-terminal of HSA, the internal peptides are 
not found. Signals from peptides R4 and R21 were seen but at substantially lower levels than 
that of the true N-terminal peptide. In the case of R4 the ion is present at an intensity of 
2.25E4 compared with 5.77E6 for the true N-terminal peptide ion. However, on closer 
inspection of the MS data it can be seen that the ion at m/z 661.327 is not clearly 
distinguishable as the [M+3H]3+ ion and no MS/MS data was generated for this peptide (Figure 
4.14). The peptide ion corresponding to R21 is present at an intensity of 7.72E5. In this case, 
the major species in the MS spectrum is the ion at m/z 697.847 corresponding to the R21 
[M+2H]2+ peptide ion. However, the product ion spectrum is not easily interpretable and for 
this reason it is not possible to confirm the sequence of this peptide (Figure 4.15).
This analysis shows that even in the case of HSA, which is by far the most abundant 
protein in human plasma, the method is not significantly ‘leaky’ it terms of the removal of 
internal peptides.
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Figure 4.12. Manual analysis of complement component C3 fragment N-terminal 
sequences.
The N-terminal peptide preparation of human plasma was resolved by RP 
chromatography and analysed by high resolution ion trap MS on the Orbitrap instrument. 
The N-terminal Arg-C peptide was determined for each of the complement C3 derived 
fragments (m /z values determined using the Bioworks protein/peptide editor in 
MassLynx). Values within the mass range of the instrument were used to prepare 
extracted ion chromatograms.
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Figure 4.13. Screen for internal peptides from HSA.
An N-terminal peptide preparation of human plasma was resolved by RP 
chromatography and analysed by high resolution ion trap MS on the Orbitrap 
instrument. Extracted ion chromatograms were prepared for acetylated Arg-C peptides 
from human serum albumin (m /z values determined using the Bioworks 
protein/peptide editor in MassLynx). In all cases the intensity scale was fixed to that 
observed for the HSA mature N-terminal peptide (5.77 x 106).
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Figure 4.13. Screen for internai peptides from HSA. continued
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Figure 4.14. Presence of Arg-C peptide R4 from serum albumin in the human 
plasma N-terminal preparation.
The [M +3H]3+ value of the internal Arg-C peptide R4 from HSA was used to prepare an 
extracted ion chromatogram on the LC -M S/M S data obtained from the Orbitrap 
analysis.
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Figure 4.15. Presence of Arg-C peptide R4 from HSA in the plasma N-terminal 
preparation.
The [M+2H]2* value of the internal Arg-C peptide R21 from HSA was used to prepare 
an extracted ion chromatogram on the LC-M S/M S data obtained from the Orbitrap 
analysis (upper panel). The corresponding M S/M S fragmentation data was also 
extracted (lower panel).
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4.5.7 Screen for truncated N-terminal peptides
N and C-terminal regions of proteins are subjected to a variety of exopeptidases that are 
capable of shortening the peptide chain by effectively cleaving or “trimming” individual or 
multiple amino acids in succession. Aminopeptidases catalyse the cleavage of amino acids 
from the amino terminus of protein or peptide substrates (Taylor, 1993) and 
carboxypeptidases catalyse the cleavage of amino acids from the C-terminus (Christianson 
and Lipscomb, 1989). These processes are common in plasma, as this fluid contains a large 
amount of protease (Redlitz et a!., 1995; Durinx et al., 2000). Consequently, plasma proteins 
may exist in multiple forms consisting of varying degrees of truncation.
When searching the N-terminal MS/MS data using the standard Mascot parameters 
(listed in Section 2.11.3), the enzyme Arg-C is chosen, which limits the search space to 
arginine terminated, complete, N-terminal peptides. Alternatively, by altering the enzyme 
specificity to semi-trypsin, the search space is increased to allow for incomplete tryptic 
peptides (i.e. will allow for truncation at the N-terminus). In this case, N-terminal peptides that 
have been subjected to aminopeptidase cleavage will also be identified.
MS/MS data from the human plasma N-terminal preparation was searched against 
the human N-terminal data base, using the local Mascot server, with semi-trypsin as a 
parameter. The search identified multiple forms of N-terminal regions in many of the classical 
plasma proteins (data not shown). These multiple forms consisted of trimmed or shortened 
versions of the full length peptide from the N-terminal end of the protein. Low scores indicated 
that these shortened forms were present at lower intensities than the true N-terminal Arg-C 
peptides. Figure 4.16 shows extracted ion chromatograms for various forms of the C3a 
anaphylatoxin and serum amyloid N-terminal Arg-C peptide.
In all cases, the full length peptide is present at higher intensities than the N-terminally 
trimmed versions, assuming equal response factors. To assess the extent of this trimming 
process extracted ion chromatograms were prepared for various shortened forms of Arg-C N- 
terminal peptides from N-terminal preptides identified in Table 4.5. MS intensities for each 
peptide were recorded (Table 4.6) and used to plot the relative intensities (expressed as a 
percentage of the intensity of the true N-terminal Arg-C peptide) of the truncated forms (Figure 
4.17).
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Figure 4.16. Identification of full length and truncated forms N-terminal peptides.
The N-terminal peptide preparation of human plasma was resolved by RP 
chromatography and analysed by high resolution ion trap MS on the Orbitrap 
instrument. Extracted ion chromatograms were prepared for full length and truncated 
N-terminal Arg-C peptides from C3a anaphylatoxin and serum amyloid (m /z values 
determined using the Bioworks protein/peptide editor in MassLynx).
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Protein m/z Charge Intensity Sequence
Serum albumin 638.30 2 2.43x10° DAHKSEVAHR
580.79 2 3.13x10° AHKSEVAHR
545.27 2 5.02x10° HKSEVAHR
476.71 2 7.85x10“ KSEVAHR
740.37 2 0 SEVAHR
Serum amyloid 529.64 3 1.09x10° HTDLSGKFVFPR
745.39 2 0 TDLSGKFVFPR
695.87 2 5.39x10“ DLSGKFVFPR
637.35 2 0 LSGKFVFPR
581.81 2 5.05x10“ SGKVFPR
Fibrinogen alpha 789.85 2 2.72x10° ADSGEGDFLAEGGGVR
754.34 2 1.4x10° DSGEGDFLAEGGGVR
696.83 2 1.03x10° SGEGDFLAEGGGVR
653.31 2 0 GEGDFLAEGGGVR
624.8 2 6.53x10“ EGDFLAEGGGVR
Alpha-1 -anantichymotrypsin 1089.49 2 2.9x10° HPNSPLDEENLTQENQDR
1020.96 0 0 PNS PLDEENLTQENQDR
972.44 2 7.22x10“ NS PLDEENLTQENQDR
915.41 2 6.46x10° SPLDEENLTQENQDR
871.90 2 0 PLDEENLTQENQDR
Carboxypeptiase B 664.86 2 5.04x10° FQSGQVLAALPR
591.35 2 1.70x10“ QSGQVLAALPR
527.31 2 4.34x10“ SGQVLAALPR
483.79 2 0 GQVLAALPR
455.28 2 0 QVLAALPR
Apollpoprotein C 901.45 3 5.90x10“ TPDVSSALDKLKEFGNTLEDKAR
867.77 3 0 PDVSSALDKLKEFGNTLEDKAR
835.42 3 1.83x10“ DVSSALDKLKEFGNTLEDKAR
797.08 3 0 VSSALDKLKEFGNTLEDKAR
764.06 3 0 SSALDKLKEFGNTLEDKAR
Alpha-2-HS-glycoprotein 561.81 2 1.67x10° APHGPGLIYR
526.29 2 0 PHGPGLIYR
477.76 2 7.71x10“ HGPGLIYR
817.46 1 0 GPGLIYR
760.44 1 0 PGLIYR
C3a anaphylatoxin 522.79 2 6.05x10° SVQLTEKR
957.54 1 0 VQLTEKR
858.45 1 8.02x10“ QLTEKR
730.41 1 6.76x10“ LTEKR
617.31 1 1.15x10° TEKR
Table 4.6. Identification of N-terminally trimmed proteins by manual extraction of ions 
from the Orbitap acquisition of human plasma N-terminal peptides.
N-terminal Arg-C masses were determined for full and truncated forms of the major plasma 
proteins. Various m/z values were used to prepare extracted Ion chromatograms from the 
Orbltrap LC-M S/M S analysis (three hour RP gradient) of the plasma N-terminal preparation.
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Figure 4.17. N-terminal trimming of human plasma proteins.
Extracted ion chromatograms were prepared using m/z values of complete sequences 
and trimmed forms of mature N-terminal peptides from the LC-M S/M S analysis on the 
Orbitrap instrument. The percentage intensities relative to the most intense species 
were plotted against the peptide length.
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In most cases, the full length, mature, N-terminal peptide represents the most 
abundant species. However, in the case of serum amyloid, the C-2 peptide and the C-4 
peptide are also present in high quantities (50% intensity of the unmodified N-terminal).
The existence of proteolytically trimmed N-termini in the preparation will undoubtedly 
increase the overall complexity of the sample. Even if these shortened forms are present in 
lower quantities, the presence of truncated versions of high abundant proteins in the sample 
will compromise signals from N-terminal peptides originating from low abundance species.
In five out of eight cases, there is evidence that trimming is caused by dipeptidyl 
peptidase activity, whereby two amino acids are cleaved together. Dipeptidyl peptidases are a 
group of enzymes capable of cleaving dipeptides from the N-terminal regions of proteins. 
Dipeptidyl aminopeptidase IV (DPP IV) was discovered in 1966 (Hopsu-Havu and Glenner, 
1966) and is a serine peptidase which removes N-terminal dipeptides from polypeptides with 
penultimate proline and alanine residues (Kenny et a l, 1976). DPP IV is in close contact with 
proteins circulating in the blood, since it is located on endothelial cells (Lojda, 1979) and, more 
importantly, is found as a soluble enzyme in blood plasma (Durinx et al., 2000). For more than 
20 years, increased DPP IV activity has been linked to various diseases, including malignant 
processes (Hino et al., 1976), rheumatoid arthritis (Hagihara et al., 1987) and more recently 
diabetes mellitus (Ryskjaer e ta l, 2006).
The classical plasma proteins: serum albumin, a-1-antichymotrypsin, apolipoprotein C 
and a-2-HS-glycoprotein each contain either alanine or proline at the penultimate position. 
Given the data presented in Figure 4.14, these proteins are all strong candidates for dipeptidyl 
peptidase activity. It may therefore be feasible to measure the activity of dipeptidyl peptidases 
by identifying and quantifying the substrates of these enzymes i.e. trimmed protein N-termini. 
The N-terminal positional proteomics strategy provides an ideal tool in which to measure the 
activity of these enzymes as it targets the processed region of the putative substrates.
4.5.8 Normalisation of plasma proteins
In an attempt to reduce the dynamic range of proteins in human plasma, Protein Equalizer™ 
technology was used to normalise the concentrations of individual components within the 
sample (a detailed description can be found in Section 1.5.5). For normalisation, 20mg of 
Equalizer™ beads were washed and swollen in 50% (v/v) methanol, prior to equilibration in 
20mM Na2C0 3  buffer. Human plasma proteins (100mg) were incubated with the beads for 2h,
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after which beads were washed thoroughly to remove unbound protein. It was necessary to 
use a large excess of protein in order to saturate all of the potential binding sited on the ligand 
library beads. The washed bead suspension was subjected to 1-D SDS-PAGE along with 
15pg of starting material (Figure 4.18). Wash fractions were also analysed to ensure that all 
unbound proteins had been removed (data not shown). From 1-D SD-PAGE analysis it can be 
seen that the dynamic range was successfully reduced in the plasma sample treated with the 
Equalizer™ beads. The two gel profiles are quite distinct, in the lane containing the starting 
material, the band at 66kDa corresponding to HSA dominates the gel and Coomassie staining 
fails to pick out many other protein bands. In contrast, the 1-D profile from the normalised 
sample contains many more bands visible by Coomassie staining and the gel lane is not 
dominated by one single band.
To establish if normalisation increases the amount of protein identifications obtained 
by in-solution digestion and LC-MS/MS analysis, the protein/bead suspension was subjected 
to tryptic digestion and the resulting peptides were analysed by RP LC-MS/MS, using an 
extended three hour gradient. Peptide sequences were searched against SwissProt using the 
Mascot search engine with taxonomy restricted to Homo sapiens. Proteins identified with a 
Mowse score of greater than 50 (ion score threshold) were accepted as confident (Table 4.7). 
Following normalisation 41 proteins were identified, which is a substantial improvement in 
comparison to the starting material, which generated only five significant hits (Table 4.4).
4.5.9 N-terminal tryptic peptide isolation of normalised plasma proteins
To investigate if normalisation in combination with the positional proteomics strategy would 
further improve the efficiency of protein identification, the N-terminal isolation protocol was 
performed on plasma proteins coupled to Protein Equalizer™ beads. The N-terminal protocol 
was performed directly on the beads without elution of proteins. The proteins were acetylated 
whilst coupled to the beads, subsequent proteolysis of the acetylated proteins liberated 
peptides from the beads. The resulting peptide mixture was removed from the beads in the 
supernatant fraction. N-terminal purification by NHS-activated Sepharose gave rise to a new 
set of N-terminal peptides. Figure 4.19 shows the N-terminal MALDI-ToF spectrum from the 
normalised human plasma preparation. The peak at 1233.6Da corresponding to the N- 
terminal of HSA, which dominates the N-terminal MALDI-ToF spectrum obtained from the 
starting material (Figure 4.6), is present but at a much lower intensity relative to the base peak 
ion (apolipoprotein A-l). Reduction of the intensity of the HSA N-terminal peptide, in turn,
1 9 7
Figure 4.18. Normalisation of protein concentrations in human plasma.
Human plasma (100mg, Sigma) was normalised using Protein Equalizer™ beads. 
The normalised protein/bead suspension (1 Op.l) was separated by 1-D SD S-PAG E  
alongside 10ng of starting material.
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1 Apolipoprotein A-l P02647 4461 61 28 30.76
2 Apolipoprotein A-IV P06727 2796 32 16 45.37
3 Fibrinogen alpha chain P02671 1647 13 12 94.91
4 Complement C4-B P0C0L5 1631 5 6 192.64
5 Serum albumin P02768 1113 19 13 69.32
6 Prothrombin P00734 726 16 14 69.99
7 Vitronectin P04004 380 9 5 54.271
8 Gelsolin P06396 782 8 4 85.64
9 Inter-alpha-trypsin inhibitor heavy chain H1 P19827 191 3 2 101.32
10 Hemoglobin subunit beta P68871 262 27 3 15.99
11 Apolipoprotein C-lll P02656 216 15 2 10.86
12 Ceruloplasmin P00450 256 9 7 122.13
13 Clusterin P10909 716 12 7 52.46
14 Apolipoprotein E P02649 598 22 5 36.12
15 Apolipoprotein B-100 P04114 368 3 7 51.52
16 Ig lambda-1 chain C region P15814 250 4 1 36.03
17 Fibronectin P02751 209 7 13 262.44
18 Alpha-2-HS-glycoprotein P02765 211 8 2 39.30
19 Complement C3 P01024 1341 6 11 187.03
20 Plasminogen P00747 57 5 4 90.51
21 Apolipoprotein A-ll P02652 526 33 3 11.16
22 Complement C1q subcomponent subunit A P02746 128 12 2 25.75
23 Inter-alpha-trypsin inhibitor heavy chain H1 Q14624 193 11 10 106.37
24 Fibrinogen beta chain P02675 574 9 4 55.89
25 Fibrinogen gamma chain P02679 289 13 3 51.48
26 Inter-alpha-trypsin inhibitor heavy chain H2 P19823 176 11 10 106.30
27 Complement factor H P08603 173 3 3 123.98
28 Ig kappa chain C region P01834 168 15 2 11.7
29 Hemoglobin subunit apha P69905 51 10 1 15.24
30 Complement C1q subcomponent subunit B P02746 117 11 2 26.42
31 Transthyretin P02766 102 8 2 15.77
32 Plasminogen P00747 100 6 4 90.10
33 Alpha-1-antitrypsin P01011 75 25 3 46.70
34 Hemoglobin subunit delta P02042 71 31 3 16.45
35 Complement C1q subcomponent subunit C P02747 74 3 2 25.57
36 Complement C1s subcomponent P09871 70 4 7 76.64
37 Pigment epithelium-derived factor P36955 68 25 4 39.24
38 Complement component C8 alpha chain P07357 64 5 2 67.00
39 Hemoglobin subunit epsilon P02100 61 16 1 16.19
40 Complement component C8 beta chain P07358 55 3 1 67.03
41 Apolipoprotein C-l P02654 55 20 1 9.33
Table 4.7. Identification of normalised human plasma proteins by in-solution digestion and 
LC-MS/MS analysis.
The normalised bead/protein suspension (5pl) was subjected to proteolysis using trypsin (0.1 pg). The  
supernatant containing the digested peptides was removed from the suspension and diluted 1 in 50 
with 0.1%  FA prior to LC -M S/M S analysis using a three hour RP gradient. M S/M S data was used to 
search the human N-terminal database using the M ASCO T search engine. The taxonomy was 
restricted to Homo sapiens; fixed modifications: carbamidomethylation of cysteine; variable 
modification: oxidation of methionine; protease: trypsin; missed cleavages: 1; peptide tolerance: 
1.5Da; M S/M S tolerance: 0.6Da; instrument: ESI-TRAP; peptide charge: 1+, 2+ and 3+. Protein 
identifications with a Mowse score greater than 50 were accepted as confident identifications.
1 9 9
Figure 4.19. Normalised human plasma N-terminal preparation.
Normalised human plasma proteins (Sigma) coupled to Protein Equalizer™  beads 
were acetylated, washed and digested with trypsin. The peptides were separated from 
the bead suspension and incubated with 10Ofxl NHS-activated Sepharose. A small 
portion (10pl) of the of supernatant was removed and desalted using a C 18 ZipTip. 
The desalted peptides were analysed by M ALDI-ToF MS. The major ions in the 
spectrum can be assigned to masses of acetylated, arginine terminated, true N- 
terminal peptides from plasma proteins.
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allows signals from the other species in the spectrum to emerge. The cluster of peaks seen in 
the analysis from the starting material that arise from the multiple immunoglobulin isoforms is 
not visible in the normalised sample. New peaks at m/z 1044.5, 1545.6, 1837.8 and 2233.97 
are present in the normalised MALDI-ToF N-terminal spectrum, corresponding to C3a 
anaphylatoxin, complement C3, apolipoprotein E and C17 orf46 respectively. Analysis of the 
normalised N-terminal preparation by LC-MS/MS using the ion trap instrument yielded a total 
of 55 protein identifications, 23 of which were not identified in the N-terminal preparation from 
untreated plasma (Table 4.8). A summary of proteins identified from human plasma, using in- 
solution digest and N-terminal purification of untreated plasma and normalised preparations 
can be seen in Table 4.9. A total of 102 unique protein identifications were made.
4.6 Summary
This study demonstrates the use of a positional proteomics approach to characterise the true 
N-terminal region of proteins in human plasma. Although the use of N-terminal purification 
failed to deliver as comprehensive a survey of the plasma proteome compared with other 
methods (Omenn et al., 2005; Shen et. a!., 2005), the approach has the added advantage of 
defining the true N-terminal peptide sequence from each protein. As highlighted in this study 
many plasma proteins undergo extensive processing at their N-terminal. This processing 
results in a variety of isoforms from each protein giving rise to multiple N-terminal sequences. 
Dipeptidyl peptidase activity appears to play a major role in N-terminal trimming. Many of the 
truncated forms identified were two amino acids shorter than the previously identified form. 
The implication of multiple N-terminal forms is increased complexity of the overall N-terminal 
preparation. Even though the truncated forms are present in lower quantities they will be 
significant enough to suppress the signal intensity of other less abundant proteins in the 
mixture. Identification and quantification of dipeptidyl peptidase substrates could provide a 
useful tool for measuring the activity of these enzymes which have roles in disease processes.
Application of the positional proteomics strategy to untreated human plasma resulted 
in the identification of over 20 N-terminal sequences corresponding to the variable region of 
immunoglobulin chains. Although this presents a problem in terms of global protein 
identification, the rapid identification of multiple immunoglobulin isoforms by N-terminal 
peptide isolation could have potential clinical implications in immunoglobulin profiling.
The use of Protein Equalizer™ technology to effectively normalise protein 
concentrations in the sample led to the identification of a new subset of proteins, in addition to
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1 lipopolysaccharide-binding protein 838.47 ANPGLVAR SP 21
2 C6orf21 variant protein 865.36 ASSAMSDR M 26
3 unknown 964.41 MKGMGSDR 41
4 Telomeric repeat-binding factor 2 1005.41 AGGGGSSDGSGR M 28
5 DNA-binding protein inhibitor ID-2 (Q02363) 1019.53 MKAFSPVR 20
6 Caveolin-1 1024.43 SGGKYVDSE M 29
7 Knjppel-like factor 6 1038.55 SAANPLTAPR M 36
8 Protein C1orf97 (Q9BRT7) 1127.54 MDKKSTHR 39
9 Mitochondrial ribosomal protein S24 1171.60 AASVCSGLLGPR M 48
10 Puromydn-sensitive aminopeptidase 1298.68 MWLAAAAPSLAR 51
11 Nudear receptor coactivator 2 1320.53 SGMGENTSDPSR M 20
12 Cydic AMP-dependent transcription factor ATF-5 (Q9Y2D1) 1347.75 SLLATLGLELOR M 31
13 GranzymeK (P49863) 1449.76 EIIGGKEVSPHSR SP 34
14 Complement C5 (P01024) 1545.82 SPMYSIITPNILR SP 45
15 meiotic nudear divisions 1 homolog 1570.84 SKKKGLSAEEKR M 25
16 Cholinesterase 9 1696.9 EDDIIIATKNGKVR SP 22
17 potassium large conductance caldum-activated channel 1717.74 ANGGGGGGGSSGGGGGGGGSSLR M 30
18 GRAM domain-containing protein 1B (Q3KR37) 1726.84 MKGFKLSCTASNSNR 36
19 . EPC1 protein 1764.77 MEKEEESEHHLQR 45
20 B-cell linker protein (Cytoplasmic adapter protein) 2009.10 MDKLNKITVPASQKLR 32
21 Uncharacterized protein C17orf46 (Q96LK8) 2233.01 GVTGAHGFPCCGKGSVEVAEMR M 40
22 Beta-sarcoglycan 2269.11 AAAAAAAAEQQSSNGPVKKSMR M 20
23 alpha-1-antitrypsin 2774.14 EDPQGDAAQKTDTSHHDQDHPTFNR SP 55
Table 4.8. N-terminal identifications from normalised human plasma proteins.
The N-terminal peptide preparation of normalised human plasma was analysed by LC-MS/MS using 
a three hour reverse-phase gradient. MS/MS data was used to search the human N-terminal 
database using the M ASCOT search engine. The taxonomy was restricted to Homo sapiens; fixed 
modifications: N-terminal acetylation and lysine acetylation; variable modification: oxidation of 
methionine; protease: Arg-C; missed cleavages: 1; peptide tolerance: 1.5Da; MS/MS tolerance: 
0.6Da; instrument: ESI-TRAP; peptide charge: 1+, 2+ and 3+. Protein identifications with a Mowse 
score greater than 20 were accepted as confident identifications.
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Protein U ntreated N orm alised
T ota l NT Total NT
1 Apolipoprotein A-l * * * *
2 Apolipoprotein A-IV * * *
3 Fibrinogen alpha chain * * *
4 Complement C4-B *
5 Serum albumin * * * *
6 Prothrombin *
7 Vitronectin *
8 Transferrin * * Dr
9 Inter-alpha-trypsin inhibitor heavy chain H1 *
10 Hemoglobin subunit beta * * *
11 Apolipoprotein C-lll *
12 Ceruloplasmin *
13 Clusterin *
14 Apolipoprotein E *
15 Apolipoprotein B-100 *
16 Ig lambda-1 chain C region *
17 Fibronectin W
18 Alpha-2-HS-glycoprotein * * *
19 Complement C3 * * *
20 Plasminogen *
21 Apolipoprotein A-ll *
22 Complement C1q subcomponent subunit A *
23 Inter-alpha-trypsin inhibitor heavy chain H1 *
24 Fibrinogen beta chain
25 Fibrinogen gamma chain *
26 Inter-alpha-trypsin inhibitor heavy chain H2 *
27 Complement factor H *
28 Ig kappa chain C region *
29 Hemoglobin subunit apha * * *
30 Complement C1q subcomponent subunit B *
31 Transthyretin *
32 Plasminogen *
33 Alpha-1-antitrypsin * *
34 Hemoglobin subunit delta *
35 Complement C1q subcomponent subunit C *
36 Complement C1s subcomponent *
37 Pigment epithelium-derived factor *
38 Complement component C8 alpha chain *
39 Hemoglobin subunit epsilon *
40 Complement component C8 beta chain *
41 Apolipoprotein C-l * * *
42 Transmembrane protein 163
43 C3a anaphylatoxin * *
44 Mitochondrial import receptor
45 antigen MLAA-39
46 Glutathione S-transferase Mu 1 *
47 Oxidoreductase HTATIP2
48 Antithrombin-lll
49 antigen NY-CO-43
50 Transcription factor ETV6
Table 4.9. Total protein identifications from human plasma.
Identifications from the in-solution tryptic digest of the starting material (untreated plasma) and 
normalised samples and identifications from the N-terminal preparations of the starting material and 
normalised samples were collated.
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Protein U ntreated N orm alised
Total NT Total N T
51 Inter-alpha-trypsin Inhibitor *
52 FBXW12 mature *
53 Tyrosin kinase receptor erbB-3 * *
54 cyclin G associated kinase * *
55 Alpha-1 -antichymotrypsin * •
56 Guanylate kinase * *
57 Replication protein A 30 kDa subunit * *
58 HIV-1 like protein * *
59 lipopolysaccharide-binding protein *
60 C6orf21 variant protein *
61 unknown *
62 Telomeric repeat-binding factor 2 *
63 DNA-binding protein inhibitor ID-2 *
64 Caveolin-1
65 Kruppel-like factor 6
66 Protein C1orf97 *
67 Mitochondrial ribosomal protein S24 *
68 Puromvcin-sensitive aminopeptidase *
69 Nuclear receptor coactivator 2 *
70 lipopolysaccharide-binding protein
71 Cyclic AMP-dependent transcription factor ATF-5 *
72 GranzymeK *
73 Complement C5 *
74 meiotic nuclear divisions 1 homolog
75 Cholinesterase 9 *
76 potassium large conductance calcium-activated channel *
77 GRAM domain-containing protein 1B *
78 EPC1 protein *
79 B-cell linker protein (Cytoplasmic adapter protein) *
80 Uncharacterized protein C17orf46 *
81 Beta-sarcoglycan *
82 immunoglobulin heavy chain variable region *
83 immunoglobulin heavy chain variable region *
84 Ig heavy chain V-lll region CAM *
85 Ig heavy chain V-lll region GA *
86 Ig heavy chain V-lll region BRO *
87 Ig kappa chain V-l region BAN *
88 Ig kappa chain V-l region Mev *
89 Ig kappa chain V-l region Wes *
90 Ig heavy chain VHDJ region *
91 Ig lambda chain V-lll region SH *
92 Ig kappa chain V-l region DEE *
93 Ig heavy chain V-lll region LAY *
94 Ig heavy chain V-lll region BRO *
95 Ig kappa chain V-lll region SIE *
96 Ig kappa chain V-l region CAR *
97 Ig heavy chain V-lll region TIL *
98 Ig kappa chain V-lll region VG mature *
99 Ig heavy chain V-lll region JON *
100 Ig heavy chain V-lll region BUT *
101 Ig kappa chain V-IV region Len *
102 Ig heavy chain V-lll region TRO *
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the proteins already identified from the N-terminal analysis of untreated plasma. Identification 
of the colorectal tumour biomarker C3a anaphylatoxin was enhanced in the ligand library 
treated plasma sample (Figure 4.19).
/
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5: M A S S  IS O T O P E  D I S T R I B U T I O N  A N A L Y S IS  OF A M IN O  A C ID  
R E S I D U E S
5.1 Intr o d u c tio n
5.1.1 Stable isotopes
Stable isotope labelling is an important tool in proteomics and is becoming increasingly 
popular (reviewed in Beynon and Pratt, 2005). In general, the introduction of a stable isotope 
does not affect the physicochemical properties of a protein, with differentially labelled species 
behaving the same during processes such as cell growth, proteolysis, chromatographic 
separation and fragmentation. Only at the final stage of analysis (MS), can they can be 
distinguished. Stable isotope labelling in vivo has mainly focused on comparative proteomic 
methods, in which the incorporation of a metabolic label is used to identify one of the 
components in a pair wise comparison (Blagoev et a/., 2003; Everley et a!., 2004; Ong et a!., 
2002). Methods for the incorporation of stable isotopes in vitro include ICAT (Gygi, et al., 
1999; Shiio and Aebersold, 2006), [180] labelling during proteolysis (Reynolds et al., 2002; 
Yao e ta l., 2001) and guanidination (Beardsley and Reilly, 2002; Brancia et al., 2001; Thevis 
et al., 2003).
Incorporation of a labelled amino acid can also be used to provide additional 
information for both de novo sequencing and database searching, for instance, in counting the 
number of amino acids in a given peptide. If the frequency of a specific amino acid is readily 
apparent from manual inspection of the MS data, it is possible to incorporate this information 
as an additional parameter in the database search. The MASCOT search engine has the 
capability to allow the inclusion of amino acid composition data using appropriate search 
terms. For example, the string “[M+H] + comp (X[n])” not only submits the peptide mass to the 
search, but permits the addition of limited compositional information. Knowledge of the 
frequency (n) of a specific amino acid (x), significantly restricts the amount of search space 
required (Engen et al., 2002; Hunter et al., 2001; Martinovic et al., 2002; Pan et al., 2003; Zhu 
et al., 2002; Pratt et al., 2002). A separate approach utilising metabolic labelling (both [15N] 
and [13C]) has been adopted to determine the carbon and nitrogen composition of peptides 
(Snijders et al., 2005).
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5.1.2 Mass isotope distribution analysis
Mass isotope distribution analysis (MIDA) is a technique traditionally used for measuring the 
synthesis of biological polymers. The technique involves the quantification (by MS) of the 
relative abundance of molecular species of a polymer, differing in mass only (mass 
isotopomers), following the introduction of a stable isotope. Mass isotopomers differ by the 
number of heavy atoms in their molecules, e.g., [14N2] and [15N2] urea; or [H2] and [2H3] acetic 
anhydride.
The polymers measured can range from simple fatty acids synthesised from acetyl- 
CoA units to complex protein molecules. MIDA analysis is based on the analysis of numerical 
distributions, therefore it is essential that different combinatorial possibilities exist for the 
molecule analysed (Hellerstein and Neese, 1992).
5.1.3 Development of a novel acetylation reagent
When developing the N-terminal positional proteomics strategy (Chapter 1), acetylation using 
acetic anhydride or sulfo-NHS acetate was chosen as the amino group blocking reagent 
because it converges, in terms of downstream chemistry, naturally acetylated peptides with 
those acetylated chemically as part of the protocol. However, a stable isotope labelled variant 
of acetic anhydride (C[2H3]C0)20 was also used to discriminate naturally Na-acetylated 
peptides from those that are acetylated chemically. During the use of this reagent a minor ion 
was observed, 1Da smaller than the monoisotopic ion, corresponding to the chemically 
acetylated peptide (Figure 5.1). This feature is due to a trace (circa 1%) of (C[2H2]C0)20 in the 
reagent preparation, which also labels a and £ amino groups in peptides, but with a 1Da mass 
difference. The “minus 1” ion was not evident in naturally acetylated peptides that lacked 
lysine residues. It is possible to exploit this property of the reagent in order to identify the 
occurrence of a chemical acetylation site on each peptide in a mixture, which in turn provides 
information for identification of proteins by virtue of the N-terminal peptide. This chapter 
describes the design of a new reagent, comprising (C[2H3]C0)20 and ([13C]H3[13C]0)20 mixed 
in a 9:1 ratio. The relative ion intensity of the “minus 1” ion reflects the number of acetylated 
sites in the protein, which allows the number of amino groups (lysine residues) to be counted. 
This reagent, referred to as MIDAR (mass isotope distribution analysis of amino acid residues) 
introduces the principle of using mixed isotope tags to gain further information for protein 
identification and in particular, to count the frequency of specific amino acids.
2 0 7
Copper-resistance protein D Elongation factor Tu  (E F -T u )
M ND LIM IV IR  [M +H]* 1275.66  
1275.67
SKEKFER [M +2H]+ 528.29
528.29
Enolase p-lactamase (mature)
t t
♦ S K IV K IIG R  [M +2H]+ 574.89
t t
♦-H PETLVK VK DA ED Q LQ R  [M +3H]+ 1275.66
574.89 714.72
Figure 5.1. Observation of a slight impurity peak in (C[2H3]C0)20  labelled 
peptides.
The (C[2H3]C 0 )20  labelled, E. coli N-terminal preparation was analysed on the 
Orbitrap mass spectrometer by RP LC-M S/M S using an extended, three hour, 
gradient. Extracted ion chromatograms were prepared for N-terminal peptides 
containing 0, 2 and 3 acetyl groups.
2 0 8
Chapter 5: Mass isotope distribution analysis of amino acid residues
The logic behind the design and use of the reagent is straightforward (Figure 5.2). 
Consider a peptide with n free amino groups (a and s). If the acetic anhydride (of mass offset 
0) is a pure reagent, then complete reaction generates a single mass shift such that the 
product will have the mass increment of n.O Da. However, if the reagent is an isotopically 
coded mixture where the proportion of the heavier reagent is P (for example, P=0.9,90% 0=3, 
10% 0=2, the properties of the reagent used here) the resulting spectra are more complex. 
For a peptide with a single amino group (n=1) there are two products M+2Da and M+3Da in a 
10:90 ratio, where M is calculated as the mass of the peptide after modification with acetic 
anhydride showing the natural isotope distribution (+42Da).
When a peptide contains more than a single amino group, the products become more 
complex. For instance, a peptide with three amino groups will, when reacted, generate four 
products M+(3*3)=M+9Da, (M+2*3+1*2)=M+8Da, (M+1*3+2*2)=M+7Da, (M+3*2)=M+6Da. 
Two of the species are labelled uniformly with either the 0=2 reagent M+6Da or the 0=3 
M+9Da reagent, but the middle two (0=2,0=2,0=3, M+7Da) and (0=2,0=3,0=3, M+8Da) are 
characterised by mixed labelling patterns. Additionally, because of the positional 
combinations, there are three different ways to obtain peptides of these mass offsets (M+7Da: 
[+2,+2,+3], [+2,+3,+2] and [+3,+2,+2] for the lighter intermediate, and (M+8Da: [+2,+3,+3], 
[+3,+3,+2] and [+3,+2,+3] for the heavier) and their intensities are higher, as predicted by a 
binomial expansion (1:3:3:1 in this instance, where there are three labelling sites). The 
intensity ratio of the four ions is therefore dictated by the relative proportion of the two variants 
of the reagent. At P=0.9, the intensities will be in the proportions [M+9]: 72.9%, [M+8]: 24.3%, 
[M+7]: 2.7%, [M+6]: 0.1%. The combined spectrum, encompassing the reagent variants and 
the natural isotope abundance of each of the variants, will be complex to calculate, but at 10% 
0=2, the distinction between n=1,2,3 is clear without detailed analysis (Figure 5.3).
Further complexity in the mass spectrum for each labelled peptide derives from the 
combinatorial nature of the labelling by each form of the reagent (0=2, 0=3). For a peptide 
with a single amino group (whether the a amino group, or an internal z amino group derived 
from a lysine residue in a peptide that is blocked by natural acetylation), there can only be two 
variants, modified as 0=2, and as 0=3. Thus, the M+2Da ion will have an intensity in the 
mass spectrum that is approximately 10% of the M+3Da ion. The relative ion intensity is only 
approximately 10% because the mass spectrum is now the composite of two overlapping 
envelopes (monoisotopic mass, first [13C] ion, second [13C] ion etc for each of the M+2Da and 
M+3Da modified peptides). As the mass of the peptide increases, and as the number of amino
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Figure 5.2. General principle of MIDAR.
Peptides containing different numbers of amino groups will be modified by the two 
isotope-coded (black circles, mass offset #=3, light circles, mass offset 0=2) variants 
of acetic anhydride. For peptides containing more than one amino group (n=2, n=3 in 
the figure), the two isotopic variants will be incorporated according to the combinatorial 
probabilities of the two variants. The intensities of the different mass variants is 
dictated by the relative proportion P of the two variants; in this example, the calculated 
intensities (in parentheses, as a percentage of the total intensity) are calculated for 
P(#=3)=0.9 and P(O=2)=0.1. In this illustration, the peptide illustrated for n=1 is 
provided by an N-terminal peptide that is naturally acetylated (closed squares), and 
which is therefore unavailable for further modification.
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Figure 5.3. The effect of number of amino groups and peptide mass on the 
MIDAR isotope profile.
A series of theoretical peptides were created using an hveragine’ composition, at 
1000Da, 2000D a and 3000D a, and the natural isotope distributes were calculated 
using the MS-lsotope program (described in Chapter 2). This distribution was then 
used to simulate the total isotopic profile, based on the combinatorial probabilities for 
incorporation of two variants of isotope-coded acetic anhydride. For each peptide 
mass, and for different numbers of amino groups, these isotope profiles were then 
used to calculate the intensity of the ion 1 Da less than the monoisotopic mass (the 
fninus-1 value).
211
Chapter 5: Mass isotope distribution analysis of amino acid residues
groups also increases, the deviation becomes larger, but at no time does it compromise the 
simple assessment of the number of modified sites by visual inspection of the intensity of the 
“minus 1” ion and the monoisotopic ion of the species labelled with 0=3. The incorporation of 
the doubly-labelled acetic anhydride is readily apparent from the highly atypical presence of 
the “minus 1" ion in the mass spectrum of each peptide.
5.1.4 Accurate mass and retention time
For simple peptide mixtures, there is increasing interest in the use of accurate mass tags, 
coupled with precise elution times, as sufficient parameters for proteome profiling (AMT 
strategy; Conrads et al., 2000; Lipton et at., 2006; Liu et ai, 2007). HPLC, which is used 
primarily as a simplification device, can be exploited to provide additional information 
regarding the properties of the species eluted from the chromatographic media. Although the 
resolving capabilities of HPLC and modern MS are not comparable, such information can be 
used to differentiate between peptides present in a complex mixture and more importantly, to 
provide additional information for protein/peptide identification. Models that are used to predict 
retention time are based on the assumption that the chromatographic behaviour of a peptide is 
dependent on its amino acid composition. However, modification of a peptide will affect the 
rate at which it is eluted from the reverse phase media by altering the physiochemical 
properties of the amino acid residues affected.
Protein modification by acetylation is heavily used in the strategies described in this 
thesis. In order to employ an AMT based approach to N-terminal identification, it is necessary 
to investigate the effect of acetylation on peptide retention time.
5.2 A ims and objectives
This aim of this chapter is to demonstrate the application of the MIDAR reagent to report the 
number of lysine residues contained within a peptide. The reagent will be used to modify 
various model peptides, purified proteins and naturally occurring proteins in order to establish 
its reproducibility. The reagent will then be used to replace unlabelled acetic anhydride as the 
acetylation reagent in the N-terminal positional proteomics strategy. This reagent is of 
particular interest in studying proteins from prokaryotes as these proteins are, in general, 
unmodified at the N-terminus. When used in higher eukaryotes, the majority of proteins will be
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blocked by Na-acetylation, therefore, modification by MIDAR is restricted to lysine residues. 
For these reasons, the soluble protein fraction of E. coli cell lysate will be the sample of choice 
to demonstrate MIDAR labelling of N-terminal peptides. Cells (E. coli K12) grown on both 
normal medium and an isotope-depleted medium ([13C] and [15N] deficient) were used in the 
analysis. The rationale behind the isotope depleted medium is simplification of the complex 
overlapping sets of naturally occurring isotope distributions seen in composite spectra of the 
differentially labelled variants.
Acetylation alters the physicochemical properties of proteins and peptides and will 
subsequently affect the relative hydrophobicity of a given peptide sequence. This modification 
will make retention time prediction using standard methods more challenging. An additional 
aim to this chapter is to investigate the extent to which acetylation affects the retention time of 
a set of peptides generated from the acetylation of a standard tryptic digest and an N-terminal 
preparation of a complex proteome. Once determined, this alteration may be used to suggest 
ways in which to predict the standard retention time of acetylated NTPeps.
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5.3 Results and discussion
5.3.1 Labelling pattern
To assess labelling patterns, the model peptide ACTH18-39, sequence 
RPVKVYPNGAEDESAEAFPLEF, m/z 2465.13 was modified using the MIDAR reagent. The 
peptide, which contains two potential acetylation sites (the free N-terminal and side chain of 
the lysine residue), was reacted incompletely with the reagent to generate a mixture of single 
and doubly acetylated products (Figure 5.4). Two products were generated, at the expected 
values of m/z 2510.30 and m/z 2555.34 based on an increase in mass of 45Da and 90Da. At 
the same time, additional ions, not apparent in the unmodified peptide, were observed at 
2509.32 m/z and 2554.32 m/z, consistent with the incorporation of both [13C2] and PH3] acetyl 
groups. The intensities of these two additional “minus 1” ions were, relative to the 
monoisotopic peak, 11.5% and 22.4%, compared to the predicted values of between 9% and 
10% for a single amino group, and between 17% and 19% for two amino groups (Figure 5.3). 
The slightly higher values might reflect the fact that the reagent was slightly more than 10% 
[13C2] acetic anhydride. Even so, it is readily apparent that even on visual inspection of the 
mass spectra of the modified peptides, it should be possible to assign the number of modified 
amino groups to each species.
5.3.2 Acetylation of model peptides and proteins
To determine the variance in the intensity of the isotope depleted ion, the same analysis was 
performed on a range of model peptides (Figure 5.5), purified proteins (Figure 5.6) and 
proteins from a real biological sample (mouse skeletal muscle; Figure 5.7 and 5.8). For all 
samples, the acetylated products were analysed by MALDI-ToF MS to examine the isotope 
distribution. In all instances, the number of acetylation sites was known, and ranged from one 
to five (Sequence details of model peptides and proteins can be found in Chapter 2). For each 
peptide, the intensity (peak height) of the “minus 1” ion was calculated as a percentage of the 
monoisotopic ion intensity (Figure 5.9). The correlation between the number of amino groups 
and the intensity ratio was 0.988 (P0.0001). The slope of the line (approx. 11.5) suggested 
that the proportion of the lighter isotope variant in the preparation was slightly greater than 
10%. This has no impact on the efficacy of the method, as the reagent is readily ‘titrated’ with 
model peptides. The slightly higher value is assumed to reflect the small percentage of the 
lighter species that was already present in the heavier variant of the reagent -  the same
2 1 4
2466.14
2511.34 2557.33
1 1 .5 % 2 2 .4 %
Figure 5.4. MIDAR profile for ACTH 18-39.
ACTH fragment 18-39 (RPVKVYPNGAEDESAEAFPLEF) was deliberately partially 
acetylated using combinatorially-coded acetic anhydride (P(O=3)=0.9 and 
P(O=2)=0.1) and the modified peptides were analysed by MALDI-ToF MS. The mass 
spectra of the two products with mass offsets of 45Da are apparent, corresponding to 
the singly-acetylated and doubly-acetylated forms of the peptide. For each, the 
intensity of the “minus 1” ion (shaded) was calculated relative to the monoisotopic 
intensity.
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Figure 5.5. MIDAR analysis of model peptides.
A variety of model peptides were acetylated using combinatorially-coded acetic 
anhydride (P(O=3)=0.9 and P(O=2)=0.1) and the modified peptides were analysed by 
MALDI-ToF MS. The mass spectrum of the product is displayed alongside the mass 
spectrum of the unmodified peptide. For each, the intensity of the “minus 1" ion 
(shaded) was calculated relative to the monoisotopic intensity.
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(a) Pyruvate kinase
Figure 5.6. In-solution tryptic digest of MIDAR treated model proteins.
A series of purified proteins (pyruvate kinase (a). BSA (b) and triose phosphate 
isomerase (c)) were fully acetylated using the M IDAR reagent. The proteins were then 
subpcted to in-solution proteolysis with trypsin, which cleaves the acetylated proteins 
exclusively after arginine residues. The digested peptides were analysed by MALDI- 
ToF M S. Each spectrum was inspected manually and the intensity of the fninus 1”ion 
was assessed relative to the monoisotopic ion for as many peptides as possible.
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Figure 5.7.1-D SDS-PAGE of acetylated mouse skeletal muscle soluble proteins.
Mouse skeletal muscle soluble fraction (10pg) was acetylated with the M IDAR reagent. 
The sample was precipitated with 50pl TC A  and washed with ether to remove residual 
acid. The pellet was resuspended in 20m M  Na2CO 3 (10pl) and separated by SDS-PAGE  
alongside 10pl of unmodified sample.
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Figure 5.8. In-gel tryptic digest of MIDAR reacted mouse skeletal muscle proteins.
The gel plug was excised from an SD S-PAG E gel of M IDAR reacted mouse skeletal 
muscle soluble proteins. The protein was digested with trypsin (150 enzym e to substrate 
ratio) overnight. The peptides were analysed by MALDI-ToF MS. For each peptide, the 
intensity of the hiinus T ’ion was calcul ated relative to the monoisotopic ion.
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Figure 5.9. Relationship between MIDAR ‘“minus 1” and number of amino 
groups for model peptides and proteins.
A group of model peptides were fully acetylated using combinatorially-coded acetic 
anhydride (P(O=3)=0.9 and P(O=2)=0.1). Additionally, a series of purified proteins 
(BSA, TP I and PK) were acetylated prior to proteolysis with the same reagent. Finally, 
a natural protein mixture (soluble proteins of mouse skeletal muscle) was acetylated 
using the same reagent in vitro prior to SD S-PAG E. For each peptide, the intensity of 
the “minus 1" ion was calculated relative to the monoisotopic ion, and plotted 
according to number of free amino groups. Data are presented as mean ± SEM, for 
differing numbers of peptides (defined in parentheses adjacent to each symbol).
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impurity that stimulated the design of the reagent described here (see Figure 5.2). The 95% 
confidence limits of the fitted line confirm the consistency and general utility of this reagent for 
a simple, integral assessment of the number of available amino groups.
5.3.3 N-terminal purification of £  coli proteins using the MIDAR reagent
The N-terminal positional proteomics strategy, described in Chapter 3, has considerable 
appeal for large-scale proteome analysis, reducing analyte complexity to one peptide per 
protein. The positional fixation of the peptide to the N-terminus greatly enhances search 
specificity and preliminary data suggest that for a preparation of N-terminal peptides (NTPeps) 
from a simple organism such as £  coli, the mass of the peptide at the mass accuracy 
attainable with an instrument such as an Orbitrap might be enough for unambiguous 
identification. Since the positional proteomic method includes an N-acetylation step, simple 
replacement of unlabelled acetic anhydride by the MIDAR reagent described here would 
simultaneously identify peptides that were naturally acetylated at the N-terminus and permit 
accurate (integral) determination of the number of free amino groups in each peptide.
NTPeps were prepared from exponentially grown cells of £. coli, using the MIDAR 
acetylation reagent. This peptide mixture was fractionated over a 120min RP gradient and 
analysed by ESI-MS using the Orbitrap mass spectrometer. For model peptides, extracted ion 
chromatograms for the monoisotopic mass of heavy variants were prepared in order to locate 
the specific MS ion. Subsequently, the mass spectra were summed across the peak and the 
composite mass spectrum analysed to yield the ratio of the “minus 1” ion relative to the 
monoisotopic ion. Representative data for two such peptides are presented in Figure 5.10. In 
both instances, the intensity of the “minus 1” ion (22.2% and 33.3% respectively) gives a clear 
indication of the number of modified amino groups (two and three respectively). Indeed, the 
linearity of the data obtained with the Orbitrap instrument is superior, which may reflect the 
markedly diminished chemical noise signal and the enhanced baseline processing/noise 
rejection of the Orbitrap instrument. To test the approach further, a large number of NTPeps 
from the £  coli K12 preparation were evaluated and the relative intensity of the “minus 1” ion 
was assessed manually (Figure 5.11). Over the mass range 600Da to 3000Da, data for over 
200 peptides were manually extracted and the “minusl” intensity assessed, without 
knowledge of the identity of the peptide. The distribution of these values was restricted to 
discrete regions, and despite scatter in the data, the mean “minus 1” values (displayed on the 
figure with boundaries of ± 3 SD) showed no overlap, and the separation between categories
223
f
•-T IK V G IN G F G R  [M+2H]2« 626.38 ft•-SKIVKIIGR [M+2H]2 574.90
1000)oc 8 0
CO•Oc3 6 0
jO
<0) 4 0>s<0
<13 20QC 0
86.25min
i »i  i  i  i i  r  v w  n  f  i * i  i  i 11  i  i i  i
40 80 120 160
Time (min)
1001 
801 
601 
40; 
20- 
0--
101.39min
.........h .................
40  80 120 160
Time (min)
626.37 574.89
Figure 5.10. MIDAR analysis of E .co li N-terminal peptides.
An N-terminal peptide preparation derived from E.coli and grown in normal media was 
treated with the M IDAR reagent, and the mixture was resolved by RP chromatography 
and analysed by high resolution ion trap mass spectrometry on the Orbitrap 
instrument. Representative data are shown for two peptides. The top panels are the 
extracted ion chromatograms for two peptides (T IK VG IN G FG R: glyceraldehyde-3- 
phosphate dehydrogenase A, P0A9B4 and SKIVKIIGR:enolase, P0A6P9). The lower 
panels are the mass spectra corresponding to those ions, and in both instances, the 
hrinus one’lon is clearly visible.
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Figure 5.11. Determination of amino group frequency in E. co li peptides.
An N-terminal peptide preparation derived from E.coli and grown in normal media was 
treated with the M IDAR reagent, and the mixture was resolved by RP chromatography 
and analysed by high resolution ion trap mass spectrometry. The entire chromatogram  
was inspected manually, and where ions were readily identified, the intensity of the 
“minus 1” ion was assessed relative to the monoisotopic ion and plotted as a function 
of peptide mass. For each of the discrete planes of data, the error boundaries (± 3 SD, 
99.7%  of observations) are plotted around the mean value, to emphasis the lack of 
overlap.
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was sufficient that an assignment of the number of amino groups would be unambiguous. For 
one to four amino groups, the mean “minus 1” value ± SEM were 11.6%±0.09 (n=82), 
23.9%±0.12 (n=94), 37.0%±0.17 (n=34) and 48.0%±0.30 (n=12).
Part of the ambiguity in interpretation of these spectra derives from the complex 
overlapping sets of naturally occurring isotope distributions for the different labelled variants. If 
the mass spectra could be further simplified, a combination of accurate mass, MIDAR and 
retention time might offer a novel approach to complete proteome profiling that would lend 
itself to rapid genome annotation, relative or absolute quantification. To this end, £  coli K12 
cells were grown in an isotope-depleted medium from which most of the [13C] and [15N] had 
been removed. As anticipated, the peptides derived from cells grown in this medium yielded 
remarkably different mass spectra (Figure 5.12) but the “minus 1” ion was clearly defined, and 
the intensity of this ion was slightly higher than from normal medium-grown cells, as 
anticipated. Again, there was a strong correlation between the number of available amino 
groups and the relative intensity of the “minus 1” ion relative to the monoisotopic ion (data not 
shown, regression of % ‘minus 1” ion intensity on number of amino groups: slope = 12.55% ± 
0.23%, intercept = -1 ± 0.4, correlation coefficient = 0.997, n=17, p<0.001). Coding of a simple 
acetylation reagent thus gives unequivocal encoding of the integral number of such reactive 
groups within a peptide, and has general utility in peptide characterisation and even, 
identification of post-translational modifications that are targeted to lysine residues.
The set of N-terminal peptides manually analysed from the £  coli MIDAR N-terminal 
preparation, were also analysed in terms of their retention time (Figure 5.13). As expected, 
there was some correlation between retention time and mass of the peptides, suggesting that 
these are not two entirely independent parameters for proteome characterisation. 
Furthermore, the predicted set of N-terminal peptides from £  coli K12 were analysed 
according to mass, predicted retention time (Krokhin et al, 2004) and number of lysine 
residues between the most accessible masses of 1000Da and 5000Da (Figure 5.14). Again, 
there was correlation between retention time and mass of the peptides. The abundance of 
lysine residues in most proteomes is around 5% (MSDB ver 08/09/2006, lysine frequency = 
5.4%). Knowledge of the number of amino groups (lysine residues with or without an exposed 
a-amino group) in a peptide therefore has the potential to increase the efficiency of database 
searching. For example, two N-terminal peptides (YFAU_ECOLI: MNALLSNPFKER and 
MALG_ECOLI: MAMVQPKSQKAR) have masses of 1463.734 and 1463.738Da in their N- 
acetylated forms respectively, a separation of approximately 3ppm. That difference would be
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Figure 5.12. MIDAR analysis of N-terminal peptides from E. co li grown in 
isotopically depleted media.
Representative data are shown for a peptide (S W P V A D V L Q G R , asparaginyl-tRNA  
synthetase, P0A8M 0) from cells grown in normal media and isotopically depleted 
media. The top panels are the extracted ion chromatograms for the peptide grown in 
either media. The lower panels are the mass spectra corresponding to those ions, and 
in both instances, the fninus one”ion is clearly visible.
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Figure 5.13. Relationship between mass and retention time for E. co li N-terminal 
peptides.
The N-terminal peptide preparation derived from E.coli and grown in normal media 
was treated with the M IDAR reagent. The mixture was resolved by RP 
chromatography and analysed by high resolution ion trap mass spectrometry. The 
entire chromatogram was inspected manually, and where ions were readily identified, 
the retention time was determined and plotted as a function of peptide mass.
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Figure 5.14. Theoretical analysis of E .co li N-terminal peptides.
A database of predicted N-terminal peptides from E .c o li K12 was compiled and used 
to generate a data set of mass, chromatographic retention time and number of lysine 
residues. The calculation of retention time was not derived according to a specific 
chromatographic system but serves to distribute the peptides in chromatographic 
space, using the default parameters embedded in the software (A=8, B=1.5). 
Furthermore, the addition of acetyl groups would be expected to modify the retention 
time, probably delaying peptide elution to a small degree. The data set was distributed 
over the mass, retention time axes and is presented for peptides containing between 
zero and five lysine residues.
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difficult to resolve on mass alone but because the first peptide contains a single lysine residue 
and the latter contains two, they occupy discretely resolved lysine ‘planes’ and are readily 
resolved, permitting unambiguous identification of both spectra. For peptides larger than 
1000Da at 20ppm mass resolution, there are 1132 instances of peptides having unresolvable 
mass, and of these, 699 (62%) could be resolved in the lysine plane. At 10ppm, 5ppm and 
2ppm, knowledge of the lysine count resolved 61%, 57% and 39% of the contentious 
peptides, respectively. Most (80%) of NTpeps were characterised as containing zero, one or 
two lysine residues, yielding “minus one” intensities between 0 and 30%, depending on the 
acetylation state of the true N-terminus. This might argue a case for increasing the proportion 
of the “minus one” component to greater than 10%, which would increase the separation 
between peptides that contain the most common numbers of lysine residues, although our 
analysis of over 200 NTpeps suggests this is not necessary. A strategy based on positional 
proteomics, isotopically-depleted media, and MIDAR could generate a substantially simplified 
analyte mixture that would allow extensive profiling of a proteome in a single experiment, 
permitting higher levels of biological replication and increased statistical certainty.
There are other advantages to this approach. First, because the preparation of 
positionally located peptides is essentially a self-cleaning method (McDonald et a/., 2005; 
McDonald and Beynon, 2006); partially acetylated peptides would be removed by the clean up 
steps. An added advantage of lysine modification is that it removes ambiguity between lysine 
and glutamine residues, which differ in mass by 0.036Da.
5.3.4 Effect of acetylation on retention time
It is possible to predict the retention time of a peptide by virtue of its amino acid composition 
and the conditions required for chromatographic separation (slope of gradient and delay time; 
Krokhin et at., 2004). However, modification of a peptide can affect the rate at which it is 
eluted from the RP media, at a rate dependent on the nature of the modification. For example, 
the small hydrophilic -PO3H2 group has only a minor affect on the chromatographic retention 
time of peptides (Browne et at., 1982) To be able to effectively predict the retention time of 
acetylated NTpeps it is necessary to determine the extent to which acetylation effects the 
retention time of peptides. For this purpose, two purified proteins (bovine serum albumin 
(BSA) and pyruvate kinase (PK)) were digested with trypsin and differentially modified with 
acetic anhydride prior to chromatographic fractionation.
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Calibration
Retention time (RT) vs. hydrophobicity (HP) of Peptides, is a linear function (Krokhin et al., 
2004):
RT=A+B*(HP);
Where intercept A is the gradient delay time (individual for each HPLC system used) and 
slope B is a value related to the slope of acetonitrile gradient. B is constant for different HPLC 
systems as long as the same slope of the linear gradient is used. Before investigating the 
effect of acetylation on retention time it was necessary to determine the slope of the 
acetonitrile gradient and the gradient delay time (intercept). This was achieved using a tryptic 
digest of purified BSA. The digested peptides were analysed by LC-MS/MS on the ion trap 
instrument using the extended, three hour RP gradient. The retention times of the matched 
peptides were determined by preparing extracted ion chromatograms on the MS/MS data. 
Hydrophobicities for identified peptides were calculated using the Sequence Specific 
Retention (SSR) Calculator (Table 5.1; Krokhin et al., 2004). RT was plotted against relative 
HP for each BSA peptide (intercept = 2.97 (A), slope = 1.60 (B); Figure 5.15). The SSR 
calculator was then used to determine the theoretical retention times for the BSA peptides 
analysed and the results were plotted alongside the experimental data (Figure 5.16a). The 
change in RT (ART) between the experimental and theoretical times were also plotted (Figure 
5.16b). This data suggests a loose correlation between ART and HP.
Retention time of differentially acetylated purified protein digests
To ascertain the affect of acetylation on peptide retention time, two purified proteins were 
proteolysed with trypsin and partially acetylated, to ensure that both unmodified and 
acetylated intermediates were present. The tryptic digest was split into two aliquots, the first 
was treated with 0.1mg sulfo-NHS acetate in (dissolved in 20mM Na2C03 pH 8.5), for 10 min 
(for incomplete acetylation) and the second remained unmodified. The acetylation reaction 
was quenched by the addition of 5mg polymer bound Tris, which was subsequently removed 
by centrifugation. The two aliquots (modified and unmodified), were combined, diluted 1 in 50 
using 0.1% (v/v) FA and analysed by LC-MS/MS on the LTQ ion trap instrument, using a three 
hour RP gradient. The MS/MS data were used to search the SwissProt database using the 
MASCOT search engine.
Retention times were determined by preparing extracted ion chromatograms for 
identified peptides from the MASCOT search (Figure 5.17). The theoretical retention times 
were predicted using the SSR calculator for comparison (Table 5.2). Retention times for
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Peptide Sequence HP RT
4 D LG E E H FK 16.23 21.21
6 LV N E LTE FA K 2 7 .4 2 4 9 .8 9
10 E TY G D M A D C C E K 11.81 21.21
11/12 Q E P E R N E C F L S H K 14.71 18.47
1 2 /1 3 N E C F LS H K D D S P D L P K 2 2 .0 9 32 .76
14 LK P D P N T LC D E F K 22.92 4 3 .4 5
18 YLYE1AR 25.97 37 .88
21 Y N G V F Q E C C Q A E D K 18.19 32 .43
2 2 G A C LLPK 18.33 2 5 .2 6
31 A W S V A R 15.88 2 2 .5 8
3 5 LVTDLTK 16.36 2 4 .9 3
3 7 E C C H G D LL E C A D D R 16.63 2 8 .9 9
3 7 /3 8 E C C H G D LL E C A D D R A D L A K 22 .4 8 3 7 .7 2
3 9 Y IC D N Q D T IS S K 13.12 2 1 .9 5
4 0 /4 1 LK EC CD K PLLEK 16.39 18.04
5 0 E Y E A TLE E C C A K 16.4 28.81
5 1 /5 2 D D P H A C Y S T V FD K L K 23.36 4 7 .0 9
5 3 H LV D E P Q N LIK 22.12 36.81
5 7 /5 8 K V P Q V S T P T L V E V S R 23.15 36.81
5 8 V P Q V S T P T L V E V S R 23.92 41.81
6 7 R P C F S A L T P D E T Y V P K 27.66 4 7 .4 6
7 2 Q TA LV E LLK 30.68 55 .28
7 8 L W S T Q T A L A 23 .4 2 4 5 .1 7
HH-HjJtt-Qf II I III ) H—i
**  <P'<Pr -O' o\t3- -0%
0 — 0
Table 5.1. Relative hydrophobicity and retention time of BSA.
BSA (10pg, Pierce) was reduced and alkylated prior to digestion with trypsin (1:50 
enzyme: substrate ratio). The digested peptides were analysed using a three hour RP 
gradient on the ion trap instrument. M S/M S data were used to search the SwissProt 
database using the M ASCO T search engine. The taxonomy was restricted to Homo 
sapiens; fixed modifications: carbamidomethylation of cysteine; variable modification: 
oxidation of methionine; protease: trypsin; missed cleavages: 1; peptide tolerance: 
1.5Da; M S/M S tolerance: 0.6Da; instrument: ESI-TRAP; peptide charge: 1+, 2+ and 
3+. Protein identifications with a Mowse score greater than 50 were accepted as 
confident identifications. Extracted ion chromatograms were prepared for BSA 
peptides using the values matched in M ASCO T and retention times (RT) recorded. 
Relative hydrophobicity (HP) was determined from the amino acid sequences using 
the sequence specific retention calculator.
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Figure 5.15. Calibration of chromatography gradient using BSA.
Purified BSA (10pg, Pierce) was reduced and alkylated prior to digestion with trypsin 
(1:50 enzyme: substrate ratio). The digested peptides were analysed using a three 
hour RP gradient on the ion trap instrument. M S/M S data were used to search the 
SwissProt database using the M ASCO T search engine. The taxonomy was restricted 
to mammalia; fixed modifications: carbamidomethylation of cysteine; variable 
modification: oxidation of methionine; protease: trypsin; missed cleavages: 1; peptide 
tolerance: 1.5Da; M S/M S tolerance: 0.6Da; instrument: ESI-TRAP; peptide charge: 1+, 
2+ and 3+. Extracted ion chromatograms were prepared using the values of peptides 
matched in M ASCO T and retention times recorded. Relative hydrophobicity 
(determined from the amino acid sequences using the SSR calculator) was plotted 
against the experimental RT.
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Figure 5.16. Comparison of experimental and theoretical retention times for BSA 
peptides.
The values obtained from the slope and the intercept of the plot (experimental data) 
were used to calculate the theoretical RT from the sam e group of peptides (SSR  
calculator) and the data plotted onto the same graph (a). The A R T between the 
experimental RT and theoretical RT was also plotted (b).
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Figure 5.17. Effect of acetylation on peptide retention time.
Purified proteins (BSA and PK) were proteolysed by trypsin prior to incomplete 
acetylation with sulfo-NHS acetate. The peptide mixtures were analysed using the 
LTQ ion trap instrument. Extracted ion chromatograms were prepared for non- 
acetylated and acetylated forms of each peptide. Representative data are shown for 
(LD IDSAPITAR from PK). The top panels are extracted ion chromatograms and the 
lower panels are the mass spectra corresponding to those ions.
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unmodified and differentially acetylated forms of the peptides, along with the theoretical 
retention times (RTth), were plotted (Figure 5.18). Tryptic peptides were plotted according to 
increasing [M+H]+. In general, the theoretical and observed retention times are comparable 
and correlate with peptide size. However, in the case of BSA, the two largest peptides (11/12 
and 37/38) display relatively short retention times in relation to the other peptides. Both of 
these peptides contain internal arginines along with a high content of other hydrophilic 
residues (glutamate, aspartate and histidine), which may cause them to elute from the RP 
media early. In cases for which there are two possible acetylation sites on the peptide it is 
apparent that the second acetyl group causes a smaller ART than addition of the first. One 
possible explanation for this would be that the initial acetyl group is being placed on the £- 
amino group causing the otherwise hydrophilic lysine residue to become substantially more 
hydrophobic thus displaying a marked increase in retention. The second acetyl group, which 
will be located on the a-amino group, will cause a smaller ART compared with the first 
modification. This theory is supported by the difference in pKa exhibited by a and £-amino 
groups (9.04 and 10.4 respectively; Mikami and Takao, 2007). Since the acetylation reaction 
is performed at high pH (0.5M NaaCCh), it is likely that the £-amino groups will be more 
reactive under these conditions.
Retention time of E. coli NTpeps
The LC-MS/MS gradient used for fractionation of E. coli NTpeps prior to analysis on the 
Orbitrap mass spectrometer, was much shallower than that used for the ion trap instrument 
(slope 2.48 compared to 1.60). For this reason the affect of modification on peptide retention 
time will be much more apparent. To determine the extent of ART for the acetylated E. coli 
NTpeps, a range of known peptides were used to compare theoretical RT values, for 
unmodified peptides, with observed values from the acetylated peptides. The values obtained 
for a set of 25 known E. coli NTpeps are represented in Table 5.3. In each case ART was 
used in combination with the number of acetylation sites (n) to calculate the shift in retention 
time for one acetyl group. The resulting values were highly variable, ranging from 11.37 min to 
62.32 min. This wide degree of variation in retention time will make the prediction of acetylated 
retention times using existing algorithms highly challenging. For this reason it is unlikely that 
the AMT strategy, at present, will be successful when applied to the analysis of NTpeps.
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B S A
Peptide Sequence [M+H]* No.
amino
groups
Predicted
RT
Observed RT
0 1 2
31 AWSVAR 689.37 1 27 22.58 41.58
22 GACLLPK 759.4 2 31.2 25.26 45.07 63.7
35 LVTDLTK 789.46 2 27.8 24.93 56.14 75.12
18 YLYEIAR 927.48 1 44.1 37.88 66.07
4 DLGEEHFK 974.45 2 27.6 21.21 32.28 49.67
78 LWSTQTALA 1002.58 1 39.8 45.17 64.31
72 QTALVELLK 1014.61 1 52.2 55.2 73.4
6 LVNELTEFAK 1163.62 2 46.6 49.89 82.49 98.31
58 VPQVSTPTLVEVSR 1511.84 2 40.7 41.8 76.52 93.83
11/12 QEPERNECFLSHK 1674.75 2 25 18.47 27.82 40.46
37/38 ECCHGDLLECADDRADLAK 2250.89 2 38.2 37.72 44.77 53.97
PK
Peptide Sequence [NI+HJ* No.
amino
groups
Predicted
RT
Observed RT
0 Ac 1 Ac 2 Ac
25 DIQDLK 731.39 2 21.8 16.24 36.91 60.21
53 APIIAVTR 840.52 1 32.2 27 53.81
45 MQHLIAR 868.47 1 25.4 13.78 37.2
44 GDYPLEAVR 1019.51 1 37.9 34.5 50
46 EAEAAMFHR 1061.48 1 26.8 19.8 38.23
3 LDIDSAPITAR 1171.62 1 38.2 39.69 59.28
4 NTGIICTIGPASR 1302.7 1 41.7 37.73 52.46
20 VYVDDGLISLQVK 1448.79 2 53.9 59.98 95.13
35/36 RFDEILEASDGIMVAR 1821.91 1 57.2 61.3 76.83
8 MNFSHGTHEYHAETIK 1901.85 2 33.2 18.7 40.45
10 TATESFASDPILYRPVAVALDTK 2465.29 2 57.8 67.31 87.24
43 AEGSDVANAVLDGADCIMLSGETAK 2437.12 2 52.6 76.5 99.43
Table 5.2 Effect of acetylation on peptide retention time on peptides from purified 
proteins.
Purified BSA and PK (10pg, Pierce) were reduced and alkylated prior to digestion with trypsin 
(1:50 enzyme: substrate ratio). The digested peptides were incompletely acetylated to yield a 
mixture of unmodified, partially acetylated and fully acetylated peptides. The peptide mixtures 
were fractionated using a three hour RP gradient and analysed by LC -M S/M S on the LTQ ion 
trap instrument. M S/M S data was used to interrogate the SwissProt database using the 
M ASCO T search engine. The taxonomy was restricted to mammalia; fixed modifications: 
carbamidomethylation of cysteine; variable modification: oxidation of methionine, acetyl lysine 
and acetyl N-terminal; protease: trypsin; missed cleavages: 1; peptide tolerance: 1.5Da; 
M S/M S tolerance: 0.6Da; instrument: ESI-TRAP; peptide charge: 1+, 2+ and 3+. Identified 
peptides (unmodified and acetylated versions) were used to prepare extracted ion 
chromatograms from the raw LC-M S/M S data in order to determine peptide retention times. 
Theoretical retention times were determined using the peptide sequence and the SSR  
calculator.
2 3 7
Re
te
nt
io
n 
tim
e 
(m
in
)
Tryptic peptide
Figure 5.18. Retention time of unmodified and acetylated peptides from purified 
proteins.
The observed retention times were plotted alongside the theoretical retention times 
(determined using the peptide seqence and t he SSR  calculator) in order of increasing 
peptide mass.
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Chapter 5: Mass isotope distribution analysis of amino acid residues
5.4 Summary
This chapter reports a new isotope coded acetylation reagent that comprises a mixture of two 
differentially labelled chemicals, separated by 1Da. The reagents are mixed asymmetrically 
(10% of the lighter and 90% of the heavier variant). When peptides are labelled with this 
reagent, the isotope pattern of the products is complex, but the ratio of the two specific ions 
gives a precise measure of the number of amino groups in each peptide. This approach, 
termed MIDAR, may be of value in global proteomics, as it resolves a peptide mixture into a 
new fundamental set, reflecting the number of amino groups in the peptide. The approach is 
generally applicable to any peptide-based proteome analysis, but is illustrated here by a 
strategy of positional proteomics based on the analysis of N-terminal peptides. Knowledge of 
the number of amino groups can provide an integral statistic that can be used as an added 
parameter in database searching strategies.
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Chapter 6: Conclusions
6. C O N C L U S I O N S
To date, post-genomic research has focused on quantifying changes in DNA and mRNA 
expression as a result of disease or other environmental factors (Duggan et a!., 1999; 
Quackenbush, 2006; Hoheisel, 2006). However, DNA and mRNA changes do not always 
correlate with changes in protein expression (Anderson and Seilhamer, 1997; Chen et a!., 
2002; Gygi et al, 1999). Since proteins are the functional representations of the genes which 
encode them, proteomics is rapidly becoming the method of choice for life science research.
The primary challenge in proteomics is identification, characterisation and 
quantification of all proteins expressed within any proteome. There is a pressing need for 
strategies and reagents that reduce the complexity of a total proteome analyte, particularly 
when the first step in proteome characterisation is the increase in complexity brought about by 
the total proteolytic digestion, usually with trypsin, which increases the number of analyte 
species by about 30-50 fold.
Traditionally, the main methods for proteome characterisation have been protein 
separation by 1-D and 2-D SDS-PAGE, followed by proteolysis of resolved proteins and MS 
analysis. More recently, there has been a move towards global methods of proteome 
characterisation, employing direct analysis of complex protein mixtures. However, the 
complete set of peptides generated from an entire proteome will potentially contain many 
hundreds of thousands of peptides, which generates a formidable analytical challenge. Even 
with the benefit of 2-D chromatography (MudPIT), it is likely that the mixture will deliver more 
peptides to the mass spectrometer than can feasibly be analysed in the time frame it takes the 
ionised sample to reach the ESI source. Furthermore, data-dependent acquisition is likely to 
direct MS analysis to peptides originating from the most abundant proteins in the mixture, thus 
limiting dynamic range.
The growing popularity of so called “shotgun” MS approaches has led to a plethora of 
strategies aimed at purifying a subset of target peptides in an attempt to gain simplification of 
a complex analyte mixture. These methods aim to eliminate the majority of the proteome- 
derived peptides but retain sufficient information necessary for analysis. An efficient strategy 
for proteome simplification is the isolation of a single peptide from every protein within the 
mixture. Furthermore, if the location of the peptide is anchored to a precise position within the 
parent protein, this will reduce the amount of search space required for identification. The
2 41
Chapter 6: Conclusions
most obvious regions for positional specific isolation are the extremities of protein molecules 
(i.e. the N or C-termini).
6.1 N -ter m inal  po sitio nal  pr o teo m ic s
The primary aim of this thesis was to develop an efficient strategy for N-terminal peptide 
isolation that would reduce the complexity of a complete proteome and provide added 
‘positional’ information for database searching.
The initial N-terminal “positional proteomics” strategy developed consisted of a series 
of a chemical derivatisation steps, followed by affinity capture of internal peptides, as follows:
1. Acetylation of intact proteins in their native state in order to block primary amino 
groups (a and z).
2. Proteolysis of acetylated proteins using trypsin to yield a mixture of N-terminally 
blocked (Na-acetylated) N-terminal and unblocked internal, arginine terminated 
peptides.
3. Biotinylation of the peptide mixture, using an NHS-ester of biotin, resulting in a 
mixture of biotinylated internal and non-biotinylated (Na-acetylated), N-terminal 
peptides.
4. Affinity capture of biotinylated internal peptides using streptavidin Sepharose resulting 
in a preparation enriched in N-terminal peptides, which can then be analysed by MS.
This first method, although effective, required multiple peptide-purification steps to separate 
the peptides from the excess reagents used. The consequence of this is a reduced yield of 
material (N-terminal peptides). The original method was revised to generate a new strategy 
consisting of fewer analytical stages and resulting in a higher yield of N-terminal peptides. The 
improved method utilised the same N-blocking and proteolysis steps as in the initial method 
(steps 1 and 2), however, the biotinylation and subsequent streptavidin coupling steps were 
replaced with a single step, consisting of the removal of internal peptides via coupling to NHS- 
activated Sepharose. This enhanced protocol results in a substantially increased amount of 
material available for MS analysis and led to a ten-fold increase in the number of protein 
identifications when applied to mouse skeletal muscle. The two strategies for N-terminal 
purification are summarised in Figure 6.1.
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Figure 6.1. Comparison of the two protocols developed for N-terminal positional 
proteomics.
In both protocols, the intact protein m ixture w as  acetylated in o rder to block exposed am ino  
groups (a  and e). Proteolysis o f the acetylated protein m ixture g en era ted  blocked N -term inal and  
unblocked internal and ¿ -te rm in a l peptides. Following proteolysis, Protocol 1 (left) used N H S -  
Biotin to m odify the  exposed am ino groups on the internal and C -term inal peptides. Th e  
biotinylated peptides w ere  rem oved via incubation with streptavidin S ep h aro se . A lternatively, in 
Protocol 2 (right), the biotinylation stage w as om itted and the  acety la ted  peptide mixture w as  
incubated directly with N H S -activa ted  S epharo se w ithout any further derivatisation steps.
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When applied to the complex proteomes of mouse liver, S. cerevisiae and E. coli, the 
NHS-Sepharose strategy resulted in the identification of 333, 185 and 210 proteins 
respectively. Complete lists of N-terminal peptide identifications can be found in 
Supplementary data B. In addition to simplification, the positional proteomics strategy has the 
advantage of characterising the true N-terminal region of the identified protein, which has 
implications for genome annotation. Furthermore, by substituting the acetylation reagent used 
in the initial stage of the positional proteomics strategy to a labelled form of acetic anhydride 
(C[2H3]C0)20), it is possible to determine the Na-acetylation status of the proteins identified. 
When applied to the three complex proteomes, this modified version of the N-terminal protocol 
confirmed the Na-acetylation status of 98 mouse liver, 128 S. cerevisiae and 239 £. coli 
proteins. In accordance with published data 87% of the mouse proteins and 44% of the S. 
cerevisiae identified were NQ-acetylated in vivo (Polevoda and Sherman, 2000; Lee et al, 
1989b). In contrast to the eukaryotic samples, the majority of the E. coli proteins analysed 
were not N°-acetylated in vivo (99%). The £. coli protein Elongation factor Tu is known to be 
Na-acetylated in vivo (Arai et al., 1980). However, this study also provided strong evidence 
(MS/MS sequence data) for the in vivo N°-acetylation of copper resistance protein D, which is 
not reported in the literature. A complete representation of the data obtained on N°-acetylation 
status can be found in Supplementary data B.
6.2 Limitations to the N-terminal ‘positional proteomics’ strategy
The limitations relating to the effectiveness of the approach are small. First, some tryptic 
fragments are too small or too large to be amenable to this analysis, although these can be 
accessed by alternative fragmentation methods such as the use of different proteases. 
Second, the presence of a small number of internal peptides in the preparation will result in 
the identification of some false positives. Internal peptides are present in the final preparation 
either as a result of incomplete coupling to NHS-activated Sepharose (‘leakiness’) or because 
they are modified in some way. The screen for HSA internal peptides in Section 4.5 of this 
thesis, showed that the presence of internals is extremely low compared with the true N- 
terminal peptide. Furthermore, it was not possible to confirm the validity of these peptides by 
MSMS data, making their presence in the sample uncertain. The occurrence of an N-blocked 
internal (Arg-C) peptide was highlighted in Section 3.9.10. This peptide was present in the E. 
coli N-terminal preparation and was derived from (3-lactamase. This peptide contained a 
pyroglutamic acid at the N-terminal position which inhibited coupling to NHS-activated 
Sepharose. The observation that this peptide was in fact an Arg-C proteolysis product
2 4 4
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suggests that this peptide was modified in vitro (after proteolysis) and does not indicate that 
the protein (p-lactamase) exists in vivo in a truncated form.
In terms of global proteomics, this strategy fails to deliver the amount of protein 
identifications as other “second generation” approaches such as MudPIT and COFRADIC. 
However, the utility of the methodology, to elucidate the true N-terminal region of a large 
number of protein species should not be underestimated. This ability alone lends itself to 
numerous other applications, including the characterisation of N-terminal PTM events and N- 
terminal susceptibility to many other enzymatic processes.
6.3 Application of positional proteomics to human plasma
MS-based proteomics is mostly used as a discovery tool in understanding disease. 
Substantial improvements in the sensitivity of analytical instrumentation and the availability of 
the human genome have made possible the discovery, identification and characterisation of 
proteins of diagnostic value. Recent reports have introduced different platforms for candidate 
based targeted proteomics which utilise stable isotope labelled, synthetic peptides as 
references for the identification and quantification of a selected group of target peptides. 
However, current proteomics techniques have failed to deliver robust strategies for clinical 
application, particularly for lower abundance biomarkers. Rather, the putative biomarkers 
identified through MS-based studies must be subjected to further validation using other high- 
throughput methods. This has led to a striking shortfall in the number of protein diagnostic 
tests emerging from proteomic studies. In order to bridge the gap between biomarker 
discovery and clinical use it will be necessary to develop novel approaches to target known 
biomarkers and quantitatively detect them in multiple clinical samples.
It was anticipated that N-terminal positional proteomics strategy would provide a 
method of reducing the complexity of the sample of choice for biomarker analysis, human 
plasma. However, application of the N-terminal strategy led to the identification of only 50 
species, the majority of which were classical plasma proteins. The inability to reach deeper 
into the plasma proteome is a direct result of the large dynamic concentration range exhibited 
by this complex sample. Even with the utility of Protein Equalizer™ technology to normalise 
the protein concentrations within the plasma sample, it was not possible to identify more than 
100 proteins by virtue of their N-terminal peptide. Although the method failed to deliver a 
comprehensive profile of the plasma proteome, the study provided some interesting insights 
into the nature of plasma protein N-termini. For instance, the interrogation of accurate mass
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data from the Orbitrap instrument led to the identification of putative substrates for enzymes 
that remove dipeptides from the N-termini of proteins (dipeptidyl peptidases). Many of the 
classical plasma proteins showed evidence of N-terminal “trimming” including HSA, a-1- 
antichymotrypsin, apolipoprotein C and a-2-HS-glycoprotein. These proteins could serve as 
“catalytic reporters” in measuring the activity of dipeptidyl peptidases such as DPP IV and in 
turn provide insights into diseases associated with increased enzyme activity.
Although this study failed to identify a large number of previously identified candidate 
biomarkers, the ability to reproducibly identify the complement derived C3a anaphylatoxin is of 
substantial clinical relevance. This protein is up regulated in colorectal tumours (Habermann et 
al., 2006) and the ability to identify this protein in multiple human plasma samples could 
provide the basis of a diagnostic screen for this putative biomarker.
There is evidence to suggest that the immune system may act as a biomarker for the 
presence, type and possibly even the stage of cancer (Finn, 2005). For this reason, it is 
possible that immunoglobulin profiling may provide insights into the molecular mechanisms of 
cancer progression (Tan, 2001). The ability of the N-terminal purification strategy to access 
the variable region of immunoglobulin molecules may provide a rapid method in which to 
screen these molecules for changes associated with disease.
6.4 MIDAR
In global strategies such as MudPIT, MS/MS analysis presents the rate limiting step. The 
amount of information obtained is limited due to constraints imposed by duty cycles and 
resolution trade offs. An ideal situation for global proteomics would be a single run of high- 
resolution, high mass accuracy MS data that could alone provide comprehensive proteome 
coverage without the requirement for MS/MS data. The AMT strategy discussed in Section
5.1.4 obviates the routine need for MS/MS and in turn reduces sample requirements whilst 
increasing throughput. A desirable attribute for an AMT based proteomics experiment is added 
parameters for database searching, which can be used along with the existing MS data to 
validate a match.
A second challenge to this study was to devise a new amino group labelling reagent 
to provide information regarding the chemical composition of the targeted species. The 
MIDAR strategy is a straight forward peptide labelling step that allows the quantification of 
lysine residues within a proteolytic peptide.
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The MIDAR reagent was used to label a range of model peptides, purified proteins 
and biological samples. In all cases the labelling pattern gave unambiguous indication of the 
number of modified amino groups.
The logic behind MIDAR could also be applied using other reagents. For example, a 
simpler reagent, comprising a mixture of stable isotope labelled P C 2] and unlabelled acetic 
anhydride could also be used. In this instance, the “minus 1” signature would become “minus 
2” and the analysis should otherwise be the same. However, this approach is less reliable, as 
unlabelled peptide might reflect the number of amino groups but also be compromised by 
incomplete labelling. Incomplete reaction would be less of an issue, if used in combination 
with a positional proteomics strategy as any incompletely acetylated peptide would be 
removed downstream. However, as a general strategy for determination of the frequency of 
lysine residues, using a reagent comprising two differentially labelled compounds that are both 
stable isotope labelled means that this complication is removed, as incomplete labelling 
should not influence the relative peak intensity of the “minus one” ion.
Partial metabolic labelling with a stable isotope labelled amino acid can also be used 
to determine the frequency of that amino acid in a peptide (Beynon and Pratt, 2005; Pratt et. 
a i, 2002). Information regarding the number of leucine residues in each peptide gave an 
enhancement of search efficiency of approximately one order of magnitude. The MIDAR 
approach is an experimental protocol conducted in vitro and has a more general applicability, 
whether used for a complete proteolytic digest or as part of a positional proteomics strategy. It 
is possible that other dual-labelled reagents could be developed to provide similar data on 
amino acid frequency. Coupled with accurate mass data and N-terminal positional proteomics, 
this additional parameter will enhance the identification process in proteomics experiments, 
and allow rapid proteome profiling that would be particularly valuable for large scale screening 
or comparative studies.
6.5 Informatics challenges
N-terminal regions of proteins are generally underrepresented in routine datasets generated 
by PMF (Meinnel and Giglione, 2008). It is highly likely that the lack of N-terminal peptide 
matches in published datasets is due to modification events that introduce heterogeneity at 
this region. N-terminal trimming, involving the removal of small peptides, generates new N- 
termini that are not representative of the sequences present in databases. Additionally, 
proteins that have undergone SP cleavage will be represented in the database in their
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precursor form, making it difficult, if not impossible to identify the mature N-terminal by 
sequence similarity searching methods alone. A useful resource for positional proteomic 
strategies would be a range of databases containing sequentially truncated or ‘trimmed’ 
protein isoforms which would, in turn, allow for the identification of N-terminally trimmed 
proteins. This issue can partly be addressed using ‘no enzyme’ or ‘nonspecific (half) cleavage’ 
options that are available in current database search engines. However, searches done using 
these parameters result in significant increase in analysis time (Craig, 2003).
From a validation perspective, database search engines (for example, Mascot) will 
favour protein identifications that are supported by at least two peptide matches (Perkins et 
a!., 1999; Sun et al, 2007). For this reason, “one-hit wonders”, in which proteins are identified 
by only one MS/MS sequenced peptide, will not be classed as confident assignments in terms 
of their score. Statistical analyses can be performed on database search results to measure 
the likelihood of false-positive peptide identifications. Decoy databases consist of randomised 
or reversed sequences, which can be searched in order to estimate the number of false 
positives present in the results from the true databases. When searching MS/MS data sets 
generated from N-terminal preparations, each protein will ideally be represented by a single 
peptide. In this case, the entire database from a given species will act as a decoy database, 
as the majority of data represented will be from non N-terminal peptides. The added 
information gain obtained from the knowledge of the peptide location within the parent protein 
is sufficient, in most cases, to validate the assignment. Although, in the case of a poor quality 
MS/MS spectrum acquired from low abundance proteins, the confidence of identification will 
be poor and most likely insignificant. The fundamental problem is that currently MS search 
software does not incorporate tools to permit the inclusion of positional information. 
Subsequently, the added information gain relating to the position of the peptide is lost and will 
not directly contribute to the confidence of the match.
6.6 Future  work
Selective or multiple reaction monitoring (MRM) in mass spectrometry is a method used to 
confirm, unambiguously, the presence of a compound in a complex sample. It is not only a 
highly specific method but also has very high sensitivity. The MRM approach has been applied 
to the quantitative analysis of tryptic peptides representing high and medium abundance 
proteins in human plasma (Anderson and Hunter, 2006).
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Preliminary data reveals that targeting product ions originating from N-terminal 
peptides from an N-terminal preparation of human plasma, allows a large increase in 
sensitivity (work conducted by Gemma Davidson). It is anticipated that combining N-terminal 
enrichment of human plasma proteins with an MRM based approach will provide a powerful 
strategy for the detection of low abundance putative biomarkers in human plasma.
Although the enhanced (NHS-Sepharose) N-terminal method produced a higher yield 
of peptides than the original biotin/streptavidin method, there still remains concern regarding 
the losses of N-terminal yield throughout the post-proteolysis purification stages. It will be 
beneficial to investigate the effects of other immobilised reagents with a view to increasing the 
amount of material in the final preparation. Reagents such as CNBr and phenyl 
isothiocyanates are available as activated supports, which could be used to replace NHS- 
Sepharose in the final N-terminal purification step.
Absolute quantification of multiple proteins within a biological system is achievable 
through use of an artificial protein known as a QconCAT. The QconCAT strategy was 
developed in this laboratory (Beynon et a/., 2005) and provides a tailored approach for 
multiplexed protein quantification. Coupling of the N-terminal strategy to a QconCAT based 
approach will allow simultaneous simplification and quantification of a subset of proteins. A 
potential use for this combined technique is quantification of the immunoglobulin repertoire 
found within human individuals. To achieve this, a QconCAT would be designed using N- 
terminal peptide sequences (Arg-C), of a selected group of immunoglobulins, to quantify the 
changes between individuals. As previously described, immunoglobulin profiling may provide 
insights into cancer and autoimmune disorders. Therefore, by linking the QconCAT 
quantification strategy to a method that targets the specific region of interest (variable region 
at the N-termini of immunoglobulin molecules); this combined strategy could form the basis of 
a useful clinical application.
6.7 C onc luding  remarks
The work in this thesis demonstrates that the N-terminal positional proteomics strategy is an 
elegant technique for simplification and characterisation of complex proteomes. In addition to 
reducing sample complexity, N-terminal positional proteomics can also be used for the 
investigation of in vitro processing events such as SP removal, NME and Na-acetylation. The 
challenge for this technique, and many other global proteomic strategies, is the 
characterisation of the least abundant portion of the proteome (<90%).
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Combining targeted analysis of N-terminal protein regions with in vitro labelling using 
MIDAR to provide additional information (positional and compositional) for database searching 
is of substantial interest to the field of global proteomics. However, a fundamental problem 
associated with positional based peptide isolation strategies, is that currently MS search 
software does not incorporate tools to permit the inclusion of positional information. 
Consequently, this positional information is lost and will not directly contribute to the 
confidence of the match. In order to maximise the utility of positional proteomics approach, the 
next challenge is to develop enhanced applications for database searching allowing the 
inclusion of positional information.
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Supplementary Data
A. Identification of mouse muscle proteins by PMF
B. N-terminal identifications
C. Non N-terminal identifications
D. Identification of human plasma proteins by PMF
Supplementary Data A: Identification of mouse muscle proteins by PMF
•  Glycogen phosphorylase
•  Serum albumin
•  Phosphoglucomutase-1
•  Pyruvate kinase
•  Beta enolase
•  Creatine kinase
•  Fructose-bisphosphate aldolase A
•  Glyceraldehyde-3-phosphate dehydrogenase
•  Phosphoglycerate mutase
•  Triose phosphate isomerase
•  Adenylate kinase
Proteins from mouse skeletal muscle soluble fraction (15(jg) were separated by 1-D SDS-PAG E and 
visualised with Coomassie. Gel plugs were excised from the dominant bands and subjected to in-gel 
proteolysis with trypsin (1:50 enzyme to substrate ratio). Peptide mixtures 1pl were spotted onto a 
MALDI target and allowed to air dry with 1pl of matrix solution. Samples were analysed by MALDI-ToF  
M S using a laser energy of 30% . The resulting peptide masses were imported into the M ASCO T search 
engine. The taxonomy was restricted to Mus. musculus; fixed modification: carbamidomethylation of 
cysteine; variable modification: oxidation of methionine; protease: trypsin; missed cleavages: 1; peptide 
tolerance: 150ppm. Matched peptides are represented on the peptide coverage maps. Limit tryptic 
peptides are represented in purple and missed cleavages in green.
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Supplementary Data B: N-terminal identifications
•  Mouse liver
•  S. cerevis iae
•  E. co li
The N-terminal peptide preparation of mouse skeletal muscle, S. cerevisiae and E. coli (soluble proteins) 
w ere analysed by LC-M S/M S using three hour RP gradients on the LTQ ion trap instrument. M S/M S data 
was used to search the mouse, S. cerevisiae and E. coli N-terminal databases respectively, using the 
M A S C O T search engine. Fixed modifications: N-terminal acetylation and lysine acetylation; variable 
modification: oxidation of methionine; protease: Arg-C; missed cleavages: 1; peptide tolerance: 1.5Da, 
M S /M S  tolerance: 0.6Da, instrument: ESI-TRAP, peptide charge: 1+, 2+ and 3+. The N-terminal 
processing events M (methionine excision) and SP (signal peptides removal) along with N°-acetylation 
status are represented.
Supplementary data B: Mouse liver N-terminal identifications
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1 Transcription factor Sp3 (070494) 516.23 EGGGR M 18 -
2 Golgi membrane protein 1 (Q91XA2) 614.31 GLGNGR M 24 -
3 zinc finger domain protein 1B (Q9Z277) 667.4 APLLGR M 12 N
4 Angiotensin-converting enzyme (P09470) 687.33 GAASGQR M 14 -
5 Peroxisomal bifunctional enzyme (Q9DBM2) 692.35 AEYLR M 20 -
6 Vitamin K epoxide reductase complex (Q6TEK5) 738.48 AAPVLLR M 32 N
7 Alcohol dehydrogenase class 3 (P28474) 741.41 ANQVIR M 32 N
8 BTB/POZ domain-containing protein (Q6WVG3) 747.4 ALADSAR M 12 C
9 Adenylate kinase isoenzyme 4 (Q9WUR9) 770.47 ASKLLR M 15 N
10 Glycine N-methyltransferase (Q9QXF8) 779.38 VDSVYR M 89 N
11 Signal recognition particle 54 kDa protein (P14576) 784.44 VLADLGR M 15 -
12 Translation initiation factor elF-2B subunit delta (Q61749) 797.48 AAVAVAVR M 14 N
13 T-complex protein 1 subunit delta (P80315) 813.4 PENVASR M 52 N/C
14 Clathrin heavy chain (Q68FD5) 851.52 AQILPIR M 27 N
15 Citrate synthase (Q9CZU6) 857.5 ALLTAATR M 19 -
16 39S ribosomal protein L9 (Q99N94) 868.48 AASVAPGVR M 147 N
17 Cysteine sulfinic acid decarboxylase (Q9DBE0) 872.48 ADSKPLR M 36 C
18 Galactokinase (Q9R0N0) 894.48 AAWRPPR M 28 N
19 Carbonic anhydrase 5B (Q9QZA0) 897.45 AVMNHLR M 24 N
20 40S ribosomal protein S3a (P97351 ) 897.5 AVGKNKR M 85 C
21 Quinone oxidoreductase (P47199 ) 897.5 ATGQKLMR M 45 N
22 Ezrin (p81) (P26040) 906.53 PKPINVR M 21 C
23 Ectodysplasin A receptor-associated adapter protein (Q8VHX2) 911.43 ASPDDPLR M 101 -
24 Kynurenine-oxoglutarate transaminase 1 (Q8BTY1) 913.5 SKQLQAR M 32 N
25 Guanine nucleotide-binding protein subunit beta (P68040) 919.44 TEQMTLR M 53 -
26 Autocrine motility factor receptor (Q9R049) 928.54 PLLFLER M 17 C
27 Bromodomain-containing protein 4 (Q9ESU6) 932.42 STESGPGTR M 15 N
28 Glucose-6-phosphate 1 -dehydrogenase (P97324) 932.47 AEQVTLSR M 21 N
29 26S proteasome non-ATPase regulatory subunit 9 (Q9CR00) 937.43 SGEDVPHR M 28 N
30 Inorganic pyrophosphatase (Q9D819) 939.39 SGFSSEER M 67 N
31 60S ribosomal protein L39 (P62892) 945.47 SSHKTFR M 58 N
32 60S ribosomal protein L18a (P62717) 946.49 MKASGTLR 107 -
33 40S ribosomal protein S30 (P62862) 950.53 KVHGSLAR M 25 C
34 Thiosulfate sulfurtransferase (P52196) 955.52 VHQVLYR M 74 C
35 Ankyrin repeat and SO CS box protein 1 (Q9WV74) 957.42 AEGGTGPDGR M 21 N
36 TFIIH basal transcription factor complex p44 subunit (Q9JIB4) 962.37 MDEEPER 65 N
37 Glucosidase 2 subunit beta precursor (008795 ) 966.56 VEVKRPR SP 23 N
38 Eukaryotic initiation factor 4A-II (P10630) 967.4 SGGSADYNR M 26 N
39 Protein C14orf4 homolog (Q8K3X4) 975.46 SAAQVSSSR M 47 N
40 Ferritin heavy chain (P09528) 987.5 TTASPSQVR M 36 -
41 40S ribosomal protein S24 (P62849) 990.48 MNDTVTIR 47 N
42 Fizzy-related protein homolog (Q9R1K5) 997.38 MDQDYER 23 N
43 Protein-glutamine gamma-glutamyitransferase 2 (P21981) 1013.54 AEELLLER M 38 N
44 Fibroblast growth factor 14 (P70379) 1025.59 AAAIASGLIR M 33 N
45 Mitochondrial 28S ribosomal protein S14 (Q9CR88) 1027.6 AASVLGSLLR M 17 N
46 Nonspecific lipid-transfer protein (P32020) 1037.59 PSVALKSPR M 45 C
47 Embryonal Fyn-associated substrate (Q64355) 1042.58 AIATSAQLAR M 46 -
48 4ÛS ribosomal protein S3 (P62908) 1054.65 AVQISKKR M 103 N
49 Thiamine-triphosphatase (Q8JZL3) 1055.56 AQGLIEVER M 20 -
50 Protein patched homolog 1 (Q61115) 1056.53 ASAGNAAGALGR M 26 N
51 Calcium-binding protein 1 (CaBP1) (Q9JLK7) 1056.54 GNCVKSPLR M 10 N
52 Nephrin (Q9QZS7) 1080.56 QSPVPTSAPR SP 19 -
53 3'(2’),5’-bisphosphate nucleotidase 1 1084.53 ASSHTVLMR M 45 N
54 Succinate dehydrogenase (Q9CQA3) 1084.62 AATVGVSLKR M 12 N
55 Succinyl-CoA ligase [GDP-forming] subunit alpha (Q9WUM5) 1088.55 VSSSSGLAAAR M 33 -
56 SON protein (Q9QX47) 1089.55 AADIEQVFR M 177 N
57 ADAMTS-15 (P59384) 1098.9 AIPAGASSIDR M 15 N
58 Esterase D (Q9R0P3) 1099.6 ALKQISSNR M 81 N
59 5-formyltetrahydrofolate cyclo-ligase (Q9D110) 1099.6 AAVTVNSAKR M 39 -
60 Long-chain-fatty-acid-CoA ligase 1 1101.53 MEVHELFR 12 C
61 Gastrin/cholecystokinin type B receptor (P56481) 1101.59 MDLLKLNR 47 N
62 26S proteasome regulatory subunit S9 (Q8BG32) 1102.58 AAAAWEFQR M 67 N
63 NG.NG-dimethylarginine dimethylaminohydrolase 1 (Q9CWS0) 1110.56 AGLGHPSAFGR M 42 N
64 Glyceraldehyde-3-phosphate dehydrogenase (P16858) 1115.61 VKVGVNGFGR M 118 C
65 Adenylyl cyclase-associated protein 1 (P40124) 1116.52 ADMQNLVER M 31 -
66 Long-chain-fatty-acid-CoA ligase 1 (P41216) 1117.52 MEVHELFR 29 N
67 M-phase inducer phosphatase 1 (P48964) 1121.55 MELGPSPPPR 18 N
68 Elongation factor 2 (P58252) 1132.59 VNFTVDQIR M 58 C
69 Acyl-coenzyme A thioesterase 4 (Q8BWN8) 1142.59 AATLSVEPTGR M 17 N
70 40S ribosomal protein S10 (P63325) 1142.59 MLMPKKNR 65 N
Supplementary data B: Mouse liver N-terminal identifications
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71 Polymerase delta-interacting protein 3 (Q8BG81) 1143.61 ADLSLDELIR M 45 C
72 High mobility group protein 1 (P63158) 1149.61 GKGDPKKPR M 38 N
73 14-3-3 protein eta (P68510) 1155.6 GDREQLLQR M 39 N
74 Estradiol 17 beta-dehydrogenase 5 (P70694) 1175.56 MDSKQQTVR 125 N
75 Importin alpha-3 subunit (035344) 1177.55 AENPGLENHR M 12 N
76 Hippocampus abundant transcript 1 protein (P70187) 1182.67 TQGKKKKR M 15 -
77 Annexin A6 1191.61 AKIAQGAMYR M 152 N
78 Ezrin-radixin-moesin binding phosphoprotein 50 (P7Û441) 1195.58 SADAAAGEPLPR M 33 N
79 Oligodendrocyte transcription factor 3 (Q6PFG8) 1197.49 MNSDSSSVSSR 15 N
80 60S ribosomal protein L13a (P19253) 1197.64 AEGGVLVLDGR M 70 N
81 5*-AMP-activated protein kinase catalytic subunit alpha-1 (Q5EG47) 1199.62 AEKQKHDGR M 14 N
82 Ras association domain-containing protein 1 (Q99MK9) 1200.64 SAEPELIELR M 11 C
83 2 days neonate thymus thymic cells cDNA (Q8C7C3) 1229.66 AGTTTIEAVKR M 15 N
84 Argininosuccinate lyase (Q91YI0) 1230.6 ASESGKLWGGR M 158 N
85 Tropomyosin alpha-4 chain (Q6IRU2) 1240.68 AGLNSLEAVKR M 27 N
86 Selenoprotein T precursor (P62342) 1252.64 SANLGGVPSK*R SP 48 N
87 Aldehyde dehydrogenase (P47739) 1257.68 SNISSIVNRAR M 65 N
88 Serum albumin precursor (P07724) 1260.62 EAHKSEIAHR PP 129 C
89 Phenylalanine-4-hydroxylase (P16331 ) 1268.71 AAW LENGVLSR M 126 N
90 Laminin subunit alpha-3 mature (Q61789) 1269.58 WGQDHPMSSR M 19 -
91 Fatty acid-binding protein (P55050) 1277.6 AFDGTWKVDR M 92 N
92 40S ribosomal protein S15  (P62843) 1282.69 AEVEQKKKR M 79 N
93 Heterogeneous nuclear ribonucleoproteins C1/C2 (Q9Z204) 1285.63 ASNVTNKTDPR M 49 N
94 Glutathione S-transferase Mu 1 (P10649) 1289.66 PMILGYWNVR M 247 C
95 Glutathione S-transferase Mu 2 (P15626) 1292.62 PMTLGYWDIR M 102 C
96 JmjC domain-containing histone déméthylation protein 3A (Q8BW72 ) 1302.61 ASESETLNPSAR M 25 N
97 Glycogen phosphorylase, liver form (Q9ET01) 1310.68 AKPLTDQEKR M 105 N
98 Dihydropyrimidinase-related protein 3 (Q62188) 1315.69 SYQGKKNIPR M 17 N
99 Paired box protein Pax-5 (Q02650) 1318.66 DLEKNYPTPR M 158 N
100 Homeobox protein orthopedia (009113) 1324.64 MLSHADLLDAR 123 -
101 Macrophage migration inhibitory factor (P34884) 1331.71 PMFIVNTNVPR M 208 C
102 Peptidyl-prolyl cis-trans isomerase (P26883) 1355.67 GVQVETISPGDGR M 45 N
103 Tyrosyl-tRNA synthetase (Q91WQ3) 1355.67 GDAPSPEEKLHLITR M 36 -
104 Acyl-coenzyme A thioesterase 1 (055137) 1358.65 MEATLNLEPSGR 28 N
105 Exosome complex exonuclease RRP41 (Q921I9) 1362.68 AGLELLSDQGYR M 22 N
106 Sterol-4-alpha-carboxylate 3-dehydrogenase (Q9R1J0) 1370.64 MEQAVHGESKR 20 N
107 Glutathione S-transferase P 1 (P19157) 1392.74 PPYTIVYFPVR M 356 C
108 Eukaryotic translation initiation factor 1A (Q8BMJ3) 1392.75 PKNKGKGGKNR M 117 C
109 Eukaryotic translation initiation factor 3 subunit I (Q9QZD9) 1404.75 MKPILLQGHER 98 -
110 Mitochondrial import receptor subunit TOM34 (Q9CYG7) 1411.73 APKVSDSVEQLR M 27 C
111 14-3-3 protein gamma (P61982) 1424.77 VDREQLVQKAR M 31 N
112 Fatty acid-binding protein, epidermal (E-FABP) (Q05816) 1427.33 ASLKDLEGKWR M 29 N
113 Fatty acid-binding protein (Q05816) 1427.74 ASLKDLEGKWR M 58 N
114 Male-enhanced antigen 1 (Q64327) 1429.69 AAWLGGDTMGPER M 26 N
115 Histone deacetylase 5 (Q9Z2V6) 1438.55 MNSPNESDGMSGR 16 -
116 Septin-11 (Q8C1B7) 1438.75 AVAVGRPSNEELR M 30 N
117 Glutathione S-transferase Yc (P30115) 1442.73 AGKPVLHYFDGR M 161 N
118 Mitochondrial import inner membrane translocase (P62077) 1471.68 AELGEADEAELQR M 75 N
119 60S ribosomal protein L 11 (Q9CXW4) 1485.65 AQDQGEKENPMR M 50 N
120 Sal-like protein 3 (Q62255) 1493.59 PGDGAEDADSGSESR M 45 C
121 Signal recognition particle 9 kDa protein (P49962) 1495.67 PQFQTWEEFSR M 15 C
122 D-dopachrome tautomerase (035215) 1513.78 PFVELETNLPASR M 349 C
123 Cytoplasmic dynein 1 intermediate chain 1(088485) 1515.74 SDKSDLKAELER M 10 N
124 4-hydroxyphenylpyruvate dioxygenase 1529.75 TTYNNKGPKPER M 75 -
125 L-serine dehydratase (Q8VBT2) 1532.83 AAQESLHVKTPLR M 128 N
126 Glutathione S-transferase P 2 (P46425) 1534.78 PPYTIVYFPSPGR M 50 N
127 Peroxisomal carnitine O-octanoyltransferase (Q9OC50) 1546.73 MENQLTKSVEER 20 N
128 Polypyrimidine tract-binding protein 1 (P17225) 1554.81 MDGIVPDIAVGTKR 45 N
129 Ras suppressor protein 1 (Q01730) 1570.86 SKSLKKLVEESR M 58 N
130 Eukaryotic translation initiation factor 2 subunit 3 (Q9Z0N1 ) 1576.8 AGGEGGVTLGQPHLSR M 40 N
131 Serine/threonine-protein phosphatase 6 (Q9CQR6) 1586.84 APLDLDKYVEIAR M 22 -
132 Kynureninase (Q9CXF0) 1593.81 MEPSPLELPVDAVR 83 N
133 T-complex protein 1 subunit zêta (P80317) 1598.93 AAVKTLNPKAEVAR M 59 N
134 Microsomal triglyceride transfer protein large subunit (008601) 1608.82 VKGHTTGLSLNNER M 39 -
135 Liver carboxylesterase 31 precursor (Q63860) 1619.85 PKVTQPEVDTPLGR SP 100 C
136 Serine/threonine-protein phosphatase PP1 (P62137) 1629.82 SDSEKLNLDSIIGR M 35 -
137 60S ribosomal protein L29 (P47915) 1633.79 AKSKNHTTHNQSR M 25 -
138 Heterogeneous nuclear ribonucleoprotein A1 (P49312) 1639.81 SKSESPKEPEQLR M 41 N
139 Hnrpa3 protein 1648.75 MEGHDPKEPEQLR 25 N
140 Vitamin K-dependent protein Z precursor (Q9CQW3) 1651.87 SVFLPAPKANNVLR SP 48 N
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141 Sorting nexin-5 (Q9D8U8) 1667.8 AAVPELLEQQEEDR M 73 N
142 C-1-tetrahydrofolate synthase, cytoplasmic (Q922D8) 1690.97 APAGILNGKLVSAQIR M 38 C
143 Protein disutfide-isomerase A3 precursor (P27773 ) 1694.76 DVLELTDENFESR SP 32 -
144 Protein disuffide-isomerase A3 precursor (P27773) 1694.76 SDVLELTDENFESR SP 183 C
145 Protein transport protein Sec23A (Q01405) 1711.81 TTYLEFIQQNEER M 120 -
146 Fructose-1,6-bisphosphatase 1 (Q9QXD6) 1713.83 ANHAPFETDISTLTR M 304 N
147 Signal recognition particle 14 kDa protein (P16254) 1718.91 VLLESEQFLTELTR M 59 -
148 Acyl-CoA-binding protein (P31786) 1732.83 SQAEFDKAAEEKVR M 391 N
149 F-actin-capping protein subunit alpha-2 (P47754) 1743.82 ADLEEQLSDEEKVR M 110 -
150 Serine/threonine-protein kinase PRP4 homolog (Q61136) 1754.9 AAGIGKDFKENPNLR M 98 -
151 Liver fructose 1,6  Bisphoshate (O-accetylated) (Q9QXD6) 1755.83 ANHAPFETDISTLTR M 45 -
152 BTG3 protein (Tob5 protein) (P50615) 1755.91 MKNEIAAWFFFTR 23 C
153 40 kDa peptidyl-prolyl cis-trans isomerase (Q9CR16) 1773.88 SHASPAAKPSNSKNPR M 95 -
154 Adenylate kinase isoenzyme 2 (Q9WTP6) 1773.96 APNVLASEPEIPKGIR M 22 c
155 Betaine-homocysteine S-methyltransferase (035490) 1775.03 APVAGKKAKKGILER M 678 c
156 40S ribosomal protein S19 (Q9CZX8) 1798.92 PGVTVKDVNQQEFVR M 189 c
157 Docking protein 1 (P97465) 1819.86 MDGAVMEGPLFLQSQR 16 -
158 Glutamate-cysteine ligase catalytic subunit (P97494) 1828.91 GLLSQGSPLSWEETQR M 77 c
159 Splicing factor 3B subunit 1 (Q99NB9) 1847.97 AKIAKTHEDIEAQIR M 105 N
160 Developmentally-regulated GTP-binding protein 2 (Q9QXB9) 1853.01 GILEKISEIEKEIAR M 38 -
161 Guanine nucleotide-binding protein (Q61017) 1895.04 MEVEQLKKEVKNPR 28 N
162 60S ribosomal protein L32 (P17932) 1926.21 AALRPLVKPKIVKKR M 70 -
163 60S ribosomal protein L30 (P62889) 1969.08 VAAKKTKKSLESINSR M 89 -
164 Cytosolic nonspecific dipeptidase (Q9D1A2) 1979.96 SALKAVFQYIDENQDR M 67 N
165 40S ribosomal protein S27 2026.04 PLAKDLLHPSPEEEKR M 103 c
166 26S proteasome non-ATPase regulatory subunit 6 (Q99JI4) 2046.03 PLENLEEEGLPKNPDLR M 29 C
167 Peptidyl-prolyl cis-trans isomerase A (P17742) 2046.99 VNPTVFFDITADDEPLGR M 243 N/C
168 Guanidinoacetate methyltransferase (035969) 2046.99 SSSAASPLFAPGEDCGPAWR M 44 N
169 Endoplasmin mature (P08113) 2060.9 DDEVDVDGTVEEDLGKSR SP 81 -
170 Histone H2A.Z (H2A/z)(P0C0S6) 2068.09 AGGKAGKDSGKAKTKAVSR M 18 N
171 T-complex protein 1 subunit beta (P80314) 2071.06 ASLSLAPVNIFKAGADEER M 51 N
172 KruppeMike factor 2 (Q60843) 2077.02 ALSEPILPSFATFASPCER M 46 N
173 Thyrotroph embryonic factor (Q9JLC6) 2081.99 SD AG G G KKP P VE PQAGPG PG R M 58 N
174 PCTP-like protein (PCTP-L) (Q9JMD3) 2082.02 MEKPAASTEPQGSRPALGR 35 N
175 Sorbitol dehydrogenase 2084.1 AAPAKGENLSLWHGPGDIR M 85 N
176 Adenosylhomocysteinase (P50247) 2085.09 SDKLPYKVADIGLAAWGR M 92 N
177 40S ribosomal protein S20 (P60867) 2120.09 AFKDTGKTPVEPEVAI HR M 119 N
178 Phosphoglycerate kinase 1 (P09411) 2124.18 SLSNKLTLDKLDVKGKR M 98 N
179 Serine/threonine-protein phosphatase 2A (Q76MZ3) 2158.08 AAADGDDSLYPIAVLIDELR M 32 N
180 myosin regulatory light chain 2166.21 SSKKAKTKTTKKRPQR M 47 N
181 26S protease regulatory subunit 8 (P62196) 2170.02 ALDGPEQMELEEGKAGSGLR M 43 N
182 Peroxiredoxin 6 (008709) 2183.06 PGGLLLGDEAPNFEANTTIGR M 247 C
183 Homogentisate 1 ,2-dioxygenase 2210.98 AELKYISGFGNECASEDP M 58 -
184 Cofilin-1 (P18760) 2233.14 ASGVAVSDGVIKVFNDMKVR M 128 N
185 Abhydrolase domain-containing protein 14B (Q8VCR7) 2285.12 AGVDQHEGTIQVQGQNLFFR M 64 N
186 14-3-3 protein theta (P68254) 2292.23 MEKTELIQKAKLAEQAER 321 N
187 14-3-3 protein zeta/delta (P63101) 2293.19 MDKNELVQKAKLAEQAER 383 N
188 Arginase-1 (Q61176) 2294.23 SSKPKSLEIIGAPFSKGQPR M 24 N
189 Small nuclear ribonucleoprotein Sm D2 (P62317) 2295.18 SLLNKPKSEMTPEELQKR M 21 -
190 Catalase (P24270) 2317.04 SDSRDPASDQMKQWKEQR M 78 N
191 Cytoplasmic aconitate hydratase (P28271) 2332.16 MKNPFAHLAEPLDAAQPGKR 29 -
192 14-3-3 protein beta/alpha (Q9CQV8) 2341.25 TMDKSELVQKAKLAEQAER M 125 -
193 Cofilin-2 (P45591) 2346.19 ASGVTVNDEVIKVFNDMKVR M 38 N
194 14-3-3 protein epsilon (P62259) 2363.11 MDDREDLVYQAKLAEQAER 66 N
195 Calreticulin (P14211) 2369.1 DPAIYFKEQFLDGDAWTNR SP 109 -
196 Retinitis pigmentosa 1-like 1 protein (Q8CGM2) 2424.09 MNSTPGDTRDAPAPSHPAPSHR 26 -
197 Selenium-binding protein 2 (Q63836) 2473.18 ATKCTKCGPGYPTPLEAMKGPR M 26 N
198 Histidine triad nucleotide-binding protein 1 (P70349) 2523.33 ADEIAKAQVAQPGGDTIFGKIIR M 58 N
199 Phosphog!ucomutase-1 (Q9D0F9) 2553.38 VKIVTVKTQAYPDQKPGTSGLR M 28 -
200 Fructose-bisphosphate aldolase B (Q91Y97) 2580.39 AHRFPALTPEQKKELSEIAQR M 100 N
201 Transitional endoplasmic reticulum ATPase(Q01853) 2709.37 ASGADSKGDDLSTAILKQKNRPNR M 29 N
202 Thioredoxin-like protein 2 (Q9CQM9) 2784.39 AAGAAEAGEAAVAWEVGSAQQFE M 39 N
203 Lysyl-tRNA synthetase (Q99MN1) 2838.46 ATLQESEVKVDGEQKLSKNELKR M 41 N
204 Glutathione synthetase (P51855) 2854.43 ATSWGSILQDEKQLEELAKQAIDR M 32 N
205 U6 snRNA-associated Sm-like protein LSm7 (Q9CQQ8) 3084.66 ADKEKKKKESILDLSKYIDKTIR M 37 -
206 Hemoglobin beta-1 subunit (P02088) 3278.59 VHLTDAEKAAVSCLWGKVNSDEVG M 15 -
207 40S ribosomal protein S 12  (P63323) 3361.72 AEEGIAAGGVMDVNTALQEVLKTALI M 71 N
208 Hemoglobin alpha subunit (P01942) 3380.66 VLSGEDKSNIKAAWGKIGGHGAEYG M 337 C
209 Alpha-1-antitrypsin 1-4 (Q00897) 3385.55 EDVQETDTSQKDQSPASHEIATNLG SP 40 -
210 Aminopeptidase B (Q8VCT3) 3400.59 MESGGPGNYSGAARRPLHSAQAVD 25
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1 40S ribosomal protein S19-B (P07281) 629.35 AGVSVR M 45 C
2 40S ribosomal protein S19-A (P07280) 655.37 PGVSVR M 26 C
3 40S ribosomal protein S23 (P32827) 767.43 GKGKPR M 28 C
4 40S ribosomal protein S24 (P26782) 802.42 SDAVTIR M 48 N
5 40S ribosomal protein S14-A (P06367) 814.43 SNW QAR M 36 N
6 APC/C-CDH1 modulator 1 (Q08981) 827.45 SPSKKR M 14 N
7 Vacuolar ATP synthase catalytic subunit A (P17255) 842.42 AGALENAR M 19 N
8 60S ribosomal protein L39 (P04650) 848.45 AAQKSFR M 65 C
9 60S ribosomal protein L42 (P02405) 896.51 VNVPKTR M 78 C
10 40S ribosomal protein S1-A  (P23248) 897.50 AVGKNKR M 47 C
11 Phosphoglycerate mutase 1 (P00950) 907.59 PKLVLVR M 147 C
12 Famesyl pyrophosphate synthetase (P08524) 915.47 ASEKEIR M 101 -
13 40S ribosomal protein S14-B (P39516) 927.48 ANDLVQAR M 169 C
14 Flavohemoprotein (P39676) 931.48 MLAEKTR 29 c
15 Adenylate kinase cytosolic (P07170) 932.41 SSSESIR M 57 N
16 TPR repeat-containing protein YDR161W (Q03771) 959.49 SELEATIR M 14 N
17 Threonine synthase (P16120) 975.48 PNASQVYR M 65 C
18 Enolase 1 (P00925) 976.53 AVSKVYAR M 98 C
19 UPF0202 protein YNL132W (P53914) 1013.55 AKKAIDSR M 21 c
20 40S ribosomal protein S30 (Q12087) 1021.57 AKVHGSLAR M 59 N
21 Fructose-bisphosphate aldolase (P14540) 1025.59 GVEQILKR M 88 C
22 40S ribosomal protein S3 (P05750) 1039.34 VAUSKKR M 36 C
23 60S ribosomal protein L31 (P0C2H9) 1041.27 AGLKDWTR M 67 C
24 Guanine nucleotide-binding protein (P38011) 1041.58 ASNEVLVLR M 54 N
25 60S ribosomal protein L 11-A  (P0C0W9) 1043.52 SAKAQNPMR M 47 N
26 PAB-dependent poly(A)-specific ribonuclease subunit PAN3 (P36102) 1048.66 KLLKYPR M 12 N
27 Putative uncharacterized protein YIL058W (P40521) 1053.50 MDGHVQGLR 19 N
28 Translation machinery-associated protein 20 (P89886) 1082.56 MFKKFTR 8 -
29 Fimbrin (P32599) 1084.61 MNIVKLQR 47 N
30 3-isopropylmalate dehydratase (P07264) 1087.57 VYTPSKGPR M 24 -
31 60S ribosomal protein L21-A (Q02753) 1088.55 GKSHGYRSR M 69 C
32 60S ribosomal protein L1 (P53030) 1088.58 SKITSSQVR M 84 N
33 60S ribosomal protein L35 (P39741) 1089.58 AGVKAYELR M 87 N/C
34 Methylthioribose-1-phosphate isomerase (Q06489) 1090.41 SLEAIVFDR M 12 N
35 Elongation factor 1 -gamma 2 (P36008) 1092.56 SQGTLYINR M 65 N
36 40S ribosomal protein S 12  (P48589) 1093.59 TALVHDGLAR M 47 -
37 40S ribosomal protein S10-A (Q08745) 1102.52 MLMPKEDR M 69 N
38 Elongation factor 2 (EF-2) (P32324) 1107.54 VAFTVDQMR M 54 C
39 Orotidine 5’-phosphate decarboxylase (P03962) 1107.56 SKATYKER M 12 N
40 Rho GDP-dissociation inhibitor (Q12434) 1113 .19 AEESTDFSQFEEÉR M 32 N
41 Uncharacterized protein YMR074C (Q04773) 1113.45 MDPELQAIR 21 N
42 5-methyltetrahydropteroyltriglutamate (P05694) 1114.61 VQSAVLGFPR M 57 C
43 60S ribosomal protein L 11-B  (Q3E757) 1115.54 STKAQNPMR M 32 N
44 40S ribosomal protein S10-B (P46784) 1115.55 MLMPKQER 49 -
45 40S ribosomal protein S15  (Q01855) 1126.61 SQAVNAKKR M 57 N
46 Cel) division control protein 11 (P32458) 1130.59 SGIIDASSALR M 31 N
47 Ubiquitin-like modifier HUB1 (Q6Q546) 1134.58 MIEVWNDR 26 C
48 U3 small nucleolar RNA-associated protein 14 (Q04500) 1141.65 AKKKSKSR M 19 C
49 60S ribosomal protein L37-A (P51402) 1159.60 GKGTPSFGKR M 39 C
50 Glycyl-tRNA synthetase 1 (P38088) 1170.62 SVEDIKKARAAVP FN R M 28 N
51 40S ribosomal protein S 1 1 (P26781) 1190.58 STELTVQSER M 158 N
52 60S ribosomal protein L23 (P04451) 1205.58 SGNGAQGTKFR M 109 N
53 Proteasome component C7-alpha (P21243) 1208.54 SGAAAASAAGYDR M 32 N
54 40S ribosomal protein S2 (P25443) 1225.61 SAPEAQQQKR M 108 N
55 DNA-directed RNA polymerase II (P16370) 1225.63 SEEGPQVKIR M 25 N
56 Ubiquitin carboxyl-terminal hydrolase 6 (P43S93) 1240.57 SGETFEFNIR M 12 N
57 DNA-directed RNA polymerase II subunit RPB1(P04050) 1246.63 VGQQYSSAPLR M 10 -
58 ATP phosphoribosyltransferase (P00498) 1254.60 MDLVNHLTDR 36 -
59 26S proteasome regulatory subunit RPN6 (Q12377) 1269.66 SLPGSKLEEAR M 28 N
60 Gamma-glutamyl phosphate reductase (P54885) 1272.64 SSSQQIAKNAR M 18 N
61 Acetyl-CoA acetyltransferase (P41338) 1278.66 SQNVYIVSTAR M 36 N
62 60S ribosomal protein L26-A (P53221) 1288.63 AKQSLDVSSDR M 49 C
63 60S ribosomal protein L37-A 1305.65 SYNWGAKAKR M 69 N
64 DNA-directed RNA polymerase I subunit RPA2 (P22138) 1305.74 SKVIKPPGQAR M 45 N
65 Vacuolar amino acid transporter 3 (P36062) 1307.58 MNGKEVSSGSGR 24 -
66 Cystathionine beta-synthase (P32582) 1316.58 TKSEQQADSR M 14 -
67 Phosphate system positive regulatory protein PH081 (P17442) 1325.68 MKFGKYLEAR 9 -
68 UPF0303 protein YBR137W (P38276) 1337.79 WLDKKLLER M 25 C
69 Reduced viability upon starvation protein 167 (P39743) 1352.71 SFKGFTKAVSR M 23 N
70 Hexokinase-2 (P04807) 1355.77 VHLGPKKPQAR M 58 C
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71 40S ribosomal protein S4 (P05753) 1357.79 ARGPKKHLKR M 69 C
72 Protein PUF6 (Q04373) 1380.77 APLTKKTNGKR M 12 C
73 ATP-dependent RNA helicase DBP3 (P20447) 1384.72 TKEEIADKKR M 10 C
74 Transcription factor tau 138 kDa subunit (P34111) 1386.00 SSVGIASASLWLR M 16 N
75 Phospho-2-dehydro-3-deoxyheptonate aldolase (P14843) 1386.64 MFIKNDHAGDR 36 C
76 Glucokinase GLK1 (P17709) 1401.65 SFDDLHKATER M 28 N
77 Multiprotein-bridging factor 1(014467) 1405.65 SDWDTNTIIGSR M 9 N
78 Bud emergence protein 1 (P29366) 1405.78 MLKNFKLSKR 32 -
79 40S ribosomal protein S29-B (P41058) 1420.66 AHENVWFSHPR M 158 C
80 60S ribosomal protein L20 (P0C2I0) 1430.73 AHFKEYQVIGR M 269 C
81 60S ribosomal protein L18 (P07279) 1431.72 GIDHTSKQHKR M 78 c
82 Uncharacterized protein YOR051C (Q08421) 1435.83 AKRPLGLGKQSR M 25 c
83 AdoMet-dependent rRNA methyltransferase SPB1 (P25582) 1440.77 GKTQKKNSKGR M 8 c
84 FK506-binding protein 1 (P20081) 1441.74 SEVIEGNVKIDR M 19 N
85 Actin-binding protein (P15891) 1443.70 ALEPIDYTTHSR M 58 N
86 Mannose-1-phosphate guanyltransferase (P15891) 1447.79 MKGLILVGGYGTR 36 C
87 60S ribosomal protein L15-A (P05748) 1452.72 GAYKYLEELQR M 87 c
88 60S ribosomal protein L15-B (P54780) 1453.71 GAYKYLEELER M 47 c
89 Protein LTV1 (P34078) 1463.74 SKKFSSKNSQR M 25 N
90 F-actin-capping protein subunit beta (P13517) 1475.73 SDAQFDAALDLLR M 30 N
91 Suppressor of kinetochore protein 1 (P52286) 1486.58 V TSN W IVSG EG ER M 27 C
92 60S ribosomal protein L14-A (P36105) 1488.72 STDSIVKASNWR M 47 N
93 Spore-specific protein YSW1 (P38280) 1490.72 SSLADTVEGSEAKR M 9 N
94 Eukaryotic translation initiation factor 1A (P38912) 1509.83 GKKNTKGGKKGR M 54 C
95 Protein BCP1 (Q06338) 1536.86 VQAIKLNDLKNR M 12 C
96 Uroporphyrinogen decarboxylase (P32347) 1537.83 GNFPAPKNDLILR M 10 c
97 Pyruvate decarboxylase isozyme 2 (P06169) 1538.80 SEITLGKYLFER M 78 N
98 T-complex protein 1 subunit beta (P39076) 1548.74 SVQIFGDQVTEER M 12 N
99 T-complex protein 1 subunit zeta (P39079) 1551.86 SLQLLNPKAESLR M 10 N
100 Uncharacterized protein YNR034W-A (Q3E841) 1553.85 MKSSIPITEVLPR 12 C
101 Adenylosuccinate lyase (Q05911) 1572.71 PDYDNYTTPLSSR M 45 C
102 Eukaryotic translation initiation factor 3 (P38249) 1575.85 APPPFRPENAIKR M 78 C
103 Protein transport protein SEC23 (P15303) 1580.68 MDFETNEDINGVR 63 N
104 Deoxyuridine 5'-triphosphate nucleotidohydrolase (P33317) 1597.90 TATSDKVLKIQLR M 12 C
105 Prefoldin subunit 3 (P48363) 1609.74 MDTLFNSTEKNAR 55 N
106 60S ribosomal protein L29 (P05747) 1617.80 AKSKNHTAHNQTR M 87 C
107 Ribose-phosphate pyrophosphokinase 3 (P38689) 1643.90 PTNSIKILAPDVHR M 25 c
108 T-complex protein 1 subunit gamma (P39077) 1648.77 MQAPWFMNASQER 14 N
109 60S ribosomal protein L27 (P0C2H7) 1653.13 AKFLKAGKVAVWR M 78 C
110 Anaphase spindle elongation protein (P50275) 1658.82 METATSSPLPIKSR 56 -
111 60S ribosomal protein L5 (P26321) 1670.79 AFQKDAKSSAYSSR M 69 c
112 Serine/threonine-protein phosphatase PP1-2 (P32598) 1673.76 MDSQPVDVDNIIDR 32 N
113 Co-chaperone protein SBA1 (P28707) 1694.87 SDKVINPQVAWAQR M 13 C
114 tRNA (guanine-N(7)-)-methyltransferase (Q12009) 1709.88 MKAKPLSQDPGSKR 21 c
115 Alanyl-tRNA synthetase, cytoplasmic (P40825) 1742.90 TIGDKQKWTATNVR M 41 c
116 Eukaryotic translation initiation factor 3 (P40825) 1756.81 SEVAPEEIIENADGSR M 71 N
117 40S ribosomal protein S27-A (P38711) 1760.94 VLVQDLLHPTAASEAR M 45 C
118 U3 small nucleolar RNA-associated protein 11 (P34247) 1766.03 AKLVHDVQKKQHR M 32 C
119 Histone H2A.1 (P04912) 1771.88 SGGKGGKAGSAAKASQSR M 12 N
120 60S ribosomal protein L13-A (Q12690) 1776.00 AISKNLPILKNHFR M 54 C
121 40S ribosomal protein S18 (P35271) 1781.94 SLWQEQGSFQHILR M 78 N
122 Phosphoribosylformylglycinamidine synthase (P38972) 1788.94 TDYILPGPKALSQFR M 41 -
123 Transketolase 1 (P23254) 1790.94 TQFTDIDKLAVSTIR M 58 C
124 Aspartate-semialdehyde dehydrogenase (P23254) 1795.00 AGKKIAGVLGATGSVGQR M 47 c
125 Cell division control protein 48 (P25694) 1802.88 GEEHKPLLDASGVDPR M 18 c
126 Spermidine synthase (Q12074) 1810.90 AQEITHPTIVDGWFR M 24 c
127 Peptidyl-prolyl cis-trans isomerase (P14832) 1821.85 SQVYFDVEADGQPIGR M 95 N
128 Proliferating cell nuclear antigen (P15873) 1823.91 MLEAKFEEASLFKR 47 C
129 60S ribosomal protein L16-B (P26785) 1830.00 SQPVWIDAKDHLLGR M 69 N
130 Ribosomal RNA-processing protein 1 (P35178) 1837.86 METSNFVKQLSSNNR 98 -
131 Uncharacterized GTP-binding protein (P53295) 1840.96 GIIDKIKAIEEEMAR M 22 -
132 60S ribosomal protein L16-A (P53295) 1844.02 SVEPVWtDGKGHLVGR M 150 N
133 26S proteasome regulatory subunit RPN10 (P38886) 1848.95 VLEATVLVIDNSEYSR M 54 C
134 Ankyrin repeat-containing protein (P53066) 1862.87 MNTEGASLSEQLLDAAR 18 N
135 DNA repair protein REV1 (P12689) 1862.93 GLVDLLDSDLEYSINR M 21 C
136 Glycerol-3-phosphate dehydrogenase (Q00055) 1864.95 SAAADRLN LTSG H LNAGR M 204 N
137 40S ribosomal protein S21-A  (Q3E754) 1873.92 MENDKGQLVELYVPR 147 N
138 U6 snRNA-associated Sm-like protein LSm3 (P57743) 1882.97 METPLDLLKLNLDER 18 N
139 Vacuolar ATP synthase subunit H (P41807) 1915.95 GATKILMDSTHFNEIR M 14 C
140 Nonhistone chromosomal protein 6B (P11633) 1961.06 AATKEAKQPKEPKKR M 25 C
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141 GTP-binding protein RBG1 (P39729) 1968.00 STTVEKIKAIEDEMAR M 22 N
142 Kelch repeat-containing protein 3 (Q08979) 1978.08 AKKNKKDKEAKKAR M 14 N
143 Heat shock protein homolog SSE1 (P32589) 1986.02 STPFGLDLGNNNSVLAVAR M 58 N
144 Ribonucleoside-diphosphate reductase small chain 2 (P49723) 2031.98 MEAHNQFLKTFQKER 14 -
145 Low specificity L-threonine aldolase (P37303) 2061.04 TEFELPPKYITAANDLR M 44 C
146 Adenosylhomocysteinase (P39954) 2076.06 SAPAQNYKIADISLAAFGR M 47 N
147 6,7-dimethyl-8-ribityllumazine synthase (P50861) 2098.11 AVKGLGKPDQVYDGSKIR M 24 C
148 Phosphoglycerate kinase (P00560) 2099.11 SLSSKLSVQDLDLKDKR M 158 N
149 40S ribosomal protein S28-B (P0C0X0) 2123.20 MDSKTPVTLAKVIKVLGR 89 -
150 Cytochrome c iso-1 (P00044) 2150.14 TEFKAGSAKKGATLFKTR M 87 C
151 40S ribosomal protein S28-A (Q3E7X9) 2150.21 MDNKTPVTLAKVIKVLGR 107 -
152 O-lactate dehydrogenase (P39976) 2176.16 TAAHPVAQLTAEAYPKVKR M 65 c
153 Seryl-tRNA synthetase, cytoplasmic (P07284) 2285.14 MLDINQFIEDKGGNPELIR 47 -
154 Ribosome biogenesis protein RLP7 (P40693) 2285.15 SSTQDSKAQTLNSNPEILLR M 153 N
155 RuvB-like protein 1 (Q03940) 2298.15 VAISEVKENPGVNSSNSGAVTR M 21 C
156 Aromatic amino acid aminotransferase 1 (P53090) 2303.06 TLPESKDFSYLFSDETNAR M 15 C
157 RNA annealing protein YRA1 (Q12159) 2314.14 SANLDKSLDEIIGSNKAGSNR M 18 N
158 Protein BMH1 (P29311) 2362.13 STSREDSVYLAKLAEQAER M 31 N
159 Nascent polypeptide-associated complex subunit alpha (P38879) 2363.24 SAIPENANVTVLNKNEKKAR M 24 N
160 60S ribosomal protein L6-A (Q02326) 2363.24 SAQKAPKWYPSEDVAALKKTR M 69 N
161 Ribose-5-phosphate isomerase (Q12189) 2389.25 AAGVPKIDALESLGNPLEDAKR M 47 C
162 60S ribosomal protein L32 (Q12189) 2436.40 ASLPHPKIVKKHTKKFKR M 54 C
163 T-complex protein 1 subunit delta (P39078) 2467.67 SAKVPSNATFKNKEKPQEVR M 31 N
164 Protein MET17 (P06106) 2468.12 PSHFDTVQLHAGQENPGDNAHR M 52 C
165 60S ribosomal protein L8-A (P17076) 2492.34 APGKKVAPAPFGAKSTKSNKTR M 87 N
166 Glutamine synthetase (P32288) 2501.30 AEASIEKTQILQKYLELDQR M 78 N
167 tRNA pseudouridine synthase 1 (Q12211) 2524.03 SEENLRPAYDDQVNEDVYKR M 36 N
168 60S ribosomal protein L6-B (P05739) 2539.27 TAQQAPKWYPSEDVAAPKKTR M 98 C
169 Cytochrome c iso-2 (P00Û45) 2561.35 AKESTGFKPGSAKKGATLFKTR M 35 C
170 Leu/Val/lle amino-acid permease (P38084) 2641.21 MLSSEDFGSSGKKETSPDSISIR 12 -
171 Phosphoglucomutase-2 (P37012) 2703.34 SFQIETVPTKPYEDQKPGTSGLR M 187 N
172 Nascent polypeptide-associated complex subunit (Q02642) 2717.47 PIDQEKLAKLQKLSANNKVGGTR M 25 C
173 40S ribosomal protein SO-A (P32905) 2776.44 SLPATFDLTPEDAQLLLAANTHLGAR M 158 N
174 Actin (P32905) 2833.25 DSEVAALVIDNGSGMCKAGFAGDDA M 108 C
175 H/ACA ribonucleoprotein complex subunit 2 (P32495) 2843.32 GKDNKEHKESKESKTVDNYEAR M 44 C
176 Acetyl-CoA carboxylase (Q00955) 2866.25 SEESLFESSPQKMEYEITNYSER M 65 N
177 40S ribosomal protein S20 (Q3E7X9) 2926.47 SDFQKEKVEEQEQQQQQIIKIR M 48 N
178 60S ribosomal protein L25 (P04456) 2928.68 APSAKATAAKKAWKGTNGKKALKV M 89 C
179 Vacuolar ATP synthase subunit B (P16140) 2939.58 VLSDKELFAINKKAVEQGFNVKPR M 45 C
180 Elongation factor 3A (P16521) 2973.49 SDSQQSIKVLEELFQKLSVATADNR M 58 N
181 GTP-binding nuclear protein GSP1/CNR1 (P32835) 3184.68 SAPAANGEVPTFKLVLVGDGGTGKT M 22 N
182 NADPH-dependent 1-acyldihydroxyacetone phosphate reductase 3241.72 SELQSQPKKIAW TGASGGIGYEVTK M 44 N
183 60S ribosomal protein L7-A (P05737) 3432.81 AAEKILTPESQLKKSKAQQKTAEQVA M 48 C
184 Histone H2A.Z (Q12692) 2094.05 SGKAHGGKGKSGAKDSGSLR M 25 N
185 Phosphomannomutase (P07283) 3135.60 SIAEFAYKEKPETLVLFDVDGTLTPA M 87 N
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1 Acetoacetate metabolism regulatory protein (Q06065) 615.33 TAINR M 21 -
2 Phage shock protein A (P0AFM7) 620.35 GIFSR 20 C
3 UPF0352 protein yejL (P0AD24) 641.35 PQISR M 24 C
4 50S ribosomal protein L24 (P60625) 641.39 AAKIR -
5 30S ribosomal protein S2 (P0A7V2) 705.35 ATVSMR M 21 -
6 Outer membrane usher protein afaC mature (P53517) 744.38 AESGIAR SP 39 N
7 Transcriptional repressor protein korC (Q52331) 744.38 SDVNIR 19 -
8 Hypothetical protein ydiZ (P64480) 758.39 ASGDLVR M 23 C
3 Ribosome recycling factor (P0A805) 775.39 MISDIR 5 -
10 Hypothetical protein ydjl (P77704) 775.39 MLADIR met ox 17 C
11 Carbon storage regulator (P69913) 787.46 MLILTR 33 c
12 Hypothetical protein yncE mature (P76116) 789.37 AEEMLR M 23 c
13 Galactitol-specific phosphotransferase enzyme HA component 790.43 TNLFVR M 30 c
14 Methylgiyoxal synthase (P0A732) 791.38 MELTTR 21 c
15 30S ribosomal protein S21 (P68681) 794.50 PVIKVR M 23 c
16 Hypothetical protein yciW (P76035) 799.43 MLS-PIR 21 -
17 Hypothetical protein yebV 804.41 MKTSVR 20 c
18 Stringent starvation protein A (P0ACA3) 812.45 AVAANKR M 39 c
19 Hypothetical protein ydcD (P31991) 814.47 MLQIIR 23 c
20 Lysine-arginine-ornithine-binding periplasmic protein mature (P09551) 826.45 ALPETVR SP 19 c
21 Succinate dehydrogenase flavoprotein subunit (P0AC41) 826.47 MKLPVR 32 c
22 phosphoribosylformylglycinamidine synthase (Q8XA46) 833.41 MMEILR 22 -
23 Enoyl-[acyl-carrier-protein] reductase (P0AEK4) 847.45 GFLSGKR M 35 c
24 Protein trap (P41068) 862.36 ANNMS-SR 10 c
25 Endonuclease III (P0AB84) 872.45 MNKAKR 22 c
26 GTP-binding protein typA/BipA (P32132) 872.48 MIEKLR 30 c
27 D-erythro-7,8-dihydroneopterin triphosphate epimerase (P0AC19) 880.51 AQPAAIIR M 18 c
28 Aconitate hydratase 2 (P36683) 881.40 MLEEYR 25 c
23 DNA-invertase from lambdoid prophage e14 (P03014) 892.48 MLIGYVR 21 c
30 Dihydrodipicolinate reductase (Q8FLB4) 897.41 MHDANIR 35 -
31 Porphobilinogen deaminase (Q8XAP3) 901.47 MLDNVLR 23 c
32 Glutamyl-tRNA synthetase (Q8XBN2) 901.51 MKIKTR 24 -
33 Endonuclease V (P68739) 904.43 MDLASLR 29 -
34 Putative tagatose 6-phosphate kinase gatZ (P37191) 915.52 MKTLIAR 50 c
35 Cell division protein ftsY (P10121) 926.52 AKEKKR M 25 c
36 Elongation factor G (P0A6M8) 926.53 ARTTPIAR M 22 -
37 Chaperone protein sfmC mature (P77249) 927.51 AGGIALGATR SP 19 c
38 Probable enoyl-CoA hydratase paaF (P76082) 928.49 S-ELIVS-R M 46 -
39 Chaperone protein htpG (P0A6Z4) 932.44 MKGQETR 24 c
40 Transposase for insertion sequence element IS3411 (P11257) 937.56 PLLDKLR M 35 c
41 30S ribosomal protein S 12  (P0A7S5) 941.53 ATVNQLVR M 9 c
42 Cell division protein ftsQ (P06136) 943.47 S-QAALNTR M 5 -
43 Histidine biosynthesis bifunctional protein hislE (Q8FG47) 946.03 MLTEQQR 46 -
44 Rod shape-determining protein mreB (P0A9X4) 947.53 MLKKFR 63 -
45 Protein tusB (Q8X885) 948.49 MLHTLHR 20 N
46 HTH-type transcriptional regulator dsdC (P46068) 953.53 EPLREIR M 31 -
47 Succinate dehydrogenase hydrophobic membrane anchor protein 957.49 VS-NASALGR M 27 c
48 Protein elaB (P0AEH7) 965.42 SNQFGDTR M 33 c
49 Ribose operon repressor (P0ACQ0) 974.49 ATMKDVAR M 57 c
50 Alanyl-tRNA synthetase (P00957) 974.50 SKSTAEIR M 32 c
51 Large-conductance mechanosensitive channel (P0A742) 975.54 SIIKEFR M 36 c
52 Phosphoheptose isomerase (P63224) 979.48 MYQDLIR 42 c
53 30S ribosomal protein S10 (P0A7R7) 986.51 MQNQRIR 56 c
54 Hypothetical protein yeeL (P76349) 991.55 MFLASLLR 22 c
55 P53517) Outer membrane usher protein afaC mature 992.43 MRDTS-SGR 15 -
56 Protein cysZ (Q8FFB9) 992.49 VSSFTSAPR M 56 c
57 DNA polymerase III beta subunit (P0A990) 993.50 MKFTVER 32 c
58 Histidyl-tRNA synthetase (P60906) 996.57 AKNIQAIR M 40 c
59 Ribonuclease III (P0A7Y1) 997.54 MNPIVINR 23 c
60 Ankyrin-repeat protein B (P76205) 999.53 SQNDIIIR M 72 -
61 Cation efflux system protein cusA (P38054) 1001.54 MIEWIIR 29 c
62 Maltoporin mature (Q8X5W7) 1005.47 VDFHGYAR SP 52 c
63 Penicillin-binding protein 6 mature (P08506) 1008.52 TQYSSLLR SP 50 c
64 Seryl-tRNA synthetase (P0A8L1) 1012.54 MLDPNLLR 36 c
65 Transcriptional repressor pifC (P10030) 1015.55 MLSGLNLR 32 c
66 Transaldolase B (P0A870) 1016.55 TDKLTSLR M 44 c
67 5,10-methylenetetrahydrofolate reductase (P0AEZ1) 1020.48 SFFHASQR M 7 -
68 UPF0304 protein yfbU (P0A8W8) 1021.43 MEMTNAQR 60 c
69 Hypothetical protein yfcL (P64540) 1023.47 MIAEFESR 49 c
70 Hypothetical protein yhiD (P0AFV3) 1024.55 MTAEFIIR 25 -
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71 Multidrug translocase mdfA (P0AEZ0) 1027.54 QNKLASGAR M 41 -
72 Hypothetical protein yaiA (P0AAN5) 1038.55 PTKPPYPR M 7 C
73 Nickel transport system permease protein nikC (P0AFB0) 1042.49 MNFFLSSR 27 C
74 Hypothetical protein ymgC (P75994) 1043.47 MNNSIPER 24 -
75 30S ribosomal protein S14 (P0AG61) 1044.54 AKQSMKAR M 32 c
76 Protein iscX (P0C0L9) 1045.52 GLKWTDSR M 47 c
77 Succinate dehydrogenase hydrophobic membrane anchor protein 1046.52 MVSNASALGR 135 c
78 Hypothetical UPF0042 protein yhbj (P0A894) 1046.56 MVLMIVSGR 12 -
79 Hypothetical protein yqgC (P64570) 1048.49 GITSAGMQSR M 54 c
80 Elongation factor Tu (EF-Tu) (P0A6N1 ) 1048.52 SKEKFER M 103 N
81 Hypothetical UPF0263 protein yciU (P0A8L7) 1049.43 MDMDLNNR 49 C
82 Galactoslde O-acetyltransferase (P07464) 1050.43 MNMPMTER 35 c
83 Inner membrane transport permease ybhS (P0AFQ4) 1055.54 S-NPILSWR M 18 -
84 Phage shock protein E mature 1066.52 AEHWIDVR SP 30 c
85 Protein yifE (P0ADN2) 1067.49 AESFTTTNR M 53 -
86 50S ribosomal protein L22 (P61177) 1068.54 METIAKHR 44 c
87 UPF0306 protein yhbP (P67762) 1074.57 METLIAISR 18 c
88 Protein cyaY (P27838) 1076.43 MNDSEFHR 35 c
89 Hypothetical protein ydcY (P64455) 1080.56 SHLDEVIAR M 36 c
90 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase 1081.69 AVTKLVLVR M 46 c
91 Lipoyl synthase (P60717) 1084.56 S-KPIVMER M 33 -
92 Hypothetical fimbrial-like protein ydeR mature (P77294) 1086.57 ADVTITVNGR SP 60 N
93 Protein ygiN (P0ADU2) 1086.61 MLTVIAEIR 55 C
94 Uroporphyrinogen decarboxylase (P29680) 1089.51 MTELKNDR 23 C
95 4-hydroxy-3-methylbut-2-enyl diphosphate reductase (P62623) 1096.61 MQILLANPR 27 C
96 Transcription elongation factor greA (P0A6W5) 1101.57 MQAIPMTLR 15 -
97 Protein slyX (P0A8R4) 1103.53 MQDLSLEAR 14 -
98 Inner membrane protein yjgQ (P0ADC7) 1103.54 MQPFGVLDR 41 c
99 Bifunctional purine biosynthesis protein purH (Q8X611) 1111.60 MQQRRPVR 11 c
100 Esterase yeiG (P33018) 1115.47 MEMLEEHR 58 c
101 Histidinol-phosphate aminotransferase (Q9S5G6) 1117.60 STVTITDLAR M 54 -
102 Cell division topological specificity factor (P0A734) 1122.61 ALLDFFLSR M 57 c
103 Iron-binding protein iscA (P0AAC8) 1132.57 SITLSDSAAAR M 71 -
104 4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase (P62620) 1135.56 MHNQAPIQR 61 c
105 Hypothetical protein yfeK mature (Q47702) 1137.58 KLTAHEEAR SP 29 c
106 Hypothetical UPF0020/UPF0064 protein ycbY (P75864) 1138.54 MNSLFASTAR 18 -
107 Enolase (P0A6P9) 1138.71 SKIVKIIGR M 113 c
108 Bifunctional aspartokinase/homoserine dehydrogenase II (P00562) 1140.63 SVIAQAGAKGR M 45 c
109 Stringent starvation protein B (P0AFZ4) 1143.56 MDLSQLTPR 24 c
110 Alanine racemase, biosynthetic (Q8FB20) 1157.62 MQAATVLINR 13 -
111 Multidrug translocase mdfA (P0AEY8) 1158.58 MQNKIASGAR 25 -
112 Probable monothiol glutaredoxin ydhD (P0AC69) 1158.62 STTIEKIQR M 39 c
113 Thymidine phosphorylase (P07650) 1161.62 MFLAGEIIR 60 -
114 Curlin genes transcriptional activatory protein (P24251) 1162.61 TLPSGHPKSR M 22 c
115 Hypothetical protein yjaG (P3268Û) 1162.63 MLQNPIHLR 46 c
116 Outer membrane protein W mature (P0A915) 1164.50 HEAGEFFMR SP 69 c
117 Ribonucleoside-diphosphate reductase 1 subunit alpha (P00452) 1168.66 NQNLLVTKR M 20 c
118 Putative colanic biosynthesis UDP-glucose lipid carrier transferase 1169.65 TNLKKRER M 10 -
119 Arginine N-succinyltransferase (P0AE37) 1171.62 MMVIRPVER 33 c
120 UPF0098 protein ybhB (P12994) 1172.62 MKLISNDLR 69 c
121 Hydrogenase-4 component G (P77329) 1175.49 MNVNS-S-S-NR 11 c
122 Elongation factor P (P0A6N4) 1177.50 ATYYSNDFR M 23 c
123 50S ribosomal protein L27 (P0A7M0) 1179.60 AHKKAGGSTR M 18 c
124 Long-chain fatty acid transport protein mature (P10384) 1180.50 AGFQLNEFSSSGLGR SP 80 c
125 30S ribosomal protein S20 (P0A7U9) 1182.67 ANIKSAKKR M 25 c
126 30S ribosomal protein S3 (P0A7V5) 1188.64 GQKVHPNGIR M 53 c
127 2,5-diketo-D-gluconic acid reductase B (P30863) 1190.64 AIPAFGLGTFR M 52 c
128 10 kDa chaperonin (groES protein) (P0A6G1) 1192.61 MNIRPLHDR 39 c
129 Dihydroorotase (P05020) 1195.69 TAPSQVLKIR M 46 c
130 Putative 6-pyruvoyl tetrahydrobiopterin synthase (P65870) 1195.69 STTLFKDFTFEAAHR M 54 c
131 Protein traB (P27188) 1196.63 MNKVQIGAPR 12 c
132 30S ribosomal protein S9 (P0A7X5) 1199.52 AENQYYGTGR M 22 c
133 33 kDa chaperonin (HSP33) (P0A6Y5) 1202.56 MPQHDQLHR 35 -
134 Deoxyribose-phosphate aldolase (P0A6L0) 1204.61 MTDLKASSLR 46 c
135 UPF0082 protein yebC (P0A8A0) 1210.58 AGHSKWANTR M 20 c
136 Hypothetical protein ydcY (P64455) 1211.60 MSHLDEVIAR 55 -
137 Hypothetical protein in sul1 3'region (P26837) 1214.52 MDSEEPPNVR -
138 Threonyl-tRNA synthetase (P0A8M3) 1223.65 PVITLPDGSQR M 21 c
139 Phosphoribosylamine-glycine ligase (Q8FB69) 1226.68 MKVLVIGNGGR 83 c
140 Oxygen-insensitive NAD(P)H nitroreductase (P38489) 1228.68 MDIISVALKR 57 c
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141 Peptide transport periplasmic protein sapA mature 1230.60 APESPPHADIR M 26 -
142 Hypothetical protein yfaQ mature (P76463) 1238.69 EETPLQLVLR SP 42 -
143 Beta-glucuronidase (P05804) 1240.66 MLRPVETPTR 15 C
144 Gtyceraldehyde-3-phosphate dehydrogenase A (P0A9B4) 1244.69 TIKVGINGFGR M 123 C
145 Phosphoribosylaminoimidazole-succinocarboxamide synthase 1249.61 MQKQAELYR M 40 C
146 Hypothetical UPF0069 protein yjeK (P39280) 1249.68 AHIVTLNTPSR M 14 c
147 Biotin carboxylase (P24182) 1255.70 MLDKMANR 47 c
148 Exodeoxyribonuclease V  beta chain (P08394) 1256.62 SDVAETLDPLR M 57 -
149 GMP synthase (P04079) 1264.60 MTENIHKHR 17 c
150 Uridylate kinase (P0A7E9) 1272.68 ATNAKPVYKR M 26 c
151 Peptide chain release factor 2 (P66024) 1274.61 MFEINPVNNR 42 c
152 Copper resistance protein D (Q47455) 1274.67 MNDLIMIVIR 40 N
153 Asparaginyl-tRNA synthetase (P0A8M0) 1280.71 SW PVADVLQGR M 66 c
154 50S ribosomal protein L30 (P0AG53) 1284.74 AKTIKITQTR M 30 c
155 UDP-N-acetylmuramate--L-alanine ligase (P17952) 1285.68 MNTQQLAKLR 10 c
156 Multifunctional CCA protein (P06961) 1289.72 MKIYLVGGAVR 45 -
157 DNA replication protein dnaC (P0AEF0) 1290.61 MKNVGDLMQR 11 c
158 Aspartate-semialdehyde dehydrogenase (P0A9Q9) 1290.65 MKNVGFIGWR 39 c
159 3-phosphoshikimate 1-carboxyvinyltransferase (Q8FJB6) 1299.69 MESLTLQPIAR 62 -
160 0,0-heptose 1,7-bisphosphate phosphatase (Q8FKZ1) 1299.72 AKSVPAIFLDR M 42 c
161 Glutamate-1-semialdehyde 2,1-aminomutase (P23893) 1308.63 SKSENLYSAAR M 47 c
162 5-methyltetrahydropteroyltrig!utamate--homocysteine 1309.71 TILNHTLGFPR M 76 c
163 Protein yciN (P0AB61) 1314.62 MNKETQPIDR 40 -
164 Hypothetical ABC transporter ATP-binding protein yheS (P63389) 1318.70 MIVFS-S-LQIR 31 -
165 Cysteinyl-tRNA synthetase (P21888) 1319.73 MLKIFNTLTR 44 -
166 Hypothetical protein yqjD (P64581) 1320.64 SKEHTTEHLR M 102 c
167 Aspartate-ammonia ligase (P00963) 1334.70 MKTAYIAKQR 49 -
168 Pantoate-beta-alanine ligase (P31663) 1352.81 MLIIETLPLLR 62 -
169 Putative HTH-type transcriptional regulator yeaT (P76250) 1353.71 MNNLPLLNDLR 31 c
170 DNA-binding protein H-NS (P0ACF8) 1353.76 SEALKILNNIR M 43 c
171 Pyridoxine kinase (P40191) 1362.06 SSLLLFNDKSR M 31 c
172 Phosphoribosylglycinamide formyltransferase 2 (P33221) 1381.80 TLLGTALRPAATR M 31 c
173 Protein ydjA (P0ACV1) 1384.75 MDALELLINRR 39 -
174 Hypothetical oxidoreductase yqhD (Q46856) 1385.65 MNNFNLHTPTR 46 c
175 HIT-like protein ycfF (P0ACE7) 1389.75 AEETIFSKIIR M 49 c
176 Hypothetical ABC transporter ATP-binding protein yheS (P63389) 1390.78 MIVFSSLQIRR 13 -
177 Inner membrane protein yagll (P0AAA1) 1403.65 MNIFEQTPPNR 35 c
178 Regulator of sigma D (P0AFX4) 1403.67 MLNQLDNLTER 25 c
179 Elongation factor Ts (EF-Ts) (P0A6P1) 1412.79 AEITASLVKELR M 285 c
180 60 kDa chaperonin (Protein Cpn60) (groEL protein) (P0A6F7) 1416.70 AAKDVKFGNDAR M 13 c
181 Cysteine desulfuration protein sufE (Q7ADI5) 1420.83 ALLPDKEKLLR M 22 c
182 Hypothetical UPF0001 protein yggS (P67080) 1422.70 MNDIAHNLAQVR 71 c
183 Thiosulfate-binding protein mature (P16700) 1424.70 TELLNSSYDVSR SP 55 c
184 Probable holo-[acyl-carrier-protein] synthase 2 (Q8XAN7) 1430.76 MRIGTDIVEIAR 19 -
185 Glutaminyl-tRNA synthetase (Q8FJW4) 1431.71 SEAEARPTNFIR M 40 c
186 Glycerophosphoryl diester phosphodiesterase mature (P09394) 1435.73 ADSNEKMAHR SP 76 -
187 Outer membrane protein tolC mature (P02930) 1436.67 ENLMQVYQQAR SP 21 c
188 Hypothetical UPF0267 protein yqfB (P67603) 1437.67 MQPNDITFFQR 30 c
189 S-ribosylhomocysteine lyase (P45578) 1441.72 PLLDSFTVDHTR M 205 c
190 Argininosuccinate synthase (Q8X9M0) 1445.84 TTILKHLPVGQR M 48 c
191 Trigger factor (TF) (Q8FKA7) 1446.71 MQVSVETTQGLGR 54 -
192 Peptide deformylase (P0A6K3) 1446.78 SVLQVLHIPDER M 51 -
193 Mannitol-1-phosphate 5-dehydrogenase (P09424) 1454.75 MKALHFGAGNIGR 78 -
194 RNA polymerase sigma-E factor (P0AGB7) 1457.74 SEQLTDQVLVER 25 -
195 TyrosyMRNA synthetase (Q8FH88) 1469.77 ASSNLIKQLQER M 35 c
196 Hypothetical protein ybjS (P75821) 1472.80 MKVLVTGATSGLGR 18 c
197 DNA-directed RNA polymerase alpha chain (P0A7Z4) 1475.74 MQGSVTEFLKPR 15 c
198 ArginyMRNA synthetase (P11875) 1484.80 MNIQALLSEKVR 48 c
199 Protease III mature (P05458) 1498.74 ETGWQPIQETIR SP 17 c
200 RNA polymerase sigma-E factor (P0AGB8) 1499.75 S-EQLTDQVLVER M 41 -
201 Protein yfgD (P76569) 1508.81 TKQVKIYHNPR M 45 c
202 50S ribosomal protein L3 (P60440) 1514.83 MIGLVGKKVGMTR 64 c
203 Galactitol-1 -phosphate 5-dehydrogenase (P0A9S3) 1516.76 MKSWNDTDGIVR 50 -
204 Aerobactin siderophore biosynthesis protein iucC (Q47318) 1526.69 MNHKDWDLVNR 17 c
205 Thioredoxin 2 (P0AGG6) 1531.67 MNTVCTHCQAINR 30 -
206 Protein icc (P0AEW4) 1541.81 MESLLTLPLAGEAR 21 c
207 Glutamate synthase (NADPH) small chain (P09832) 1551.77 SQNVYQFIDLQR M 39 c
208 Adenosine deaminase (P22333) 1566.81 MIDTTLPLTDIHR 20 -
209 Fumarate reductase iron-sulfur protein (P0AC47) 1570.84 AEMKNLKIEWR M 27 -
210 Acyl-CoA thioester hydrolase yciA (P0A8Z0) 1577.82 STTHNVPQGDLVLR M 37 c
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211 Glutaminase 2 (P0A6W2) 1583.83 AVAMDNAILENILR M 40 -
212 Protein-export membrane protein secF (P0AG93) 1585.75 AQEYTVEQLNHGR M 40 -
213 SOS ribosomal protein L21 (P0AG49) 1591.76 MYAVFQSGGKQHR 71 C
214 Acidic protein msyB (P25738) 1595.75 TM YATLEE Al DAAR M 144 C
215 Glucokinase (P0A6V8) 1604.82 TKYALVGDVGGTNAR M 82 C
216 D-aianine-D-alanine ligase B (P07862) 1613.86 TDKIAVLLGGTSAER M 33 c
217 Periplasmic beta-glucosidase mature (P33363) 1622.77 DDLFGNHPLTPEAR SP 46 c
218 Hypothetical protein yieF (P0AGE6) 1625.94 SEKLQW TLLGSLR M 30 -
219 Tryptophanase (P0A853) 1627.78 MENFKHLPEPFR 42 c
220 Probable exodeoxyribonuclease VII large subunit (Q8FF64) 1632.82 MLPSQSPAIFTVSR 28 c
221 Ribonuclease Z (P0A8V0) 1632.85 MELIFLGTSAGVPTR 20 c
222 Multidrug resistance protein mdtG (P25744) 1642.74 SPCENDTPINWKR M 11 -
223 Regulatory protein rop (RNA one modulator) (P03051) 1646.81 MTKQEKTALNMAR 62 c
224 Regulator of nucleoside diphosphate kinase (P0AFW4) 1653.87 SRPTIIINDLDAER M 40 c
225 6-phosphogluconate dehydrogenase (P00350) 1659.84 SKQQIGWGMAVMGR M 85 c
226 Erythronate-4-phosphate dehydrogenase (P05459) 1662.81 MKILVDENMPYAR 47 -
227 1-(5-phosphoribosyl) imidazole-4-carboxamide i (Q9S5G4) 1666.93 MIIPALDLIDGTWR 91 c
228 Phosphoglycerate kinase (P0A799) 1671.89 SVIKMTDLDLAGKR M 97 c
229 3-oxoacyl-[acyl-carrier-protein] reductase (P0AEK2) 1676.86 MN FEGKIALVT GASR 71 -
230 Hypothetical protein ycdB mature (P31545) 1681.83 QKTQS-APGTLSPDAR SP 36 c
231 HTH-type transcriptional regulator chbR (P17410) 1682.84 MMQPVINAPEIATAR 30 c
232 HAM1 protein homolog (Q8XCU5) 1696.93 MQKWLAT GNAGKVR 47 c
233 50S ribosomal protein L13 (P0AA12) 1703.89 MKTFTAKPETVKR 56 -
234 Ornithine decarboxylase, constitutive (P21169) 1706.83 MKSMIMIAASSELVSR 21 -
235 Pyruvate dehydrogenase E1 component (P0AFG9) 1715.81 SERFPNDVDPIETR M 29 -
236 Phospholipase A1 mature (P0A921) 1732.87 QEATVKEVHDAPAVR SP 69 c
237 FolD bifunctional protein (P24186) 1736.98 AAKIIDGKTIAQQVR M 69 -
238 Serine transporter (P0AAD6) 1738.80 METTQTSTIASKDSR 94 -
239 Protein trbF (P15068) 1739.90 MRENKSNPEL KIR 16 c
240 Protein hfq (Hostfactor-I protein) (P0A6X3) 1740.92 AKGQSLQDPFLNALR M 71 c
241 Methionine aminopeptidase (P0AE18) 1755.91 AISIKTPEDIEKMR M 28 c
242 2,3,4,5-tetrahydropyridine N-succinyltransferase (P0A9D8) 1761.87 MQQLQNIIETAFER 109 c
243 Hypothetical protein yceD (G30K) (P0AB28) 1763.00 MQKVKLPLTLDPVR 31 -
244 Protein-export protein secB (P0AG86) 1766.79 SEQNNTEMTFQIQR M 69 c
245 Hypothetical protein yjgD (P0AF90) 1769.82 ANPEQLEEQREETR M 34 c
246 Acetylornithine deacetylase (P23908) 1773.95 MKNKLPPFIEIYR 48 -
247 Inner membrane protein ygaP (P55734) 1776.94 ALTTISPHDAQELIAR M 71 c
248 Homoserine O-succinyltransferase (P07623) 1776.99 PIRVPDELPAVNFLR M 59 c
249 Protein syd (P0A8U1) 1778.85 MDDLTAQALKDFTAR 25 c
250 30S ribosomal protein S 15  (Q8X9M2) 1778.90 SLSTEATAKIVSEFGR M 50 c
251 Acetyl-coenzyme A synthetase (P27550) 1783.92 SQIHKHTIPANIADR M 40 c
252 NifU-like protein (P0ACD4) 1803.84 AYSEKVIDHYENPR M 58 c
253 Chaperone protein hscA (P0A6Z1) 1828.98 ALLQISEPGLSAAPHQR M 39 c
254 Peptide chain release factor 1 (P0A7I2) 1847.00 MKPSIVAKLEALHER 111 -
255 Periplasmic oligopeptide-binding protein mature (P23843) 1851.01 ADVPAGVTLAEKQTLVR SP 92 c
256 ATP synthase alpha chain (P0ABB0) 1872.96 MQLNSTEISELIKQR 59 -
257 GTP cyclohydrolase I (P0A6T7) 1874.03 PSLSKEAALVHEALVAR M 92 c
258 Glutamyl-tRNA reductase 1887.09 TLLALGIN HKTAP VSLR M 36 c
259 Hypothetical protein yaiS (P71311) 1888.96 MDKVLDSALLSSANKR 17 c
260 Protein sirA (P0A890) 1898.94 TDLFSSPDHTLDALGLR M 75 c
261 Hypothetical protein ybcW (P64436) 1900.88 MNKEQSADDPSVDLIR 23 -
262 Transcriptional repressor mprA (Protein emrR) (P0ACR9) 1912.91 MDSSFTPIEQMLKFR 62 -
263 Protein yfiA (P0AD49) 1916.97 TMNITSKQMEITPAIR M 62 -
264 50S ribosomal protein L14 (P0ADY5) 1918.89 MIQEQTMLNVADNSGAR 120 -
265 Blue copper oxidase cueO mature (P36649) 1920.03 AERPTLPIPDLLTTDAR SP 39 c
266 Outer membrane protein assembly factor yaeT mature (P0A942) 1927.98 AEGFWKDIHFEGLQR M 110 c
267 FKBP-type peptidyl-prolyl cis-trans isomerase slyD (P0A9K9) 1945.07 MKVAKDLWSLAYQVR 199 c
268 Putative HTH-type transcriptional regulator yfgA (P27434) 2000.89 MNTEATHDQNEALTTGAR 118 c
269 Putative HTH-type transcriptional regulator yfgA (P27434) 2000.89 MNTEATHDQNEALTTGAR 140 c
270 MTA/SAH nucleosidase (P0AF12) 2018.04 MKIGIIGAMEEEVTLLR 20 -
271 Glycerol kinase (P0A6F4) 2022.01 TEKKYIVALDQGTTSSR M 83 c
272 Isoleucyl-tRNA synthetase (P00956) 2038.97 SDYKSTLNLPETGFPMR M 68 c
273 3-oxoacyl-[acyl-carrier-protein] synthase III (P0A6R0) 2039.04 MYTKIIGTGSYLPEQVR 59 .
274 Glucose-1-phosphatase mature 2049.00 QTVPEGYQLQQVLMMSR SP 60 c
275 Glucose-1-phosphate thymidylyltransferase 2 (P61887) 2061.15 MKGIILAGGSGTRLHPITR 25 -
276 Peroxiredoxin osmC (P0C0L2) 2071.06 TIHKKGQAHWEGDIKR M 39 c
277 Peptide methionine sulfoxide reductase msrA (P0A744) 2076.10 SLFDKKHLVSPADALPGR M 65 c
278 Hypothetical UPF0289 protein yacF (P36680) 2084.02 MQTQVLFEHPLNEKMR 91 -
279 Carbamoyl-phosphate synthase small chain (P0A6F1) 2098.09 MIKSALLVLEDGTQFHGR 136 -
280 Nitrate/nitrite response regulator protein narL (P0AF28) 2104.06 SNQEPATILLIDDHPMLR M 82 c
Supplementary data B: E. coli N-terminal identifications
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281 Hypoxanthine phosphoribosyltransferase (P0A9M2) 2107.08 MKHTVEVMIPEAEIKAR 27 -
282 Ferric uptake regulation protein (P0A9A9) 2107.16 TDNNTALKKAGLKVTLPR M 31 -
283 Cysteine synthase A (P0ABK5) 2110.11 SKIFEDNSLTIGHTPLVR M 64 C
284 Probable glucarate transporter (Q46916) 2132.02 MS-S-LSQAAS-SVEKRTNAR 10 -
285 Beta-lactamase (P62593) 2132.30 HPETLVKVKDAEDQLQR SP 313 c
286 Protein ycil (P0AB55) 2168.08 MLYVIYAQDKADSLEKR 85 -
287 UTP-glucose-1-phosphate uridylyltransferase (P0AEP3) 2174.28 AAI NTKVKKAVIPVAGLGTR M 35 -
288 Protein ygaD (P0A6G3) 2187.08 TDSELMQLSEQVGQALKAR M 62 -
289 Glycine cleavage system H protein (P0A6T9) 2211.10 SNVPAELKYSKEHEWLR M 78 c
290 30S ribosomal protein S5 (PÛA7W3) 2272.22 AHIEKQAGELQEKLIAVNR M 20 c
291 Lysine-sensitive aspartokinase III (P08660) 2313.09 SEIWSKFGGTSVADFDAMNR M 29 c
292 Aspartate aminotransferase (P00509) 2316.18 MFENITAAPADPILGLADLFR 215 c
293 6-phosphofructokinase isozyme 1 (P0A797) 2325.22 MIKKIGVLTSGGDAPGMNAAIR OX 40 -
294 6-phosphofructokinase (Q8FBD0) 2325.22 MIKKIGVLTSGGDAPGMNAAIR 59 -
295 Transcription elongation protein nusA (P0AFF6) 2336.24 MNKEILAWEAVSNEKALPR 132 c
296 tRNA (guanine-N(7)-)-methyltransferase (P0A8I5) 2356.16 MKNDVISPEFDENGRPLRR 27 c
297 Acetylglutamate kinase (P0A6C8) 2409.28 MNPLIIKLGGVLLDSEEALER 62 c
298 UPF0010 protein yeaD (P39173) 2423.39 MIKKIFALPVIEQISPVLSR 50 c
299 Uracil phosphoribosyltransferase (P0A8F0) 2481.40 MKIVEVKHPLVKHKLGLMR 43 c
300 Integration host factor alpha-subunit (P0A6X7) 2483.26 ALTKAEMSEYLFDKLGLSKR M 25 c
301 DNA-binding protein HU-beta (P0ACF4) 2496.30 MNKSQLIDKIAAGADISKAAAGR 58 c
302 Lysyl-tRNA synthetase (Q8XD57) 2534.25 SEQHAQGADAWDLNNELKTRR M 26 c
303 Riboflavin synthase alpha chain (P0AFU8) 2576.33 MFTGIVQGTAKLVSIDEKPNFR 42 -
304 Trimethylamine-N-oxide reductase 1 mature (P33225) 2577.32 AQAATDAVIS-KEGILTGSHWGAIR SP 63 c
305 Hypothetical protein ychN (P0AB52) 2577.33 MQKIVIVANGAPYGSESLFNSLR 72 c
306 Phosphoribosylformylglycinamidine cyclo-ligase (Q8XAC5) 2591.27 TDKTSLSYKDAGVDIDAGNALVGR M 75 c
307 ATP synthase beta chain (P0ABB4) 2591.40 ATGKIVQVIGAWDVEFPQDAVPR M 48 c
308 Mannose permease IID component (P69807) 2595.22 S-EMVDTTQTTTEKKLTQSDIR M 26 c
309 Glutamate/aspartate periplasmic-binding protein (P37902) 2600.36 DDAAPAAGSTLDKIAKNGVIWGHR SP 36 c
310 UPF0078 membrane protein ygiH (P60782) 2605.37 SAIAPGMIUAYLCGSISSAILVCR M 42 c
311 Guanosine-5'-triphosphate,3'-diphosphate pyrophosphatase (P25552) 2650.26 GSTSSLYAAIDLGSNSFHMLWR M 15 c
312 Tryptophanyl-tRNA synthetase (P00954) 2690.37 TKPIVFSGAQPSGELTIGNYMGALR M 62 c
313 Hypothetical protein yrfD (P45753) 2701.51 AFKIWQIGLHLQQQEAVAVAIVR M 18 c
314 Thymidylate synthase (P0A884) 2734.33 MKQYLELMQKVLDEGTQKNDR 31 -
315 Universal stress protein G (P39177) 2740.35 MYKTIIMPVDVFEMELSDKAVR 21 -
316 Oligopeptide transport ATP-binding protein oppD (P76027) 2776.50 SVIETATVPLAQQQADALLNVKDLR M 39 c
317 30S ribosomal protein S1 (P0AG69) 2849.44 TESFAQLFEESLKEIETRPGSIVR M 154 c
318 NH(3)-dependent NAD(+) synthetase (P18843) 2872.58 TLQQQIIKALGAKPQINAEEEIRR M 120 c
319 Adenylosuccinate synthetase (P0A7D4) 2922.51 GNNVWLGTQWGDEGKGKIVDLLTER M 67 c
320 Phosphoserine aminotransferase (P23721) 2956.51 AQIFNFSSGPAMLPAEVLKQAQQELR M 46 c
321 Leucyl-tRNA synthetase (P07813) 2983.41 MQEQYRPEEIESKVQLHWDEKR 64 -
322 Protein yhbO (P45470) 2999.40 SKKIAVLITDEFEDSEFTSPADEFR M 75 c
323 Phosphoserine aminotransferase (Q8XEA7) 3000.54 AQIFNFSSGPAMLPVEVLKQAQQELR 45 c
324 3-mercaptopyruvate sulfurtransferase (P31142) 3039.46 STTWFVGADWLAEHIDDPEIQIIDAR M 24 c
325 Phosphoenolpyruvate-protein phosphotransferase (P08839) 3110.69 MISGILASPGIAFGKALLLKEDEIVIDR 56 c
326 Protein sseB (P0AF21) 3124.55 SETKNELEDLLEKAATEPAHRPAFFR M 60 c
327 50S ribosomal protein L10 (P0A7J5) 3177.69 ALNLQDKQAIVAEVSEVAKGALSAWADSR M 49 c
328 Glycine betaine-binding periplasmic protein mature (P0AFM2) 3197.67 ADLPGKGITVNPVQSTITEETFQTLLVSR SP 20 c
329 Transcription termination factor rho (P0AG30) 3199.61 MNLTELKNTPVSELITLGENMGLENLAR ■ 33 c
330 Ferrichrome-iron receptor mature 3202.61 AVEPKEDTITVTAAPAPQESAWGPAATIAAR SP 41 c
331 Protein recA (Recombinase A) (P0A7G6) 3240.68 AIDENKQKALAAALGQIEKQFGKGSIMR M 62 c
332 D-3-phosphoglycerate dehydrogenase (P0A9T0) 3329.86 AKVSLEKDKIKFLLVEGVHQKALESLR M 72 c
333 Adenine phosphoribosyltransferase (P695Û3) 3389.79 TATAQQLEYLKNSIKSIQDYPKPGILFR M 39 c
Supplementary Data C: non N-terminal identifications
•  Mouse liver
•  S. cerevisiae
•  E. co li
To screen for internal peptides, M S/M S data from the N-terminal preparations of mouse liver, S. 
cerevisiae and E. coli were used to search the entire SwissProt database through M ASCO T. Fixed 
modification: lysine acetylation; variable modifications: N-terminal acetylation, oxidation of methionine; 
protease: Arg-C; missed cleavages: 1; peptide tolerance: 1.5Da, M S/M S tolerance: 0.6Da, instrument: 
ESI-TRAP, peptide charge: 1 +, 2+ and 3+.
Supplementary data C: mouse liver non N-terminal identifications
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1 Glutathione S-transferase P 1 1791.78 EAAQMDMVNDGVEDLR 77
2 Glutathione S-transferase Mu 1 1562.70 KHHLDGETEEER 64
3 1389.66 ADIVENQVMDTR 70
4 Argininosuccinate lyase 1932.08 INVLPLGSGAIAGNPLGVDR 39
5 1058.54 N D Q W TD LR 62
6 Aspartate aminotransferase 1713.93 VGNLTW GKESDSVLR 45
7 1153.65 LVLGDNSPAIR 18
8 Carbamoyl-phosphate synthase 798.42 DADPILR 33
9 Argininosuccinate synthase 2099.00 EGAKYVSHGATGKGNDQVR 45
10 928.48 LKEYHR 29
11 Estradiol 17 beta-dehydrogenase 5 1199.65 SKIADGTVKR 49
12 Catalase 2230.07 GPLLVQDW FTDEMAHFDR 47
13 Betaine-homocysteine S-methyltransferase 1 1097.57 AIAEELAPER 42
14 Adenosylhomocysteinase 1113.60 ESLIDGIKR 33
15 Fructose-bisphosphate aldolase B 1428.73 IKVENTEENRR 32
16 1,4-alpha-glucan branching enzyme 1504.76 RQFNLTDDDLLR 25
Supplementary data C: S. cerevisiae non N-terminal identifications
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1 Enolase 1 1140.6 TGQIKTGAPAR 63
2 1862.9 SGETEDTFIADLW GLR 28
3 60S ribosomal protein L2 1179.7 VDKPLLKAGR 56
4 1391.7 GIVKQIVHDSGR 62
5 60S ribosomal protein L26-A 943.50 D D E VLW R 51
6 Elongation factor 2 1255.6 AGIISAAKAGEAR 67
7 Pyruvate decarboxylase isozyme 1 2038.9 WAGNANELNAAYAADGYAR 56
8 60S ribosomal protein L13-B 2994.4 DGKAPEAEQVLSAAATFPIAQPATDVEA 52
9 60S ribosomal protein L33-A 1415.7 NNLPAKTFGASVR 48
10 40S ribosomal protein S25-A 1768.8 AQHAVILDQEKYDR 48
11 Glutamine synthetase 1603.7 SVAKEGYGYFEDR 45
12 40S ribosomal protein S18 1273.6 AGELTQEELER 45
13 Suppressor protein STM1 2086.0 KGNNTANATNSANTVQKNR 42
14 40S ribosomal protein S3 1297.7 VTPTKTEVIIR 39
15 60S ribosomal protein L31 990.51 GVKGVEYR 36
16 40S ribosomal protein S30 2884.6 AGKVKSQTPKVEKTEKPKKPKGR 35
17 Histone H2A.1 1244.6 SAKAGLTFPVGR 33
18 60S ribosomal protein L5 1242.5 EGKTDYYQR 32
19 40S ribosomal protein S14-A 1414.6 IEDVTPVPSDSTR 25
20 Phosphoglycerate kinase 2014.0 VDFNVPLDGKKITSNQR 24
21 60S ribosomal protein L7-A 1172.6 GFGKINKQR 20
Supplementary data C: E. coli non N-terminal identifications
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1 Chaperone cIpB 1569.8 NKVTDAEIAEVLAR 90
2 Elongation factor Tu (EF-Tu) 1026.5 AGENVGVLLR 75
3 Beta-lactamase 1378.6 DTTMPAAMATTLR 56
4 1734.9 IW IYTTG SQ ATM DER 46
5 1455.8 KLLTGELLTLASR 32
6 Chaperone protein dnaK 926.55 IAGLEVKR 52
7 2233.0 DAEANAEADRKFEELVQTR 50
8 Elongation factor G (EF-G) 2077.0 VYSGW NSGDTVLNSVKAAR 75
9 “ 1103.5 LAKEDPSFR 50
10 Phosphoglycerate kinase 2585.3 VKDYLDGVDVAEGELW LENVR 27
11 1867.9 ADLNVPVKDGKVTSDAR 70
12 Transcription elongation protein nusA 1244.6 VQAVSTELGGER 60
13 Protein grpE 1286.6 VKAEMENLR 40
14 Phosphoribosylamine-glycine ligase 1226.6 FGDPETQPIMLR 82
15 Glyceraldehyde-3-phosphate dehydrogenase A 1494.8 VPTPNVSW DLTVR 82
16 Hypothetical protein yqjD 1400.7 LG ETGDAIAKQTR 74
17 Cysteinyl-tRNA synthetase 1319.7 ANENGESFVALVDR 62
18 Murein-lipoprotein 1152.5 LDNMATKYR 58
19 2,3-bisphosphoglyce rate-dependent 1191.6 VIIAAHGNSLR 57
20 3-oxoacyl-[acyl-carrier-protein] 1126.6 VGLIAGSGGGSPR 50
21 Phosphoribosylformylglycinamidine synthase 1568.8 DVQTLKAKGDALAR 48
22 Peptide chain release factor 1 1666.8 AGTGGDEAALFAGDLFR 46
23 Phosphoribosylformylglycinamidine cyclo-ligase 1153.7 IKGW KKTR 43
24 Pantoate--beta-alanine ligase 1058.5 AKDGLALSSR 30
Supplementary Data D: Identification of human plasma proteins by PMF
•  a-2-macroglobulin
•  Ceruplasmin
•  Complement factor b
•  Serotransferin
•  Serum albumin
•  a -1 -antitrypsin (P01009)
•  Ig gamma-1 chain C region
•  Apolipoprotein A-IV
•  Ig kappa chain V-lli region SIE
•  Apolipoprotein A-l
•  Transthyretin
Proteins from human plasma (15pg) were separated by 1-D SDS-PAGE and visualised with Coomassie. 
Gel plugs were excised from the dominant bands and subjected to in-gel proteolysis with trypsin (1:50 
enzyme to substrate ratio). Peptide mixtures 1pl were spotted onto a MALDI target and allowed to air dry 
with 1pl of matrix solution. Samples were analysed by MALDI-ToF MS using a laser energy of 30%. The 
resulting peptide masses were imported into the MASCOT search engine. The taxonomy was restricted 
to H o m o  s a p ie n s ; fixed modification: carbamidomethylation of cysteine; variable modification: oxidation 
of methionine; protease: trypsin; missed cleavages: 1; peptide tolerance: 150ppm. Matched peptides are 
represented on the peptide coverage maps. Limit tryptic peptides are represented in purple and missed 
cleavages in green.
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•  McDonald, L., Robertson, D.H., Hurst, J.L. and Beynon, R.J. (2005) Positional proteomics: 
selective recovery and analysis of N-terminal proteolytic peptides. Nat Methods 2, 955- 
957.
I was responsible for all experimental work, including method development, and preparation of 
the draft manuscript.
•  McDonald, L. and Beynon, R.J. (2006) Positional proteomics: preparation of amino- 
terminal peptides as a strategy for proteome simplification and characterization. Nat Protoc 
1,1790-1798.
I designed enhanced methodologies for N-terminal purification (NHS-Sepharose method) and 
demonstrated the use of the method in simplification of a complex proteome (£. coli cell 
lysate). I was responsible for preparation of the draft manuscript.
•  Rivers, J., McDonald, L., Edwards, I.J. and Beynon, R.J. (2008) Asparagine deamidation 
and the role of higher order protein structure. J Proteome Res 7,921-927.
Along with Ian Edwards, I made the initial observation of the atypical isotope distribution. I then 
went on to demonstrate the presence of the deamidated asparagine residue using methyl 
esterification.
•  McDonald, L. and Beynon, R.J. et at. (2008) Mass isotope distribution analysis of amino 
acid residues (MIDAR): a novel acetylation reagent for proteomics. (In preparation for 
molecular and cellular proteomics).
I was responsible for all experimental work, including proof of principle data and the global N- 
terminal analysis, and preparation of the draft manuscript
•  McDonald, L. and Beynon, R.J. et at. (2008) Utilisation of a positional proteomics strategy 
for biomarker identification in human plasma. (In preparation for molecular and cellular 
proteomics).
I was responsible for the initial N-terminal preparations of human plasma and data analysis, 
and for preparation of the draft manuscript
•  McDonald, L. and Beynon, R.J. et at. (2008) Analysis of N-terminal acetylation status 
using positional proteomics. (In preparation for Journal of Biological Chemistry).
I conducted all of the experimental work and prepared the draft manuscript (work in progress).
•  Siepen, J., McDonald, L., Hubbard, S.J. and Beynon, R.J. (2008) Positional proteomics 
enhances proteome coverage: a benchmarking study. (In preparation for bioinformatics). I
I conducted all of the experimental work and, along with Jennifer Siepen, I am presently 
involved in the preparation of the draft manuscript.
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Positional proteomics: 
selective recovery and 
analysis of N-terminal 
proteolytic peptides
Lucy McDonald1, Duncan H L Robertson1,
Jane L Hurst2 & Robert J Beynon1
Bottom-up proteomics is the analysis of peptides derived from  
single proteins or protein mixtures, and because each protein  
generates tens o f peptides, there is scope for controlled 
reduction in complexity. We report here a new strategy for 
selective isolation of the  N-term inal peptides of a protein 
mixture, yielding positionally defined peptides. The method is 
tolerant of several fragm entation methods, and the databases 
th a t must be searched are substantially less complex.
Positionally defined peptides would yield a substantial informa­
tion gain in protein identification strategies. Most obviously, the 
two positional locations within every protein are the extreme 
ends— the N-terminal and the C-terminal peptides. Methods for 
recovery o f C-terminal peptides have been reported, predominantly 
based on the ability o f a catalytically disabled trypsin, anhydro- 
trypsin, to selectively bind peptides that terminate in a lysine or 
arginine residue5'6. There are several reports that indicate routes to 
selective recovery o f N-terminal peptides, including specific N- 
terminal sequencing by mass spectrometry o f gel-separated and 
blotted proteins7, selective modification o f N-terminal serine or 
threonine residues8, modification o f the hydrophobicity o f a 
peptide mixture to preferentially expose N-terminal peptides by
R,N----------K ---------------------K ----------- -  ------------- COOH
I I
NHg NH2
Bottom-up proteomics operates at the level proteolytic peptides, 
generated from single proteins or from complex mixtures of 
proteins1. These peptides, generated by exhaustive proteolysis to 
limit peptides in vitro, are then analyzed by various mass spectro­
métrie methods. Mass spectrometric analysis yields either the 
masses o f a formally connected set o f peptides that were all derived 
from a single protein (peptide mass fingerprinting) or, by tandem 
mass spectrometry, sequence-derived information that can identify 
the parent protein o f a single peptide2,3. It can be argued that more 
peptides are analyzed than strictly necessary, and comprehensive 
proteomic analysis should focus on the minimal number of 
peptides that are required for protein identification. Methods 
such as ICAT4 implicitly adopt this principle, in as much as the 
selective chemistry recovers only those peptides that contain at least 
one cysteine residue. Cysteine-mediated peptide recovery, however, 
is likely to abstract more than one peptide for each protein, and it is 
not possible to target the recovered peptide(s) positionally, as 
cysteine residues can occur anywhere in the protein sequence.
Figure 1 | Protocol fo r  recovery o f N-terminal peptides in a proteome.
Free a- and E-amino groups are acetylated before proteolysis (trypsin in  the 
figures, but potentia lly any other fragmentation method), which is followed 
by biotinylation of proteolytica lly exposed a-amino groups. Subsequent 
subtractive binding to  immobilized streptavidin creates a preparation enriched 
in  those peptides th a t were orig inally derived from the N terminus, blocked by 
acetylation and therefore refractory to  b io tinylation .
+  HN----------  K --------------------K -----------  -  ------------- COOH
I I
NH NH♦ ♦
Tryptic proteolysis
( b ) H N -----
♦ h n ----------K -----------R w
—  K -  
I
-------R
1
NH
♦
NH
♦ ( b ) H N ----------COOH
( J ) H N ----------R
Passage over M
immobilized streptavidin ^  '— — . 
♦  h n ----------K ---------- R
Biotinylated peptides
retained
and discarded
♦  Acetyl n h
(b )  Biotin ^
N-terminal peptides 
analyzed by MS or MS/MS
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Figure 2 \ Isolation o f N-terminal peptides 
from soluble proteins o f mouse skeletal muscle. 
(a,b) Skeletal muscle was homogenized in  10 ml 
o f 20 mM sodium phosphate buffer (pH 8.0) and 
centrifuged for 45 min at 13,000g. The resultant 
supernatant fraction was used w ithou t further 
purification for preparation o f N-terminal peptides 
(acetylation, tryptic proteolysis, N -biotinylation 
and subtractive purifica tion). Detailed protocols 
are available in  Supplementary Methods online. 
The entire tryptic digest o f the mixture was 
analyzed by MALDI-ToF mass spectrometry 
(a). After application o f the  positional 
simplification protocol, the  MALDI-ToF mass 
spectrum (b) contained major ions labeled in the 
figure, mass shifted by 42 Da through the  addition 
o f acetyl groups._______________________________
diagonal chromatography9,10 and selective 
capture o f all non-N-terminal peptides by 
amine scavenging beads11,12 We report here 
a new approach to selective recovery o f the 
N-terminal-most peptides o f a complex 
protein mixture. The method, based on 
subtractive removal o f internal peptides, is 
not reliant on any particular endopeptidase 
cleavage—a flexibility that can compensate 
for the limitations in N-terminal peptide
m/z
b roc-, ’ 048ss
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♦ -AMQKIFAR ßenolase
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1.118.67 
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m/z
size distributions. Moreover, in contrast to 
other approaches7,11,12, protein N termini 
that are naturally acetylated are automati­
cally included in the analyte set. Indeed, if 
stable isotope-labeled acetic anhydride was 
used, it would be possible to identify and 
discriminate between naturally and chemi­
cally acetylated peptides. In brief, all 
available amino groups are blocked by 
acetylation. Subsequently, proteolysis 
generates new peptides, and all but the 
N-terminal peptide (whether naturally or 
artificially acetylated) expose a new amino 
group that is subsequently biotinylated.
These biotinylated internal peptides are 
removed by recovery onto immobilized 
avidin or strepatividin, leaving behind the 
set of N-terminal peptides (Fig. 1 and 
Supplementary Methods online, which 
contains a protocol for N-terminal peptide recovery and a descrip­
tion of the analysis o f protein databases).
One of our major interests is in proteome dynamics in skeletal 
muscle13-15. The tryptic digest o f the soluble protein fraction of 
mouse skeletal muscle contains peptides derived from a large 
number of proteins, and a matrix-assisted laser desorption/ 
ionization-time-of-flight (MALDI-ToF) spectrum on an instru­
ment of medium-level performance (resolution 12,000 FHWM 
(full width at half maximum)) yielded a detailed but complex mass 
spectrum (Fig. 2a). Owing to the complexity o f the peptide 
mixture, we were unable to identify any N-terminal peptides in 
the spectrum. We passed the N-acetylated, trypsin-digested, bioti­
nylated mixture over immobilized streptavidin. The unbound
eluate gave a much simpler mass spectrum (Fig. 2b), and we 
were able to assign the highest intensity signals to true N-terminal 
peptides, confirmed by tandem mass spectrometry (Supplemen­
tary Fig. 1 online). To test the method with a more complex 
mixture, we applied the same protocol to the soluble proteins 
o f mouse liver. After purification o f N-terminal peptides, the 
MALDI-ToF spectrum remained complex. By liquid chromatogra­
phy-tandem mass spectrometry, and even without optimized 
separation or mass spectrometric analysis, many peptides (over 
90) could immediately be assigned as N  termini o f mouse proteins 
(Supplementary Fig. 2 and Supplementary Table 1 online). As 
predicted, all terminated at C-terminal arginine residues. Moreover, 
the data were consistent with known or inferred N-terminal
956 | VOL2 N0.12 I DECEMBER 2005 I NATURE METHODS
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processing (removal o f initiator methionine, loss of signal peptide 
or propeptide) but in other cases have provided new information 
on N-terminal processing of liver proteins. All identifications were 
from a search of the entire database of mouse proteins rather than a 
restricted N-terminal database— there were virtually no peptides 
identified as internal sequences.
An analysis of extracted N-terminal peptides from mouse entries 
in Swissprot (Supplementary Fig. 3 online) confirmed that over 
85% of all proteins yielded an informative N-terminal peptide with 
trypsin digest, and that this value rose to almost 90% if we used two 
endopeptidases (trypsin and endopeptidase Glu-C). Thus, a sub­
stantial fraction o f proteins in a proteome can be uniquely 
-§ identified simply by the mass o f the N-terminal peptide, using
£  one or multiple endopeptidase digests. But the complexity o f
E most N-terminal peptide preparations would require liquid
2 chromatography-electrospray tandem mass spectrometry or liquid
<2 chromatography-MALDI tandem mass spectrometry. Even partial 
1  sequence data considerably enhance identification, and remove the 
q need for multiple proteolytic digests—the residual 4% unidentifi- 
^ able proteins represent sequences in the database that are either 
g  replicated entries or which represent paralogous proteins. There has
3 recently been discussion about the uncertainty o f ‘one hit wonders’
3  in proteomics, and we conjecture that part of the uncertainty relates
o. to the lack of information about the location o f the peptide in the
£  parent proteins. A positional proteomics strategy anchors the 
Q. peptides at a precise location within the parent protein, greatly
o  reducing the search space for identification algorithms. As an
® average protein might be predicted to yield 50 tryptic peptides,
c  the approximate reduction in search space is also 50-fold. Further,!£
eo
5
3
C La)1—3+-»
CO
©
selective isolation and partial sequencing o f N- and C-terminal 
peptides would allow virtually full length PCR-amplification o f the 
cDNA corresponding to an expressed protein sequence.
Note: Supplementary information is available on the Nature Methods website.
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We describe a protocol fo r selective extraction of the  amino (N )-term inal-m ost peptide of a protein or a m ixture of proteins a fter  
proteolysis. The firs t stage of the protocol blocks the free amino groups a and £ (th e  la tte r being lysyl residues) on the in tact 
proteins by acetylation. In  the  second stage, proteolysis o f the  acetylated proteins yields a m ixture of N -term inally acetylated 
(true N-term inal) and non-acetylated (in ternal and carboxy-terminal) peptides. A ffin ity  capture of peptides bearing free amino 
groups using an im m obilized am ine-reactive reagent removes in ternal peptides from  the  mixture. The unbound fraction is highly 
enriched in  N -term inal peptides, which can be analyzed w ithout fu rther treatm ent. This method is com patible w ith a range of 
proteolytic enzymes and fragm entation methods, and should take 2 d to  complete. The N-term inal peptides can then be analyzed 
by mass spectrometry. This low cost, rapid method is readily adopted using o ff the shelf reagents.
INTRODUCTION
Although other strategies have been proposed, most proteomics in which a mixture o f proteins (sometimes an entire proteome) is 
studies are based on ‘bottom-up’ approaches and employ mass initially proteolyzed after which the complex mixture o f peptides is 
spectrometry (MS) for the analysis o f limit proteolytic peptides separated before mass-spectrometric analysis, often with direct 
(i.e., the products o f proteolytic digestion o f proteins in which 
all cleavable bonds have been hydrolyzed) that are derived, usually 
by tryptic hydrolysis, from single proteins or protein mixtures1.
In all proteomics studies, there is a decision to be made about 
when to leave ‘protein space’ and to move into ‘peptide space’, 
with the transfer usually being a tryptic digestion (Fig. la ) . Most 
proteomics studies aim to simplify a complex proteome, to the 
level of subproteomes (e.g., a subcellular fraction) or individual 
proteins (e.g., proteins separated by 2D gel electrophoresis) 
before proteolysis. After separation o f the proteins by, for example,
2D gel electrophoresis, it is reasonably inferred that the connectivity 
o f the entire set o f peptides is such that they are all derived from 
the same parent protein. However, any mixture o f proteins 
generates a correspondingly mixed set of limit peptides, and 
the connectivity between different peptides therefore cannot be 
assumed. This would usually mean that tandem MS (MS/MS) 
is required, as further information must be extracted from a 
single peptide. The extreme resolution of MS and o f the informa­
tion obtained by MS/MS can be used to obviate exhaustive 
protein separation in favor o f more global ‘shotgun’ approaches2,
Figure 1 | Outline o f a standard approach to  protein identifica tion . A complex 
proteome is simplified using a variety o f separation techniques, e ither in 
protein space or, a fte r proteolysis, in  peptide space. The resulting 
subproteomes can be e ither proteolyzed directly or further subjected to  
separation in to  ind iv idua l proteins before proteolysis. The resulting peptides 
are analyzed by mass spectrometry, w ith  or w ithout chromatographic sepa­
ration, depending on the  complexity o f the final peptide mixture, (a) Strategy 
for selective/targeted peptide simplification. Proteolysis o f a complete 
proteome creates a peptide mixture th a t is so complex th a t mass-spectrometric 
analysis is highly challenging, (b) By targeting specific structural regions 
on peptides, the mixture can be selectively purified in such a way th a t the 
majority o f the proteome is discarded. LC, liquid chromatography.
Protein space Peptide space
Complex 
proteome
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coupling between the separation fluidics and the mass spectro­
meter. However, the complete repertoire o f limit peptides generated 
from an entire proteome might contain many hundreds o f 
thousands o f peptides, which imposes a formidable analytical 
challenge. Even with the benefit o f 2D chromatography (multi­
dimensional protein identification technology or MUDPIT3), 
the mixture might deliver more peptides to the mass spectrometer 
than can feasibly be analyzed as the liquid stream flows through 
the electrospray source. Moreover, the data system is likely to 
direct MS analysis to more abundant proteins, therefore limiting 
dynamic range.
As a consequence o f  this complexity, there have been a number o f 
attempts to simplify peptide mixtures. These approaches target 
specific chemical reactivities o f the proteins or peptides within 
complex mixtures (Fig. lb). The purpose o f such methods is to 
eliminate the majority o f the proteome-derived peptides but retain 
sufficient information necessary for analysis4. Lower abundance 
amino acids can be targeted as a means o f extracting informative 
peptides. Methods such as isotope-coded affinity tagging (ICAT)5 
implicitly adopt this principle, using selective chemistry that 
recovers only those peptides that contain at least one cysteinyl 
residue and at the same time introducing tags for relative quanti­
fication. Immobilized metal-affinity chromatography (IMAC)6, 
titanium dioxide-affinity chromatography7, is used for the enrich­
ment of phosphopeptides and lectin-affinity chromatography is 
used to target glycopeptides8. All o f these simplification techniques 
have the potential to abstract more than one peptide for each 
protein and, in some instances, no peptides will be recovered. 
Furthermore, because the peptide could have been derived from 
any part o f the parent protein sequence, no information on its 
location is obtained, which complicates the search strategy for 
identification proteomics. Finally, combined diagonal chromato­
graphy (COFRADIC) methods are able to enrich a subset of 
peptides according to their chemical composition (e.g., by the 
presence o f methionyl residues) or enrich for amino (N)-terminal 
peptides9-11.
An efficient strategy for proteome simplification would be the 
isolation o f a single signature peptide from each protein in the
proteome, optimizing the balance between analyte complexity and 
completeness o f representation. As the disposition o f protease 
cleavage sites within a protein is effectively random, the most 
obvious choice for a signature or proteotypic peptide would be the 
(amino N) or carboxy (C) terminus. Methods for recovery of 
C-terminal peptides have been reported, which are predominantly 
based on the capture o f internal tryptic peptides using an anhydro- 
trypsin column12,13. Several strategies have been developed in 
order to selectively purify N-terminal peptides, including specific 
N-terminal sequencing by MS o f gel-separated and blotted 
proteins14, selective modification o f N-terminal serine or threonine 
residues15, and modification o f the hydrophobicity o f a peptide 
mixture to preferentially expose N-terminal peptides by diagonal 
chromatography9.
We have previously described a strategy to selectively purify 
N-terminal peptides16. This approach required blocking o f avail­
able amino groups on the intact proteins by acetylation, followed by 
proteolysis o f the acetylated proteins. The resulting peptide mixture 
consisted o f blocked N-terminal peptides mixed with internal 
peptides containing free amino groups on the proteolytically 
formed N-termini. Biotinylation o f the peptide mixture using an 
N-hydroxysuccinimide (NHS) ester-derivative o f biotin added a 
biotin moiety to the N-termini o f the internal peptides, whereas 
true N-terminal peptides that had been previously blocked by 
acetylation would not be able to be biotinylated. The biotinylated 
peptides were removed by passing the mixture over streptavidin, 
and the unbound material containing the N-terminal peptides was 
analyzed without further treatment. As each protein yielded a single 
peptide, the resultant mixture had the same level o f complexity as 
the initial proteome sample (Box I).
The previously published protocol, although effective, required 
multiple peptide-purification steps to separate the peptides from 
the excess reagents that were used, which had the consequence of 
reducing the yield o f material. Hence there was a need for an 
enhanced methodology that minimized the processing steps in 
order to maximize the yield. We have therefore developed an 
improved strategy, which is described here. The most significant 
enhancement to the method was the elimination o f the
BOX 1 | REMOVAL OF INTERNAL PEPTIDES BY BIOTINYLATION AND STREPTAVIDIN  
PURIFICATION
1. Using a C18 ZipTip (following the manufacturer's instructions), desalt a small portion (10  p i) o f the digested peptide mixture and elute into  
10 pi elution solution.
2. Add 40  p i o f 20  mM phosphate buffer (20  mM NajHPO,; (pH 7 .5 ))  to  give a to ta l volume o f 50 pi.
A CRITICAL STEP Do not use an amine-containing buffer (e .g ., Tris or ammonium bicarbonate). The free amines w ill quench the NHS-biotin 
reagent and prevent biotinylation o f peptides.
3. Reconstitute 1 mg EZ-Link NHS biotin in 50 p i DMF.
A CRITICAL STEP EZ-Link NHS biotin should be prepared im mediately before use, and the solution should not be stored and reused.
4 . Add 1 p i biotin solution to  the desalted peptide mixture and incubate overnight a t 4  °C.
5. Using a C18 ZipTip, desalt the entire biotinylated peptide mixture and elute in to  10 p i elution solution.
6. Dilute the b iotinylated peptides in 10 p i binding buffer (20  mM Na2HP04 and 0.15 M NaCl (pH 7 .5 )) to  give a to ta l volume of 20 pi.
7. Remove 20 p i streptavidin Sepharose from the  stock preparation in ethanol and pipette in to  a 0 .5  ml microcentrifuge tube.
8. Remove excess ethanol and wash the streptavidin Sepharose in 100 p i (five volumes) of binding buffer.
9. Centrifuge the Sepharose a t 2,000g a t room temperature for 20 s, remove the binding buffer and discard.
10. Add the  desalted biotinylated peptide mixture, vortex and incubate w ith turning for 4 h a t room temperature.
11. Centrifuge the  Sepharose/peptide mixture a t  2 ,000g a t room temperature for 20 s, remove and retain supernatant (peptide m ixture).
12. Proceed to  mass-spectrometric analysis.
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biotinylation step. An initial acetylation step is still required to 
block N-terminal peptides, but instead o f targeting internal pep­
tides by biotinylation and removing them with streptavidin we use 
a commercially available amine reactive immobilized reagent 
(NHS-activated Sepharose) to react and retain internal peptides 
in one step. NHS-Sepharose is efficient both in respect o f amine 
binding and subsequent leakage o f bound amines17. The peptide 
mixture is incubated with the NHS-activated Sepharose until 
coupling is complete, the Sepharose beads are then removed by 
brief centrifugation, and the unbound fraction is removed and 
analyzed without further treatment (Fig. 2).
In brief, samples are exchanged into a compatible (non-amine 
containing) buffer prior to acetylation —  if the protein mixture can 
be generated directly in such a buffer this step is not required. After 
excess acetylation reagent is removed, the proteins are concentrated 
by acid precipitation prior to digestion with trypsin or another 
protease. The proteolyzed mixture is then exposed to activated 
NHS Sepharose, which removes all peptides with proteolytically 
exposed amino groups —  in other words, all internal peptides 
(Fig. 3). To illustrate the method, we use soluble proteins from 
Escherichia coli, but this approach is amenable to any protein or 
protein mixture. Indeed, the soluble protein preparation from 
chicken skeletal muscle (obtained frozen from a local supermarket) 
has the advantage o f a considerable bias in protein expression18,19, 
and should generate an N-terminal preparation dominated by a 
few peptides from abundant proteins, which is readily assessed 
by matrix-assisted laser desorption ionization-time o f flight 
(MALDI-ToF) MS.
We prefer to use acetylation as the amino-blocking reagent, 
although there are many other reagents that could be used. Many 
proteins are naturally acetylated at their N terminus, and by using 
the same chemical modification, we are effectively coalescing the 
N-terminal preparation into the same analytical space. It is 
straightforward to discriminate between naturally and chemically 
acetylated N-termini by the use o f [3H6] acetic anhydride, which 
reacts with primary amines and introduces a mass shift o f +45 Da 
instead o f+42 Da. If modifications other than acetylation are used, 
it introduces the possibility o f further resolving the N-terminal 
peptide mixture by, for example, affinity capture or a shift in 
hydrophobicity11.
There is concern within the field o f proteomics over the value of 
‘one hit wonders’20, whereby a protein is identified using data 
derived from a single peptide. Part o f this concern relates to the lack 
of information regarding the location o f the peptide within the 
parent protein, and also to the search space required for identifica­
tion (the entire database of candidate peptides must be given equal 
validity in the analysis). The strategy we have developed overcomes 
the stigma associated with ‘one hit wonders’, by anchoring the 
peptides at a precise location within the parent protein; it is 
therefore possible to limit the database search to a small subset 
of peptides.
The bias in the preparation o f N-terminal peptides has conse­
quences for the subsequent database search. Two strategies are used. * •
Block primary amines (amino 
terminus and lysyl residues)
Proteolyze, exposing new amino 
groups at internal peptides
HoN
Remove internal peptides by reaction with 
an immobilized amine-reactive reagent
# H N .
# H N
Preparation highly enriched in 
true N-terminal peptides
Figure 2 | Scheme showing the  chemistiy involved in  N-terminal purification. 
Free amino groups (a  and e) are acetylated prior to  proteolysis, which results 
in  a mixture o f N-terminally acetylated (true N-terminal) and non-acetylated 
(internal) peptides. Subsequent incubation of the peptide mixture w ith 
an immobilized amine-reactive reagent creates a preparation enriched in 
N-terminal peptides._____________________________________________________
First, an entire database is searched, in which case the analyte 
peptides will be identified as high quality ‘hits’ that are also true N 
termini. However, this is predicated on the availability o f know­
ledge o f the true N terminus o f each database entry. The complexity 
of post-translational processing and the fact that most proteomics 
databases are derived from cDNA or genomic data, creates a need 
for new search algorithms, yet to be developed, which capitalize on 
the drastically reduced search space and the positional bias. It is 
relevant to note that the preparation o f N-terminal peptides can be 
employed to define the true N-termini o f many proteins, and is 
therefore a useful tool in defining the true proteome.
MATERIALS
REAGENTS • Luria broth (LB; Merck)
• HPLC grade water • Bugbuster protein extraction reagent (BB; Novagen-EMD Biosciences,
• HPLC grade acetonitrile (ACN) ! CAUTION Flammable cat. no. 70584) or any equivalent bacterial protein extraction reagent
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• Coomassie Plus® protein assay (Perbio Science)
•Acetylation reagent: sulfo-NHS acetate (Pierce, cat. no. 26777)
•Acetylation buffer: 20 m M  sodium carbonate (Na2C03), pH 8.5, or other
non-amine-containing buffers, such as phosphate or HEPES (pH 7-9)
A CRITICAL Do not use an amine-containing buffer (e.g., Tris or 
ammonium bicarbonate) as the free amines will quench the reagent 
and prevent protein acetylation
• Quenching reagent: Tris(2-aminoethyl)amine, polymer bound (Sigma, 
cat. no. 472107)
• 1 m M  HC1
•Trichloroacetic add (TCA) ! CAUTION Causes severe bums 
•Trifluoroacetic add (TEA) ! CAUTION Causes severe bums
• Diethyl ether ! CAUTION Highly flammable 
•Digestion buffer: 20 m M  Na2HP04, pH 7.5
•Trypsin, sequencing grade (Roche, cat. no. 11 478 475 001) or any other 
proteolytic enzyme
•EZ-Link NHS-biotin (Pierce, cat. no. 20217)
• Dimethylformamide (DMF) ! CAUTION Harmful by inhalation, ingestion or 
skin contact
•Streptavidin Sepharose™, High Performance (GE Healthcare, 
cat. no. 17-5113-01)
• NHS-activated Sepharose™ 4 Fast Flow, stored in propanol (GE Healthcare, 
cat. no. 17-0906-01)
•Binding buffer: 20 m M  Na2HP04 and 0.15 M  NaCl (pH 7.5)
• MALDI matrix: ot-cyano-4-hydroxydnnamic acid (CHCA; Sigma, 
cat. no. C2020) ! CAUTION Irritating to eyes, respiratory system 
and skin
• Reverse-phase running buffer (A) 0.1% formic acid
• Reverse-phase eluting buffer (B) 90% ACN:0.1% formic acid
• Bacterial strains: E. coli BL21 eDE3 (any other commercially available 
laboratory strain is suitable); frozen competent cells can be obtained 
from many suppliers, including Stratagene, Promega and Genlanatis
! CAUTION Use good microbiological practice in handling and disposing 
of this E coli laboratory strain
• Chicken muscle (we used skeletal musde tissue from Gallus gallus obtained 
frozen from a local supermarket)
EQUIPMENT
• Slide-A-Lyzer® dialysis cassettes, 500 pi to 3 ml, 10,000 molecular weight 
cut-off (Pierce, cat. no. 66425)
•ZipTip C18 pipette tips (Millipore, cat. no. ZTC18S008)
• Standard spectrophotometer for absorbance readings in the visible range, 
including 600 nm
• 1.5 and 0.5 ml plain microcentrifuge tubes
• Homogenizer
•Reverse-phase column: C18 3 pm particle size (100), 75 pm diameter X 150 
mm long (Dionex)
•MALDI-ToF mass spectrometer (Waters MALDI-R, Shimadzu Axima TOF2 
or equivalent)
• Electrospray-ionization tandem mass spectrometer coupled to a 
high-resolution nanoflow chromatography system (Dionex 3000
coupled to a Thermo Finnigan LTQ or other tandem mass 
spectrometer)
REAGENT SETUP
LB Dissolve 25 g LB powder in 11 distilled water. The pH should be 7.0 ±0.2 at 
25 °C; if not, adjust with HC1 or NaOH as appropriate. Sterilize by autoclaving 
for 15 min at 121 C.
Matrix for MALDI-ToF MS Prepare 50 ml of 50% (vol/vol) acetonitrile-
0.1% (vol/vol) TFA; store at room temperature (20-25 °C). Prepare a 
fresh saturated solution of ~ lOmg CHCA in 1ml 50% (vol/vol) ACN-0.1% 
(vol/vol) TFA.
NHS-activated Sepharose Centrifuge the NHS-Sepharose slurry at 2,000g at 
room temperature for 20 s and remove excess propanol from the beads Wash the 
beads in five volumes of cold 1 m M  HC1, vortex and remove HC1 by 
centrifugation (as before). Wash in two volumes of binding buffer, remove by 
centrifugation. A CRITICAL In order to retain maximum binding capacity of the 
pre-activated medium prior to the coupling step, use cold (0-4 °C) solutions. 
The time interval for all washing steps must be minimized. Prepare all required 
solutions prior to coupling ligand.
Chicken muscle Homogenize 0.5 g chicken skeletal muscle in 5 ml acetylation 
buffer. Centrifuge for 45 min at 13,000gat 4 °C, remove the supernatant fraction 
and use immediately or store at -20 °C. Determine the protein concentration of 
the soluble fraction using the Coomassie Plus® protein assay.
E  coli cell lysate Using a single colony of E. coli, inoculate 10 ml LB and 
incubate overnight at 37 °C with shaking. Transfer 500 pi of the overnight 
culture to 50 ml prewarmed (to 37 °C) fresh LB media (1:100 dilution) and 
incubate the culture with shaking. Remove 1 ml samples at hourly intervals 
and determine the absorbance at 600 nm. Monitor growth rate until the 
early stationary phase is reached. Transfer the culture to a pre-weighed 
50 ml centrifuge tube and centrifuge at l,200g for 10 min at 4 °C. Decant 
the supernatant and weigh the tube again to determine the wet weight of 
the cell pellet. For < 1 g of wet cell pellet, add 2.5 ml BB and, to ensure good 
resuspension, place cells on a rocker platform at room temperature for 15 min. 
Centrifuge the cells at 16,000g at room temperature for 20 min. Set the 
braking speed at low to give a gentle rotor deceleration. Remove the supernatant 
(soluble fraction) and use immediately or store at -20 °C. Determine the 
protein concentration of the soluble fraction using the Coomassie Plus® Protein 
assay.
EQUIPMENT SETUP
Slide-A-Lyzer® cassettes Before using the cassettes check for leaks by injecting 
the maximum amount of distilled water (3 ml) into each. Inject water through 
one of the four valves located in each comer of the cassette. Each valve can be 
used only once, so mark the cassette using a pen when a valve has been used. 
Attach a float to the top of the cassette and place into 1 litre acetylation buffer for 
20 s in order to wet the membrane. Dry off the cassette by tapping it lightly 
onto a paper towel.
HPLC reverse-phase gradient The reversed phase chromatography was 
conducted at a flow rate of 0.3 pi min*1 over 3 h. The three phases of the 
gradients were as follows: 0-140 min, 0-50% buffer B (linear); 140-160 min, 
50% buffer to 80% buffer B (linear); and 160-180 min, 80% buffer B to 
0% buffer B.
PROCEDURE
Dialysis of £. coli proteins into 
acetylation buffer •  TIMING 4 h
1 1 Dialyze E. coli cell lysate into 
acetylation buffer using Slide-A-Lyzer® 
cassettes (see EQUIPMENT SETUP). 
Inject 3 ml E. coli cell lysate into the 
cassette through an unused valve. 
Attach the float and place into 1 1 
acetylation buffer. Leave to dialyze for 
4 h at room temperature with stirring. 
■  PAUSE POINT Dialyzed samples 
can be used immediately or stored for 
several months at -20 °C.
Day 1
~ T  r -~ l T - - - I  T -
Day 2
Z . 7 . 1 m. J  1
Prepare  proteins
Acetylation
s reagent 
I  Protein precipitation
I Overnight proteolysis 
0  Checkpoint: M ALDI-ToF
| Rem ove internal peptides (I)
Rem ove internal peptides (II)
| Prelim inary M S  analysis
Figure 3 | Gantt chart fo r a typical N-terminal peptide-purification experiment. The entire procedure takes 
< 2  d.
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2 1 Determine the protein concentration of the dialyzed soluble fraction using the Coomassie Plus® protein assay. The protein 
concentration should be in the range of 1 to 5 pg p i-1.
Acetylation of intact proteins •  TIMING 2 h 
3 1 Reconstitute 1 mg sulfo-NHS acetate into 50 p i acetylation buffer.
▲ CRITICAL STEP Reconstitute sulfo-NHS acetate immediately before use. The NHS-ester readily hydrolyses and becomes 
unreactive.
4| Add 50 p i (1 mg) of the reconstituted acetylation reagent to 50 pg of the protein recovered from the dialyzed £. coli cell 
lysate (or protein mixture of choice). Incubate at room temperature for 2 h.
Removal of excess acetylation reagent •
5| Add ~5 mg quenching reagent 
(Tris(2-aminoethyl)amine, polymer 
bound), vortex for 1 min and incubate 
with gentle agitation for 1 h.
▲ CRITICAL STEP This treatment has a 
major influence on the overall success of 
the process, and obviates the addition of 
free amines to inactivate excess reagent, 
which would then have to be removed 
before proceeding.
6| Remove amine-scavenging beads 
by filtration or centrifugation.
Precipitation of acetylated proteins 
•  TIMING ~1 .5  h
7 1 Add 600 p i (five volumes) of cold 
30% TCA to the protein mixture, vortex 
and incubate on ice for 1 h.
8| Centrifuge at 13,000g at room tem­
perature for 2 min to pellet the protein.
TIMING 1 h
C h ic k e n  s ke le ta l m u s cle
A c e ty la te d  tryp tic  d ig e s t
9 1 Carefully remove the TCA superna­
tant fraction from the pellet and discard.
101 Add 200 p i diethyl ether to the 
pellet and agitate using a pipette tip.
! CAUTION Use a fume hood when 
pipetting ether.
111 Centrifuge for 10 s at 13,OOOg at 
room temperature.
121 Repeat Steps 10 and 11 twice more 
(three ether washes in total).
131 Remove diethyl ether and place 
tube at 37 °C for 5 min with the lid 
open to evaporate the excess.
Proteolysis • TIMING overnight 
14| Resuspend the diethyl ether- 
washed protein pellet in 50 p i digestion 
buffer. Digest overnight at 37 °C with 1 
pg trypsin (or any other proteolytic 
enzyme; 1:50 enzyme:substrate).
■  PAUSE POINT Once digested, acetyl­
ated peptides can be stored for a few 
months at -20 °C.
Figure 4 | Isolation o f N-terminal peptides from chicken skeletal muscle soluble fraction. The starting 
material is  a complex mixture o f proteins, which sim plifies to  a relatively straightforward N-terminal 
peptide mix. (a) The entire tryp tic  digest o f acetylated proteins, (b) Following application o f the 
sim plification p ro toco l the major ions labeled correspond to  the N-terminal peptides from some o f the 
most abundant soluble proteins in skeletal muscle.
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PROTOCOL I
MALDI-ToF analysis • TIMING ~1 h
15| At this stage in the protocol, i t  is good practice to monitor acetylation and proteolysis of the digested peptides by 
MALDI-ToF using a Waters MALDI-R or any equivalent MALDI-ToF mass spectrometer. Prepare samples as follows: (i) dilute 
sample 1:20 in matrix (2 p i sample + 38 p i matrix); (ii) pipette 1 p i onto a clean MALDI target and allow to air dry; (iii)  acquire 
data over the range of 900 to 3,500 m/z. At this stage of the protocol, a complex spectrum should be observed (corresponding 
to peptides derived from the entire protein mixture). The level of acetylation is difficult to determine; however, the observation 
of ArgC (as opposed to tryptic) peptides is a good indication that a sufficient degree of modification has occurred. Internal 
peptides can now be removed using NHS-activated Sepharose (continue to Step 16) or by biotinylation and streptavidin 
purification (Box 1).
Coupling of internal peptides to NHS-activated Sepharose • TIMING ~24 h
161 Dilute the digested peptides in 50 p i binding buffer (20 mM Na2HP04 and 0.15 M NaCl (pH 7.5)).
171 Remove 100 p i NHS-activated 
Sepharose from the stock preparation 
in propanol, and pipette into a 1.5-ml 
microcentrifuge tube. Wash as described 
in the REAGENT SETUP.
181 Add acetylated peptides (50 pg) 
to NHS-Sepharose, vortex and 
incubate with turning for 4 h at 
room temperature.
191 Centrifuge the Sepharose/peptide 
mixture at 2,000c/ at room temperature 
for 20 s, then remove and retain the 
supernatant (peptide mixture).
20| Prepare a second aliquot (100 pi) 
of NHS-activated Sepharose (repeat Step 
17) and add the peptide mixture.
211 Incubate overnight at 4 °C with 
turning.
▲ CRITICAL STEP A second incubation 
with NHS Sepharose is necessary for 
complete coupling of peptides to 
Sepharose and to minimize leakiness of 
| | { k  the procedure, wherein internal peptides 
t r  can appear in the N-terminal peptide 
preparation.
221 Remove the peptide mixture from 
NHS-Sepharose (as before), divide 
into 10 p i aliquots and proceed to 
mass-spectrometric analysis.
■  PAUSE POINT The peptide mixture 
can be stored at -20 °C prior to MS.
MALDI-ToF analysis • TIMING ~1 h 
231 Prepare samples for MALDI-ToF 
analysis as described in Step 15.
Tandem mass-spectrometric analysis 
• TIMING ~3 h for one sample
2 4 1 Separate the samples using a 
microcapillary reverse-phase column
m/z
Figure 5 | Isolation o f N-terminal peptides from E. coli cell lysate, (a) The entire tryp tic  digest o f 
acetylated proteins, (b) Following application o f the simplification protocol, the major ions labeled 
correspond to  N-terminal peptides from some o f the most abundant proteins in  the  sample.
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(using reverse phase running buffer (A) and reverse phase eluting buffer (B)) in line with an eletrospray-ionization ion-trap 
tandem mass spectrometer.
Data analysis
251 Search the tandem mass spectra against Swiss-Prot using MASCOT or the TurboSequest program (ThermoElectron). Database 
search parameters include the fixed modifications of N-terminal acetylation and lysine acetylation, and the variable modification 
of O-acetylated serine (this is rare, however, so searches should be conducted both with and without this modification).
• TIMING
Dialysis of E. coli proteins into acetylation buffer: 4 h 
Acetylation of intact proteins: 2 h 
Removal of excess acetylation reagent: 1 h 
Precipitation of acetylated proteins: ~1 .5  h 
Proteolysis: overnight 
MALDI-ToF analysis: ~  1 h
Coupling of internal peptides to NHS-activated Sepharose: ~ 2 4  h 
MALDI-ToF analysis: ~  1 h
Tandem mass-spectrometric analysis: ~ 3  h for one sample
? TROUBLESHOOTING 
See Table 1.
TABLE 1 | Troubleshooting for the preparation of N-term inal peptides. 
Problem Possible cause
Incomplete acetylation Instab ility  o f acetylation regent (sulfo-NHS acetate and 
acetic anhydride)
Acidification o f mixture by excess acetic anhydride 
lowers pH
Accessibility of some primary amino groups is impaired 
by the 3D structure of the protein
Amines present in sample buffer compete with proteins 
for acetylation
Incomplete proteolysis Precipitated proteins not washed adequately to  remove 
all residual trichloroacetic acid, which w ill acidify the  
digestion buffer and shift the pH down from the  optim al 
value for trypsin action
Incomplete removal o f Insufficient NHS-activated Sepharose used in the  
peptides, identified by coupling step 
database searching.
Not enough tim e allowed for coupling
pH o f coupling reactions not optim al
Poor MALDI spectra Phosphate buffer/PBS affecting ionization
Sample too complex for meaningful interpretation
Solutions___________________________________________
Prepare sulfo-NHS acetate freshly and use im mediately
Use an acetylation buffer th a t is able to  maintain the pH 
a t ~ 8 .5  for the duration of the reaction 
Use buffers th a t denature or partially unfold the protein, 
or increase the tim e for acetylation (e.g., chaotropic 
buffers and /or reducing agents)
Ensure th a t the buffer used does not contain amines
Wash protein pellets carefully w ith ether to  remove all 
TCA, or precipitate proteins w ith acetone; TCA w ill 
denature the protein mixture more effectively and 
increase the efficiency o f proteolysis
Use a larger excess o f NHS-activated Sepharose; ensure 
the  NHS-Sepharose is freshly prepared
Use longer coupling times; repeat the reaction w ith a 
second batch of freshly washed NHS-Sepharose 
Ensure the system is buffered effectively a t pH 8 .0  ± 0.5; 
ensure th a t no am ine-containing buffers, including Tris, 
have been added to  the mixture; make sure th a t the  
in ternal peptide is not a true intracellular N terminus 
generated by endogenous proteolysis or by ectopic 
digestion after tissue breakage
Dilute the sample further or desalt using a C18 column; 
change the proteolysis buffer to  a d ifferent system, such 
as HEPES
This w ill be normal for a complex protein mixture in 
which no proteins predominate; separate the sample 
using HPLC (as in Step 24) and analyze fractions by 
MALDI, or move directly to  LC-MS/MS or LC2-MS/MS 
(MUDPIT)
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TABLE 2 | E. coli N-term inal peptides from MALDI spectrum.
Spot Protein Mass (Da) Sequence
1 UPF0304 protein yfbU (P0A8W8) 1,021 .43 MEMTNAQR
2 Elongation factor Tu (EF-Tu) (P0A6N1) 1,048 .52 SKEKFER
3 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase (P62707) 1,081 .69 AVTKLVLVR
4 Enolase (P0A6P9) 1,138 .71 SKIVKIIGR
5 10 kDa chaperonin (P0A6G1) 1,192 .61 MNIRPLHDR
6 Glyceraldehyde-3-phosphate dehydrogenase A (P0A9B4) 1 ,244 .69 TIKVGINGFGR
7 Copper-resistance protein D (Q47455) 1 ,274 .67 MNDLIMIVIR
8 D,D-heptose 1,7-bisphosphate phosphatase (Q8FKZ1) 1 ,299 .72 AKSVPAIFLDR
9 Putative HTH-type transcriptional regulator yeaT (P76250) 1,353 .71 MNNLPLLNDLR
10 Elongation factor Ts (EF-Ts) (P0A6P1) 1,412 .79 AEITASLVKELR
11 Phosphoglycerate kinase (P0A799) 1,671 .89 SVIKMTDLDLAGKR
12 P-lactamase (P62593) 2 ,132 .30 HPETLVKVKDAEDQLQR
These ions should be visible even in a MALDI-ToF spectrum of an entire N-terminal preparation of E.coli soluble proteins.
ANTICIPATED RESULTS
MALDI spectra of a digest of acetylated proteins should yield a complex mass spectrum, which represents the most abundant 
peptides in the sample. This analysis serves as a 'check point' in which the extent of acetylation can be monitored, provided 
that a few key peptides can be recognized. Due to the complexity of the peptide mixture, i t  is difficult to assign peptides 
to individual peaks at this stage in the protocol. Following abstraction of internal peptides to NHS-activated Sepharose, the 
N-terminally enriched supernatant should produce a notably simpler mass spectrum. At this stage, i t  might be possible to 
assign the highest intensity signals to true N-terminal peptides.
Skeletal muscle soluble protein preparations are dominated by ~  10-20 major proteins that are predominantly glycolytic 
enzymes19-20. This preparation has the advantage of generating relatively simple spectra, and is a valuable test system with 
which to practice the method. Figures 4a and 5a show the entire tryptic digests for the acetylated chicken muscle and £. coli 
cell lysate samples. As expected the spectra are complex and i t  is not possible to identify any N-terminal peptides. However, 
Figures 4b and 5b represent the unbound fraction for the two samples, which should be substantially N-terminally enriched. 
These elicit much simpler mass spectra, and i t  is possible to assign identities to the most intense signals (E. coli MALDI-ToF 
peak assignments are listed in Table 2). Due to the dynamic range of the skeletal muscle proteome, the N-terminal spectrum 
for chicken muscle is substantially less complex than the E. coli sample. The high abundance of glycolytic proteins found in 
skeletal muscle means that the lower-abundance proteins are not visible at this stage of analysis.
Using a 3-h HPLC gradient, tandem mass-spectrometric analysis should provide data on hundreds of N-terminal peptides 
(depending on sample complexity). When analyzed in this way, the E. coli N-terminally enriched preparation yielded >300 
protein identifications. All identifications were from a search of the entire SwissProt database of £. coli proteins, and relatively 
few peptides were identified as internal sequences.
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The 'protein world' exhibits additional complexity caused by post-translational modifications. One such 
process is nonenzymic deamidation of asparagine which is controlled partly by primary sequence, but 
also higher order protein structure. We have studied the deamidation of an N-terminal peptide in muscle 
glyceraldehyde 3-phosphate dehydrogenase to relate three-dimensional structure, proteolysis, and 
deamidation. This work has significant consequences for identification of proteins using peptide mass 
fingerprinting.
K e y w o rd s : D eam id atio n  •  proteo lysis •  protein  structure • asparag ine  •  aspartic  acid •  peptide mass 
fingerprin ting
Introduction
The emergence of new analytical methods for protein 
characterization has led to the recognition that there is an 
additional dimension of complexity in the protein world created 
by a wide range of post-translational modifications. Some of 
these modifications are specific and are part of the obligatory 
maturation process of a protein, such as the removal of 
propeptides. Other changes are transient, reversible, and may 
only operate on a subset of molecules in the protein pool (the 
best understood is phosphorylation). Other irreversible changes, 
such as deamidation or lysine aldehyde mediated cross-linking, 
are nonenzymic, and the longevity of the protein may be 
reflected in the accumulation of such changes.
Deamidation of the side chain of asparagine residues is a 
nonenzymic process1 (www.deamidation.org). The conversion 
of asparagine to aspartic acid or isoaspartic acid elicits a local 
change in charge, and has the potential to impose a self-timer 
on protein molecules, altering activity or stability with lifetime 
kinetics.2-5 The ability to include a nonenzymic irreversible 
change into a protein that elicits a small steric change but a 
substantial local alteration in electrostatic potential could 
provide an opportunity to evolve a programmable irreversible 
change of state into a protein. Most studies on asparagine 
deamidation have been conducted with model peptides6 which 
are essentially devoid of higher order structure and which 
permit the peptide backbone and side chain to adopt a 
conformation compatible with the cyclic intermediate that is 
required for this reaction to take place. Since the flexibility and 
conformational freedom of the peptide is modified by the 
nature of the amino acids, the rate of deamidation of model 
peptides is strongly influenced by the flanking residues6 and 
the primary influence on the rate of asparagine deamidation 
is the amino acid C-terminal to the asparagine residue. From
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studies of model peptides, the highest rate of deamidation is 
obtained when the carboxyl neighbor is glycine, yielding a half­
time for deamidation of around 24 h.6 This is probably because 
the lack of a Q? atom minimizes steric hindrance and permits 
ready formation of the five-membered imide conducive to the 
deamidation reaction. The N-terminal neighbor has a minor 
effect on the rate of deamidation.6 While most of our under­
standing of rates of peptide deamidation has derived from 
short, model peptides, the same sequences, when incorporated 
into protein structures, might acquire a relatively immobile 
backbone trajectory that could constrain the sequence to either 
favor or disfavor deamidation.
The resolution of modem mass spectrometers used routinely 
in proteomic analyses permits ready resolution of the monoiso- 
topic peptide-ion from the 13C isotopomer variants, even at 
charge states of +2  or +3. At this level of resolution, a 
deamidation event (Asn — Asp) would be readily recognized, 
as it elicits a mass shift of +0.985 Da (-NH2 =  16.03 to -OH =  
17.01). In circumstances where a peptide exists as a mixture 
of the amide and cognate acid species, a complex mass 
spectrum would ensue that appears as an atypical isotopomer 
distribution for a peptide of that mass. It follows that partial 
deamidation events should be readily observed by examination 
of the atypical profile, particularly without prior chromato­
graphic separation that would resolve the amide and cognate 
acid in chromatographic space.
In the course of proteomics studies of soluble proteins in 
skeletal muscle,7 we observed that a peptide from one protein 
in particular exhibited a noticeable and atypical natural isotope 
distribution profile, consistent with a mixture of an asparagine- 
containing peptide and the cognate deamidation product. This 
peptide was derived from the N-terminus of an abundant 
protein, glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
We present here a comprehensive analysis that confirms that 
the ‘atypical’ isotope profile is in fact attributable to partial 
deamidation of an asparagine residue. Deamidation of-AsnGly-
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Figure 1. Atypical peptide mass spectrum consistent with deamidation. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 1 mg/mL 
diluted to 0.2 mg/mL with 50 mM ammonium bicarbonate) purified from rabbit skeletal muscle (Sigma, Dorset, U.K.) was digested in solution 
with trypsin at a substrate/protease ratio of 100:1 by weight, and the masses of the resultant tryptic peptides were assessed by MALDI-ToF 
mass spectrometry; a coverage map is included at the top of the figure, with identified peptides indicated by a shaded block and those 
identified as part of a missed cleavage by an open block. The spectrum of a typical partial cleavage tryptic peptide (T10—11, m/z 1615.9) was 
compared with the mass spectrum predicted by the MS-lsotope tool (http://prospector.ucsf.edu/). This behavior, common to almost all other 
peptides, emphasized the atypical profile observed for the N-terminal partial cleavage peptide (T1-2, m/z 1032.6).
sequences occurs during sample preparation in proteomics,8 
and proteolysis conducted at lower pH and temperature will 
minimize artifactual deamidation.9 Here, we show that dea­
midation is constrained by higher order structure and is 
enhanced after release of that conformational restraint by 
proteolysis. This observation has significance for the identifica­
tion of deamidation events by protein or peptide mass 
spectrometry10-12 and reinforces the role that protein confor­
mation can play in this process.
Experimental Section
Materials and Reagents. Trypsin (sequence grade) was 
obtained from Roche Diagnostics (Lewes, U.K.). All other 
chemicals and solvents (HPLC grade) were purchased from 
Sigma-Aldrich Company Ltd. (Dorset, U.K.) and VWR Interna­
tional Laboratory Supplies (Leicestershire, U.K.).
One-Dimensional Gel Electrophoresis (1DGE). Purified 
GAPDH from rabbit skeletal muscle (Sigma, Dorset, U.K.) (10 
/ig) was electrophoresed through a 12.5% polyacrylamide gel 
and visualized with Biosafe Coomassie Brilliant Blue stain (Bio- 
Rad, Hemel Hempstead, U.K.). Gels were destained with a 10% 
acetic acid 10% methanol solution.
In-Gel Trypsin Digestion. Gel plugs containing GAPDH 
(identification confirmed by MALDI-ToF MS, results not shown) 
were excised from ID gels using a glass pipet and transferred 
to an Eppendorf tube. To each tube, 25 fiL of 50 mM am­
monium bicarbonate, pH 8.2, and 50% (v/v) acetonitrile (ACN) 
was added and incubated at 37 °C for 20 min. This process 
was repeated until all of the stain had been removed. The plugs
were then washed in 50 mM ammonium bicarbonate, which 
was subsequently discarded. The gel was dehydrated using 5 
fiL of ACN, and incubation at 37 °C was resumed for 30 min. 
Once dry, the gel was rehydrated in 50 mM ammonium 
bicarbonate (9 fih) containing trypsin (l^L of 100 ng/^L trypsin 
stock reconstituted in 50 mM acetic acid), and digestion was 
allowed to continue overnight at 37 °C; the digestion was halted 
by the addition of 2 uL of formic acid.
MALDI-ToF Mass Spectrometry. Peptides were analyzed by 
MALDI-ToF (M@LDI; Waters, Manchester, U.K.) mass spec­
trometry. For this, 1 fiL of digested material was mixed with 
an equal volume of a-cyano-hydroxycinnamic acid in 50% (v/ 
v) ACN and 0.1% (v/v) trifluoroacetic acid. This was allowed 
to dry, and peptides were acquired over the range 900-3000 
mlz. For each combined spectrum, 20-30 spectra were ac­
quired (laser energy typically 30%) with 10 shots per spectrum 
and a laser firing rate of 5 Hz. Data were processed using 
MassLyrrx software to subtract background noise using poly­
nomial order 10 with 40% of the data points below this 
polynomial and a tolerance of 0.01. Spectral data were also 
smoothed by performing two mean smooth operations with a 
window of three channels. To confirm the assumption that both 
acid and amide forms of the peptide ionize with equal signal 
response in MALDI-ToF MS, the synthetic peptide for the 
amide form was allowed to fully deamidate (by incubation at 
37 °C) and mixed in a known ratio with asparagine-containing 
peptide in a strong acidic solution to prevent further deami­
dation. The signal response from the two variants was identical.
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Figure 2. Esterification of acidic residues in the N-terminal peptide of GAPDH. Tryptic peptides recovered from an in-gel tryptic digest 
of GAPDH (purified from rabbit skeletal muscle, Sigma, Dorset, U.K.) were reacted with acetyl chloride and methanol to convert acidic 
residues to their corresponding methyl esters. The upper mass spectrum is the peptide resulting from partial deamidation of Asn6, 
thus, is a mixture of two forms (asparagine containing and aspartic acid containing). The lower spectrum, obtained after esterification 
has resolved the peptide into two distinct reaction products at 1046.63 m/z and 1061.65 m/z, consistent with the addition of one and 
two methyl groups (+14.03 Da), respectively.
In-Solution Tryptic Digestion. Soluble protein (purified 
GAPDH; 1 mg/mL) was diluted 10-fold with 50 mM ammonium 
bicarbonate prior to addition of trypsin (100:1 substrate/ 
protease). The reaction mixture was incubated at 37 °C for 24 h, 
and peptides were analyzed by MALDI-ToF MS.
Esterification o f Peptides. A stock solution of methanol (1 
mL, previously stored at -20  °C for 15 min) and acetyl chloride 
(150 fiL) was prepared. An aliquot (10 tiL) of this mixture was 
then added to a dried portion of the peptide pool recovered 
after in-gel digestion of the protein. The mixture was incubated 
at room temperature for 45 min prior to drying in a vacuum 
centrifuge. Esterified peptides were analyzed by MALDI-ToF 
MS.
Monitored Proteolysis of GAPDH. Digestion reaction mix­
tures with trypsin were stopped at selected time points after 
addition of enzyme by removing 10 /A. and adding to an equal 
volume of 10% (v/v) formic acid. The fractions were subse­
quently stored at -20  °C until the end of the time course. 
Peptides were analyzed by MALDI-ToF MS.
Data Processing. The natural isotope profile for the acid 
VKVGVDGFGR and amide VKVGVNGFGR variants of the 
GAPDH N-terminal peptide were predicted using the MSIso- 
tope tool provided online within the Protein Prospector Package 
(http://prospector.ucsf.edU/ucsfhtml4.0/msiso.htm). The in­
tensities of each isotopomer peak were added, and the com­
bined theoretical spectrum was compared with the intensities 
derived from the experimental mass spectrum. The sum of the 
squares of the deviation between predicted and experimental 
data was used to generate the object function, and the sole 
parameter (PA) was the proportion of the acidic component 
(by definition, equal to 1 -  PN, where PN is the proportion of 
amide). The nonlinear optimization function (Solver) within 
Excel was used to obtain the best fit value of PA. Additionally, 
some samples were analyzed by a high speed spectrum
deconvolution tool, implemented as computer hardware in a 
field programmable gate array.13
Absolute Quantification of Proteolysis Using a  Stable 
Isotope-Labeled Synthetic Peptide. The N-terminal peptide of 
GAPDH, of sequence VKVGVNGFGR and neutral mass 1041.59 
Da, was synthesized by Sigma-Genosys (Dorset, U.K.) and was 
labeled at the arginine residue with both [13C6] and [15N j giving 
a 10 Da mass offset from the analyte peptide. For quantification 
of proteolysis, the synthetic peptide was added to digested 
material in 10% (v/v) formic acid to stop digestion and deami­
dation. Peptides were analyzed by MALDI-ToF MS, and the 
relative intensities of analyte peptide and internal standard 
were used to quantify the amount of peptide released from the 
protein during incubation with trypsin at 37 °C. As conversion 
of asparagine to aspartic acid alters the isotope envelope of 
the analyte peptide, the composite abundance of the entire 
isotopic envelope for both analyte and internal standard 
peptide was summed in each case. These data permitted the 
kinetics of proteolytic release of the N-terminal peptide from 
GAPDH to be calculated and were used along with the kinetics 
of deamidation to investigate the interaction between these two 
alternative processes. The rate of deamidation was measured 
across the time course of digestion by calculating the propor­
tion of acid and amide variants of the peptide at each time 
point. This was done during proteolysis of GAPDH and for the 
synthetic peptide, at different temperatures.
Results and Discussion
One of the most abundant soluble sarcoplasmic proteins in 
skeletal muscle is glyceraldehyde 3-phosphate dehydrogenase, 
amounting to 11 ±  1% (mean ±  SEM, n — 3) of soluble protein 
when resolved by ID gel electrophoresis (1DGE) and analyzed 
by densitometry (data not shown) and up to 500 ±  50 nmol/g 
(mean ±  SEM, n =  4) tissue when analyzed using the QconCAT 
method for absolute quantification.13' 15 MALDI-ToF spectra
Journal of Proteome Research • Vol. 7, No. 3, 2008 923
research a rtic le s Rivers et al.
1032.59m/z
Figure 3. Time course of deamidation of the N-terminal peptide 
of GAPDH. Purified rabbit skeletal muscle GAPDH (Sigma, Dorset, 
U.K.; 1 mg/mL diluted to 0.2 mg/mL with 50 mM ammonium  
bicarbonate) was digested with trypsin (trypsin/protein 1:100) 
over 24 h at 37 °C. Proteolysis was stopped at 0, 2, 5, 10, 30, 60, 
120, 240, 480, and 1440 min by mixing 10 fiL from the digestion 
mixture with 10 f it  of 10% (v/v) formic acid. The resulting 
peptides were analysed by MALDI-ToF mass spectrometry, and 
deamidation was monitored during proteolysis for the N-terminal 
peptide of sequence VKVGVNGFGR at 1032.59 mlz. The propor­
tion of acid and amide variants was assessed as described in 
Experimental Section, from peak height data, and plotted as a 
function of time (closed squares). Peptide envelopes illustrating 
the conversion of acid to amide form in MALDI-ToF mass spectra 
corresponding to time points over 24 h are inserted above the 
data. To compare this with model peptide studies, the N-terminal 
peptide of GAPDH, of sequence VKVGVNGFGR and mass 1041.59 
Da, was synthesised by Sigma-Genosys (Dorset, U.K.) and was 
labelled at the arginine residue with both [13C6] and [15N4] giving 
a 10 Da mass offset from the analyte peptide. This peptide was 
incubated in 50 m M ammonium bicarbonate at 37 °C, and a 
sample of the peptide was added to an equal volume of 10% 
(v/v) formic acid at selected time points. The relative amounts 
of acid and amide variants of the peptide were measured using 
MALDI-ToF MS, and this was used to calculate the rate of 
deamidation. These data are presented as open circles. The solid 
lines are the trajectories taken by first-order decay for the 
synthetic peptide and the proteolyzed glyceraldehyde 3-phos- 
phate dehydrogenase.
for this protein, isolated by 1DGE and digested with trypsin 
prior to MS analysis are of high quality, give very high 
probability identification of this protein (not shown), and yield 
approximately 20 peptides, ranging from 805.5 m lz  to 2265.4 
mlz. Close inspection of each peptide indicated that for most, 
the observed mass isotopomer distribution was as expected, 
and was in close agreement to the distribution predicted by 
the Mslsotope program (http://prospector.ucsf.edu/). One pep­
tide in particular (VKVGVNGFGR, [M+H]+ 1032.58 mlz) was 
notably different from the others, inasmuch as the isotope 
distribution profile was far removed from the predicted profile 
(Figure 1). In particular, the relative intensity of the monoiso- 
topic ion was diminished, and of lower intensity than the first 
[13C] isotopomer, a relative intensity pattern that is unexpected 
for a peptide of mass 1031.58 Da, given an empirical formula 
of C46H78N150 12.
The mass isotopomer envelope is consistent with the analyte 
being a mixture of two peptides, one of monoisotopic mlz
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Figure 4. Model of proteolysis and deamidation of the N-terminal 
peptide of GAPDH. The simultaneous processes of proteolysis 
and release of the N-terminal peptide of GAPDH followed by 
deamidation of the asparagine residue to aspartic acid were 
modelled according to this scheme. The model also included the 
subsequent proteolysis of the N-terminal peptide (VKVGVNGFGR 
or VKVGVDGFGR) at the internal arginine residue to generate a 
dipeptide and a truncated peptide (VK+VGVNGFGR or VK+  
VGVDGFGR). In this scheme, we assumed that the rate of 
deamidation was the same, whether in the full length or 
truncated N-terminal peptide, and that the rate of removal of the 
N-terminal dipeptide was independent of the amide/acid variants.
1032.58 and a second at a monoisotopic mlz of 1033.58. The 
higher mlz peptide could have been a contaminant or it could 
have been generated from the peptide at mlz 1032.58. In the 
latter case, the most probable explanation for the mass increase 
was deamidation of the asparagine residue, which, by conver­
sion to an aspartate residue, would increase the mass by 0.985 
Da (-NH2 to -OH). To prove that the atypical profile was a 
consequence of deamidation, we esterified the peptide mixture 
to convert carboxyl groups to their methyl esters. The mass 
shift on esterification would be 14.03 Da. Because the peptide 
V2KVGVNGFGR10 would possess a single carboxyl group in the 
amide form (the alpha carboxyl group), and two in the acid 
form, esterification should therefore deconvolute the atypical 
peptide into two products, one esterified at a single position 
(+14.03 Da), and a second modified in two positions (+28.06 
Da). When the peptide mixture was analyzed after esterifica­
tion, the MALDI-ToF ions in the 1032-1036 mlz region 
disappeared, and two new ions appeared, one representing the 
single modified amide (mlz 1032.58 +  14.03 =  1046.61) and 
the second reflecting the double modified acid (mlz 1033.58 
+  28.06 =  1061.64; Figure 2).
From this analysis, it was not possible to assess whether the 
residue had deamidated in vivo or was an artifact of sample 
preparation and processing. To assess the extent of deamida­
tion of this peptide in the native protein, we treated purified 
rabbit GAPDH with trypsin and monitored the proteolysis and 
the partition between the acid and amide variants of the 
peptide in MALDI-ToF mass spectra (Figure 3; the same 
experiments were repeated for an in-solution tryptic digest of 
chicken skeletal muscle soluble proteins and the same behavior 
was apparent, results not shown). The N-terminal peptide of 
GAPDH (VKVGVNGFGR) was released within a few minutes 
and was readily detected as the first analyte ion to appear in 
the MALDI-ToF spectrum. In the early stages of digestion, the 
mass spectrum of this peptide was entirely consistent with it 
being exclusively in the amide form. However, as time pro­
gressed during proteolysis, the mass spectrum of the peptide 
showed that the peptide was converted to a mixture of the 
amide and acid variants, and after 10 h of digestion, the peptide 
was over 80% in the acid form. The first-order rate constant 
for this process was approximately 0.0017 min-1, which was 
higher than the value derived from model peptides; for the 
sequence NH2GVNGGOH, the first-order rate constant was
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Figure 5. Absolute quantification of proteolysis of the GAPDH 
N-terminus. Purified rabbit skeletal muscle GAPDH (Sigma, 
Dorset, U.K.; 1 mg/mL diluted to 0.2 mg/mL with 50 mM  
ammonium bicarbonate) was digested with trypsin (trypsin/ 
protein 1:10) over 24 h at 37 °C. The N-terminal peptide of 
GAPDH, of sequence V K V G VN G FG R  and mass 1041.59 Da, was 
synthesised by Sigma-Genosys (Dorset, U.K.) and was labelled 
at the arginine residue with both [13C6] and [15N4] giving a 10 Da 
mass offset from the analyte peptide. For quantification of 
proteolysis, the synthetic peptide was added to digested material 
in 10% (v/v) formic acid to stop digestion at selected time points. 
Peptides were analyzed by MALDI-ToF MS, and the relative 
intensities of analyte peptide and internal standard were used 
to quantify the amount of peptide released from the protein 
during incubation with trypsin at 37 °C. Both the N-terminal 
peptide (VKVG VNG FG R/VKVG VDG FG R; m/z 1032.59 [M +H ]+; 
closed triangles) and the shorter peptide produced by further 
proteolysis (VG VNG FG R/VG VDG FG R; m/z 805.59 [M +H]+; open 
circles) were monitored. As conversion of asparagine to aspartic 
acid alters the isotope envelope of the analyte peptide, the 
composite abundance of the entire isotopic envelope for both 
analyte and internal standard peptide was summed in each case. 
The solid lines reflect the fitted curves for the transient appear­
ance of the N-terminal peptide (VKVGVNGFGR/VKVGVDGFGR) 
and the truncated product (VGVNG FG R/VG VDG FG R), modelled 
and fitted as sequential first-order reactions (see text).
previously measured at 0.0004. min-1.16 However, the buffer 
conditions for the two experiments are not identical, and pH 
has a large affect on deamidation rate. The rate of deamidation 
under these buffer conditions was confirmed using a synthetic 
peptide of the same sequence; for this peptide, the rate of 
deamidation was 0.0023 min-1. The higher rate of deamidation 
of the synthetic peptide might reflect an association between 
the partially digested protein and the N-terminal peptide which 
introduced a degree of conformational ‘freezing’ of the peptide, 
diminishing the deamidation rate, but this remains conjecture 
at present.
To investigate the kinetics of both deamidation and pro­
teolysis, a synthetic peptide of sequence VKVGVNGFGR, mass 
1041.59 Da, was synthesized and was labeled at the arginine 
residue with both [13C6] and [15N4] giving a 10 Da mass offset 
relative to the natural peptide. This peptide, identical to the 
N-terminal peptide of GAPDH, was used to monitor the be­
havior of the peptide, and for quantification.17 Because the 
N-terminal peptide itself contains an internal tryptic cleavage 
site (VK - VGVDGFGR), the peptide VKVGVDGFGR (summed
across acid or amide forms) decreased slowly as digestion 
continued. We created a model (Figure 4) that took into 
account the sequential first-order processes of proteolysis (k j  
of the native protein (ZVnative) to release the amide form of the 
peptide (VKVGVNGFGR) followed by deamidation (k to 
generate the acid form (VKVGVDGFGR).
^ n a t i v e  - 1  VKVGVNGFGR —  VKVGVDGFGR
Furthermore, the model also included a secondary process 
of proteolysis of the released peptide in either the acid or amide 
form to release the ValLys dipeptide. The rate of appearance 
of the deamidated peptide is given by
VKVGV(N/D)GFGR VK +  VGV(N/D)GFGR
We assumed that the rate of deamidation (fc,) was indepen­
dent of the N-terminal ValLys dipeptide and that the rate of 
tryptic removal of the N-terminal dipeptide i k j  was the same, 
irrespective of whether the peptide was in acid or amide form. 
The change in amount (relative to the initial amount of pro­
tein, A/native(t=0)) of the larger peptides (VKVGVNGFGR +  
VKVGVDGFGR, N  +  D) as a function of time, is given by
N + D =  Arnative( ^ A _ (e-*.‘ + e-fe‘)J (l)
As part of the same process, the shortened peptide (VGVNGFGR 
+  VGVDGFGR, AT +  DO appears according to
« ’ + »■ = » - . f 1 -  « r h ; ' " " + <a
Assuming that the rate of tryptic cleavage is consistent for 
both acid and amide variants, from these equations, we were 
able to calculate the second-order rate constants (first-order 
rate constant divided by protease concentration) for initial 
release of the large peptide (k j  and the rate of proteolysis of 
this large peptide (fcj (Figure 5). The value of fc, was estimated 
to be 1.22 ±  0.025 min-1 - ¡ u M  and for fc,, 0.50 ±  0.008 min-1 - f j M  
(trypsin =  0.2 ,«M). As expected, the endoproteolytic release of 
the longer peptide is faster than the release of the N-terminal 
dipeptide, as trypsin is known to act poorly as a dipeptidyl 
peptidase. However, the release of the longer peptide is likely 
to be suppressed by the three-dimensional structure of the 
protein.
To investigate the effects of the higher order structure of 
GAPDH on proteolysis and subsequent deamidation, we ana­
lyzed the X-ray crystal structure of rabbit GAPDH (PDB code 
1J0X.PDB). First, we used the tool NickPred,18 which although 
designed to predict sites of proteolytic attack, can generate a 
comprehensive analysis of the environment of every residue 
in a protein sequence. The N-terminal region of GAPDH is 
rather constrained, exhibiting low temperature factors (B- 
values) and low protrusion and accessibility (results not shown). 
Close inspection of the structure in the vicinity of Asn6 revealed 
this region of the polypeptide chain was folded in an extended 
f} configuration, constrained by 14 hydrogen bonds in a 
network that might be expected to constrain main chain 
flexibility and therefore reduce the propensity for asparagine 
deamidation (Figure 6). However, once the peptide was re­
leased by proteolysis, deamidation proceeded at a higher rate 
than that predicted from model studies. These experiments are 
consistent with the following propositions; that the residue in
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Figure 6. 3D structure of rabbit skeletal muscle GAPDH. X-ray crystal structure of the N-terminal region of rabbit skeletal muscle GAPDH 
(PDB code 1J0X) highlighting the Asn6Gly7 deamidation site and the local hydrogen bonded environment. The green dashed lines 
denote hydrogen bonds.
Figure 7. The effect of denaturing protein structure by heating 
on the rate of deamidation. GAPDH (1 mg/mL diluted to 0.2 mg/ 
mL with 50 mM ammonium bicarbonate) purified from rabbit 
skeletal muscle (Sigma, Dorset, U.K.) was digested with trypsin 
in solution at a ratio trypsin/protein 1:100 at 37 °C for 24 h. Prior 
to digestion, GAPDH was incubated for 1 h at 4 °C (open 
triangles), 1 h at 60 °C (closed squares), and 1 h at 60 °C followed 
by 24 h at 37 °C (open squares). For each, deamidation was 
monitored over 24 h proteolysis and the proportion of acid and 
amide was calculated from the relative peak intensities of the 
two ions in MALDI-ToF mass spectra.
the intact protein is exclusively in the amide form, that the 
tryptic fragment containing the amide residue can undergo 
deamidation, and that deamidation is not an artifact of the 
mass spectrometric analysis. Excision of the peptide from the 
GAPDH structure relieves the constraint in the peptide back­
bone trajectory, permitting the deamidation reaction to take 
place. It followed therefore that prior dénaturation of the 
protein might permit deamidation prior to digestion with 
trypsin. We conducted experiments in which we denatured 
GAPDH by heating to 60 °C for 1 h before proteolysis (Figure 
7), a dénaturation treatment that was not sufficient to cause 
the protein to precipitate. Subsequently, when trypsin was 
added, the N-terminal peptide was again released rapidly, and 
the proportion of amide and acid variants of the peptide was 
assessed as previously described. Under these circumstances, 
the peptide first released was approximately 80% amide, with 
a significant proportion of acid form being measurable. This
contrasted markedly with proteolysis of the native protein, 
when the peptide is initially all in the amide form. We attribute 
this behavior to the increased conformational flexibility of the 
peptide in the heat-treated protein, such that the peptide could 
acquire a conformation that allowed deamidation. Further, this 
unfolded and flexible component might be expected to be 
hypersensitive to proteolysis and to be released first. As the 
digestion proceeded, additional peptide in the amide form was 
released, and the proportion of amide therefore increased 
transiendy, until the deamidation reaction dominated the 
peptide profile. When the functions derived previously were 
used, we obtained a value for deamidation of 0.0023 min“ 1, in 
close agreement with that observed previously. If the heat- 
treated peptide was allowed to incubate at 37 °C for 24 h after 
the 60 min denaturation period at 60 °C, and then proteolyzed 
with trypsin, the peptide first released was now only 50% in 
the amide form, consistent with extensive deamidation prior 
to proteolysis, consequential to denaturation. Again, as ex­
pected, proteolysis led to the slower release of peptide that was 
constrained and unable to deamidate, and there was a transient 
increase in the proportion of amide which again decayed at 
the same rate as observed previously =  0.0024 min“ 1). The 
behavior of the system was consistent with the GAPDH 
preparation being 76% in the amide form, and 26% in a 
denatured form that was then rapidly proteolyzed to generate 
the free acid form of the peptide. The effect of denaturation 
on the availability of the N-terminal peptide of GAPDH for 
deamidation is quite striking and defines the importance of 
monitoring the two processes of proteolysis and deamidation 
simultaneously, especially as this effect is only observed upon 
loss of higher order structure, and not upon increasing 
concentration of protease (results not shown).
Conclusions
Deamidation is recognized as a potential source of micro­
heterogeneity in protein structure, and it may play a significant 
role as a biological ‘timer’ that is mediated nonenzymatically.1-5 
Although many studies have emphasized the deamidation of 
short, flexible peptides, protein deamidation can be limited by 
higher order structure and might only occur at the peptide level
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following proteolytic release.8 The ease with which some 
peptides deamidated could then lead to the erroneous inter­
pretation of a deamidation event as occurring in the intact 
protein. Difficulties of measuring deamidation have been 
discussed,19 and analyses often use electrospray ionization 
mass spectrometry® and reversed-phase chromatographic ma­
trices8 to resolve acid and amide variants of a peptide, 
precluding analysis of complex mixtures. There is also consid­
erable scope for MALDI sample ionization, which, when 
coupled with a simple esterification reaction, can clearly 
identify and characterize such deamidation variants. We sug­
gest that there may be merit in closer examination of the 
isotope distribution profile of peptide mass fingerprints, to 
search for anomalies such as that noticed here. In particular, 
it is advantageous to monitor deamidation and proteolysis 
simultaneously when characterizing post-translational behavior 
of known proteins and peptides. This will also unravel informa­
tion about the higher order structure of a protein, the influence 
of which not only on proteolysis but also on subsequent 
modifications to newly accessible regions of the protein, is 
paramount.
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